Protein/(poly)peptide libraries

ABSTRACT

The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins/(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome. Furthermore, the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.

This application is a divisional of Ser. No. 09/025,769, filed 18 Feb. 1998 now U.S. Pat. No. 6,300,064, which is a continuation of PCT EP96/03647 filed 19 Aug. 1996.

FIELD OF THE INVENTION

The present invention relates to synthetic DNA sequences which encode one or more collections of homologous proteins(poly)peptides, and methods for generating and applying libraries of these DNA sequences. In particular, the invention relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences which cover the structural repertoire of antibodies encoded in the human genome. Furthermore, the invention relates to the use of a single consensus antibody gene as a universal framework for highly diverse antibody libraries.

BACKGROUND TO THE INVENTION

All current recombinant methods which use libraries of proteins/(poly)peptides, e.g. antibodies, to screen for members with desired properties, e.g. binding a given ligand, do not provide the possibility to improve the desired properties of the members in an easy and rapid manner. Usually a library is created either by inserting a random oligonucleotide sequence into one or more DNA sequences cloned from an organism, or a family of DNA sequences is cloned and used as the library. The library is then screened, e.g. using phage display, for members which show the desired property. The sequences of one or more of these resulting molecules are then determined. There is no general procedure available to improve these molecules further on.

Winter (EP 0 368 684 B1) has provided a method for amplifying (by PCR), cloning, and expressing antibody variable region genes. Starting with these genes he was able to create libraries of functional antibody fragments by randomizing the CDR3 of the heavy and/or the light chain. This process is functionally equivalent to the natural process of VJ and VDJ recombination which occurs during the development of B-cells in the immune system.

However the Winter invention does not provide a method for optimizing the binding affinities of antibody fragments further on, a process which would be functionally equivalent to the naturally occurring phenomenon of “affinity maturation”, which is provided by the present invention. Furthermore, the Winter invention does not provide for artificial variable region genes, which represent a whole family of structurally similar natural genes, and which can be assembled from synthetic DNA oligonucleotides. Additionally, Winter does not enable the combinatorial assembly of portions of antibody variable regions, a feature which is provided by the present invention. Furthermore, this approach has the disadvantage that the genes of all antibodies obtained in the screening procedure have to be completely sequenced, since, except for the PCR priming regions, no additional sequence information about the library members is available. This is time and labor intensive and potentially leads to sequencing errors.

The teaching of Winter as well as other approaches have tried to create large antibody libraries having high diversity in the complementarity determining regions (CDRs) as well as in the frameworks to be able to find antibodies against as many different antigens as possible. It has been suggested that a single universal framework may be useful to build antibody libraries, but no approach has yet been successful.

Another problem lies in the production of reagents derived from antibodies. Small antibody fragments show exciting promise for use as therapeutic agents, diagnostic reagents, and for biochemical research. Thus, they are needed in large amounts, and the expression of antibody fragments, e.g. Fv, single-chain Fv (scFv), or Fab in the periplasm of E. coli (Skerra & Plückthun, 1988; Better et al., 1988) is now used routinely in many laboratories. Expression yields vary widely, however. While some fragments yield up to several mg of functional, soluble protein per liter and OD of culture broth in shake flask culture (Carter et al., 1992, Plückthun et al. 1996), other fragments may almost exclusively lead to insoluble material, often found in so-called inclusion bodies. Functional protein may be obtained from the latter in modest yields by a laborious and time-consuming refolding process. The factors influencing antibody expression levels are still only poorly understood. Folding efficiency and stability of the antibody fragments, protease lability and toxicity of the expressed proteins to the host cells often severely limit actual production levels, and several attempts have been tried to increase expression yields. For example, Knappik & Plückthun (1995) could show that expression yield depends on the antibody sequence. They identified key residues in the antibody framework which influence expression yields dramatically. Similarly, Ullrich et al. (1995) found that point mutations in the CDRs can increase the yields in periplasmic antibody fragment expression. Nevertheless, these strategies are only applicable to a few antibodies. Since the Winter invention uses existing repertoires of antibodies, no influence on expressibility of the genes is possible.

Furthermore, the findings of Knappik & Plückthun and Ullrich demonstrate that the knowledge about antibodies, especially about folding and expression is still increasing. The Winter invention does not allow to incorporate such improvements into the library design.

The expressibility of the genes is important for the library quality as well, since the screening procedure relies in most cases on the display of the gene product on a phage surface, and efficient display relies on at least moderate expression of the gene.

These disadvantages of the existing methodologies are overcome by the present invention, which is applicable for all collections of homologous proteins. It has the following novel and useful features illustrated in the following by antibodies as an example:

Artificial antibodies and fragments thereof can be constructed based on known antibody sequences, which reflect the structural properties of a whole group of homologous antibody genes. Therefore it is possible to reduce the number of different genes without any loss in the structural repertoire. This approach leads to a limited set of artificial genes, which can be synthesized de novo, thereby allowing introduction of cleavage sites and removing unwanted cleavages sites. Furthermore, this approach enables (i), adapting the codon usage of the genes to that of highly expressed genes in any desired host cell and (ii), analyzing all possible pairs of antibody light (L) and heavy (H) chains in terms of interaction preference, antigen preference or recombinant expression titer, which is virtually impossible using the complete collection of antibody genes of an organism and all combinations thereof.

The use of a limited set of completely synthetic genes makes it possible to create cleavage sites at the boundaries of encoded structural sub-elements. Therefore, each gene is built up from modules which represent structural sub-elements on the protein/(poly)peptide level. In the case of antibodies, the modules consist of “framework” and “CDR” modules. By creating separate framework and CDR modules, different combinatorial assembly possibilities are enabled. Moreover, if two or more artificial genes carry identical pairs of cleavage sites at the boundaries of each of the genetic sub-elements, pre-built libraries of sub-elements can be inserted in these genes simultaneously, without any additional information related to any particular gene sequence. This strategy enables rapid optimization of, for example, antibody affinity, since DNA cassettes encoding libraries of genetic sub-elements can be (i), pre-built, stored and reused and (ii), inserted in any of these sequences at the right position without knowing the actual sequence or having to determine the sequence of the individual library member.

Additionally, new information about amino acid residues important for binding, stability, or solubility and expression could be integrated into the library design by replacing existing modules with modules modified according to the new observations.

The limited number of consensus sequences used for creating the library allows to speed up the identification of binding antibodies after screening. After having identified the underlying consensus gene sequence, which could be done by sequencing or by using fingerprint restriction sites, just those part(s) comprising the random sequence(s) have to be determined. This reduces the probability of sequencing errors and of false-positive results.

The above mentioned cleavage sites can be used only if they are unique in the vector system where the artificial genes have been inserted. As a result, the vector has to be modified to contain none of these cleavage sites. The construction of a vector consisting of basic elements like resistance gene and origin of replication, where cleavage sites have been removed, is of general interest for many cloning attempts. Additionally, these vector(s) could be part of a kit comprising the above mentioned artificial genes and pre-built libraries.

The collection of artificial genes can be used for a rapid humanization procedure of non-human antibodies, preferably of rodent antibodies. First, the amino acid sequence of the non-human, preferably rodent antibody is compared with the amino acid sequences encoded by the collection of artificial genes to determine the most homologous light and heavy framework regions. These genes are then used for insertion of the genetic sub-elements encoding the CDRs of the non-human, preferably rodent antibody.

Surprisingly, it has been found that with a combination of only one consensus sequence for each of the light and heavy chains of a scFv fragment an antibody repertoire could be created yielding antibodies against virtually every antigen. Therefore, one aspect of the present invention is the use of a single consensus sequence as a universal framework for the creation of useful (poly)peptide libraries and antibody consensus sequences useful therefor.

DETAILED DESCRIPTION OF THE INVENTION

The present invention enables the creation of useful libraries of (poly)peptides. In a first embodiment, the invention provides for a method of setting up nucleic acid sequences suitable for the creation of said libraries. In a first step, a collection of at least three homologous proteins is identified and then analyzed. Therefore, a database of the protein sequences is established where the protein sequences are aligned to each other. The database is used to define subgroups of protein sequences which show a high degree of similarity in both the sequence and, it information is available, in the structural arrangement. For each of the subgroups a (poly)peptide sequence comprising at least one consensus sequence is deduced which represents the members of this subgroup; the complete collection of (poly)peptide sequences represent therefore the complete structural repertoire of the collection of homologous proteins. These artificial (poly)peptide sequences are then analyzed, if possible, according to their structural properties to identify unfavorable interactions between amino acids within said (poly)peptide sequences or between said or other (poly)peptide sequences, for example, in multimeric proteins. Such interactions are then removed by changing the consensus sequence accordingly. The (poly)peptide sequences are then analyzed to identify sub-elements such as domains, loops, helices or CDRs. The amino acid sequence is backtranslated into a corresponding coding nucleic acid sequence which is adapted to the codon usage of the host planned for expressing said nucleic acid sequences. A set of cleavage sites is set up in a way that each of the sub-sequences encoding the sub-elements identified as described above, is flanked by two sites which do not occur a second time within the nucleic acid sequence. This can be achieved by either Identifying a cleavage site already flanking a sub-sequence of by changing one or more nucleotides to create the cleavage site, and by removing that site from the remaining part of the gene. The cleavage sites should be common to all corresponding sub-elements or sub-sequences, thus creating a fully modular arrangement of the sub-sequences in the nucleic acid sequence and of the sub-elements in the corresponding (poly)peptide.

In a further embodiment, the invention provides for a method which sets up two or more sets of (poly)peptides, where for each set the method as described above is performed, and where the cleavage sites are not only unique within each set but also between any two sets. This method can be applied for the creation of (poly)peptide libraries comprising for example two α-helical domains from two different proteins, where said library is screened for novel hetero-association domains.

In yet a further embodiment, at least two of the sets as described above, are derived from the same collection of proteins or at least a part of it. This describes libraries comprising for example, but not limited to, two domains from antibodies such as VH and VL, or two extracellular loops of transmembrane receptors.

In another embodiment, the nucleic acid sequences set up as described above, are synthesized. This can be achieved by any one of several methods well known to the practitioner skilled in the art, for example, by total gene synthesis or by PCR-based approaches.

In one embodiment, the nucleic acid sequences are cloned into a vector. The vector could be a sequencing vector, an expression vector or a display (e.g. phage display) vector, which are well known to those skilled in the art. Any vector could comprise one nucleic acid sequence, or two or more nucleic sequences, either in different or the same operon. In the last case, they could either be cloned separately or as contiguous sequences.

In one embodiment, the removal of unfavorable interactions as described above, leads to enhanced expression of the modified (poly)peptides.

In a preferred embodiment, one or more sub-sequences of the nucleic acid sequences are replaced by different sequences. This can be achieved by excising the sub-sequences using the conditions suitable for cleaving the cleavage sites adjacent to or at the end of the sub-sequence, for example, by using a restriction enzyme at the corresponding restriction site under the conditions well known to those skilled in the art, and replacing the sub-sequence by a different sequence compatible with the cleaved nucleic acid sequence. In a further preferred embodiment, the different sequences replacing the initial sub-sequence(s) are genomic or rearranged genomic sequences, for example in grafting CDRs from non-human antibodies onto consensus antibody sequences for rapid humanization of non-human antibodies. In the most preferred embodiment, the different sequences are random sequences, thus replacing the sub-sequence by a collection of sequences to introduce variability and to create a library. The random sequences can be assembled in various ways, for example by using a mixture of mononucleotides or preferably a mixture of trinucleotides (Virnekäs et al., 1994) during automated oligonucleotide synthesis, by error-prone PCR or by other methods well known to the practitioner in the art. The random sequences may be completely randomized or biased towards or against certain codons according to the amino acid distribution at certain positions in known protein sequences. Additionally, the collection of random sub-sequences may comprise different numbers of codons, giving rise to a collection of sub-elements having different lengths.

In another embodiment, the invention provides for the expression of the nucleic acid sequences from a suitable vector and under suitable conditions well known to those skilled in the art.

In a further preferred embodiment, the (poly)peptides expressed from said nucleic acid sequences are screened and, optionally, optimized. Screening may be performed by using one of the methods well known to the practitioner in the art, such as phage-display, selectively infective phage, polysome technology to screen for binding, assay systems for enzymatic activity or protein stability. (Poly)peptides having the desired property can be identified by sequencing of the corresponding nucleic acid sequence or by amino acid sequencing or mass spectrometry. In the case of subsequent optimization, the nucleic acid sequences encoding the initially selected (poly)peptides can optionally be used without sequencing. Optimization is performed by repealing the replacement of sub-sequences by different sequences, preferably by random sequences, and the screening step one or more times.

The desired property the (poly)peptides are screened for is preferably, but not exclusively, selected from the group of optimized affinity or specificity for a target molecule, optimized enzymatic activity, optimized expression yields, optimized stability and optimized solubility.

In one embodiment, the cleavage sites flanking the sub-sequences are sites recognized and cleaved by restriction enzymes, with recognition and cleavage sequences being either identical or different, the restricted sites either having blunt or sticky ends.

The length of the sub-elements is preferably, but not exclusively ranging between 1 amino acid, such as one residue in the active site of an enzyme or a structure-determining residue, and 150 amino acids, as for whole protein domains. Most preferably, the length ranges between 3 and 25 amino acids, such as most commonly found in CDR loops of antibodies.

The nucleic acid sequences could be RNA or, preferably, DNA.

In one embodiment, the (poly)peptides have an amino acid pattern characteristic of a particular species. This can for example be achieved by deducing the consensus sequences from a collection of homologous proteins of just one species, most preferably from a collection of human proteins. Since the (poly)peptides comprising consensus sequences are artificial, they have to be compared to the protein sequence(s) having the closest similarity to ensure the presence of said characteristic amino acid pattern.

In one embodiment, the invention provides for the creation of libraries of (poly)peptides comprising at least part of members or derivatives of the immunoglobulin superfamily, preferably of member or derivatives of the immnoglobulins. Most preferably, the invention provides for the creation of libraries of human antibodies, wherein said (poly)peptides are or are derived from heavy or light chain variable regions wherein said structural sub-elements are framework regions (FR) 1, 2, 3, or 4 or complementary determining regions (CDR) 1, 2, or 3. In a first step, a database of published antibody sequences of human origin is established where the antibody sequences are aligned to each other. The database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold of CDR loops (as determined by analysis of antibody structures). For each of the subgroups a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.

These artificial genes are then constructed e.g. by total gene synthesis or by the use of synthetic genetic subunits. These genetic subunits correspond to structural sub-elements on the (poly)peptide level. On the DNA level, these genetic subunits are defined by cleavage sites at the start and the end of each of the sub-elements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of corresponding genetic sub-sequences. Most preferably, said (poly)peptides are or are derived from the HuCAL consensus genes: Vκ1, Vκ2, Vκ3, Vκ4, Vλ1, Vλ2, Vλ3, VH1A, VH1B, VH2, VH3, VH4, VH5, VH6, Cκ, Cλ, CH1 or any combination of said HuCAL consensus genes.

This collection of DNA molecules can then be used to create libraries of antibodies or antibody fragments, preferably Fv, disulphide-linked Fv, single-chain Fv (scFv), or Fab fragments, which may be used as sources of specificities against new target antigens. Moreover, the affinity of the antibodies can be optimized using pre-built library cassettes and a general procedure. The invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule. Preferably, an scFv fragment library comprising the combination of HuCAL VH3 and HuCAL Vλ2 consensus genes and at least a random sub-sequence encoding the heavy chain CDR3 sub-element is screened for binding antibodies. If necessary, the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements. The expression and screening steps can then be repeated until an antibody having the desired affinity is generated.

Particularly preferred is a method in which one or more of the genetic subunits (e.g. the CDRs) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are selected, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomized as described above.

A further embodiment of the present invention relates to fusion proteins by providing for a DNA sequence which encodes both the (poly)peptide, as described above, as well as an additional moiety. Particularly preferred are moieties which have a useful therapeutic function. For example, the additional moiety may be a toxin molecule which is able to kill cells (Vitetta et al., 1993). There are numerous examples of such toxins, well known to the one skilled in the art, such as the bacterial toxins Pseudomonas exotoxin A, and diphtheria toxin, as well as the plant toxins ricin, abrin, modeccin, saporin, and gelonin. By fusing such a toxin for example to an antibody fragment, the toxin can be targeted to, for example, diseased cells, and thereby have a beneficial therapeutic effect. Alternatively, the additional moiety may be a cytokine, such as IL-2 (Rosenberg & Lotze, 1986), which has a particular effect (in this case a T-cell proliferative effect) on a family of cells. In a further embodiment, the additional moiety may confer on its (poly)peptide partner a means of detection and/or purification. For example, the fusion protein could comprise the modified antibody fragment and an enzyme commonly used for detection purposes, such as alkaline phosphatase (Blake et al., 1984). There are numerous other moieties which can be used as detection or purification tags, which are well known to the practitioner skilled in the art. Particularly preferred are peptides comprising at least five histidine residues (Hochuli et al., 1988), which are able to bind to metal ions, and can therefore be used for the purification of the protein to which they are fused (Lindner et al., 1992). Also provided for by the invention are additional moieties such as the commonly used C-myc and FLAG-tags (Hopp et al., 1988; Knappik & Plückthun, 1994).

By engineering one or more fused additional domains, antibody fragments or any other (poly)peptide can be assembled into larger molecules which also fall under the scope of the present invention. For example, mini-antibodies (Pack, 1994) are dimers comprising two antibody fragments, each fused to a self-associating dimerization domain. Dimerization domains which are particularly preferred include those derived from a leucine zipper (Pack & Plückthun, 1992) or helix-turn-helix motif (Pack et al., 1993).

All of the above embodiments of the present invention can be effected using standard techniques of molecular biology known to anyone skilled in the art.

In a further embodiment, the random collection of sub-sequences (the library) is inserted into a singular nucleic acid sequence encoding one (poly)peptide, thus creating a (poly)peptide library based on one universal framework. Preferably a random collection of CDR sub-sequences is inserted into a universal antibody framework, for example into the HuCAL H3κ2 single-chain Fv fragment described above.

In further embodiments, the invention provides for nucleic acid sequencers), vector(s) containing the nucleic acid sequence(s), host cell(s) containing the vector(s), and (poly)peptides, obtainable according to the methods described above.

In a further preferred embodiment, the invention provides for modular vector systems being compatible with the modular nucleic acid sequences encoding the (poly)peptides. The modules of the vectors are flanked by restriction sites unique within the vector system and essentially unique with respect to the restriction sites incorporated into the nucleic acid sequences encoding the (poly)peptides, except for example the restriction sites necessary for cloning the nucleic acid sequences into the vector. The list of vector modules comprises origins of single-stranded replication, origins of double-stranded replication for high- and low copy number plasmids, promotor/operator, repressor or terminator elements, resistance genes, potential recombination sites, gene III for display on filamentous phages, signal sequences, purification and detection tags, and sequences of additional moieties. The vectors are preferably, but not exclusively, expression vectors or vectors suitable for expression and screening of libraries.

In another embodiment, the invention provides for a kit, comprising one or more of the list of nucleic acid sequence(s), recombinant vector(s), (poly)peptide(s), and vector(s) according lo the methods described above, and suitable host cell(s) for producing the (poly)peptide(s).

In a preferred embodiment, the invention provides for the creation of libraries of human antibodies. In a first step, a database of published antibody sequences of human origin is established. The database is used to define subgroups of antibody sequences which show a high degree of similarity in both the sequence and the canonical fold (as determined by analysis of antibody structures). For each of the subgroups a consensus sequence is deduced which represents the members of this subgroup; the complete collection of consensus sequences represent therefore the complete structural repertoire of human antibodies.

These artificial genes are then constructed by the use of synthetic genetic subunits. These genetic subunits correspond to structural sub-elements on the protein level. On the DNA level, these genetic subunits are defined by cleavage sites at the start and the end of each of the subelements, which are unique in the vector system. All genes which are members of the collection of consensus sequences are constructed such that they contain a similar pattern of said genetic subunits.

This collection of DNA molecules can then be used to create libraries of antibodies which may be used as sources of specificities against new target antigens. Moreover, the affinity of the antibodies can be optimised using pre-built library cassettes and a general procedure. The invention provides a method for identifying one or more genes encoding one or more antibody fragments which binds to a target, comprising the steps of expressing the antibody fragments, and then screening them to isolate one or more antibody fragments which bind to a given target molecule. If necessary, the modular design of the genes can then be used to excise from the genes encoding the antibody fragments one or more genetic sub-sequences encoding structural sub-elements, and replacing them by one or more second sub-sequences encoding structural sub-elements. The expression and screening steps can then be repeated until an antibody having the desired affinity is generated.

Particularly preferred is a method in which one or more of the genetic subunits (e.g. the CDR's) are replaced by a random collection of sequences (the library) using the said cleavage sites. Since these cleavage sites are (i) unique in the vector system and (ii) common to all consensus genes, the same (pre-built) library can be inserted into all artificial antibody genes. The resulting library is then screened against any chosen antigen. Binding antibodies are eluted, collected and used as starting material for the next library. Here, one or more of the remaining genetic subunits are randomised as described above.

DEFINITIONS

Protein

The term protein comprises monomeric polypeptide chains as well as homo- or heteromultimeric complexes of two or more polypeptide chains connected either by covalent interactions (such as disulphide bonds) or by non-covalent interactions (such as hydrophobic or electrostatic interactions).

Analysis of Homologous Proteins

The amino acid sequences of three or more proteins are aligned to each other (allowing for introduction of gaps) in a way which maximizes the correspondence between identical or similar amino acid residues at all positions. These aligned sequences are termed homologous it the percentage of the sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15% of the amino acids in the aligned genes are identical, and at least 30% are similar. Examples for families of homologous proteins are: immunoglobulin superfamily, scavenger receptor superfamily, fibronectin superfamilies (e.g. type II and III), complement control protein superfamily, cytokine receptor superfamily, cystine knot proteins, tyrosine kinases, and numerous other examples well known to one of ordinary skill in the art.

Consensus Sequence

Using a matrix of at least three aligned amino acid sequences, and allowing for gaps in the alignment, it is possible to determine the most frequent amino acid residue at each position. The consensus sequence is that sequence which comprises the amino acids which are most frequently represented at each position. In the event that two or more amino acids are equally represented at a single position, the consensus sequence includes both or all of those amino acids.

Removing Unfavorable Interactions

The consensus sequence is per se in most cases artificial and has to be analyzed in order to change amino acid residues which, for example, would prevent the resulting molecule to adapt a functional tertiary structure or which would block the interaction with other (poly)peptide chains in multimeric complexes. This can be done either by (i) building a three-dimensional model of the consensus sequence using known related structures as a template, and identifying amino acid residues within the model which may interact unfavorably with each other, or (ii) analyzing the matrix of aligned amino acid sequences in order to detect combinations of amino acid residues within the sequences which frequently occur together in one sequence and are therefore likely lo interact with each other, These probable interaction-pairs are then tabulated and the consensus is compared with these “interaction maps”. Missing or wrong interactions in the consensus are repaired accordingly by introducing appropriate changes in amino acids which minimize unfavorable interactions.

Identification of Structural Sub-elements

Structural sub-elements are stretches of amino acid residues within a protein/(poly)peptide which correspond to a defined structural or functional part of the molecule. These can be loops (e.g. CDR loops of an antibody) or any other secondary or functional structure within the protein/(poly)peptide (domains, α-helices, β-sheets, framework regions of antibodies, etc.). A structural sub-element can be identified using known structures of similar or homologous (poly)peptides; or by using the above mentioned matrices of aligned amino acid sequences. Here the variability at each position is the basis for determining stretches of amino acid residues which belong to a structural sub-element (e.g. hypervariable regions of an antibody).

Sub-sequence

A sub-sequence is defined as a genetic module which is flanked by unique cleavage sites and encodes at least one structural sub-element. It is not necessarily identical to a structural sub-element.

Cleavage Site

A short DNA sequence which is used as a specific target for a reagent which cleaves DNA in a sequence-specific manner (e.g. restriction endonucleases).

Compatible Cleavage Sites

Cleavage sites are compatible with each other, if they can be efficiently ligated without modification and, preferably, also without adding an adapter molecule.

Unique Cleavage Sites

A cleavage site is defined as unique if it occurs only once in a vector containing at least one of the genes of interest, or if a vector containing at least one of the genes of interest could be treated in a way that only one of the cleavage sites could be used by the cleaving agent.

Corresponding (poly)Peptide Sequences

Sequences deduced from the same part of one group of homologous proteins are called corresponding (poly)peptide sequences.

Common Cleavage Sites

A cleavage site in at least two corresponding sequences, which occurs at the same functional position (i.e. which flanks a defined subsequence), which can be hydrolyzed by the same cleavage tool and which yields identical compatible ends is termed a common cleavage site.

Excising Genetic Sub-sequences

A method which uses the unique cleavage sites and the corresponding cleavage reagents to cleave the target DNA at the specified positions in order to isolate, remove or replace the genetic sub-sequence flanked by these unique cleavage sites.

Exchanging Genetic Sub-sequences

A method by which an existing sub-sequence is removed using the flanking cleavage sites of this sub-sequence, and a new sub-sequence or a collection of sub-sequences, which contain ends compatible with the cleavage sites thus created, is inserted.

Expression of Genes

The term expression refers to in vivo or in vitro processes, by which the information of a gene is transcribed into mRNA and then translated into a protein/(poly)peptide. Thus, the term expression refers to a process which occurs inside cells, by which the information of a gene is transcribed into mRNA and then into a protein. The term expression also includes all events of post-translational modification and transport, which are necessary for the (poly)peptide to be functional.

Screening of Protein/(poly)peptide Libraries

Any method which allows isolation of one or more proteins/(poly)peptides having a desired property from other proteins/(poly)peptides within a library.

Amino Acid Pattern Characteristic for a Species

A (poly)peptide sequence is assumed to exhibit an amino acid pattern characteristic for a species if it is deduced from a collection of homologous proteins from just this species.

Immunoglobulin Superfamily (IgSF)

The IgSF is a family of proteins comprising domains being characterized by the immunoglobulin fold. The IgSF comprises for example T-cell receptors and the immunoglobulins (antibodies).

Antibody Framework

A framework of an antibody variable domain is defined by Kabat et al. (1991) as the part of the variable domain which serves as a scaffold for the antigen binding loops of this variable domain.

Antibody CDR

The CDRs (complementarity determining regions) of an antibody consist of the antigen binding loops, as defined by Kabat et al. (1991). Each of the two variable domains of an antibody Fv fragment contain three CDRs.

HuCAL

Acronym for Human Combinatorial Antibody Library. Antibody Library based on modular consensus genes according to the invention (see Example 1).

Antibody Fragment

Any portion of an antibody which has a particular function, e.g. binding of antigen. Usually, antibody fragments are smaller than whole antibodies. Examples are Fv, disulphide-linked Fv, single-chain Fv (scFv), or Fab fragments. Additionally, antibody fragments are often engineered to include new functions or properties.

Universal Framework

One single framework which can be used to create the full variability of functions, specificities or properties which is originally sustained by a large collection of different frameworks, is called universal framework.

Binding of an Antibody to its Target

The process which leads to a light and specific association between an antibody and a corresponding molecule or ligand is called binding. A molecule or ligand or any part of a molecukle or ligand which is recognized by an antibody is called the target.

Replacing Genetic Sub-sequences

A method by which an existing sub-sequence is removed using the flanking cleavage sites of this sub-sequence, and a new sub-sequence or collection of sub-sequences, which contains ends compatible with the cleavage sites thus created, is inserted.

Assembling of Genetic Sequences

Any process which is used to combine synthetic or natural genetic sequences in a specific manner in order to get longer genetic sequences which contain at least parts of the used synthetic or natural genetic sequences.

Analysis of Homologous Genes

The corresponding amino acid sequences of two or more genes are aligned to each other in a way which maximizes the correspondence between identical or similar amino acid residues at all positions. These aligned sequences are termed homologous if the percentage of the sum of identical and/or similar residues exceeds a defined threshold. This threshold is commonly regarded by those skilled in the art as being exceeded when at least 15 percent of the amino acids in the aligned genes are identical, and at least 30 percent are similar.

LEGENDS TO FIGURES AND TABLES

FIG. 1: Flow chart outlining the process of construction of a synthetic human antibody library based on consensus sequences.

FIGS. 2A-2G: Alignment of consensus sequences designed for each subgroup (amino acid residues are shown with their standard one-letter abbreviation). (2A-2B) (SEQ ID NOS 28-31, respectively) kappa sequences, (2C-2D) (SEQ ID NOS 32-34, respectively) lambda sequences and (2E-2G) (SEQ ID NOS 35-41, respectively), heavy chain sequences. The positions are numbered according to Kabat (1991). In order to maximize homology in the alignment, gaps (−) have been introduced in the sequence at certain positions.

FIGS. 3A-3K: Gene sequences (SEQ ID NOS 42, 44, 46 and 48, respectively) of the synthetic V kappa consensus genes. The corresponding amino acid sequences (SEQ ID NOS 43, 45, 47 and 49, respectively) (see FIGS. 2A-2B) as well as the unique cleavage sites are also shown.

FIGS. 4A-4I: Gene sequences (SEQ ID NOS 50, 52 and 54, respectively) of the synthetic V lambda consensus genes. The corresponding amino acid sequences (SEQ ID NOS 51, 53 and 55, respectively) (see FIGS. 2C-2D) as well as the unique cleavage sites are also shown.

FIGS. 5A-5U: Gene sequences (SEQ ID NOS 56, 58, 60, 62, 64, 66 and 68, respectively) of the synthetic V heavy chain consensus genes. The corresponding amino acid sequences (SEQ ID NOS 57, 59, 61, 63, 65, 67 and 69, respectively) (see FIGS. 2E-2G) as well as the unique cleavage sites are also shown.

FIGS. 6A-6G: Oligonucleotides (SEQ ID NOS 70-164, respectively) used for construction of the consensus genes. The oligos are named according to the corresponding consensus gene, e.g. the gene Vκ1 was constructed using the six oligonucleotides O1K1 to O1K6. The oligonucleotides used for synthesizing the genes encoding the constant domains Cκ (OCLK1 to 8) and CH1 (OCH1 to 8) are also shown.

FIGS. 7A-7D: Sequences of the synthetic genes (SEQ ID NOS 165 and 167, respectively) encoding the constant domains Cκ (7A-7B) and CH1(7C-7D). The corresponding amino acid sequences (SEQ ID NOS 166 and 168, respectively) as well as unique cleavage sites introduced in these genes are also shown.

FIGS. 7E-7H: Functional map and sequence (SEQ ID NOS 169-170, respectively) of module M24 comprising the synthetic Cλ gene segment (huCL lambda).

FIGS. 7I-7J: Oligonucleotides (SEQ ID NOS 171-176) used for synthesis of module M24.

FIGS. 8A-8E: Sequence (SEQ ID NOS 177-178, respectively) and restriction map of the synthetic gene encoding the consensus single-chain fragment VH3-Vκ2. The signal sequence (amino acids 1 to 21) was derived from the E. coli phoA gene (Skerra & Plückthun, 1988). Between the phoA signal sequence and the VH3 domain, a short sequence stretch encoding 4 amino acid residues (amino acid 22 to 25) has been inserted in order to allow detection of the single-chain fragment in Western blot or ELISA using the monoclonal antibody M1 (Knappik & Plückthun, 1994) The last 6 basepairs of the sequence were introduced for cloning purposes (EcoRI site).

FIG. 9: Plasmid map of the vector pIG10.3 used for phage display of the H3κ2 scFv fragment. The vector is derived from pIG10 and contains the gene for the lac operon repressor, lac, the artificial operon encoding the H3κ2-gene3ss fusion under control of the lac promoter, the Ipp terminator of transcription, the single-strand replication origin of the E. coli phage 11 (F1_ORI), a gene encoding β-lactamase (bIa) and the ColEI derived origin of replication.

FIGS. 10A-10B: Sequencing results of independent clones from the initial library, translated into the corresponding amino acid sequences. (A) (SEQ ID NO: 179) Amino acid sequence of the VH3 consensus heavy chain CDR3 (position 93 to 102, Kabat numbering). (B) (SEQ ID NOS 180-191, respectively) Amino acid sequences of 12 clones of the 10-mer library. (C) (SEQ ID NOS 192-202, respectively) Amino acid sequences of 11 clones of the 15-mer library, *: single base deletion.

FIG. 11: Expression test of individual library members. (A) Expression of 9 independent clones of the 10-mer library. (B) Expression of 9 independent clones of the 15-mer library. The lane designated with M contains the size marker. Both the gp3-scFv fusion and the scFv monomer are indicated.

FIG. 12: Enrichment of specific phage antibodies during the panning against FITC-BSA. The initial as well as the subsequent fluorescein-specific sub-libraries were panned against the blocking buffer and the ratio of the phage eluted from the FITC-BSA coated well vs. that from the powder milk coated well from each panning round is presented as the “specificity factor”.

FIG. 13: Phage ELISA of 24 independent clones after the third round of panning tested for binding on FITC-BSA.

FIG. 14: Competition ELISA of selected FITC-BSA binding clones. The ELISA signals (OD_(405nm)) of scFv binding without inhibition are taken as 100%.

FIG. 15: Sequences results of the heavy chain CDR3s of independent clones after 3 rounds of planning against FITC-BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 203-218, respectively) (position 93 to 102. Kabat numbering).

FIG. 16: Coomassie-Blue stained SDS-PAGE of the purified anti-fluorescein scFv fragments: M: molecular weight marker, A: total soluble cell extract after induction, B: fraction of the flow-through, C, D and E: purified scFv fragments 1HA-3E4, 1HA-3E5 and 1HA-3E10, respectively.

FIG. 17: Enrichment of specific phage antibodies during the panning against β-estradiol-BSA, testosterone-BSA, BSA, ESL-1, inlerleukin-2, lymphotoxin-β, and LeY-BSA after three rounds of panning.

FIG. 18: ELISA of selected ESL-1 and β-estradiol binding clones

FIG. 19: Selectivity and cross-reactivity of HuCAL antibodies: in the diagonal specific binding of HuCAL antibodies can be seen, off-diagonal signals show non-specific cross-reactivity.

FIG. 20: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against β-estradiol-BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 219-230 respectively) (position 93 to 102, Kabat numbering). One clone is derived from the 10 mer library.

FIG. 21: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against testosterone-BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 231-236, respectively) (position 93 to 102, Kabat numbering).

FIG. 22: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against lymphotoxin-β, translated into the corresponding amino acid sequences (SEQ ID NOS 237-244, respectively) (position 93 to 102, Kabat numbering). One clone comprises a 14 mer CDR, presumably introduced by incomplete coupling of the trinucleolide mixture during oligonucleotide synthesis.

FIG. 23: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning agains ESL-1, translated into the corresponding amino acid sequences (SEQ ID NOS 245-256, respectively) (position 93 to 102, Kabat numbering). Two clones are derived from the 10 mer library. One clone comprises a 16 mer CDR, presumably introduced by chain elongation during oligonucleotide synthesis using trinucleotides.

FIG. 24: Sequencing results of the heavy chain CDR3s of independent clones after 3 rounds of panning against BSA, translated into the corresponding amino acid sequences (SEQ ID NOS 257-262, respectively) (position 93 to 102, Kabat numbering).

FIG. 25A: Schematic representation of the modular pCAL vector system.

FIGS. 25B-25C: List of restriction sites already used in or suitable for the modular HuCAL genes and pCAL vector system.

FIG. 26: List of the nodular vector elements for the pCAL vector series: shown are only those restriction sites which are part of the modular system.

FIGS. 27A-27B: Functional map and sequence (SEQ ID NO: 263) of the multi-cloning site module (MCS).

FIGS. 28A-28G: Functional map and sequence (SEQ ID NO: 264-265, respectively) of the pMCS cloning vector series.

FIGS. 29A-29B: Functional map and sequence (SEQ ID NO: 266) of the pCAL module M1 (see FIGS. 26A-26D).

FIGS. 30A-30C: Functional map and sequence (SEQ ID NOS 267-268, respectively) of the pCAL module M7-III (see FIGS. 26A-26D).

FIGS. 31A-31B: Functional map and sequence (SEQ ID NO: 269) of the pCAL module M9-II (see FIGS. 26A-26D).

FIGS. 32A-32C: Functional map and sequence (SEQ ID NO: 270) of the pCAL module M11-II (see FIGS. 26A-26D).

FIGS. 33A-33D: Functional map and sequence (SEQ ID NO: 271) of the pCAL module M14-Ext2 (see FIGS. 26A-26D).

FIGS. 34A-34D: Functional map and sequence (SEQ IO NOS 272-273, respectively) of the pCAL module M17 (see FIGS. 26A-26D).

FIGS. 35A-35I: Functional map and sequence (SEQ ID NOS 274-276, respectively) module vector pCAL4.

FIGS. 35J-35XXX: Functional maps and sequences (SEQ ID NOS 277-300, respectively) of additional pCAL modules (M2, M3, M7I, M7II, M8, M10II, M11II, M12, M13, M19, M20, M21, M41) and of low-copy number plasmid vectors (pCALO1 to pCALO3).

FIGS. 35YYY-35CCCC: List of oligonucleotides and primers (SEQ ID NOS 301-360, respectively) used for synthesis of pCAL vector modules.

FIGS. 36A-36F: Functional map and sequence (SEQ ID NOS 361-362, respectively) of the β-lactamase cassette for replacement of CDRs for CDR library cloning.

FIGS. 37A-37D: Oligo and primer (SEQ ID NOS 363-367, respectively) design for Vκ CDR3 libraries.

FIGS. 38A-38D: Oligo and primer (SEQ ID NOS 368-371, respectively) design for Vλ CDR3 libraries.

FIG. 39: Functional map of the pBS13 expression vector series.

FIGS. 40A-40B: Expression of all 49 HuCAL scFvs obtained by combining each of the 7 VH genes with each of the 7 VL genes (pBS 13, 30° C.): Values are given for the percentage of soluble vs. insoluble material, the total and the soluble amount compared to the combination H3P2, which was set to 100%. In addition, the corresponding values for the McPC603 scFv are given.

Table 1: Summary of human immunoglobulin germline sequences used for computing the germline membership of rearranged sequences. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. (1) The germline name used in the various calculations, (2) the references number for the corresponding sequence (see appendix for sequence related citations), (3) the family where each sequence belongs to and (4), the various names found in literature for germline genes with identical amino acid sequences.

Table 2: Rearranged human sequences used for the calculation of consensus sequences. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. The table summarized the name of the sequence (1), the length of the sequence in amino acids (2), the germline family (3) as well as the computed germline counterpart (4). The number of amino acid exchanges between the rearranged sequence and the germline sequence is tabulated in (5), and the percentage of different amino acids is given in (6). Column (7) gives the references number for the corresponding sequence (see appendix for sequence related citations).

Table 3: Assignment of rearranged V sequences lo their germline counterparts. (A) kappa sequences, (B) lambda sequences and (C), heavy chain sequences. The germline genes are tabulated according to their family (1), and the number of rearranged genes found for every germline gene is given in (2).

Table 4: Computation of the consensus sequence of the rearranged V kappa sequences. (A) (SEQ ID NO: 14), V kappa subgroup 1, (B) (SEQ ID NO: 15), V kappa subgroup 2, (C) (SEQ ID NO: 16), V kappa subgroup 3 and (D) (SEQ ID. NO: 17), V kappa subgroup 4. The number of each amino acid found at each position is tabulated together with the statistical analysis data. (1) Amino acids are given with their standard one-letter abbreviations (and B means D or N, Z means E or Q and X means any amino acid). The statistical analysis summarizes the number of sequences found at each position (2), the number of occurrences of the most common amino acid (3), the amino acid residue which is most common at this position (4), the relative frequency of the occurrence of the most common amino acid (5) and the number of different amino acids found at each position (6).

Table 5: Computation of the consensus sequence of the rearranged V lambda sequences. (A) (SEQ ID NO: 18), V lambda subgroup 1, (B) (SEQ ID NO: 19), V lambda subgroup 2, and (C) (SEO ID NO: 20), V lambda subgroup 3. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.

Table 6: Computation of the consensus sequence of the rearranged V heavy chain sequences. (A) (SEQ ID NO: 21), V heavy chain subgroup 1A, (B) (SEQ ID NO: 22), V heavy chain subgroup 1B. (C) (SEQ ID NO: 23), V heavy chain subgroup 2, (D) (SEQ ID NO: 24), V heavy chain subgroup 3, (E) (SEQ ID NO: 25), V heavy chain subgroup 4, (F) (SEQ ID NO: 26), V heavy chain subgroup 5, and (G) (SEQ ID NO: 27), V heavy chain subgroup 6. The number of each amino acid found at each position is tabulated together with the statistical analysis of the data. Abbreviations are the same as in Table 4.

EXAMPLES Example 1 Design of a Synthetic Human Combinatorial Antibody Library (HuCAL)

The following example describes the design of a fully synthetic human combinatorial antibody library (HuCAL), based on consensus sequences of the human immunoglobulin repertoire, and the synthesis of the consensus genes. The general procedure is outlined in FIG. 1.

1.1 Sequence Database

1.1.1 Collection and Alignment of Human Immunoglobulin Sequences

In a first step, sequences of variable domains of human immunoglobulins have been collected and divided into three sub bases: V heavy chain (VH), V kappa (Vκ) and V lambda (Vλ). For each sequence, the gene sequence was then translated into the corresponding amino acid sequence. Subsequently, all amino acid sequences were aligned according to Kabat et al. (1991). In the case of Vλ sequences, the numbering system of Chuchana et al. (1990) was used. Each of the three main databases was then divided into two further sub bases: the first sub base contained all sequences derived from rearranged V genes, where more than 70 positions of the sequence were known. The second sub bass contained all germline gene segments (without the D- and J-minigenes; pseudogenes with internal stop codons were also removed). In all cases, where germline sequences with identical amino acid sequence but different names were found, only one sequence was used (see Table 1). The final databases of rearranged sequences contained 386, 149 and 674 entries for Vκ, Vλ and VH, respectively. The final databases of germline sequences contained 48, 26 and 141 entries for Vκ, Vλ and VH, respectively.

1.1.2 Assignment of Sequences to Subgroups

The sequences in the three germline databases where then grouped according to sequence homology (see also Tomlinson et al., 1992, Williams & Winter, 1993, and Cox et al., 1994). In the case of Vκ, 7 families could be established. Vλ was divided into 8 families and VH into 6 families. The VH germline genes of the VH7 family (Van Dijk et al., 1993) were grouped into the VH1 family, since the genes of the two families are highly homologous. Each family contained different numbers of germline genes, varying from 1 (for example VH6) to 47 (VH3).

1.2 Analysis of Sequences

1.2.1 Computation of Germline Membership

For each of the 1209 amino acid sequences in the databases of rearranged genes, the nearest germline counterpart, i.e. the germline sequence with the smallest number of amino acid differences was then calculated. After the germline counterpart was found, the number of somatic mutations which occurred in the rearranged gene and which ted to amino acid exchanges could be tabulated. In 140 cases, the germline counterpart could not be calculated exactly, because more than one germline gene was found with an identical number of amino acid exchanges. These rearranged sequences were removed from the database. In a few cases, the number of amino acid exchanges was found to be unusually large (>20 for VL and >25 for VH), indicating either heavily mutated rearranged genes or derivation from germline genes not present in the database. Since it was not possible to distinguish between these two possibilities, these sequences were also removed from the database. Finally, 12 rearranged sequences were removed from the database because they were found to have very unusual CDR lengths and composition or unusual amino acids at canonical positions (see below). In summary, 1023 rearranged sequences out of 1209 (85%) could be clearly assigned to their germline counterparts (see Table 2).

After this calculation, every rearranged gene could be arranged in one of the families established for the germline genes. Now the usage of each germline gene, i.e. the number of rearranged genes which originate from each germline gene, could be calculated (see Table 2). It was found that the usage was strongly biased towards a subset of germline genes, whereas most of the germline genes were not present as rearranged genes in the database and therefore apparently not used in the immune system (Table 3). This observation had already been reported in the case of Vκ (Cox, et al., 1994). All germline gene families, where no or only very few rearranged counterparts could be assigned, were removed from the database, leaving 4 Vκ, 3 Vλ, and 6 VH families.

1.2.2 Analysis of CDR Conformations

The conformation of the antigen binding loops of antibody molecules, the CDRs, is strongly dependent on both the length of the CDRs and the amino acid residues located at the so-called canonical positions (Chothia & Lesk, 1987). It has been found that only a few canonical structures exist, which determine the structural repertoire of the immunoglobulin variable domains (Chothia et al., 1989). The canonical amino acid positions can be found in CDR as well as framework regions. The 13 used germline families defined above (7 VL and 6 VH) were now analyzed for their canonical structures in order to define the structural repertoire encoded in these families.

In 3 of the 4 Vκ families (Vκ1, 2 and 4), one different type of CDR1 conformation could be defined for every family. The family Vκ3 showed two types of CDR1 conformation: one type which was identical to Vκ1 and one type only found in Vκ3. All Vκ CDR2s used the same type of canonical structure. The CDR3 conformation is not encoded in the germline gene segments. Therefore, the 4 Vκ families defined by sequence homology and usage corresponded also to 4 types of canonical structures found in Vκ germline genes.

The 3 Vλ families defined above showed 3 types of CDR1 conformation, each family with one unique type. The Vλ1 family contained 2 different CDR1 lengths (13 and 14 amino acids), but identical canonical residues, and it is thought that both lengths adopt the same canonical conformation (Chothia & Lesk, 1987). In the CDR2 of the used Vλ germlines, only one canonical conformation exists, and the CDR3 conformation is not encoded in the germline gene segments. Therefore, the 3 Vλ families defined by sequence homology and usage corresponded also to 3 types of canonical structures.

The structural repertoire of the human VH sequences was analyzed in detail by Chothia et al., 1992. In total, 3 conformations of CDR1 (H1-1, H1-2 and H1-3) and 6 conformations of CDR2 (H2-1, H2-2, H2-3, H2-4, H2-5 and H2-x) could be defined. Since the CDR3 is encoded in the D- and J-minigene segments, no particular canonical residues are defined for this CDR.

All the members of the VH1 family defined above contained the CDR1 conformation H1-1, but differed in their CDR2 conformation: the H2-2 conformation was found in 6 germline genes, whereas the conformation H2-3 was found in 8 germline genes. Since the two types of CDR2 conformations are defined by different types of amino acid at the framework position 72, the VH1 family was divided into two subfamilies: VH1A with CDR2 conformation H2-2 and VH1B with the conformation H2-3. The members of the VH2 family all had the conformations H1-3 and H2-1 in CDR1 and CDR2, respectively. The CDR1 conformation of the VH3 members was found in all cases to be H1-1, but 4 different types were found in CDR2 (H2-1, H2-3, H2-4 and H2-x). In these CDR2 conformations, the canonical framework residue 71 is always defined by an arginine. Therefore, it was not necessary to divide the VH3 family into subfamilies, since the 4 types of CDR2 conformations were defined solely by the CDR2 itself. The same was true for the VH4 family. Here, all 3 types of CDR1 conformations were found, but since the CDR1 conformation was defined by the CDR itself (the canonical framework residue 26 was found to be glycine in all cases), no subdivisions were necessary. The CDR2 conformation of the VH4 members was found to be H2-1 in all cases. All members of the VH5 family were found to have the conformation H1-1 and H2-2, respectively. The single germline gene of the VH6 family had the conformations H1-3 and H2-5 in CDR1 and CDR2, respectively.

In summary, all possible CDR conformations of the Vκ and Vλ genes were present in the 7 families defined by sequence comparison. From the 12 different CDR conformations found in the used VH germline genes, 7 could be covered by dividing the family VH1 into two subfamilies, thereby creating 7 VH families. The remaining 5 CDR conformations (3 in the VH3 and 2 in the VH4 family) were defined by the CDRs themselves and could be created during the construction of CDR libraries. Therefore, the structural repertoire of the used human V genes could be covered by 49 (7×7) different frameworks.

1.2.3 Computation of Consensus Sequences

The 14 databases of rearranged sequences (4 Vκ, 3 Vλ, and 7 VH) were used to compute the HuCAL consensus sequences of each subgroup (4 HuCAL-Vκ, 3 HuCAL-Vλ, 7 HuCAL-VH, see Table 4, 5 and 5). This was done by counting the number of amino acid residues used at each position (position variability) and subsequently identifying the amino acid residue most frequently used at each position. By using the rearranged sequences instead of the used germline sequences for the calculation of the consensus, the consensus was weighted according to the frequency of usage. Additionally, frequently mutated and highly conserved positions could be identified. The consensus sequences were cross-checked with the consensus of the germline families to see whether the rearranged sequences were biased at certain positions towards amino acid residues which do not occur in the collected germline sequences, but this was found not to be the case. Subsequently, the number of differences of each of the 14 consensus sequences to each of the germline sequences found in each specific family was calculated. The overall deviation from the most homologous germline sequence was found to be 2.4 amino acid residues (s.d.=2.7), ensuring that the “artificial” consensus sequences can still be considered as truly human sequences as far as immunogenicity is concerned.

1.3 Structural Analysis

So far, only sequence information was used to design the consensus sequences. Since it was possible that during the calculation certain artificial combinations of amino acid residues have been created, which are located far away in the sequence but have contacts to each other in the three dimensional structure, leading to destabilized or even mistolded frameworks, the 14 consensus sequences were analyzed according to their structural properties.

It was rationalized that all rearranged sequences present in the database correspond to functional and therefore correctly folded antibody molecules. Hence, the most homologous rearranged sequence was calculated for each consensus sequence. The positions where the consensus differed from the rearranged sequence were identified as potential “artificial residues” and inspected.

The inspection itself was done in two directions. First, the local sequence stretch around each potentially “artificial residue” was compared with the corresponding stretch of all the rearranged sequences. If this stretch was found to be truly artificial, i.e. never occurred in any of the rearranged sequences, the critical residue was converted into the second most common amino acid found at this position and analyzed again. Second, the potentially “artificial residues” were analyzed for their long range interactions. This was done by collecting all available structures of human antibody variable domains from the corresponding PDB files and calculating for every structure the number and type of interactions each amino acid residue established to each side-chain. These “interaction maps” were used to analyze the probable side-chain/side-chain interactions of the potentially “artificial residues”. As a result of this analysis, the following residues were exchanged (given is the name of the gene, the position according to Kabat's numbering scheme, the amino acid found at this position as the most abundant one and the amino acid which was used instead):

VH2: S₆₅T

Vκ1: N₃₄A,

Vκ3: G₉A, D₆₀A, R₇₇S

Vκ3: V₇₈T

1.4 Design of CDR Sequences

The process described above provided the complete consensus sequences derived solely from the databases of rearranged sequences. It was rationalized that the CDR1 and CDR2 regions should be taken from the databases of used germline sequences, since the CDRs of rearranged and mutated sequences, are biased towards their particular antigens. Moreover, the germline CDR sequences are known to allow binding to a variety of antigens in the primary immune response, where only CDR3 is varied. Therefore, the consensus CDRs obtained from the calculations described above were replaced by germline CDRs in the case of VH and Vκ. In the case of Vλ, a few amino acid exchanges were introduced in some of the chosen germline CDRs in order to avoid possible protease cleavage sites as well as possible structural constraints.

The CDRs of following germline genes have been chosen:

HuCAL gene CDR1 CDR2 HuCAL-VH1A VH1-12-1 VH1-12-1 HuCAL-VH1B VH1-13-16 VH1-13-6,-7,-8,-9 HuCAL-VH2 VH2-31-10,-11,-12,-13 VH2-31-3,-4 HuCAL-VH3 VH3-13-8,-9,-10 VH3-13-8,-9,-10 HuCAL-VH4 VH4-11-7 to -14 VH4-11-8,-9,-11,-12,-14,-16 VH4-31-17,-18,-19,-20 HuCAL-VH5 VH5-12-1,-2 VH5-12-1,-2 HuCAL-VH6 VH6-35-1 VH6-35-1 HuCAL-Vκ1 Vκ1-14,-15 Vκ1-2,-3,-4,-5,-7,-8,-12,-13, -18,-19 HuCAL-Vκ2 Vκ2-6 Vκ2-6 HuCAL-Vκ3 Vκ3-1,-4 Vκ3-4 HuCAL-Vκ4 Vκ4-1 Vκ4-1 HuCAL-Vλ1 HUMLV117,DPL5 DPL5 HuCAL-Vλ2 DPL11,DPL12 DPL12 HuCAL-Vλ3 DPL23 HUMLV318

In the case of the-CDR3s, any sequence could be chosen since these CDRs were planned to be the first to be replaced by oligonucleotide libraries. In order to study the expression and folding behavior of the consensus sequences in E. coli, it would be useful to have all sequences with the same CDR3, since the influence of the CDR3s on the folding behavior would then be identical in all cases. The dummy sequences QQHYTTPP (see, for instance, positions 89-96 of SEQ ID NO: 28 and positions 88-95 of SEQ ID NO: 34) and ARWGGDGFYAMDY (positions 97-109 of SEQ ID NOS 35 & 36) were selected for the VL chains (kappa and lambda) and for the VH chains, respectively. These sequences are known to be compatible with antibody folding in E. coli (Carter et al., 1992).

1.5 Gene Design

The final outcome of the process described above was a collection of 14 HuCAL amino acid sequences, which represent the frequently used structural antibody repertoire of the human immune system (see FIG. 2). These sequences were back-translated into DNA sequences. In a first step, the back-translation was done using only codons which are known to be frequently used in E. Coli. These gene sequences were then used for creating a database of all possible restriction endonuclease sites, which could be introduced without changing the corresponding amino acid sequences. Using this database, cleavage sites were selected which were located at the flanking regions of all sub-elements of the genes (CDRs and framework regions) and which could be introduced in all HuCAL VH, Vκ or Vλ genes simultaneously at the same position. In a few cases it was not possible to find cleavage sites for all genes of a subgroup. When this happened, the amino acid sequence was changed, it this was possible according to the available sequence and structural information. This exchange was then analyzed again as described above. In total, the following 6 amino acid residues were exchanged during this design (given is the name of the gene, the position according to Kabat's numbering scheme, the amino acid found at this position as the most abundant one and the amino acid which was used instead):

VH2: T₃Q

VH6: S₄₂G

Vκ3: E₁D, I₅₈V

Vκ4: K₂₄R

Vλ3: T₂₂S

In one case (5′-end of VH framework 3) it was not possible to identify a single cleavage site for all 7 VH genes. Two different type of cleavage sites were used instead: BstEII for HuCAL VH1A, VH1B, VH4 and VH5, and NspV for HuCAL VH2, VH3, VH4 and VH6.

Several restriction endonuclease sites were identified, which were not located at the flanking regions of the sub-elements but which could be introduced in every gene of a given group without changing the amino acid sequence. These cleavage sites were also introduced in order to make the system more flexible for further improvements. Finally, all but one remaining restriction endonuclease sites were removed in every gene sequence. The single cleavage site, which was not removed was different in all genes of a subgroup and could be therefore used as a “fingerprint” site to ease the identification of the different genes by restriction digest. The designed genes, together with the corresponding amino acid sequences and the group-specific restriction endonuclease sites are shown in FIG. 3, 4 and 5, respectively.

1.6 Gene Synthesis and Cloning

The consensus genes were synthesized using the method described by Prodromou & Pearl, 1992, using the oligonucleotides shown in FIG. 6. Gene segments encoding the human constant domains Cκ, Cλ and CH1 were also synthesized, based on sequence information given by Kabat et al., 1991 (see FIG. 6 and FIG. 7). Since for both the CDR3 and the framework 4 gene segments identical sequences were chosen in all HuCAL Vκ, Vλ and VH genes, respectively, this part was constructed only once, together with the corresponding gene segments encoding the constant domains. The PCR products were cloned into pCR-Script KS(+) (Stratagene, Inc.) or pZErO-1 (Invitrogen, Inc.) and verified by sequencing.

Example 2 Cloning and Testing of a HuCAL-Based Antibody Library

A combination of two of the synthetic consensus genes was chosen after construction to test whether binding antibody fragments can be isolated from a library based on these two consensus frameworks. The two genes were cloned as a single-chain Fv (scFv) fragment, and a VH-CDR3 library was inserted. In order to test the library for the presence of functional antibody molecules, a selection procedure was carried out using the small hapten fluorescein bound to BSA (FITC-BSA) as antigen.

2.1 Cloning of the HuCAL VH3-Vκ2 scFv Fragment

2.1 Cloning of the HuCAL VH3-Vk2 scFv Fragment

In order to test the design of the consensus genes, one randomly chosen combination of synthetic light and heavy gene (HuCAL-Vκ2 and HuCAL-VH3) was used for the construction of a single-chain antibody (scFv) fragment. Briefly, the gene segments encoding the VH3 consensus gene and the CH1 gene segment including the CDR3—framework 4 region, as well as the Vκ2 consensus gene and the Cκ gene segment including the CDR3—framework 4 region were assembled yielding the gene for the VH3-CH1 Fd fragment and the gene encoding the Vκ2-Cκ light chain, respectively. The CH1 gene segment was then replaced by an oligonucleotide (SEQ ID NOS 2 & 3, respectively) cassette encoding a 20-mer peptide linker (SEO ID NO: 1) with the sequence AGGGSGGGGSGGGGSGGGGS. The two oligonucleotides encoding this linker were 5′-TCAGCGGGTGGCGGTTCTGGCGGCGGTGGGAGCGGTGGCGGTGGTTCTGGCGGTGGTGGTTCCGATATCGGTCCACGTACGG-3′ and 5′-MTTCCGTACGTGGACCGATATCGGMCCACCACCGCCAGAACCACCGCCACCGCTCCCACCGCCGCCAGAACCGCCACCCGC-3′, respectively. Finally, the HuCAL-Vκ2 gene was inserted via EcoRV and BsiWI into the plasmid encoding the HuCAL-VH3-linker fusion, leading to the final gene HuCAL-VH3-Vκ2, which encoded the two consensus sequences in the single-chain format VH-linker-VL. The complete coding sequence is shown in FIG. 8.

2.2 Construction of a Monovalent Phage-display Phagemid Vector pIG10.3

Phagemid pIG10.3 (FIG. 9) was constructed in order to create a phage-display system (Winter et al., 1994) for the H3κ2 scFv gene. Briefly, the EcoRI/HindIII restriction fragment in the phagemid vector pIG10 (Ge et al., 1995) was replaced by the c-myc followed by an amber codon (which encodes an glutamate in the amber-suppresser strain XL1 Blue and a stop codon in the non-suppresser strain JM83) and a truncated version of the gene III (fusion junction at codon 249, see Lowman et al., 1991) through PCR mutagenesis.

2.3 Construction of H-CDR3 Libraries

Heavy chain CDR3 libraries of two lengths (10 and 15 amino acids) were constructed using trinucleotide codon containing oligonucleotides (Virnekäs et al., 1994) as templates and the oligonucleotides complementing the flanking regions as primers. To concentrate only on the CDR3 structures that appear most often in functional antibodies, we kept the salt-bridge of R_(H94) and D_(H101) in the CDR3 loop. For the 15-mer library, both phenylalanine and methionine were introduced at position 100 since these two residues were found to occur quite often in human CDR3s of this length (not shown). For the same reason, valine and tyrosine were introduced at position 102. All other randomized positions contained codons for all amino acids except cystein, which was not used in the trinucleotide mixture.

The CDR3 libraries of lengths 10 and 15 were generated from the PCR fragments using oligonucleotide templates (SEQ ID NOS 4 & 5, respectively) O3HCDR103T (5′-GATACGGCCGTGTATTATTGCGCGCGT (TRI)₆ GATTATTGGGGCCAAGGCACCCTG-3′) and 03HCDR153T (5′-GATACGGCCGTGTATTATTGCGCGCGT(TRI)₁₀ (TTT/ATG)GAT(GTT/TAT)TGGGGCCAAGGCACCCTG-3′), and primers (SEQ ID NOS 6 & 7, respectively) O3HCDR35 (5′-GATACGGCCGTGTATTATTGC-3′) and O3HCDR33 (5′-CAGGGTGCCTTGGCCCC-3′), where TRI are trinucleotide mixtures representing all amino acids without cystein, (TTT/ATG) and (GTT/TAT) are trinucleotide mixtures encoding the amino acids phenylalanine/methionine and valine/tyrosine, respectively. The potential diversity of these libraries was 4.7×10⁷ and 3.4×10¹⁰ for 10-mer and 15-mer library, respectively. The library cassettes were first synthesized from PCR amplification of the oligo templates in the presence of both primers: 25 pmol of the oligo template O3HCDR103T or O3HCDR153T, 50 pmol each of the primers O3HCDR35 and O3HCDR33, 20 nmol of dNTP, 10x buffer and 2.5 units of Pfu DNA polymerase (Stratagene) in a total volume of 100 ml for 30 cycles (1 minute at 92° C., 1 minute at 62° C. and 1 minute at 72° C.). A hot-start procedure was used. The resulting mixtures were phenol-extracted, ethanol-precipitated and digested ovemight with EagI and Styl. The vector pIG10.3-scH3□2cat, where the Eagl-Styl fragment in the vector pIG10.3-scH3κ2 encoding the H-CDR3 was replaced by the chloramphenicol acetyltransferase gene (cat) flanked with these two sites, was similarly digested. The digested vector (35 μg) was gel-purified and ligated with 100 μg of the library cassette overnight at 16° C. The ligation mixtures were isopropanol precipitated, air-dried and the pellets were redissolved in 100 ml of ddH20. The ligation was mixed with 1 ml of freshly prepared electrocompetent XL1 Blue on ice. 20 rounds of electroporation were performed and the transformants were diluted in SOC medium, shaken at 37° C. for 30 minutes and plated out on large LB plates (Amp/Tet/Glucose)

In order to test the quality of the initial library, phagemids from 24 independent colonies (12 from the 10-mer and 12 from the 15-mer library, respectively) were isolated and analyzed by restriction digestion and sequencing. The restriction analysis of the 24 phagemids indicated the presence of intact vector in all cases. Sequence analysis of these clones (see FIG. 10) indicated that 22 out of 24 contained a functional sequence in their heavy chain CDR3 regions. 1 out of 12 clones of the 10-mer library had a CDR3 of length 9 instead of 10, and 2 out of 12 clones of the 15-mer library had no open reading frame, thereby leading to a non-functional scFv; one of these two clones contained two consecutive inserts, but out of frame (data not shown). All codons introduced were presented in an even distribution.

Expression levels of individual library members were also measured. Briefly, 9 clones from each library were grown in 2xYT medium containing Amp/Tet/0.5% glucose at 37° C. overnight. Next day, the cultures were diluted into fresh medium with Amp/Tet. At an OD_(600nm) of 0.4, the cultures were induced with 1 mM of IPTG and shaken at RT overnight. Then the cell pellets were suspended in 1 ml of PBS buffer+1 mM of EDTA. The suspensions were sonicated and the supernatants were separated on an SDS-PAGE under reducing conditions, blotted on nylon membrane and detected with anti-FLAG M1 antibody (see FIG. 11). From the nine clones of the 10-mer library, all express the scFv fragments. Moreover, the gene III/scFv fusion proteins were present in all cases. Among the nine clones from the 15-mer library analyzed, 6/9 (67%) led to the expression of both scFv and the gene III/scFv fusion proteins. More importantly, all clones expressing the scFvs and gene III/scFv fusions gave rise to about the same level of expression.

2.4 Biopanning

Phages displaying the antibody libraries were prepared using standard protocols. Phages derived from the 10-mer library were mixed with phages from the 15-mer library in a ratio of 20:1 (1×10¹⁰ cfu/well of the 10-mer and 5×10⁸ cfu/well of the 15-mer phages, respectively). Subsequently, the phage solution was used for panning in ELISA plates (Maxisorp, Nunc) coated with FITC-BSA (Sigma) at concentration of 100 μg/ml in PBS at 4° C. overnight. The antigen-coated wells were blocked with 3% powder milk in PBS and the phage solutions in 1% powder milk were added to each well and the plate was shaken at RT for 1 hr. The wells were then washed with PBST and PBS (4 times each with shaking at RT for 5 minutes). The bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes. The eluted phage solutions were immediately neutralized with ½ the volume of 1 M Tris.Cl, pH 7.6. Eluted phage solutions (ca. 450 μl) were used to infect 5 ml of XL1 Blue cells at 37° C. for 30 min. The infected cultures were then plated out on large LB plates (Amp/Tet/Glucose) and allowed to grow at 37° C. until the colonies were visible. The colonies were suspended in 2xYT medium and the glycerol cultures were made as above described. This panning round was repeated twice, and In the third round elution was carried out with addition of fluorescein in a concentration of 100 μg/ml in PBS. The enrichment of specific phage antibodies was monitored by panning the initial as well as the subsequent fluorescein-specific sub-libraries against the blocking buffer (FIG. 12). Antibodies with specificity against fluorescein were isolated after 3 rounds of panning.

2.5 ELISA Measurements

One of the criteria for the successful biopanning is the isolation of individual phage clones that bind to the targeted antigen or hapten. We undertook the isolation of anti-FITC phage antibody clones and characterized them first in a phage ELISA format. After the 3rd round of biopanning (see above), 24 phagemid containing clones were used to inoculate 100 μl of 2xYT medium (Amp/Tet/Glucose) in an ELISA plate (Nunc), which was subsequently shaken at 37° C. for 5 hrs. 100 μl of 2xYT medium (Amp/Tet/1 mM IPTG) were added and shaking was continued for 30 minutes. A further 100 μl of 2xYT medium (Amp/Tet) containing the helper phage (1×10⁹ cfu/well) was added and shaking was done at RT for 3 hrs. After addition of kanamycin to select for successful helper phage infection, the shaking was continued overnight. The plates were then centrifuged and the supernatants were pipetted directly into ELISA wells coated with 100 μl FITC-BSA (100 μg/ml) and blocked with milk powder. Washing was performed similarly as during the panning procedure and the bound phages were detected with anti-M13 antibody-POD conjugate (Pharmacia) using soluble POD substrate (Boehringer-Mannheim). Of the 24 clones screened against FITC-BSA, 22 were active in the ELISA (FIG. 13). The initial libraries of similar liter gave rise to no detectable signal.

Specificity for fluorescein was measured in a competitive ELISA. Periplasmic fractions of live FITC specific scFvs were prepared as described above. Western blotting indicated that all clones expressed about the same amount of scFv fragment (data not shown). ELISA was performed as described above, but additionally, the periplasmic fractions were incubated 30 min at RT either with buffer (no inhibition), with 10 mg/ml BSA (inhibition with BSA) or with 10 mg/ml fluorescein (inhibition with fluorescein) before adding to the well. Binding scFv fragment was detected using the anti-FLAG antibody M1. The ELISA signal could only be inhibited, when soluble fluorescein was added, indicating binding of the scFvs was specific for fluorescein (FIG. 14).

2.6 Sequence Analysis

The heavy chain CDR3 region of 20 clones were sequenced in order to estimate the sequence diversity of fluorescein binding antibodies in the library (FIG. 15). In total, 16 of 20 sequences (80%) were different, showing that the constructed library contained a highly diverse repertoire of fluorescein binders. The CDR3s showed no particular sequence homology, but contained on average 4 arginine residues. This bias towards arginine in fluorescein binding antibodies had already been described by Barbas et al., 1992.

2.7 Production

E. coli JM83 was transformed with phagemid DNA of 3 selected clones and cultured in 0.5 L 2xYT medium. Induction was carried out with 1 mM IPTG at OD_(600nm)=0.4 and growth was continued with vigorous shaking at RT overnight. The cells were harvested and pellets were suspended in PBS buffer and sonicated. The supernatants were separated from the cell debris via centrifugation and purified via the BioLogic system (Bio-Rad) by with a POROS®MC 20 column (IMAC, PerSeptive Biosystems, Inc.) coupled with an ion-exchange chromatography column. The ion-exchange column was one of the POROS®HS, CM or HQ or PI 20 (PerSeptive Biosystems, Inc.) depended on the theoretical pI of the scFv being purified. The pH of all the buffers was adjusted to one unit lower or higher than the pI of the scFv being purified throughout. The sample was loaded onto the first IMAC column, washed with 7 column volumes of 20 mM sodium phosphate, 1 M NaCl and 10 mM imidazole. This washing was followed by 7 column volumes of 20 mM sodium phosphate and 10 mM imidazole. Then 3 column volumes of an imidazole gradient (10 to 250 mM) were applied and the eluent was connected directly to the ion-exchanger. Nine column volumes of isocratic washing with 250 mM imidazole was followed by 15 column volumes of 250 mM to 100 mM and 7 column volumes of an imidazole/NaCl gradient (100 to 10 mM imidazole, 0 to 1 M NaCl). The flow rate was 5 ml/min. The purity of scFv fragments was checked by SDS-PAGE Coomassie staining (FIG. 16). The concentration of the fragments was determined from the absorbance at 280 nm using the theoretically determined extinction coefficient (Gill & von Hippel, 1989). The scFv fragments could be purified to homogeneity (see FIG. 16). The yield of purified fragments ranged from 5 to 10 mg/L/OD.

Example 3 HuCAL H3κ2 Library Against a Collection of Antigens

In order to test the library used in Example 2 further, a new selection procedure was carried out using a variety of antigens comprising β-estradiol, testosterone, Lewis-Y epitope (LeY), interleukin-2 (IL-2), lymphotoxin-β (LT-β). E-selectin ligand-1 (ESL-1), and BSA.

3.1 Biopanning

The library and all procedures were identical to those described in Example 2. The ELISA plates were coated with β-estradiol-BSA (100 μg/ml), testosterone-BSA (100 μg/ml), LeY-BSA (20 μg/ml) IL-2 (20 μg/ml), ESL-1 (20 μg/ml) and BSA (100 μg/ml), LT-β (denatured protein, 20 μg/ml). In the first two rounds, bound phages were eluted with 0.1 M triethylamine (TEA) at RT for 10 minutes. In the case of BSA, elution after three rounds of panning was carried out with addition of BSA in a concentration of 100 μg/ml in PBS. In the case of the other antigens, third round elution was done with 0.1 M triethylamine. In all cases except LeY, enrichment of binding phages could be seen (FIG. 17). Moreover, a repetition of the biopanning experiment using only the 15-mer library resulted in the enrichment of LeY-binding phages as well (data not shown).

3.2. ELISA Measurements

Clones binding to β-estradiol, testosterone, LeY, LT-β, ESL-1 and BSA were further analyzed and characterized as described in Example 2 for FITC. ELISA data for anti-β-estradiol and anti-ESL-1 antibodies are shown in FIG. 18. In one experiment, selectivity and cross-reactivity of binding scFv fragments were tested. For this purpose, an ELISA plate was coated with FITC, testosterone, β-estradiol, BSA, and ESL-1, with 5 wells for each antigen arranged in 5 rows, and 5 antibodies, one against each of the antigens, were screened against each of the antigens. FIG. 19 shows the specific binding of the antibodies to the antigen it was selected for, and the low cross-reactivity with the other four antigens.

3.3 Sequence Analysis

The sequencing data of several clones against β-estradiol (34 clones), testosterone (12 clones), LT-β (23 clones), ESL-1 (34 clones), and BSA (10 clones) are given in FIGS. 20 to 24.

Example 4 Vector Construction

To be able to take advantage of the modularity of the consensus gene repertoire, a vector system had to be constructed which could be used in phage display screening of HuCAL libraries and subsequent optimization procedures. Therefore, all necessary vector elements such as origins of single-stranded or double-stranded replication, promotor/operator, repressor or terminator elements, resistance genes, potential recombination sites, gene III for display on filamentous phages, signal sequences, or detection tags had to be made compatible with the restriction site pattern of the modular consensus genes. FIG. 25 shows a schematic representation of the pCAL vector system and the arrangement of vector modules and restriction sites therein. FIG. 25a shows a list of all restriction sites which are already incorporated Into the consensus genes or the vector elements as part of the modular system or which are not yet present in the whole system. The latter could be used in a later stage for the introduction of or within new modules.

4.1 Vector Modules

A series of vector modules was constructed where the restriction sites flanking the gene sub-elements of the HuCAL genes were removed, the vector modules themselves being flanked by unique restriction sites. These modules were constructed either by gene synthesis or by mutagenesis of templates. Mutagenesis was done by add-on PCR, by site-directed mutagenesis (Kunkel et al., 1991) or multisite oligonucleotide-mediated mutagenesis (Sutherland et al., 1995; Perlak, 1990) using a PCR-based assembly method.

FIG. 26 contains a list of the modules constructed. Instead of the terminator module M9 (HindIII-Ipp-PacI), a larger cassette M9II was prepared to introduce FseI as additional restriction site. M9II can be cloned via HindIII/BsrGI.

All vector modules were characterized by restriction analysis and sequencing. In the case of module M11-II, sequencing of the module revealed a two-base difference in positions 164/65 compared to the sequence database of the template. These two different bases (CA→GC) created an additional BanII site. Since the same two-base difference occurs in the f1 origin of other bacteriophages, it can be assumed that the two-base difference was present in the template and not created by mutagenesis during cloning. This BanII site was removed by site-directed mutagenesis, leading to module M11-III. The BssSI site of nodule M14 could initially not be removed without impact on the function of the ColE1 origin, therefore M14-Ext2 was used for cloning of the first pCAL vector series. FIGS. 29 to 34 are showing the functional maps and sequences of the modules used for assembly of the modular vector pCAL4 (see below). The functional maps and sequences of additional modules can be found in FIG. 35a. FIG. 35b contains a list of oligonucleotides and primers used for the synthesis of the modules.

4.2 Cloning Vector pMCS

To be able to assemble the individual vector modules, a cloning vector pMCS containing a specific multi-cloning site (MCS) was constructed. First, an MCS cassette (FIG. 27) was made by gene synthesis. This cassette contains all those restriction sites in the order necessary for the sequential introduction of all vector modules and can be cloned via the 5′-HindIII site and a four base overhang at the 3′-end compatible with an AatII site. The vector pMCS (FIG. 28) was constructed by digesting pUC19 with AatII and HindIII, isolating the 2174 base pair fragment containing the bla gene and the ColE1 origin, and ligating the MCS cassette.

4.3 Cloning of Modular Vector pCAL4

This was cloned step by step by restriction digest of pMCS and subsequent ligation of the modules M1 (via AatII/XbaI), M7III (via EcoRI/HindIII), and M9II (via HindIII/BsrGI), and M11-II (via BsrGI/NheI). Finally, the bla gene was replaced by the cat gene module M17 (via AatII/BgIII), and the wild type ColE1 origin by module M14-Ext2 (via BgIII/NheI). FIG. 35 is showing the functional map and the sequence of pCAL4.

4.4 Cloning of Low-copy Number Plasmid Vectors pCALO

A series of low-copy number plasmid vectors was constructed in a similar way using the p15A module M12 instead of the ColE1 module M14-Ext2. FIG. 35a is showing the functional maps and sequences of the vectors pCALO1 to pCALO3.

Example 5 Construction of a HuCAL scFv Library

5.1. Cloning of All 49 HuCAL scFv Fragments

All 49 combinations of the 7 HuCAL-VH and 7 HuCAL-VL consensus genes were assembled as described for the HuCAL VH3-Vκ2 scFv in Example 2 and inserted into the vector pBS12, a modified version of the pLisc series of antibody expression vectors (Skerra et al., 1991).

5.2 Construction of a CDR Cloning Cassette

For replacement of CDRs, a universal β-lactamase cloning cassette was constructed having a multi-cloning site at the 5′-end as well as at the 3′-end. The 5′-multi-cloning site comprises all restriction sites adjacent to the 5′-end of the HuCAL VH and VL CDRs, the 3′-multi-cloning site comprises all restriction sites adjacent to the 3′ end of the HuCAL VH and VL CDRs. Both 5′- and 3′-multi-cloning site were prepared as cassettes via add-on PCR using synthetic oligonucleotides as 5′- and 3′-primers using wild type β-lactamase gene as template. FIG. 36 shows the functional map and the sequence of the cassette bla-MCS.

5.3. Preparation of VL-CDR3 Library Cassettes

The VL-CDR3 libraries comprising 7 random positions were generated from the PCR fragments using oligonucleotide templates Vκ1&Vκ3, Vκ2 and Vκ4 and primers O_K3L_(—)5 and O_K3L_(—)3 (FIG. 37) for the Vκ genes, and Vλ, and primers O_L3L_(—)5 (5′-GCAGAAGGCGAACGTCC-3′) and O_L3LA_(—)3 (FIG. 38) for the Vλ genes. Construction of the cassettes was performed as described in Example 2.3.

5.4 Cloning of HuCAL scFv Genes with VL-CDR3 Libraries

Each of the 49 single-chains was subcloned into pCAL4 via XbaI/EcoRI and the VL-CDR3 replaced by the β-lactamase cloning cassette via BbsI/MscI, which was then replaced by the corresponding VL-CDR3 library cassette synthesized as described above. This CDR replacement is described in detail in Example 2.3 where the cat gene was used.

5.5 Preparation of VH-CDR3 Library Cassette

The VH-CDR3 libraries were designed and synthesized as described in Example 2.3.

5.6 Cloning of HuCAL scFv Genes with VL- and VH-CDR3 Libraries

Each of the 49 single-chain VL-CDR3 libraries was digested with BssHII/StyI to replace VH-CDR3. The “dummy” cassette digested with BssHII/StyI was inserted, and was then replaced by a corresponding VH-CDR3 library cassette synthesized as described above.

Example 6 Expression Tests

Expression and toxicity studies were performed using the scFv format VH-linker-VL. All 49 combinations of the 7 HuCAL-VH and 7 HuCAL-VL consensus genes assembled as described in Example 5 were inserted into the vector pBS13, a modified version of the pLisc series of antibody expression vectors (Skerra et al., 1991). A map of this vector is shown in FIG. 39.

E. coli JM83 was transformed 49 times with each of the vectors and stored as glycerol stock. Between 4 and 6 clones were tested simultaneously, always including the clone H3κ2, which was used as internal control throughout. As additional control, the McPC603 scFv fragment (Knappik & Plückthun, 1995) in pBS13 was expressed under identical conditions. Two days before the expression test was performed, the clones were cultivated on LB plates containing 30 μg/ml chloramphenicol and 60 mM glucose. Using this plates an 3 ml culture (LB medium containing 90 μg chloramphenicol and 60 mM glucose) was inoculated overnight at 37° C. Next day the overnight culture was used to inoculate 30 ml LB medium containing chloramphenicol (30 μg/ml). The starting OD_(600nm) was adjusted to 0.2 and a growth temperature of 30° C. was used. The physiology of the cells was monitored by measuring every 30 minutes for 8 to 9 hours the optical density at 600 nm. After the culture reached an OD_(600nm) of 0.5, antibody expression was induced by adding IPTG to a final concentration of 1 mM. A 5 ml aliquot of the culture was removed after 2 h of induction in order to analyze the antibody expression. The cells were lysed and the soluble and insoluble fractions of the crude extract were separated as described in Knappik & Plückthun, 1995. The fractions were assayed by reducing SDS-PAGE with the samples normalized to identical optical densities. After blotting and immunostaining using the α-FLAG antibody M1 as the first antibody (see Ge et al., 1994) and an Fc-specific anti-mouse antiserum conjugated to alkaline phosphatase as the second antibody, the lanes were scanned and the intensities of the bands of the expected size (appr. 30 kDa) were quantified densitometrically and tabulated relative to the control antibody (see FIG. 40).

Example 7 Optimization of Fluorescein Binders

7.1. Construction of L-CR3 and H-CDR2 Library Cassettes

A L-CDR3 library cassette was prepared from the oligonucleotide (SEQ ID NO: 9) template CDR3L (5′-TGGAAGCTGAAGACGTGGGCGTGTATTATTGCCAGCAG(TR5)(TRI)₄CCG(TRI)TTTGGCCAGGGTACGAAAGTT-3′) and primer (SEQ ID NO: 10) 5′-AATTTCGTACCCTGGCC-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (TR5) comprised a trinucleotide mixture representing the 5 codons for Ala, Arg, His, Ser. and Tyr.

A H-CDR2 library cassette was prepared from the oligonucleotide template CDRsH (SEQ ID NOS 11 & 12, respectvely) (5′-AGGGTCTCGAGTGGGTGAGC(TRI)ATT(TRI)₂₋₃(6)₂(TRI)ACC(TRI)TATGCGGATAGCGTGAAAGGCCGTTTTACCATTTCACGTGATMTTCGAAAAACACCA-3′), and primer (SEQ ID NO: 13) 5′-TGGTGTTTTTCGMTTATCA-3′ for synthesis of the complementary strand, where (TRI) was a trinucleotide mixture representing all amino acids except Cys, (6) comprised the incorporation of (ANG) (A/C/G) T, resulting in the formation of 6 codons for Ala, Asn, Asp, Gly, Ser, and Thr, and the length distribution being obtained by performing one substoichiometric coupling of the (TRI) mixture during synthesis, omitting the capping step normally used in DNA synthesis.

DNA synthesis was performed on a 40 nmole scale, oligos were dissolved in TE buffer, purified via gel filtration using spin columns (S-200), and the DNA concentration determined by OD measurement at 260 nm (OD 1.0=40 μg/ml). 10 nmole of the oligonucleotide templates and 12 nmole of the corresponding primers were mixed and annealed at 80° C. for 1 min, and slowly cooled down to 37° C. within 20 to 30 min. The fill-in reaction was performed for 2 h at 37° C. using Klenow polymerase (2.0 μl) and 250 nmole of each dNTP. The excess of dNTPs was removed by gel filtration using Nick-Spin columns (Pharmacia), and the double-stranded DNA digested with BbsI/MscI (L-CDR3), or XhoI/SfuI (H-CDR2) over night at 37° C. The cassettes were purified via Nick-Spin columns (Pharmacia), the concentration determined by OD measurement, and the cassettes aliquoted (15 pmole) for being stored at −80° C.

7.2 Library Cloning:

DNA was prepared from the collection of FITC binding clones obtained in Example 2 (approx. 10⁴ to clones). The collection of scFv fragments was isolated via XbaI/EcoRI digest. The vector pCAL4 (100 fmole, 10 μg) described in Example 4.3 was similarly digested with XbaI/EcoRI, gel-purified and ligated with 300 fmole of the scFv fragment collection over night at 16° C. The ligation mixture was isopropanol precipitated, air-dried, and the pellets were redissolved in 100 μl of dd H₂O. The ligation mixture was mixed with 1 ml of freshly prepared electrocompetent SCS 101 cells (for optimization of L-CDR3), or XL1 Blue cells (for optimization of H-CDR2) on ice. One round of electroporation was performed and the transformants were eluted in SOC medium, shaken at 37° C. for 30 minutes, and an aliquot plated out on LB plates (Amp/Tet/Glucose) at 37° C. for 6-9 hrs. The number of transformants was 5×10⁴.

Vector DNA (100 μg) was isolated and digested (sequence and restriction map of scH3κ2 see FIG. 8) with BbsI/MscI for optimization of L-CDR3, or XhoI/NspV for optimization of H-CDR2, 10 μg of purified vector fragments (5 pmole) were ligated with 15 pmole of the L-CDR3 or H-CDR2 library cassettes over night at 16° C. The ligation mixtures were isopropanol precipitated, air-dried, and the pellets were redissolved in 100 μl of dd H₂O. The ligation mixtures were mixed with 1 ml of freshly prepared electrocompetent XL1 Blue cells on ice. Electroporation was performed and the transformants were eluted in SOC medium and shaken at 37° C. for 30 minutes. An aliquot was plated out on LB plates (Amp/Tet/Glucose) al 37° C. for 6-9 hrs. The number of transformants (library size) was greater than 10⁸ for both libraries. The libraries were stored as glycerol cultures.

7.3. Biopanning

This was performed as described for the initial H3κ2 H-CDR3 library in Example 2.1. Optimized scFvs binding to FITC could be characterized and analyzed as described in Example 2.2 and 2.3, and further rounds of optimization could be made if necessary.

REFERENCES

Barbas III, C. F., Bain, J. D., Hoekstra, D. M. & Lerner, R. A., PNAS 89, 4457-4461 (1992).

Better, M., Chang, P., Robinson, R. & Horwitz, A. H., Science 240, 1041-1043 (1988).

Blake. M. S., Johnston, K. H., Russel-Jones, G. J. & Gotschlich, E. C., Anal. Biochem. 136, 175-179 (1984).

Carter, P., Kelly, R. F., Rodrigues, M. L., Snedecor, B., Covrrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts. C. E., Carver, M. E., Yang, M., Bourell, J. H., Shepard, H. M. & Henner, D., Bio/Technology 10, 163-167 (1992).

Chothia, C. & Lesk, A. M., J. Biol. Chem. 196, 910-917 (1987).

Chothia, C., Lesk, A. M., Gherardi, E., Tomlinson, I. A., Walter, G., Marks, J. D., Liewelyn, M. B. & Winter, G., J. Mol. Biol. 227, 799-817 (1992).

Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A., Davies, D., Tulip, W. R., Colman, P. M., Spinelli, S., Alzari, P. M. & Poljak, R. J., Nature 342, 877-883 (1989).

Chuchana, P., Blancher, A., Brockly, F., Alexandre, D., Lefranc, G & Lefranc, M.-P., Eur. J. Immunol. 20, 1317-1325 (1990).

Cox, J. P. L., Tomlinson, I. M. & Winier, G., Eur. J. Immunol. 24, 827-836 (1994).

Ge, L., Knappik, A., Pack, P., Freund, C. & Plückthun, A., In: Antibody Engineering. Borrebaeck, C. A. K. (Ed.). p.229-266 (1995), Oxford University Press, New York, Oxford.)

Gill, S. C. &von Hippel, P. H., Anal. Biochem. 182, 319.326 (1989).

Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. & Stüber, D., Bio/Technology 6, 1321-1325 (1988).

Hopp, T. P., Prickett, K. S., Price, V. L., Libby, R. T., March. C. J., Cerretti, D. P., Urdal, D. L. & Conlon, P. J. Bio/Technology 6, 1204-1210 (1988).

Kabat, E. A., Wu, T. T., Perry, H. M., Gottesmann, K. S. & Foeller, C., Sequences of proteins of immunological interest, NIH publication 91-3242 (1991).

Knappik, A. & Plückthun, A., Biotechniques 17, 754-761 (1994).

Knappik, A. & Plückthun, A., Protein Engineering 8, 81-89 (1995).

Kunkel, T. A. Bebenek, K. & McClary, J., Methods in Enzymol. 204, 125-39 (1991).

Lindner, P., Guth, B., Wülfing, C., Krebber, C., Steipe, B., Müller, F. & Plückthun, A., Methods: A Companion to Methods Enzymol. 4, 41-56 (1992).

Lowman, H. B., Bass, S. H., Simpson, N. and Wells, J. A., Biochemistry 30, 10832-10838 (1991).

Pack, P. & Plückthun, A., Biochemistry 31, 1579-1584 (1992).

Pack, P., Kujau, M., Schroeckh, V., Knüpfer, U., Wenderoth, R., Riesenberg D. & Plückthun, A., Bio/Technology 11, 1271-1277 (1993).

Pack, P., Ph.D. thesis, Ludwig-Maximilians-Universität München (1994).

Perlak, F. J., Nuc. Acids Res. 18, 7457-7458 (1990).

Plückthun, A., Krebber, A., Krebber, C., Horn, U., Knüpfer, U., Wenderoth, R., Nieba, L., Proba, K. & Riesenberg, D., A practical approach. Antibody Engineering (Ed. J. McCafferty). IRL Press, Oxford, pp. 203-252 (1996).

Prodromou, C. & Pearl, L. H., Protein Engineering 5, 827-829 (1992).

Rosenberg, S. A. & Lotze, M. T., Ann. Rev. Immunol. 4, 681-709 (1986).

Skerra, A. & Plückthun, A., Science 240, 1038-1041 (1988).

Skerra, A., Pfitzinger, I. & Plückthun, A., Bio/Technology 9, 273-278 (1991).

Sutherland, L., Davidson, J., Glass, L. L., & Jacobs, H. T., BioTechniques 18, 458-464, 1995.

Tomlinson, I. M., Walter, G., Marks, J. D., Llewelyn, M. B. & Winter, G., J. Mol. Biol. 227, 776-798 (1992).

Ullrich, H. D., Patten, P. A., Yang, P. L., Romesberg, F. E. & Schultz, P. G., Proc. Natl. Acad. Sci. USA 92, 11907-11911 (1995).

Van Dijk, K. W., Mortari, F., Kirkham, P. M., Schroeder Jr., H. W. & Milner, E. C. B., Eur. J. Immunol. 23, 832-839 (1993).

Virnekäs, B., Ge, L., Plückthun, A., Schneider, K. C., Wellnhofer, G. & Moroney, S. E., Nucleic Acids Research 22, 5600-5607 (1994).

Vitetta, E. S., Thorpe. P. E. & Uhr, J., Immunol. Today 14, 253-259 (1993).

Williams, S. C. & Winter, G., Eur. J. Immunol. 23, 1456-1461 (1993).

Winter, G., Griffiths, A. D., Hawkins, R. E. & Hoogenboom, H. R., Ann. Rev. Immunol. 12, 433-455 (1994).

TABLE 1A Human kappa germline gene segments Used Name¹ Reference² Family³ Germline genes⁴ Vk1-1 9 1 O8; O18; DPK1 Vk1-2 1 1 L14; DPK2 Vk1-3 2 1 L15(1); HK101; HK146; HK189 Vk1-4 9 1 L11 Vk1-5 2 1 A30 Vk1-6 1 1 LFVK5 Vk1-7 1 1 LFVK431 Vk1-8 1 1 L1; HK137 Vk1-9 1 1 A20; DPK4 Vk1-10 1 1 L18; Va″ Vk1-11 1 1 L4; L18; Va′; V4a Vk1-12 2 1 L5; L19(1); Vb; Vb4; DPK5; L19(2); Vb″; DPK6 Vk1-13 2 1 L15(2); HK134; HK166; DPK7 Vk1-14 8 1 L8; Vd; DPK8 Vk1-15 8 1 L9; Ve Vk1-16 1 1 L12(1); HK102; V1 Vk1-17 2 1 L12(2) Vk1-18 1 1 O12a(V3b) Vk1-19 6 1 O2; O12; DPK9 Vk1-20 2 1 L24; Ve″; V13; DPK10 Vk1-21 1 1 O4; O14 Vk1-22 2 1 L22 Vk1-23 2 1 L23 Vk2-1 1 2 A2; DPK12 Vk2-2 6 2 O1; O11(1); DPK13 Vk2-3 6 2 O12(2); V3a Vk2-4 2 2 L13 Vk2-5 1 2 DPK14 Vk2-6 4 2 A3; A19; DPK15 Vk2-7 4 2 A29; DPK27 Vk2-8 4 2 A13 Vk2-9 1 2 A23 Vk2-10 4 2 A7; DPK17 Vk2-11 4 2 A17; DPK18 Vk2-12 4 2 A1; DPK19 Vk3-1 11 3 A11; humkv305; DPK20 Vk3-2 1 3 L20; Vg″ Vk3-3 2 3 L2; L16; humkv328; humkv328h2; humkv328h5; DPK21 Vk3-4 11 3 A27; humkv325; VkRF; DPK22 Vk3-5 2 3 L25; DPK23 Vk3-6 2 3 L10(1) Vk3-7 7 3 L10(2) Vk3-8 7 3 L6; Vg Vk4-1 3 4 B3; VkIV; DPK24 Vk5-1 10 5 B2; EV15 Vk6-1 12 6 A14; DPK25 Vk6-2 12 6 A10; A26; DPK26 Vk7-1 5 7 B1

TABLE 1B Human lambda germline gene segments Used Name¹ Reference² Family³ Germline genes⁴ DPL1 1 1 DPL2 1 1 HUMLV1L1 DPL3 1 1 HUMLV122 DPL4 1 1 VLAMBDA 1.1 HUMLV117 2 1 DPL5 1 1 HUMLV117D DPL6 1 1 DPL7 1 1 IGLV1S2 DPL8 1 1 HUMLV1042 DPL9 1 1 HUMLV101 DPL10 1 2 VLAMBDA 2.1 3 2 DPL11 1 2 DPL12 1 2 DPL13 1 2 DPL14 1 2 DPL16 1 3 Humlv418; IGLV351 DPL23 1 3 VI III.1 Humlv318 4 3 DPL18 1 7 4A; HUMIGLVA DPL19 1 7 DPL21 1 8 VL8.1 HUMLV801 5 8 DPL22 1 9 DPL24 1 unassigned VLAMBDA N.2 gVLX-4.4 6 10 

TABLE 1C Human heavy chain germline gene segments Used Name¹ Reference² Family³ Germline genes⁴ VH1-12-1 19 1 DP10; DA-2; DA-6 VH1-12-8 22 1 RR.VH1:2 VH1-12-2 6 1 hv1263 VH1-12-9 7 1 YAC-7; RR.VH1.1; 1-69 VH1-12-3 19 1 DP3 VH1-12-4 19 1 DP21; 4d275a; VH7a VH1-12-5 18 1 I-4.1b; V1-4.1b VH1-12-6 21 1 1D37; VH7b; 7-81; YAC-10 VH1-12-7 19 1 DP14; VH1GRR; V1-18 VH1-13-1 10 1 71-5; DP2 VH1-13-2 10 1 E3-10 VH1-13-3 19 1 DP1 VH1-13-4 12 1 V35 VH1-13-5 8 1 V1-2b VH1-13-6 18 1 I-2; DP75 VH1-13-7 21 1 V1-2 VH1-13-8 19 1 DP8 VH1-13-9 3 1 1-1 VH1-13-10 19 1 DP12 VH1-13-11 15 1 V13C VH1-13-12 18 1 I-3b; DP25; V1-3b VH1-13-13 3 1 1-92 VH1-13-14 18 1 I-3; V1-3 VH1-13-15 19 1 DP15; V1-8 VH1-13-16 3 1 21-2; 3-1; DP7; V1-46 VH1-13-17 16 1 HG3 VH1-13-18 19 1 DP4; 7-2; V1-45 VH1-13-19 27 1 COS 5 VH1-1X-1 19 1 DP5; 1-24P VH2-21-1 18 2 II-5b VH2-31-1 2 2 VH2S12-1 VH2-31-2 2 2 VH2S12-7 VH2-31-3 2 2 VH2S12-9; DP27 VH2-31-4 2 2 VH2S12-10 VH2-31-5 14 2 V2-26; DP26; 2-26 VH2-31-6 15 2 VF2-26 VH2-31-7 19 2 DP28; DA-7 VH2-31-14 7 2 YAC-3; 2-70 VH2-31-8 2 2 VH2S12-5 VH2-31-9 2 2 VH2S12-12 VH2-31-10 18 2 II-5; V2-5 VH2-31-11 2 2 VH2S12-2; VH2S12-8 VH2-31-12 2 2 VH2S12-4; VH2S12-6 VH2-31-13 2 2 VH2S12-14 VH3-11-1 13 3 v65-2; DP44 VH3-11-2 19 3 DP45 VH3-11-3 3 3 13-2; DP48 VH3-11-4 19 3 DP52 VH3-11-5 14 3 v3-13 VH3-11-6 19 3 DP42 VH3-11-7 3 3 8-1B; YAC-5; 3-66 VH3-11-8 14 3 V3-53 VH3-13-1 3 3 22-2B; DP35; V3-11 VH3-13-5 19 3 DP59; VH19; V3-35 VH3-13-6 25 3 f1-p1; DP61 VH3-13-7 19 3 DP46; GL-SJ2; COS 8; hv3005; hv3005f3; 3d21b; 56p1 VH3-13-8 24 3 VH26 VH3-13-9 5 3 vh26c VH3-13-10 19 3 DP47; VH26; 3-23 VH3-13-11 3 3 1-91 VH3-13-12 19 3 DP58 VH3-13-13 3 3 1-9III; DP49; 3-30; 3d28.1 VH3-13-14 24 3 3019B9; DP50; 3-33; 3d277 VH3-13-15 27 3 COS 3 VH3-13-16 19 3 DP51 VH3-13-17 16 3 H11 VH3-13-18 19 3 DP53; COS 6; 3-74; DA-8 VH3-13-19 19 3 DP54; VH3-11; V3-7 VH3-13-20 14 3 V3-64; YAC-6 VH3-13-21 14 3 V3-48 VH3-13-22 14 3 V3-43; DP33 VH3-13-23 14 3 V3-33 VH3-13-24 14 3 V3-21; DP77 VH3-13-25 14 3 V3-20; DP32 VH3-13-26 14 3 V3-9; DP31 VH3-14-1 3 3 12-2; DP29; 3-72; DA-3 VH3-14-4 7 3 YAC-9; 3-73; MTGL VH3-14-2 4 3 VHD26 VH3-14-3 19 3 DP30 VH3-1X-1 1 3 LSG8.1; LSG9.1; LSG10.1; HUM12IGVH; HUM13IGVH VH3-1X-2 1 3 LSG11.1; HUM4IGVH VH3-1X-3 3 3 9-1; DP38; LSG7.1; RCG1.1; LSG1.1; LSG3.1; LSG5.1; HUM15IGVH; HUM2IGVH; HUM9IGVH VH3-1X-4 1 3 LSG4.1 VH3-1X-5 1 3 LSG2.1 VH3-1X-6 1 3 LSG6.1; HUM10IGVH VH3-1X-7 18 3 3-15; V3-15 VH3-1X-8 1 3 LSG12.1; HUM5IGVH VH3-1X-9 14 3 V3-49 VH4-11-1 22 4 Tou-VH4.21 VH4-11-2 17 4 VH4.21; DP63; VH5; 4d76; V4-34 VH4-11-3 23 4 4.44 VH4-11-4 23 4 4.44.3 VH4-11-5 23 4 4.36 VH4-11-6 23 4 4.37 VH4-11-7 18 4 IV-4; 4.35; V4-4 VH4-11-8 17 4 VH4.11; 3d197d; DP71; 58p2 VH4-11-9 20 4 H7 VH4-11-10 20 4 H8 VH4-11-11 20 4 H9 VH4-11-12 17 4 VH4.16 VH4-11-13 23 4 4.38 VH4-11-14 17 4 VH4.15 VH4-11-15 11 4 58 VH4-11-16 10 4 71-4; V4-59 VH4-21-1 11 4 11 VH4-21-2 17 4 VH4.17; VH4.23; 4d255; 4.40; DP69 VH4-21-3 17 4 VH4.19; 79; V4-4b VH4-21-4 19 4 DP70; 4d68; 4.41 VH4-21-5 19 4 DP67; VH4-4B VH4-21-6 17 4 VH4.22; VHSP; VH-JA VH4-21-7 17 4 VH4.13; 1-9II; 12G-1; 3d28d; 4.42; DP68; 4-28 VH4-21-8 26 4 hv4005; 3d24d VH4-21-9 17 4 VH4.14 VH4-31-1 23 4 4.34; 3d230d; DP78 VH4-31-2 23 4 4.34.2 VH4-31-3 19 4 DP64; 3d216d VH4-31-4 19 4 DP65; 4-31; 3d277d VH4-31-5 23 4 4.33; 3d75d VH4-31-6 20 4 H10 VH4-31-7 20 4 H11 VH4-31-8 23 4 4.31 VH4-31-9 23 4 4.32 VH4-31-10 20 4 3d277d VH4-31-11 20 4 3d216d VH4-31-12 20 4 3d279d VH4-31-13 17 4 VH4.18; 4d154; DP79 VH4-31-14 8 4 V4-39 VH4-31-15 11 4 2-1; DP79 VH4-31-16 23 4 4.30 VH4-31-17 17 4 VH4.12 VH4-31-18 10 4 71-2; DP66 VH4-31-19 23 4 4.39 VH4-31-20 8 4 V4-61 VH5-12-1 9 5 VH251; DP73; VHVCW; 51-R1; VHVLB; VHVCH; VHVTT; VHVAU; VHVBLK; VhAU; V5-51 VH5-12-2 17 5 VHVJB VH5-12-3 3 5 1-v; DP80; 5-78 VH5-12-4 9 5 VH32; VHVRG; VHVMW; 5-2R1 VH6-35-1 4 6 VHVI; VH6; VHVIIS; VHVITE; VHVIJB; VHVICH; VHVICW; VHVIBLK; VHVIMW; DP74; 6-1G1; V6-1

TABLE 2A rearranged human kappa sequences Com- Germ- Diff. to % diff. puted line germ- to germ- Refer- Name¹ aa² family³ gene⁴ line⁵ line⁶ ence⁷ III-3R 108 1 08 1 1.1% 70 No. 86 109 1 O8 3 3.2% 80 AU 108 1 O8 6 6.3% 103 ROY 108 1 O8 6 6.3% 43 ICA 108 1 O8 6 6.3% 70 HIV-B26 106 1 O8 3 3.2% 8 GRI 108 1 O8 8 8.4% 30 AG 106 1 O8 8 8.6% 116 REI 108 1 O8 9 9.5% 86 CLL PATIENT 88 1 O8 2 2.3% 122 16 CLL PATIENT 87 1 O8 2 2.3% 122 14 CLL PATIENT 88 1 O8 2 2.3% 122 15 GM4672 108 1 O8 11 11.6% 24 HUM. 108 1 O8 12 12.6% 110 YFC51.1 LAY 108 1 O8 12 12.6% 48 HIV-b13 106 1 O8 9 9.7% 8 MAL-NaCl 108 1 O8 13 13.7% 102 STRAb SA-1A 108 1 O2 0 0.0% 120 HuVHCAMP 108 1 O8 13 13.7% 100 CRO 108 1 O2 10 10.5% 30 Am 107 108 1 O2 12 12.6% 108 WALKER 107 1 O2 4 4.2% 57 III-2R 109 1 A20 0 0.0% 70 FOG1-A4 107 1 A20 4 4.2% 41 HK137 95 1 L1 0 0.0% 10 CEA4-8A 107 1 O2 7 7.4% 41 Va′ 95 1 L4 0 0.0% 90 TR1.21 108 1 O2 4 4.2% 92 HAU 108 1 O2 6 6.3% 123 HK102 95 1 L12(1) 0 0.0% 9 H20C3K 108 1 L12(2) 3 3.2% 125 CHEB 108 1 O2 7 7.4% 5 HK134 95 1 L15(2) 0 0.0% 10 TEL9 108 1 O2 9 9.5% 73 TR1.32 103 1 O2 3 3.2% 92 RF-KES1 97 1 A20 4 4.2% 121 WES 108 1 L5 10 10.5% 61 DILp1 95 1 O4 1 1.1% 70 SA-4B 107 1 L12(2) 8 8.4% 120 HK101 95 1 L15(1) 0 0.0% 9 TR1.23 108 1 O2 5 5.3% 92 HF2-1/17 108 1 A30 0 0.0% 4 2E7 108 1 A30 1 1.1% 62 33.C9 107 1 L12(2) 7 7.4% 126 3D6 105 1 L12(2) 2 2.1% 34 I-2a 108 1 L8 8 8.4% 70 RF-KL1 97 1 L8 4 4.2% 121 TNF-E7 108 1 A30 9 9.5% 41 TR1.22 108 1 O2 7 7.4% 92 HIV-B35 106 1 O2 2 2.2% 8 HIV-b22 106 1 O2 2 2.2% 8 HIV-b27 106 1 O2 2 2.2% 8 HIV-B8 107 1 O2 10 10.8% 8 HIV-b8 107 1 O2 10 10.8% 8 RF-SJ5 95 1 A30 5 5.3% 113 GAL(I) 108 1 A30 6 6.3% 64 R3.5H5G 108 1 O2 6 6.3% 70 HIV-b14 106 1 A20 2 2.2% 8 TNF-E1 105 1 L5 8 8.4% 41 WEA 108 1 A30 8 8.4% 37 EU 108 1 L12(2) 5 5.3% 40 FOG1-G8 108 1 L8 11 11.6% 41 1X7RG1 108 1 L1 8 8.4% 70 BLI 108 1 L8 3 3.2% 72 KUE 108 1 L12(2) 11 11.6% 32 LUNm01 108 1 L12(2) 10 10.5% 6 HIV-b1 106 1 A20 4 4.3% 8 HIV-s4 103 1 O2 2 2.2% 8 CAR 107 1 L12(2) 11 11.7% 79 BR 107 1 L12(2) 11 11.6% 50 CLL PATIENT 88 1 O2 0 0.0% 122 10 CLL PATIENT 88 1 O2 0 0.0% 122 12 KING 108 1 L12(2) 12 12.6% 30 V13 95 1 L24 0 0.0% 46 CLL PATIENT 87 1 O2 0 0.0% 122 11 CLL PATIENT 87 1 O2 0 0.0% 122 13 CLL PATIENT 88 1 O12 1 1.1% 122 9 HIV-B2 106 1 A20 9 9.7% 8 HIV-b2 106 1 A20 9 9.7% 8 CLL PATIENT 88 1 A20 1 1.1% 122 5 CLL PATIENT 88 1 L8 2 2.3% 122 1 CLL PATIENT 88 1 L8 0 0.0% 122 2 CLL PATIENT 88 1 L5 0 0.0% 122 7 CLL PATIENT 88 1 L5 0 0.0% 122 8 HIV-b5 105 1 L5 11 12.0% 8 CLL PATIENT 87 1 L8 1 1.1% 122 3 CLL PATIENT 88 1 L9 0 0.0% 122 4 CLL PATIENT 85 1 L9 6 7.1% 122 18 CLL PATIENT 86 1 L12(2) 7 8.1% 122 17 HIV-b20 107 3 A27 11 11.7% 8 2C12 108 1 L12(2) 20 21.1% 68 1B11 108 1 L12(2) 20 21.1% 68 1H1 108 1 L12(2) 21 22.1% 68 2A12 108 1 L12(2) 21 22.1% 68 CUR 109 3 A27 0 0.0% 66 GLO 109 3 A27 0 0.0% 16 RF-TS1 96 3 A27 0 0.0% 121 GAR′ 109 3 A27 0 0.0% 67 FLO 109 3 A27 0 0.0% 66 PIE 109 3 A27 0 0.0% 91 HAH 14.1 109 3 A27 1 1.0% 51 HAH 14.2 109 3 A27 1 1.0% 51 HAH 16.1 109 3 A27 1 1.0% 51 NOV 109 3 A27 1 1.0% 52 33.F12 108 3 A27 1 1.0% 126 BE10 110 3 A27 1 1.0% 25 TH3 109 3 A27 1 1.0% 25 HIC(R) 108 3 A27 0 0.0% 51 SON 110 3 A27 1 1.0% 67 PAY 109 3 A27 1 1.0% 66 GOT 109 3 A27 1 1.0% 67 mAbA6H4C5 109 3 A27 1 1.0% 12 BOR′ 109 3 A27 2 2.1% 84 RF-SJ3 96 3 A27 2 2.1% 121 SIE 109 3 A27 2 2.1% 15 ESC 109 3 A27 2 2.1% 98 HEW′ 110 3 A27 2 2.1% 98 YES8c 109 3 A27 3 3.1% 33 TI 109 3 A27 3 3.1% 114 mAb113 109 3 A27 3 3.1% 71 HEW 107 3 A27 0 0.0% 94 BRO 106 3 A27 0 0.0% 94 ROB 106 3 A27 0 0.0% 94 NG9 96 3 A27 4 4.2% 11 NEU 109 3 A27 4 4.2% 66 WOL 109 3 A27 4 4.2% 2 35G6 109 3 A27 4 4.2% 59 RF-SJ4 109 3 A11 0 0.0% 88 KAS 109 3 A27 4 4.2% 84 BRA 106 3 A27 1 1.1% 94 HAH 106 3 A27 1 1.1% 94 HIC 105 3 A27 0 0.0% 94 FS-2 109 3 A27 6 6.3% 87 JH′ 107 3 A27 6 6.3% 38 EV1-15 109 3 A27 6 6.3% 83 SCA 108 3 A27 6 6.3% 65 mAb112 109 3 A27 6 6.3% 71 SIC 103 3 A27 3 3.3% 94 5A-4A 109 3 A27 6 6.3% 120 SER 108 3 A27 6 6.3% 98 GOL′ 109 3 A27 7 7.3% 82 B5G10K 105 3 A27 9 9.7% 125 HG2B10K 110 3 A27 9 9.4% 125 Taykv322 105 3 A27 5 5.4% 52 CLL PATIENT 89 3 A27 1 1.1% 122 24 HIV-b24 107 3 A27 7 7.4% 8 HIV-b6 107 3 A27 7 7.4% 8 Taykv310 99 3 A27 1 1.1% 52 KA3D1 108 3 L6 0 0.0% 85 19.E7 107 3 L6 0 0.0% 126 rsv6L 109 3 A27 12 12.5% 7 Taykv320 98 3 A27 1 1.2% 52 Vh 96 3 L10(2) 0 0.0% 89 LS8 108 3 L6 1 1.1% 109 LS1 108 3 L6 1 1.1% 109 LS2S3-3 107 3 L6 2 2.1% 99 LS2 108 3 L6 1 1.1% 109 LS7 108 3 L6 1 1.1% 109 LS2S3-4d 107 3 L6 2 2.1% 99 LS2S3-4a 107 3 L6 2 2.1% 99 LS4 108 3 L6 1 1.1% 109 LS6 108 3 L6 1 1.1% 109 LS2S3-10a 107 3 L6 2 2.1% 99 LS2S3-8c 107 3 L6 2 2.1% 99 LS5 108 3 L6 1 1.1% 109 LS2S3-5 107 3 L6 3 3.2% 99 LUNm03 109 3 A27 13 13.5% 6 IARC/BL41 108 3 A27 13 13.7% 55 slkv2Z 99 3 A27 3 3.5% 13 POP 108 3 L6 4 4.2% 111 LS2S3-10b 107 3 L6 3 3.2% 99 LS2S3-8f 107 3 L6 3 3.2% 99 LS2S3-12 107 3 L6 3 3.2% 99 HIV-B30 107 3 A27 11 11.7% 8 HIV-B20 107 3 A27 11 11.7% 8 HIV-b3 108 3 A27 11 11.7% 8 HIV-s6 104 3 A27 9 9.9% 8 YSE 107 3 L2/L16 1 1.1% 72 POM 109 3 L2/L16 9 9.4% 53 Humkv328 95 3 L2/L16 1 1.1% 19 CLL 109 3 L2/L16 3 3.2% 47 LES 96 3 L2/L16 3 3.2% 38 HIV-s5 104 3 A27 11 12.1% 8 HIV-s7 104 3 A27 11 12.1% 8 slkv1 99 3 A27 7 8.1% 13 Humka31es 95 3 L2/L16 4 4.2% 18 slkv12 101 3 A27 8 9.2% 13 RF-TS2 95 3 L2/L16 3 3.2% 121 II-1 109 3 L2/L16 4 4.2% 70 HIV-s3 105 3 A27 13 14.3% 8 RF-TMC1 96 3 L6 10 10.5% 121 GER 109 3 L2/L16 7 7.4% 75 GF4/1.1 109 3 L2/L16 8 8.4% 36 mAb114 109 3 L2/L16 6 6.3% 71 HIV-loop13 109 3 L2/L16 7 7.4% 8 bkv16 86 3 L6 1 1.2% 13 CLL PATIENT 86 3 L6 1 1.2% 122 29 slkv9 98 3 L6 3 3.5% 13 bkv17 99 3 L6 1 1.2% 13 slkv14 99 3 L6 1 1.2% 13 slkv16 101 3 L6 2 2.3% 13 bkv33 101 3 L6 4 4.7% 13 slkv15 99 3 L6 2 2.3% 13 bkv6 100 3 L6 3 3.5% 13 R688K 108 3 L2/L16 12 12.6% 125 AL 700 107 3 L2/L16 9 9.5% 117 slkv11 100 3 L2/L16 3 3.5% 13 slkv4 97 3 L6 4 4.8% 13 CLL PATIENT 87 3 L2/L16 1 1.1% 122 26 AL Se124 103 3 L2/L16 9 9.5% 117 slkv13 100 3 L2/L16 6 7.0% 13 bkv7 100 3 L2/L16 5 5.8% 13 bkv22 100 3 L2/L16 6 7.0% 13 CLL PATIENT 84 3 L2/L16 0 0.0% 122 27 bkv35 100 3 L6 8 9.3% 13 CLL PATIENT 87 3 L2/L16 4 4.6% 122 25 slkv3 86 3 L2/L16 7 8.1% 13 slkv7 99 1 O2 7 8.1% 13 HuFd79 111 3 L2/L16 24 24.2% 21 RAD 99 3 A27 9 10.3% 78 CLL PATIENT 83 3 L2/L16 4 4.8% 122 28 REE 104 3 L2/L16 25 27.2% 95 FR4 99 3 A27 8 9.2% 77 MD3.3 92 3 L6 1 1.3% 54 MD3.1 92 3 L6 0 0.0% 54 GA3.6 92 3 L6 2 2.6% 54 M3.5N 92 3 L6 3 3.8% 54 WEI′ 82 3 A27 0 0.0% 65 MD3.4 92 3 L2/L16 1 1.3% 54 MD3.2 91 3 L6 3 3.8% 54 VER 97 3 A27 19 22.4% 20 CLL PATIENT 78 3 L6 3 3.8% 122 30 M3.1N 92 3 L2/L16 1 1.3% 54 MD3.6 91 3 L2/L16 0 0.0% 54 MD3.8 91 3 L2/L16 0 0.0% 54 GA3.4 92 3 L6 7 9.0% 54 M3.6N 92 3 A27 0 0.0% 54 MD3.10 92 3 A27 0 0.0% 54 MD3.13 91 3 A27 0 0.0% 54 MD3.7 93 3 A27 0 0.0% 54 MD3.9 93 3 A27 0 0.0% 54 GA3.1 93 3 A27 6 7.6% 54 bkv32 101 3 A27 5 5.7% 13 GA3.5 93 3 A27 5 6.3% 54 GA3.7 92 3 A27 7 8.9% 54 MD3.12 92 3 A27 2 2.5% 54 M3.2N 90 3 L6 6 7.8% 54 MD3.5 92 3 A27 1 1.3% 54 M3.4N 91 3 L2/L16 8 10.3% 54 M3.8N 91 3 L2/L16 7 9.0% 54 M3.7N 92 3 A27 3 3.8% 54 GA3.2 92 3 A27 9 11.4% 54 GA3.8 93 3 A27 4 5.1% 54 GA3.3 92 3 A27 8 10.1% 54 M3.3N 92 3 A27 5 6.3% 54 B6 83 3 A27 8 11.3% 78 E29.1 KAPPA 78 3 L2/L16 0 0.0% 22 SCW 108 1 O8 12 12.6% 31 REI-based 107 1 08 14 14.7% 39 CAMPATH-9 RZ 107 1 O8 14 14.7% 50 BI 108 1 O8 14 14.7% 14 AND 107 1 O2 13 13.7% 69 2A4 109 1 O2 12 12.6% 23 KA 108 1 O8 19 20.0% 107 MEV 109 1 O2 14 14.7% 29 DEE 106 1 O2 13 14.0% 76 OU(IOC) 108 1 O2 18 18.9% 60 HuRSV19VK 111 1 O8 21 21.0% 115 SP2 108 1 O2 17 17.9% 93 BJ26 99 1 O8 21 24.1% 1 N1 112 1 O8 24 24.2% 106 BMA 106 1 L12(1) 21 22.3% 105 0310EUCIV2 CLL PATIENT 71 1 A20 0 0.0% 122 6 BJ19 85 1 O8 16 21.9% 1 GM 607 113 2 A3 0 0.0% 58 R5A3K 114 2 A3 1 1.0% 125 R1C8K 114 2 A3 1 1.0% 125 VK2.R149 113 2 A3 2 2.0% 118 TR1.6 109 2 A3 4 4.0% 92 TR1.37 104 2 A3 5 5.0% 92 FS-1 113 2 A3 6 6.0% 87 TR1.8 110 2 A3 6 6.0% 92 NIM 113 2 A3 8 8.0% 28 Inc 112 2 A3 11 11.0% 35 TEW 107 2 A3 6 6.4% 96 CUM 114 2 O1 7 6.9% 44 HRF1 71 2 A3 4 5.6% 124 CLL PATIENT 87 2 A3 0 0.0% 122 19 CLL PATIENT 87 2 A3 0 0.0% 122 20 MIL 112 2 A3 16 16.2% 26 FR 113 2 A3 20 20.0% 101 MAL-Urine 83 1 O2 6 8.6% 102 Taykv306 73 3 A27 1 1.6% 52 Taykv312 75 3 A27 1 1.6% 52 HIV-b29 93 3 A27 14 17.5% 8 1-185-37 110 3 A27 0 0.0% 119 1-187-29 110 3 A27 0 0.0% 119 TT117 110 3 A27 9 9.4% 63 HIV-loop8 108 3 A27 16 16.8% 8 rsv23L 108 3 A27 16 16.8% 7 HIV-b7 107 3 A27 14 14.9% 8 HIV-b11 107 3 A27 15 16.0% 8 HIV-LC1 107 3 A27 19 20.2% 8 HIV-LC7 107 3 A27 20 21.3% 8 HIV-LC22 107 3 A27 21 22.3% 8 HIV-LC13 107 3 A27 21 22.3% 8 HIV-LC3 107 3 A27 21 22.3% 8 HIV-LC5 107 3 A27 21 22.3% 8 HIV-LC28 107 3 A27 21 22.3% 8 HIV-b4 107 3 A27 22 23.4% 8 CLL PATIENT 87 3 A27 15 17.2% 122 31 HIV-loop2 108 3 L2/L16 17 17.9% 8 HIV-loop35 108 3 L2/L16 17 17.9% 8 HIV-LC11 107 3 A27 23 24.5% 8 HIV-LC24 107 3 A27 23 24.5% 8 HIV-b12 107 3 A27 24 25.5% 8 HIV-LC25 107 3 A27 24 25.5% 8 HIV-b21 107 3 A27 24 25.5% 8 HIV-LC26 107 3 A27 26 27.7% 8 G3D10k 108 1 L12(2) 12 12.6% 125 TT125 108 1 L5 8 8.4% 63 HIV-s2 103 3 A27 28 31.1% 8 265-695 108 1 L5 7 7.4% 3 2-115-19 108 1 A30 2 2.1% 119 rsv13L 107 1 O2 20 21.1% 7 HIV-b18 106 1 O2 14 15.1% 8 RF-KL5 98 3 L6 36 36.7% 97 ZM1-1 113 2 A17 7 7.0% 3 HIV-s8 103 1 O8 16 17.8% 8 K-EV15 95 5 B2 0 0.0% 112 RF-TS3 100 2 A23 0 0.0% 121 HF-21/28 111 2 A17 1 1.0% 17 RPMI6410 113 2 A17 1 1.0% 42 JC11 113 2 A17 1 1.0% 49 O-81 114 2 A17 5 5.0% 45 FK-001 113 4 B3 0 0.0% 81 CD5+.28 101 4 B3 1 1.0% 27 LEN 114 4 B3 1 1.0% 104 UC 114 4 B3 1 1.0% 111 CD5+.5 101 4 B3 1 1.0% 27 CD5+.26 101 4 B3 1 1.0% 27 CD5+.12 101 4 B3 2 2.0% 27 CD5+.23 101 4 B3 2 2.0% 27 CD5+.7 101 4 B3 2 2.0% 27 VJI 113 4 B3 3 3.0% 56 LOC 113 4 B3 3 3.0% 72 MAL 113 4 B3 3 3.0% 72 CD5+.6 101 4 B3 3 3.0% 27 H2F 113 4 B3 3 3.0% 70 PB17IV 114 4 B3 4 4.0% 74 CD5+.27 101 4 B3 4 4.0% 27 CD5+.9 101 4 B3 4 4.0% 27 CD5−.28 101 4 B3 5 5.0% 27 CD5−.26 101 4 B3 6 5.9% 27 CD5+.24 101 4 B3 6 5.9% 27 CD5+.10 101 4 B3 6 5.9% 27 CD5−.19 101 4 B3 6 5.9% 27 CD5−.18 101 4 B3 7 6.9% 27 CD5−.16 101 4 B3 8 7.9% 27 CD5−.24 101 4 B3 8 7.9% 27 CD5−.17 101 4 B3 10 9.9% 27 MD4.1 92 4 B3 0 0.0% 54 MD4.4 92 4 B3 0 0.0% 54 MD4.5 92 4 B3 0 0.0% 54 MD4.6 92 4 B3 0 0.0% 54 MD4.7 92 4 B3 0 0.0% 54 MD4.2 92 4 B3 1 1.3% 54 MD4.3 92 4 B3 5 6.3% 54 CLL PATIENT 87 2 A17 2 2.3% 122 22 CLL PATIENT 84 2 A17 2 2.4% 122 23

TABLE 2B rearranged human lambda sequences Computed Germline Diff. to % diff. to Name¹ aa² family³ gene⁴ germline⁵ germline⁶ Reference⁷ WAH 110 1 DPL3 7  7% 68 1B9/F2 112 1 DPL3 7  7% 9 DIA 112 1 DPL2 7  7% 36 mAb67  89 1 DPL3 0  0% 29 HiH2 110 1 DPL3 12 11% 3 NIG-77 112 1 DPL2 9  9% 72 OKA 112 1 DPL2 7  7% 84 KOL 112 1 DPL2 12 11% 40 T2:C5 111 1 DPL5 0  0% 6 T2:C14 110 1 DPL5 0  0% 6 PR-TS1 110 1 DPL5 0  0% 55 4G12 111 1 DPL5 1  1% 35 KIM46L 112 1 HUMLV117 0  0% 8 Fog-B 111 1 DPL5 3  3% 31 9F2L 111 1 DPL5 3  3% 79 mAb111 110 1 DPL5 3  3% 48 PHOX15 111 1 DPL5 4  4% 49 BL2 111 1 DPL5 4  4% 74 NIG-64 111 1 DPL5 4  4% 72 RF-SJ2 100 1 DPL5 6  6% 78 AL EZI 112 1 DPL5 7  7% 41 ZIM 112 1 HUMLV117 7  7% 18 RF-SJ1 100 1 DPL5 9  9% 78 IGLV1.1  98 1 DPL4 0  0% 1 NEW 112 1 HUMLV117 11 10% 42 CB-201  87 1 DPL2 1  1% 62 MEM 109 1 DPL2 6  6% 50 H210 111 2 DPL10 4  4% 45 NOV 110 2 DPL10 8  8% 25 NEI 111 2 DPL10 8  8% 24 AL MC 110 2 DPL11 6  6% 28 MES 112 2 DPL11 8  8% 84 FOG1-A3 111 2 DPL11 9  9% 27 AL NOV 112 2 DPL11 7  7% 28 HMST-1 110 2 DPL11 4  4% 82 HBW4-1 108 2 DPL12 9  9% 52 WH 110 2 DPL11 11 11% 34 11-50 110 2 DPL11 7  7% 82 HBp2 110 2 DPL12 8  8% 3 NIG-84 113 2 DPL11 12 11% 73 VIL 112 2 DPL11 9  9% 58 TRO 111 2 DPL12 10 10% 61 ES492 108 2 DPL11 15 15% 76 mAb216  89 2 DPL12 1  1% 7 BSA3 109 3 DPL16 0  0% 49 THY-29 110 3 DPL16 0  0% 27 PR-TS2 108 3 DPL16 0  0% 55 E29.1 LAMBDA 107 3 DPL16 1  1% 13 mAb63 109 3 DPL16 2  2% 29 TEL14 110 3 DPL16 6  6% 49 6H-3C4 108 3 DPL16 7  7% 39 SH 109 3 DPL16 7  7% 70 AL GIL 109 3 DPL16 8  8% 23 H6-3C4 108 3 DPL16 8  8% 83 V-lambda-2.DS 111 2 DPL11 3  3% 15 8.12 ID 110 2 DPL11 3  3% 81 DSC 111 2 DPL11 3  3% 56 PV11 110 2 DPL11 1  1% 56 33.H11 110 2 DPL11 4  4% 81 AS17 111 2 DPL11 7  7% 56 SD6 110 2 DPL11 7  7% 56 KS3 110 2 DPL11 9  9% 56 PV6 110 2 DPL12 5  5% 56 NGD9 110 2 DPL11 7  7% 56 MUC1-1 111 2 DPL11 11 10% 27 A30c 111 2 DPL10 6  6% 56 KS6 110 2 DPL12 6  6% 56 TEL13 111 2 DPL11 11 10 49 AS7 110 2 DPL12 6  6% 56 MCG 112 2 DPL12 12 11% 20 U266L 110 2 DPL12 13 12% 77 PR-SJ2 110 2 DPL12 14 13% 55 BOH 112 2 DPL12 11 10% 37 TOG 111 2 DPL11 19 18% 53 TEL16 111 2 DPL11 19 18% 49 No.13 110 2 DPL10 14 13% 52 BO 112 2 DPL12 18 17% 80 WIN 112 2 DPL12 17 16% 11 BUR 104 2 DPL12 15 15% 46 NIG-58 110 2 DPL12 20 19% 69 WEIR 112 2 DPL11 26 25% 21 THY-32 111 1 DPL8 8  8% 27 TNF-H9G1 111 1 DPL8 9  9% 27 mAb61 111 1 DPL3 1  1% 29 LV1L1  98 1 DPL2 0  0% 54 HA 113 1 DPL3 14 13% 63 LA1L1 111 1 DPL2 3  3% 54 RHE 112 1 DPL1 17 16% 22 K1B12L 113 1 DPL8 17 16% 79 LOC 113 1 DPL2 15 14% 84 NIG-51 112 1 DPL2 12 11% 67 NEWM 104 1 DPL8 23 22% 10 MD3-4 106 3 DPL23 14 13% 4 COX 112 1 DPL2 13 12% 84 HiH10 106 3 DPL23 13 12% 3 VOR 112 1 DPL2 16 15% 16 AL POL 113 1 DPL2 16 15% 57 CD4-74 111 1 DPL2 19 18% 27 AMYLOID MOL 102 3 DPL23 15 15% 30 OST577 108 3 Humlv318 10 10% 4 NIG-48 113 1 DPL3 42 40% 66 CARR 108 3 DPL23 18 17% 19 mAb60 108 3 DPL23 14 13% 29 NIG-68  99 3 DPL23 25 26% 32 KERN 107 3 DPL23 26 25% 59 ANT 106 3 DPL23 17 16% 19 LEE 110 3 DPL23 18 17% 85 CLE  94 3 DPL23 17 17% 19 VL8  98 8 DPL21 0  0% 81 MOT 110 3 Humlv318 23 22% 38 GAR 108 3 DPL23 26 25% 33 32.89  98 8 DPL21 5  5% 81 PUG 108 3 Humlv318 24 23% 19 T1 115 8 HUMLV801 52 50% 6 RF-TS7  96 7 DPL18 4  4% 60 YM-1 116 8 HUMLV801 51 49% 75 K6H6 112 8 HUMLV801 20 19% 44 K5C7 112 8 HUMLV801 20 19% 44 K5B8 112 8 HUMLV801 20 19% 44 K5G5 112 8 HUMLV801 20 19% 44 K4B8 112 8 HUMLV801 19 18% 44 K6F5 112 8 HUMLV801 17 16% 44 HIL 108 3 DPL23 22 21% 47 KIR 109 3 DPL23 20 19% 19 CAP 109 3 DPL23 19 18% 84 1B8 110 3 DPL23 22 21% 43 SHO 108 3 DPL23 19 18% 19 HAN 108 3 DPL23 20 19% 19 cML23  96 3 DPL23 3  3% 12 PR-SJ1  96 3 DPL23 7  7% 55 BAU 107 3 DPL23 9  9% 5 TEX  99 3 DPL23 8  8% 19 X(PET) 107 3 DPL23 9  9% 51 DOY 106 3 DPL23 9  9% 19 COT 106 3 DPL23 13 12% 19 Pag-1 111 3 Humlv318 5  5% 31 DIS 107 3 Humlv318 2  2% 19 WIT 108 3 Humlv318 7  7% 19 LRH 108 3 Humlv318 12 11% 19 S1-1 108 3 Humlv318 12 11% 52 DEL 108 3 Humlv318 14 13% 17 TYR 108 3 Humlv318 11 10% 19 J.RH 109 3 Humlv318 13 12% 19 THO 112 2 DPL13 38 36% 26 LBV 113 1 DPL3 38 36% 2 WLT 112 1 DPL3 33 31% 14 SUT 112 2 DPL12 37 35% 65

TABLE 2C rearranged human heavy chain sequences Diff. % diff. Com- to to Ref- puted Germline germ- germ- er- Name aa² family³ gene⁴ line⁵ line⁶ ence⁷ 21/28 119 1 VH1-13-12 0 0.0% 31 8E10 123 1 VH1-13-12 0 0.0% 31 MUC1-1 118 1 VH1-13-6 4 4.1% 42 gF1 98 1 VH1-13-12 10 10.2% 75 VHGL 1.2 98 1 VH1-13-6 2 2.0% 26 HV1L1 98 1 VH1-13-6 0 0.0% 81 RF-TS7 104 1 VH1-13-6 3 3.1% 96 E55 1.A15 106 1 VH1-13-15 1 1.0% 26 HA1L1 126 1 VH1-13-6 7 7.1% 81 UC 123 1 VH1-13-6 5 5.1% 115 WIL2 123 1 VH1-13-6 6 6.1% 55 R3.5H5G 122 1 VH1-13-6 10 10.2% 70 N89P2 123 1 VH1-13-16 11 11.2% 77 mAb113 126 1 VH1-13-6 10 10.2% 71 LS2S3-3 126 1 VH1-12-7 5 5.1% 98 LS2S3-12a 126 1 VH1-12-7 5 5.1% 98 LS2S3-5 125 1 VH1-12-7 5 5.1% 98 LS2S3-12e 125 1 VH1-12-7 5 5.1% 98 LS2S3-4 125 1 VH1-12-7 5 5.1% 98 LS2S3-10 125 1 VH1-12-7 5 5.1% 98 LS2S3-12d 125 1 VH1-12-7 6 6.1% 98 LS2S3-8 125 1 VH1-12-7 5 5.1% 98 LS2 125 1 VH1-12-7 6 6.1% 113 LS4 105 1 VH1-12-7 6 6.1% 113 LS5 125 1 VH1-12-7 6 6.1% 113 LS1 125 1 VH1-12-7 6 6.1% 113 LS6 125 1 VH1-12-7 6 6.1% 113 LS8 125 1 VH1-12-7 7 7.1% 113 THY-29 122 1 VH1-12-7 0 0.0% 42 1B9/F2 122 1 VH1-12-7 10 10.2% 21 51P1 122 1 VH1-12-1 0 0.0% 105 NEI 127 1 VH1-12-1 0 0.0% 55 AND 127 1 VH1-12-1 0 0.0% 55 L7 127 1 VH1-12-1 0 0.0% 54 L22 124 1 VH1-12-1 0 0.0% 54 L24 127 1 VH1-12-1 0 0.0% 54 L26 116 1 VH1-12-1 0 0.0% 54 L33 119 1 VH1-12-1 0 0.0% 54 L34 117 1 VH1-12-1 0 0.0% 54 L36 118 1 VH1-12-1 0 0.0% 54 L39 120 1 VH1-12-1 0 0.0% 54 L41 120 1 VH1-12-1 0 0.0% 54 L42 125 1 VH1-12-1 0 0.0% 54 VHGL 1.8 101 1 VH1-12-1 0 0.0% 26 783c 127 1 VH1-12-1 0 0.0% 22 X17115 127 1 VH1-12-1 0 0.0% 37 L25 124 1 VH1-12-1 0 0.0% 54 L17 120 1 VH1-12-1 1 1.0% 54 L30 127 1 VH1-12-1 1 1.0% 54 L37 120 1 VH1-12-1 1 1.0% 54 TNF-E7 116 1 VH1-12-1 2 2.0% 42 mAb111 122 1 VH1-12-1 7 7.1% 71 III-2R 122 1 VH1-12-9 3 3.1% 70 KAS 121 1 VH1-12-1 7 7.1% 79 YES8c 122 1 VH1-12-1 8 8.2% 34 RF-TS1 123 1 VH1-12-1 8 8.2% 82 BOR′ 121 1 VH1-12-8 7 7.1% 79 VHGL 1.9 101 1 VH1-12-1 8 8.2% 26 mAb410.30F305 117 1 VH1-12-9 5 5.1% 52 EV1-15 127 1 VH1-12-8 10 10.2% 78 mAb112 122 1 VH1-12-1 11 11.2% 71 EU 117 1 VH1-12-1 11 11.2% 28 H210 127 1 VH1-12-1 12 12.2% 66 TRANSGENE 104 1 VH1-12-1 0 0.0% 111 CLL2-1 93 1 VH1-12-1 0 0.0% 30 CLL10 13-3 97 1 VH1-12-1 0 0.0% 29 LS7 99 1 VH1-12-7 4 4.1% 113 ALL7-1 87 1 VH1-12-7 0 0.0% 30 CLL3-1 91 1 VH1-12-7 1 1.0% 30 ALL56-1 85 1 VH1-13-8 0 0.0% 30 ALL1-1 87 1 VH1-13-6 1 1.0% 30 ALL4-1 94 1 VH1-13-8 0 0.0% 30 ALL56 15-4 85 1 VH1-13-8 5 5.1% 29 CLL4-1 88 1 VH1-13-1 1 1.0% 30 Au92.1 98 1 VH1-12-5 0 0.0% 49 RF-TS3 120 1 VH1-12-5 1 1.0% 82 Au4.1 98 1 VH1-12-5 1 1.0% 49 HP1 121 1 VH1-13-6 13 13.3% 110 BLI 127 1 VH1-13-15 5 5.1% 72 No.13 127 1 VH1-12-2 19 19.4% 76 TR1.23 122 1 VH1-13-2 23 23.5% 88 S1-1 125 1 VH1-12-2 18 18.4% 76 TR1.10 119 1 VH1-13-12 14 14.3% 88 E55 1.A2 102 1 VH1-13-15 3 3.1% 26 SP2 119 1 VH1-13-6 15 15.3% 89 TNF-H9G1 111 1 VH1-13-18 2 2.0% 42 G3D10H 127 1 VH1-13-16 19 19.4% 127 TR1.9 118 1 VH1-13-12 14 14.3% 88 TR1.8 121 1 VH1-12-1 24 24.5% 88 LUNm01 127 1 VH1-13-6 22 22.4% 9 K1B12H 127 1 VH1-12-7 23 23.5% 127 L3B2 99 1 VH1-13-6 2 2.0% 46 ss2 100 1 VH1-13-6 2 2.0% 46 No.86 124 1 VH1-12-1 20 20.4% 76 TR1.6 124 1 VH1-12-1 19 19.4% 88 ss7 99 1 VH1-12-7 3 3.1% 46 s5B7 102 1 VH1-12-1 0 0.0% 46 s6A3 97 1 VH1-12-1 0 0.0% 46 ss6 99 1 VH1-12-1 0 0.0% 46 L2H7 103 1 VH1-13-12 0 0.0% 46 s6BG8 93 1 VH1-13-12 0 0.0% 46 s6C9 107 1 VH1-13-12 0 0.0% 46 HIV-b4 124 1 VH1-13-12 21 21.4% 12 HIV-b12 124 1 VH1-13-12 21 21.4% 12 L3G5 98 1 VH1-13-6 1 1.0% 46 22 115 1 VH1-13-6 11 11.2% 118 L2A12 99 1 VH1-13-15 3 3.1% 46 PHOX15 124 1 VH1-12-7 20 20.4% 73 LUNm03 127 1 VH1-1X-1 18 18.4% 9 CEA4-8A 129 1 VH1-12-7 1 1.0% 42 M60 121 2 VH2-31-3 3 3.0% 103 HiH10 127 2 VH2-31-5 9 9.0% 4 COR 119 2 VH2-31-2 11 11.0% 91 2-115-19 124 2 VH2-31-11 8 8.1% 124 OU 125 2 VH2-31-14 20 25.6% 92 HE 120 2 VH2-31-13 19 19.0% 27 CLL33 40-1 78 2 VH2-31-5 2 2.0% 29 E55 3.9 88 3 VH3-11-5 7 7.2% 26 MTFC3 125 3 VH3-14-4 21 21.0% 131 MTFC11 125 3 VH3-14-4 21 21.0% 131 MTFJ1 114 3 VH3-14-4 21 21.0% 131 MTFJ2 114 3 VH3-14-4 21 21.0% 131 MTFUJ4 100 3 VH3-14-4 21 21.0% 131 MTFUJ5 100 3 VH3-14-4 21 21.0% 131 MTFUJ2 100 3 VH3-14-4 22 22.0% 131 MTFC8 125 3 VH3-14-4 23 23.0% 131 TD e Vq 113 3 VH3-14-4 0 0.0% 16 rMTF 114 3 VH3-14-4 5 5.0% 131 MTFUJ6 100 3 VH3-14-4 10 10.0% 131 RF-KES 107 3 VH3-14-4 9 9.0% 85 N51P8 126 3 VH3-14-1 9 9.0% 77 TEI 119 3 VH3-13-8 21 21.4% 20 33.H11 115 3 VH3-13-19 10 10.2% 129 SB1/D8 101 3 VH3-1X-8 14 14.0% 2 38P1 119 3 VH3-11-3 0 0.0% 104 BRO′IGM 119 3 VH3-11-3 13 13.4% 19 NIE 119 3 VH3-13-7 15 15.3% 87 3D6 126 3 VH3-13-26 5 5.1% 35 ZM1-1 112 3 VH3-11-3 8 8.2% 5 E55 3.15 110 3 VH3-13-26 0 0.0% 26 gF9 108 3 VH3-13-8 15 15.3% 75 THY-32 120 3 VH3-13-26 3 3.1% 42 RF-KLS 100 3 VH3-13-26 5 5.1% 96 OST577 122 3 VH3-13-13 6 6.1% 5 BO 113 3 VH3-13-19 15 15.3% 10 TT125 121 3 VH3-13-10 15 15.3% 64 2-115-58 127 3 VH3-13-10 11 11.2% 124 KOL 126 3 VH3-13-14 16 16.3% 102 mAb60 118 3 VH3-13-17 14 14.3% 45 RF-AN 106 3 VH3-13-26 8 8.2% 85 BUT 115 3 VH3-11-6 13 13.4% 119 KOL-based 118 3 VH3-13-13 16 16.3% 41 CAMPATH-9 B1 119 3 VH3-13-19 13 13.3% 53 N98P1 127 3 VH3-13-1 13 13.3% 77 TT117 107 3 VH3-13-10 12 12.2% 64 WEA 114 3 VH3-13-12 15 15.3% 40 HIL 120 3 VH3-13-14 14 14.3% 23 s5A10 97 3 VH3-13-14 0 0.0% 46 s5D11 98 3 VH3-13-7 0 0.0% 46 s6C8 100 3 VH3-13-7 0 0.0% 46 s6H12 98 3 VH3-13-7 0 0.0% 46 VH10.7 119 3 VH3-13-14 16 16.3% 128 HIV-loop2 126 3 VH3-13-7 16 16.3% 12 HIV-loop35 126 3 VH3-13-7 16 16.3% 12 TRO 122 3 VH3-13-1 13 13.3% 61 SA-4B 123 3 VH3-13-1 15 15.3% 125 L2B5 98 3 VH3-13-13 0 0.0% 46 s6E11 95 3 VH3-13-13 0 0.0% 46 s6H7 100 3 VH3-13-13 0 0.0% 46 ss1 102 3 VH3-13-13 0 0.0% 46 ss8 94 3 VH3-13-13 0 0.0% 46 DOB 120 3 VH3-13-26 21 21.4% 116 THY-33 115 3 VH3-13-15 20 20.4% 42 NOV 118 3 VH3-13-19 14 14.3% 38 rsv13H 120 3 VH3-13-24 20 20.4% 11 L3G11 98 3 VH3-13-20 2 2.0% 46 L2E8 99 3 VH3-13-19 0 0.0% 46 L2D10 101 3 VH3-13-10 1 1.0% 46 L2E7 98 3 VH3-13-10 1 1.0% 46 L3A10 100 3 VH3-13-24 0 0.0% 46 L2E5 97 3 VH3-13-2 1 1.0% 46 BUR 119 3 VH3-13-7 21 21.4% 67 s4D5 107 3 VH3-11-3 1 1.0% 46 19 116 3 VH3-13-16 4 4.1% 118 s5D4 99 3 VH3-13-1 0 0.0% 46 s6A8 100 3 VH3-13-1 0 0.0% 46 HIV-loop13 123 3 VH3-13-12 17 17.3% 12 TR1.32 112 3 VH3-11-8 18 18.6% 88 L2B10 97 3 VH3-11-3 1 1.0% 46 TR1.5 114 3 VH3-11-8 21 21.6% 88 s6H9 101 3 VH3-13-25 0 0.0% 46 8 112 3 VH3-13-1 6 6.1% 118 23 115 3 VH3-13-1 6 6.1% 118 7 115 3 VH3-13-1 4 4.1% 118 TR1.3 120 3 VH3-11-8 20 20.6% 88 18/2 125 3 VH3-13-10 0 0.0% 32 18/9 125 3 VH3-13-10 0 0.0% 31 3OP1 119 3 VH3-13-10 0 0.0% 106 HF2-1/17 125 3 VH3-13-10 0 0.0% 8 A77 109 3 VH3-13-10 0 0.0% 44 B19.7 108 3 VH3-13-10 0 0.0% 44 M43 119 3 VH3-13-10 0 0.0% 103 1/17 125 3 VH3-13-10 0 0.0% 31 18/17 125 3 VH3-13-10 0 0.0% 31 E54 3.4 109 3 VH3-13-10 0 0.0% 26 LAMBDA-VH26 98 3 VH3-13-10 1 1.0% 95 E54 3.8 111 3 VH3-13-10 1 1.0% 26 GL16 106 3 VH3-13-10 1 1.0% 44 4G12 125 3 VH3-13-10 1 1.0% 56 A73 106 3 VH3-13-10 2 2.0% 44 AL1.3 111 3 VH3-13-10 3 3.1% 117 3.A290 118 3 VH3-13-10 2 2.0% 108 Ab18 127 3 VH3-13-8 2 2.0% 100 E54 3.3 105 3 VH3-13-10 3 3.1% 26 35G6 121 3 VH3-13-10 3 3.1% 57 A95 107 3 VH3-13-10 5 5.1% 44 Ab25 128 3 VH3-13-10 5 5.1% 100 N87 126 3 VH3-13-10 4 4.1% 77 ED8.4 99 3 VH3-13-10 6 6.1% 2 RF-KL1 122 3 VH3-13-10 6 6.1% 82 AL1.1 112 3 VH3-13-10 2 2.0% 117 AL3.11 102 3 VH3-13-10 1 1.0% 117 32.B9 127 3 VH3-13-8 6 6.1% 129 TK1 109 3 VH3-13-10 2 2.0% 117 POP 123 3 VH3-13-10 8 8.2% 115 gF2H 127 3 VH3-13-10 9 9.2% 127 VD 115 3 VH3-13-10 9 9.2% 10 Vh38Cl.10 121 3 VH3-13-10 8 8.2% 74 Vh38Cl.9 121 3 VH3-13-10 8 8.2% 74 Vh38Cl.8 121 3 VH3-13-10 8 8.2% 74 63P1 120 3 VH3-11-8 0 0.0% 104 60P2 117 3 VH3-11-8 0 0.0% 104 AL3.5 90 3 VH3-13-10 2 2.0% 117 GF4/I.1 123 3 VH3-13-10 10 10.2% 39 Ab21 126 3 VH3-13-10 12 12.2% 100 TD d Vp 118 3 VH3-13-17 2 2.0% 16 Vh38Cl.4 119 3 VH3-13-10 8 8.2% 74 Vh38Cl.5 119 3 VH3-13-10 8 8.2% 74 AL3.4 104 3 VH3-13-10 1 1.0% 117 FOG1-A3 115 3 VH3-13-19 2 2.0% 42 HA3D1 117 3 VH3-13-21 1 1.0% 81 E54 3.2 112 3 VH3-13-24 0 0.0% 26 mAb52 128 3 VH3-13-12 2 2.0% 51 mAb53 128 3 VH3-13-12 2 2.0% 51 mAb56 128 3 VH3-13-12 2 2.0% 51 mAb57 128 3 VH3-13-12 2 2.0% 51 mAb58 128 3 VH3-13-12 2 2.0% 51 mAb59 128 3 VH3-13-12 2 2.0% 51 mAb105 128 3 VH3-13-12 2 2.0% 51 mAb107 128 3 VH3-13-12 2 2.0% 51 E55 3.14 110 3 VH3-13-19 0 0.0% 26 F13-28 106 3 VH3-13-19 1 1.0% 94 mAb55 127 3 VH3-13-18 4 4.1% 51 YSE 117 3 VH3-13-24 6 6.1% 72 E55 3.23 106 3 VH3-13-19 2 2.0% 26 RF-TS5 101 3 VH3-13-1 3 3.1% 85 N42P5 124 3 VH3-13-2 7 7.1% 77 FOGI-H6 110 3 VH3-13-16 7 7.1% 42 O-81 115 3 VH3-13-19 11 11.2% 47 HIV-s8 122 3 VH3-13-12 11 11.2% 12 mAb114 125 3 VH3-13-19 12 12.2% 71 33.F12 116 3 VH3-13-2 4 4.1% 129 4B4 119 3 VH3-1X-3 0 0.0% 101 M26 123 3 VH3-1X-3 0 0.0% 103 VHGL 3.1 100 3 VH3-1X-3 0 0.0% 26 E55 3.13 113 3 VH3-1X-3 1 1.0% 26 SB5/D6 101 3 VH3-1X-6 3 3.0% 2 RAY4 101 3 VH3-1X-6 3 3.0% 2 82-D V-D 106 3 VH3-1X-3 5 5.0% 112 MAL 129 3 VH3-1X-3 5 5.0% 72 LOC 123 3 VH3-1X-6 5 5.0% 72 LSF2 101 3 VH3-1X-6 11 11.0% 2 HIB RC3 100 3 VH3-1X-6 11 11.0% 1 56P1 119 3 VH3-13-7 0 0.0% 104 M72 122 3 VH3-13-7 0 0.0% 103 M74 121 3 VH3-13-7 0 0.0% 103 E54 3.5 105 3 VH3-13-7 0 0.0% 26 2E7 123 3 VH3-13-7 0 0.0% 63 2P1 117 3 VH3-13-7 0 0.0% 104 RF-SJ2 127 3 VH3-13-7 1 1.0% 83 PP-TS1 114 3 VH3-13-7 1 1.0% 85 KIM46H 127 3 VH3-13-13 0 0.0% 18 E55 3.6 108 3 VH3-13-7 2 2.0% 26 E55 3.10 107 3 VH3-13-13 1 1.0% 26 3.86 114 3 VH3-13-13 1 1.0% 108 E54 3.6 110 3 VH3-13-13 1 1.0% 26 FL2-2 114 3 VH3-13-13 1 1.0% 80 RF-SJ3 112 3 VH3-13-7 2 2.0% 85 E55 3.5 105 3 VH3-13-14 1 1.0% 26 BSA3 121 3 VH3-13-13 1 1.0% 73 HMST-1 119 3 VH3-13-7 3 3.1% 130 RF-TS2 126 3 VH3-13-13 4 4.1% 82 E55 3.12 109 3 VH3-13-15 0 0.0% 26 19.E7 126 3 VH3-13-14 3 3.1% 129 11-50 119 3 VH3-13-13 6 6.1% 130 E29.1 120 3 VH3-13-15 2 2.0% 25 E55 3.16 108 3 VH3-13-7 6 6.1% 26 TNF-E1 117 3 VH3-13-7 7 7.1% 42 RF-SJ1 127 3 VH3-13-13 6 6.1% 83 FOG1-A4 116 3 VH3-13-7 8 8.2% 42 TNF-A1 117 3 VH3-13-15 4 4.1% 42 PR-SJ2 107 3 VH3-13-14 8 8.2% 85 HN.14 124 3 VH3-13-13 10 10.2% 33 CAM′ 121 3 VH3-13-7 12 12.2% 65 HIV-B8 125 3 VH3-13-7 9 9.2% 12 HIV-b27 125 3 VH3-13-7 9 9.2% 12 HIV-b8 125 3 VH3-13-7 9 9.2% 12 HIV-s4 125 3 VH3-13-7 9 9.2% 12 HIV-B26 125 3 VH3-13-7 9 9.2% 12 HIV-B35 125 3 VH3-13-7 10 10.2% 12 HIV-b18 125 3 VH3-13-7 10 10.2% 12 HIV-b22 125 3 VH3-13-7 11 11.2% 12 HIV-b13 125 3 VH3-13-7 12 12.2% 12 333 117 3 VH3-14-4 24 24.0% 24 1HI 120 3 VH3-14-4 24 24.0% 24 1B11 120 3 VH3-14-4 23 23.0% 24 CLL30 2-3 86 3 VH3-13-19 1 1.0% 29 GA 110 3 VH3-13-7 19 19.4% 36 JeB 99 3 VH3-13-14 3 3.1% 7 GAL 110 3 VH3-13-19 10 10.2% 126 K6H6 119 3 VH3-1X-6 18 18.0% 60 K4B8 119 3 VH3-1X-6 18 18.0% 60 K5B8 119 3 VH3-1X-6 18 18.0% 60 K5C7 119 3 VH3-1X-6 19 19.0% 60 K5G5 119 3 VH3-1X-6 19 19.0% 60 K6F5 119 3 VH3-1X-6 19 19.0% 60 AL3.16 98 3 VH3-13-10 1 1.0% 117 N86P2 98 3 VH3-13-10 3 3.1% 77 N54P6 95 3 VH3-13-16 7 7.1% 77 LAMBDA 126 4 VH4-11-2 0 0.0% 3 HT112-1 HY18 121 4 VH4-11-2 0 0.0% 43 mAb63 126 4 VH4-11-2 0 0.0% 45 FS-3 105 4 VH4-11-2 0 0.0% 86 FS-5 111 4 VH4-11-2 0 0.0% 86 FS-7 107 4 VH4-11-2 0 0.0% 86 FS-8 110 4 VH4-11-2 0 0.0% 86 PR-TS2 105 4 VH4-11-2 0 0.0% 85 RF-TMC 102 4 VH4-11-2 0 0.0% 85 mAb216 122 4 VH4-11-2 1 1.0% 15 mAb410.7.F91 122 4 VH4-11-2 1 1.0% 52 mAbA6H4C5 124 4 VH4-11-2 1 1.0% 15 Ab44 127 4 VH4-11-2 2 2.1% 100 6H-3C4 124 4 VH4-11-2 3 3.1% 59 FS-6 108 4 VH4-11-2 6 6.2% 86 FS-2 114 4 VH4-11-2 6 6.2% 84 HIG1 126 4 VH4-11-2 7 7.2% 62 FS-4 105 4 VH4-11-2 8 8.2% 86 SA-4A 123 4 VH4-11-2 9 9.3% 125 LES-C 119 4 VH4-11-2 10 10.3% 99 DI 78 4 VH4-11-9 16 16.5% 58 Ab26 126 4 VH4-31-4 8 8.1% 100 TS2 124 4 VH4-31-12 15 15.2% 110 265-695 115 4 VH4-11-7 16 16.5% 5 WAH 129 4 VH4-31-13 19 19.2% 93 268-D 122 4 VH4-11-8 22 22.7% 6 58P2 118 4 VH4-11-8 0 0.0% 104 mAb67 128 4 VH4-21-4 1 1.0% 45 4.L39 115 4 VH4-11-8 2 2.1% 108 mF7 111 4 VH4-31-13 3 3.0% 75 33.C9 122 4 VH4-21-5 7 7.1% 129 Pag-1 124 4 VH4-11-16 5 5.2% 50 B3 123 4 VH4-21-3 8 8.2% 53 IC4 120 4 VH4-11-8 6 6.2% 70 C6B2 127 4 VH4-31-12 4 4.0% 48 N78 118 4 VH4-11-9 11 11.3% 77 B2 109 4 VH4-11-8 12 12.4% 53 WRD2 123 4 VH4-11-12 6 6.2% 90 mAb426.4.2F20 126 4 VH4-11-8 2 2.1% 52 E54 4.58 115 4 VH4-11-8 1 1.0% 26 WRD6 123 4 VH4-11-12 10 10.3% 90 mAb426.12.3F1.4 122 4 VH4-11-9 4 4.1% 52 E54 4.2 108 4 VH4-21-6 2 2.0% 26 WIL 127 4 VH4-31-13 0 0.0% 90 COF 126 4 VH4-31-13 0 0.0% 90 LAR 122 4 VH4-31-13 2 2.0% 90 WAT 125 4 VH4-31-13 4 4.0% 90 mAb61 123 4 VH4-31-13 5 5.1% 45 WAG 127 4 VH4-31-4 0 0.0% 90 RF-SJ4 108 4 VH4-31-12 2 2.0% 85 E54 4.4 110 4 VH4-11-7 0 0.0% 26 E55 4.A1 108 4 VH4-11-7 0 0.0% 26 PR-SJ1 103 4 VH4-11-7 1 1.0% 85 E54 4.23 111 4 VH4-11-7 1 1.0% 26 CLL7 7-2 97 4 VH4-11-12 0 0.0% 29 37P1 95 4 VH4-11-12 0 0.0% 104 ALL52 30-2 91 4 VH4-31-12 4 4.0% 29 EBV-21 98 5 VH5-12-1 0 0.0% 13 CB-4 98 5 VH5-12-1 0 0.0% 13 CLL-12 98 5 VH5-12-1 0 0.0% 13 L3-4 98 5 VH5-12-1 0 0.0% 13 CLL11 98 5 VH5-12-1 0 0.0% 17 CORD3 98 5 VH5-12-1 0 0.0% 17 CORD4 98 5 VH5-12-1 0 0.0% 17 CORD8 98 5 VH5-12-1 0 0.0% 17 CORD9 98 5 VH5-12-1 0 0.0% 17 CD+1 98 5 VH5-12-1 0 0.0% 17 CD+3 98 5 VH5-12-1 0 0.0% 17 CD+4 98 5 VH5-12-1 0 0.0% 17 CD-1 98 5 VH5-12-1 0 0.0% 17 CD-5 98 5 VH5-12-1 0 0.0% 17 VERG14 98 5 VH5-12-1 0 0.0% 17 PBL1 98 5 VH5-12-1 0 0.0% 17 PBL10 98 5 VH5-12-1 0 0.0% 17 STRAb SA-1A 127 5 VH5-12-1 0 0.0% 125 DOB′ 122 5 VH5-12-1 0 0.0% 97 VERG5 98 5 VH5-12-1 0 0.0% 17 PBL2 98 5 VH5-12-1 1 1.0% 17 Tu16 119 5 VH5-12-1 1 1.0% 49 PBL12 98 5 VH5-12-1 1 1.0% 17 CD+2 98 5 VH5-12-1 1 1.0% 11 CORD10 98 5 VH5-12-1 1 1.0% 17 PBL9 98 5 VH5-12-1 1 1.0% 17 CORD2 98 5 VH5-12-1 2 2.0% 17 PBL6 98 5 VH5-12-1 2 2.0% 17 CORD5 98 5 VH5-12-1 2 2.0% 17 CD-2 98 5 VH5-12-1 2 2.0% 17 CORD1 98 5 VH5-12-1 2 2.0% 17 CD-3 98 5 VH5-12-1 3 3.1% 17 VERG4 98 5 VH5-12-1 3 3.1% 17 PBL13 98 5 VH5-12-1 3 3.1% 17 PBL7 98 5 VH5-12-1 3 3.1% 17 HAN 119 5 VH5-12-1 3 3.1% 97 VERG3 98 5 VH5-12-1 3 3.1% 17 PBL3 98 5 VH5-12-1 3 3.1% 17 VERG7 98 5 VH5-12-1 3 3.1% 17 PBL5 94 5 VH5-12-1 0 0.0% 17 CD-4 98 5 VH5-12-1 4 4.1% 17 CLL10 98 5 VH5-12-1 4 4.1% 17 PBL11 98 5 VH5-12-1 4 4.1% 17 CORD6 98 5 VH5-12-1 4 4.1% 17 VERG2 98 5 VH5-12-1 5 5.1% 17 83P2 119 5 VH5-12-1 0 0.0% 103 VERG9 98 5 VH5-12-1 6 6.1% 17 CLL6 98 5 VH5-12-1 6 6.1% 17 PBL8 98 5 VH5-12-1 7 7.1% 17 Ab2022 120 5 VH5-12-1 3 3.1% 100 CAV 127 5 VH5-12-4 0 0.0% 97 HOW′ 120 5 VH5-12-4 0 0.0% 97 PET 127 5 VH5-12-4 0 0.0% 97 ANG 121 5 VH5-12-4 0 0.0% 97 KER 121 5 VH5-12-4 0 0.0% 97 5.M13 118 5 VH5-12-4 0 0.0% 107 Au2.1 118 5 VH5-12-4 1 1.0% 49 WS1 126 5 VH5-12-1 9 9.2% 110 TD Vn 98 5 VH5-12-4 1 1.0% 16 TEL13 116 5 VH5-12-1 9 9.2% 73 E55 5.237 112 5 VH5-12-4 2 2.0% 26 VERG1 98 5 VH5-12-1 10 10.2% 17 CD4-74 117 5 VH5-12-1 10 10.2% 42 257-D 125 5 VH5-12-1 11 11.2% 6 CLL4 98 5 VH5-12-1 11 11.2% 17 CLL8 98 5 VH5-12-1 11 11.2% 17 Ab2 124 5 VH5-12-1 12 12.2% 120 Vh363ex 98 5 VH5-12-1 12 12.2% 120 CLL3 98 5 VH5-12-2 11 11.2% 17 Au59.1 122 5 VH5-12-1 12 12.2% 49 TEL16 117 5 VH5-12-1 12 12.2% 73 M61 104 5 VH5-12-1 0 0.0% 103 TuO 99 5 VH5-12-1 5 5.1% 49 P2-51 122 5 VH5-12-1 13 13.3% 121 P2-54 122 5 VH5-12-1 11 11.2% 121 P1-56 119 5 VH5-12-1 9 9.2% 121 P2-53 122 5 VH5-12-1 10 10.2% 121 P1-51 123 5 VH5-12-1 19 19.4% 121 P1-54 123 5 VH5-12-1 3 3.1% 121 P3-69 127 5 VH5-12-1 4 4.1% 121 P3-9 119 5 VH5-12-1 4 4.1% 121 1-185-37 125 5 VH5-12-4 0 0.0% 124 1-187-29 125 5 VH5-12-4 0 0.0% 124 P1-58 128 5 VH5-12-4 10 10.2% 121 P2-57 118 5 VH5-12-4 3 3.1% 121 P2-55 123 5 VH5-12-1 5 5.1% 121 P2-56 123 5 VH5-12-1 20 20.4% 121 P2-52 122 5 VH5-12-1 11 11.2% 121 P3-60 122 5 VH5-12-1 8 8.2% 121 P1-57 123 5 VH5-12-1 4 4.1% 121 P1-55 122 5 VH5-12-1 14 14.3% 121 MD3-4 128 5 VH5-12-4 12 12.2% 5 P1-52 121 5 VH5-12-1 11 11.2% 121 CLL5 98 5 VH5-12-1 13 13.3% 17 CLL7 98 5 VH5-12-1 14 14.3% 17 L2F10 100 5 VH5-12-1 1 1.0% 46 L3B6 98 5 VH5-12-1 1 1.0% 46 VH6A12 119 6 VH6-35-1 13 12.9% 122 s5A9 102 6 VH6-35-1 1 1.0% 46 s6G4 99 6 VH6-35-1 1 1.0% 46 ss3 99 6 VH6-35-1 1 1.0% 46 6-1G1 101 6 VH6-35-1 0 0.0% 14 F19L16 107 6 VH6-35-1 0 0.0% 68 L16 120 6 VH6-35-1 0 0.0% 69 M71 121 6 VH6-35-1 0 0.0% 103 ML1 120 6 VH6-35-1 0 0.0% 69 F19ML1 107 6 VH6-35-1 0 0.0% 68 15P1 127 6 VH6-35-1 0 0.0% 104 VH6.N1 121 6 VH6-35-1 0 0.0% 122 VH6.N11 123 6 VH6-35-1 0 0.0% 122 VH6.N12 123 6 VH6-35-1 0 0.0% 122 VH6.N2 125 6 VH6-35-1 0 0.0% 122 VH6.N5 125 6 VH6-35-1 0 0.0% 122 VH6.N6 127 6 VH6-35-1 0 0.0% 122 VH6.N7 126 6 VH6-35-1 0 0.0% 122 VH6.N8 123 6 VH6-35-1 0 0.0% 122 VH6.N9 123 6 VH6-35-1 0 0.0% 122 VH6.N10 123 6 VH6-35-1 0 0.0% 122 VH6.A3 123 6 VH6-35-1 0 0.0% 122 VH6.A1 124 6 VH6-35-1 0 0.0% 122 VH6.A4 120 6 VH6-35-1 0 0.0% 122 E55 6.16 116 6 VH6-35-1 0 0.0% 26 E55 6.17 120 6 VH6-35-1 0 0.0% 26 E55 6.6 120 6 VH6-35-1 0 0.0% 26 VHGL 6.3 102 6 VH6-35-1 0 0.0% 26 CB-201 118 6 VH6-35-1 0 0.0% 109 VH6.N4 122 6 VH6-35-1 0 0.0% 122 E54 6.4 109 6 VH6-35-1 1 1.0% 26 VH6.A6 126 6 VH6-35-1 1 1.0% 122 E55 6.14 120 6 VH6-35-1 1 1.0% 26 E54 6.6 107 6 VH6-35-1 1 1.0% 26 E55 6.10 112 6 VH6-35-1 1 1.0% 26 E54 6.1 107 6 VH6-35-1 2 2.0% 26 E55 6.13 120 6 VH6-35-1 2 2.0% 26 E55 6.3 120 6 VH6-35-1 2 2.0% 26 E55 6.7 116 6 VH6-35-1 2 2.0% 26 E55 6.2 120 6 VH6-35-1 2 2.0% 26 E55 6.X 111 6 VH6-35-1 2 2.0% 26 E55 6.11 111 6 VH6-35-1 3 3.0% 26 VH6.A11 118 6 VH6-35-1 3 3.0% 122 A10 107 6 VH6-35-1 3 3.0% 68 E55 6.1 120 6 VH6-35-1 4 4.0% 26 FK-001 124 6 VH6-35-1 4 4.0% 65 VH6.A5 121 6 VH6-35-1 4 4.0% 122 VH6.A7 123 6 VH6-35-1 4 4.0% 122 HBp2 119 6 VH6-35-1 4 4.0% 4 Au46.2 123 6 VH6-35-1 5 5.0% 49 A431 106 6 VH6-35-1 5 5.0% 68 VH6.A2 120 6 VH6-35-1 5 5.0% 122 VH6.A9 125 6 VH6-35-1 8 7.9% 122 VH6.A8 118 6 VH6-35-1 10 9.9% 122 VH6-FF3 118 6 VH6-35-1 2 2.0% 123 VH6.A10 126 6 VH6-35-1 12 11.9% 122 VH6-EB10 117 6 VH6-35-1 3 3.0% 123 VH6-E6 119 6 VH6-35-1 6 5.9% 123 VH6-FE2 121 6 VH6-35-1 6 5.9% 123 VH6-EE6 116 6 VH6-35-1 6 5.9% 123 VH6-FD10 118 6 VH6-35-1 6 5.9% 123 VH6-EX8 113 6 VH6-35-1 6 5.9% 123 VH6-FG9 121 6 VH6-35-1 8 7.9% 123 VH6-E5 116 6 VH6-35-1 9 8.9% 123 VH6-EC8 122 6 VH6-35-1 9 8.9% 123 VH6-E10 120 6 VH6-35-1 10 9.9% 123 VH6-FF11 122 6 VH6-35-1 11 10.9% 123 VH6-FD2 115 6 VH6-35-1 11 10.9% 123 CLL10 17-2 86 6 VH6-35-1 4 4.0% 29 VH6-BB11 94 6 VH6-35-1 4 4.0% 123 VH6-B41 93 6 VH6-35-1 7 6.9% 123 JU17 102 6 VH6-35-1 3 3.0% 114 VH6-BD9 96 6 VH6-35-1 11 10.9% 123 VH6-BB9 94 6 VH6-35-1 12 11.9% 123

TABLE 3A assignment of rearranged V kappa sequences to their germline counterparts Family¹ Name Rearranged² Sum 1 Vk1-1 28 1 Vk1-2 0 1 Vk1-3 1 1 Vk1-4 0 1 Vk1-5 7 1 Vk1-6 0 1 Vk1-7 0 1 Vk1-8 2 1 Vk1-9 9 1 Vk1-10 0 1 Vk1-11 1 1 Vk1-12 7 1 Vk1-13 1 1 Vk1-14 7 1 Vk1-15 2 1 Vk1-16 2 1 Vk1-17 16 1 Vk1-18 1 1 Vk1-19 33 1 Vk1-20 1 1 Vk1-21 1 1 Vk1-22 0 1 Vk1-23 0 119 entries 2 Vk2-1 0 2 Vk2-2 1 2 Vk2-3 0 2 Vk2-4 0 2 Vk2-5 0 2 Vk2-6 16 2 Vk2-7 0 2 Vk2-8 0 2 Vk2-9 1 2 Vk2-10 0 2 Vk2-11 7 2 Vk2-12 0 25 entries 3 Vk3-1 1 3 Vk3-2 0 3 Vk3-3 35 3 Vk3-4 115 3 Vk3-5 0 3 Vk3-6 0 3 Vk3-7 1 3 Vk3-8 40 192 entries 4 Vk4-1 33 33 entries 5 Vk5-1 1 1 entry 6 Vk6-1 0 6 Vk6-2 0 0 entries 7 Vk7-1 0 0 entries

TABLE 3B assignment of rearranged V lambda sequences to their germline counterparts Family¹ Name Rearranged² Sum 1 DPL1 1 1 DPL2 14 1 DPL3 6 1 DPL4 1 1 HUMLV117 4 1 DPL5 13 1 DPL6 0 1 DPL7 0 1 DPL8 3 1 DPL9 0 42 entries 2 DPL10 5 2 VLAMBDA 2.1 0 2 DPL11 23 2 DPL12 15 2 DPL13 0 2 DPL14 0 43 entries 3 DPL16 10 3 DPL23 19 3 Humlv318 9 38 entries 7 DPL18 1 7 DPL19 0  1 entries 8 DPL21 2 8 HUMLV801 6  8 entries 9 DPL22 0  0 entries unassigned DPL24 0  0 entries 10  gVLX-4.4 0  0 entries

TABLE 3C assignment of rearranged V heavy chain sequences to their germline counterparts Family¹ Name Rearranged² Sum 1 VH1-12-1 38 1 VH1-12-8 2 1 VH1-12-2 2 1 VH1-12-9 2 1 VH1-12-3 0 1 VH1-12-4 0 1 VH1-12-5 3 1 VH1-12-6 0 1 VH1-12-7 23 1 VH1-13-1 1 1 VH1-13-2 1 1 VH1-13-3 0 1 VH1-13-4 0 1 VH1-13-5 0 1 VH1-13-6 17 1 VH1-13-7 0 1 VH1-13-8 3 1 VH1-13-9 0 1 VH1-13-10 0 1 VH1-13-11 0 1 VH1-13-12 10 1 VH1-13-13 0 1 VH1-13-14 0 1 VH1-13-15 4 1 VH1-13-16 2 1 VH1-13-17 0 1 VH1-13-18 1 1 VH1-13-19 0 1 VH1-1X-1 1 110 entries  2 VH2-21-1 0 2 VH2-31-1 0 2 VH2-31-2 1 2 VH2-31-3 1 2 VH2-31-4 0 2 VH2-31-5 2 2 VH2-31-6 0 2 VH2-31-7 0 2 VH2-31-14 1 2 VH2-31-8 0 2 VH2-31-9 0 2 VH2-31-10 0 2 VH2-31-11 1 2 VH2-31-12 0 2 VH2-31-13 1  7 entries 3 VH3-11-1 0 3 VH3-11-2 0 3 VH3-11-3 5 3 VH3-11-4 0 3 VH3-11-5 1 3 VH3-11-6 1 3 VH3-11-7 0 3 VH3-11-8 5 3 VH3-13-1 9 3 VH3-13-2 3 3 VH3-13-3 0 3 VH3-13-4 0 3 VH3-13-5 0 3 VH3-13-6 0 3 VH3-13-7 32 3 VH3-13-8 4 3 VH3-13-9 0 3 VH3-13-10 46 3 VH3-13-11 0 3 VH3-13-12 11 3 VH3-13-13 17 3 VH3-13-14 8 3 VH3-13-15 4 3 VH3-13-16 3 3 VH3-13-17 2 3 VH3-13-18 1 3 VH3-13-19 13 3 VH3-13-20 1 3 VH3-13-21 1 3 VH3-13-22 0 3 VH3-13-23 0 3 VH3-13-24 4 3 VH3-13-25 1 3 VH3-13-26 6 3 VH3-14-1 1 3 VH3-14-4 15 3 VH3-14-2 0 3 VH3-14-3 0 3 VH3-1X-1 0 3 VH3-1X-2 0 3 VH3-1X-3 6 3 VH3-1X-4 0 3 VH3-1X-5 0 3 VH3-1X-6 11 3 VH3-1X-7 0 3 VH3-1X-8 1 3 VH3-1X-9 0 212 entries  4 VH4-11-1 0 4 VH4-11-2 20 4 VH4-11-3 0 4 VH4-11-4 0 4 VH4-11-5 0 4 VH4-11-6 0 4 VH4-11-7 5 4 VH4-11-8 7 4 VH4-11-9 3 4 VH4-11-10 0 4 VH4-11-11 0 4 VH4-11-12 4 4 VH4-11-13 0 4 VH4-11-14 0 4 VH4-11-15 0 4 VH4-11-16 1 4 VH4-21-1 0 4 VH4-21-2 0 4 VH4-21-3 1 4 VH4-21-4 1 4 VH4-21-5 1 4 VH4-21-6 1 4 VH4-21-7 0 4 VH4-21-8 0 4 VH4-21-9 0 4 VH4-31-1 0 4 VH4-31-2 0 4 VH4-31-3 0 4 VH4-31-4 2 4 VH4-31-5 0 4 VH4-31-6 0 4 VH4-31-7 0 4 VH4-31-8 0 4 VH4-31-9 0 4 VH4-31-10 0 4 VH4-31-11 0 4 VH4-31-12 4 4 VH4-31-13 7 4 VH4-31-14 0 4 VH4-31-15 0 4 VH4-31-16 0 4 VH4-31-17 0 4 VH4-31-18 0 4 VH4-31-19 0 4 VH4-31-20 0 57 entries 5 VH5-12-1 82 5 VH5-12-2 1 5 VH5-12-3 0 5 VH5-12-4 14 97 entries 6 VH6-35-1 74 74 entries

TABLE 4A Analysis of V kappa subgroup 1 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 1 1 102 1 B 1 1 C 1 D 64 101 E 8 14 1 2 F 1 6 1 G 105 H I 65 4 K 1 L 6 21 96 1 M 1 66 N P 103 1 2 1 Q 62 88 1 R 94 S 89 102 80 103 103 5 T 1 88 18 6 V 1 9 8 2 98 W X 1 1 Y 1 — unknown (?) not sequenced 31 31 18 18 17 16 16 2 1 sum of seq² 74 74 87 87 88 89 89 103 104 105 105 105 105 105 105 105 105 105 oomcaa³ 64 65 62 66 88 88 89 103 102 80 96 103 102 103 98 105 101 94 mcaa⁴ D I Q M T Q S P S S L S A S V G D R rel. oomcaa⁵ 86% 88% 71% 76% 100% 99% 100% 100% 98% 76% 91% 98% 97% 98% 93% 100% 96% 90% pos occupied⁶ 4 5 5 2 1 2 1 1 3 4 3 2 3 3 5 1 4 3 Framework I CDRI amino acid¹ 19 20 21 22 23 24 25 26 27 A B C D E F 28 29 30 A 1 1 1 103 1 B 1 C 105 D 25 1 E 1 1 2 F 2 1 1 G 1 25 7 H 1 1 I 6 4 101 1 98 1 K 2 1 L 1 2 M N 1 6 16 P Q 20 100 R 81 16 S 1 102 41 2 57 T 99 103 1 1 7 V 98 2 1 4 1 W X Y 1 — 105 105 105 105 105 105 unknown (?) not sequenced sum of seq² 105 105 105 105 105 105 105 105 105 105 105 105 105 105 105 105 105 105 oomcaa³ 98 99 101 103 105 81 103 102 100 105 105 105 105 105 105 41 98 57 mcaa⁴ V T I T C R A S Q — — — — — — S I S rel. oomcaa⁵ 93% 94% 96% 98% 100% 77% 98% 97% 95% 100% 100% 100% 100% 100% 100% 39% 93% 54% pos occupied⁶ 3 4 3 3 1 5 3 4 5 1 1 1 1 1 1 6 4 12 CDRI Framework II amino acid¹ 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 A 1 1 42 94 B 1 1 C 1 D 5 7 1 E 1 2 1 3 1 1 F 7 6 1 G 3 4 100 1 H 2 2 1 2 I 4 1 1 1 100 K 7 95 95 86 L 1 101 1 89 103 M 2 N 42 50 10 P 102 104 Q 98 103 2 1 1 R 3 2 3 1 3 3 S 32 3 1 1 1 1 T 4 4 1 3 1 V 1 9 9 W 21 104 X 1 1 Y 60 98 — unknown (?) 3 3 not sequenced 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 3 sum of seq² 104 104 104 104 104 104 104 104 104 104 104 104 104 104 104 104 103 102 oomcaa³ 42 60 101 50 104 98 98 103 95 102 100 95 94 104 86 89 103 100 mcaa⁴ N Y L N W Y Q Q K P G K A P K L L I rel. oomcaa⁵ 40% 58% 97% 48% 100% 94% 94% 99% 91% 98% 96% 91% 90% 100% 83% 86% 100% 98% pos occupied⁶ 11 9 4 8 1 2 5 2 4 3 2 6 3 1 8 6 1 2 Frame- work II CDR II Framework III amino acid¹ 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 50 95 3 2 B 1 C D 21 1 1 1 1 E 1 1 33 F 3 1 1 103 G 9 2 2 105 105 4 101 H 2 1 I 1 3 4 1 3 K 16 2 5 1 1 L 101 1 M N 2 1 25 6 P 1 1 1 101 2 Q 62 1 R 1 1 2 1 103 1 1 1 S 5 1 1 99 41 2 68 2 103 98 96 T 1 4 1 31 19 1 1 2 3 V 1 1 99 1 W X 1 1 1 Y 92 1 — unknown (?) not sequenced 3 2 1 1 1 1 1 sum of seq² 102 103 104 104 104 104 104 105 105 105 105 105 105 105 105 105 105 105 oomcaa³ 92 50 95 99 41 101 62 68 105 99 101 103 103 103 98 105 96 101 mcaa⁴ Y A A S S L Q S G V P S R F S G S G rel. oomcaa⁵ 90% 49% 91% 95% 39% 97% 60% 65% 100% 94% 96% 98% 98% 98% 93% 100% 91% 96% pos occupied⁶ 4 10 6 6 9 3 6 10 1 4 4 2 3 3 5 1 5 4 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 A 1 1 1 3 1 2 101 B 1 3 2 C D 67 1 16 101 E 1 30 83 F 3 102 1 21 73 G 102 4 1 2 H 3 I 99 5 17 K 1 L 81 103 1 1 M 1 N 7 4 P 97 Q 97 R 2 2 1 2 S 100 2 1 86 94 4 1 T 101 98 102 2 1 V 1 1 2 4 1 11 W X 1 2 1 1 2 Y 1 1 1 — unknown (?) not sequenced 1 1 1 1 1 1 1 1 2 2 2 2 2 2 sum of seq² 105 105 105 105 104 104 104 104 104 104 104 104 103 103 103 103 103 103 oomcaa³ 100 102 101 67 102 98 81 102 99 86 94 103 97 97 83 101 73 101 mcaa⁴ S G T D F T L T I S S L Q P E D F A rel. oomcaa⁵ 95% 97% 96% 64% 98% 94% 78% 98% 95% 83% 90% 99% 94% 94% 81% 98% 71% 98% pos occupied⁶ 4 4 4 7 3 4 3 3 3 7 5 2 4 3 5 2 5 2 Framework III CDR III amino acid¹ 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 A 1 1 7 1 5 1 1 B 2 3 C 102 D 23 5 1 1 E 1 1 1 1 F 7 3 13 6 G 1 1 2 1 1 H 1 4 6 7 3 1 2 I 4 1 2 1 5 K 1 7 1 1 L 7 6 2 18 2 18 M 1 N 1 6 31 19 1 1 P 1 1 82 6 6 Q 90 86 1 2 1 R 1 2 2 6 S 1 27 3 58 5 10 2 T 97 3 1 15 25 2 V 1 5 2 W 1 15 X Y 101 93 42 32 1 23 16 — 3 82 88 89 89 89 89 4 unknown (?) 1 not sequenced 3 2 3 3 2 2 1 1 1 1 4 16 16 16 16 16 16 16 sum of seq² 102 103 102 102 103 103 104 104 104 104 101 89 89 89 89 89 89 89 oomcaa³ 97 101 93 102 90 86 42 32 58 25 82 82 88 89 89 89 89 18 mcaa⁴ T Y Y C Q Q Y Y S T P — — — — — — L rel. oomcaa⁵ 95% 98% 91% 100% 87% 83% 40% 31% 56% 24% 81% 92% 99% 100% 100% 100% 100% 20% pos occupied⁶ 6 3 3 1 4 5 11 12 10 14 8 3 2 1 1 1 1 17 CDR III Framework IV amino acid¹ 97 98 99 100 101 102 103 104 105 106 A 107 108 sum A 627 B 1 1 19 C 209 D 15 459 E 2 65 258 F 86 2 451 G 87 29 87 2 894 H 1 40 I 1 72 606 K 1 77 79 480 L 1 1 22 4 2 793 M 1 5 77 N 1 2 232 P 7 1 620 Q 48 1 865 R 6 2 70 413 S 2 1636 T 82 87 3 2 1021 V 1 63 3 440 W 141 X 14 Y 564 — 1 85 1 1250 unknown (?) 7 not sequenced 16 18 18 18 18 18 18 19 19 20 20 20 31 589 sum of seq² 89 87 87 87 87 87 87 86 86 85 85 85 74 oomcaa³ 82 86 87 48 87 87 77 63 65 72 85 79 70 mcaa⁴ T F G G G T K V E I — K R rel. oomcaa⁵ 92% 99% 100% 55% 100% 100% 89% 73% 76% 85% 100% 93% 95% pos occupied⁶ 7 2 1 5 1 1 4 3 5 6 1 4 4

TABLE 4B Analysis of V kappa subgroup 2 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A B C D 14 E 3 15 F 1 1 G 22 H I 8 K L 3 1 17 18 6 M 15 N P 18 18 15 22 Q 18 7 R S 18 17 T 17 21 V 6 17 1 18 W X Y — unknown (?) 1 not sequenced 5 5 5 5 4 4 4 4 4 4 4 4 4 1 1 sum of seq² 17 17 17 17 18 18 18 18 18 18 18 18 18 21 21 22 22 22 oomcaa³ 14 8 17 15 17 18 18 18 17 17 18 18 18 21 15 22 15 22 mcaa⁴ D I V M T Q S P L S L P V T P G E P rel. oomcaa⁵ 82% 47% 100% 88% 94% 100% 100% 100% 94% 94% 100% 100% 100% 100% 71% 100% 68% 100% pos occupied⁶ 2 3 1 3 1 1 1 1 2 2 1 1 1 1 2 1 2 1 Framework I CDRI amino acid¹ 19 20 21 22 23 24 25 26 27 A B C D E F 28 29 30 A 22 B C 22 D 1 9 1 E F 2 G 1 22 H 16 I 22 K 1 L 1 22 13 M 1 N 10 7 P Q 1 21 R 21 2 S 22 21 22 22 22 19 1 T V 8 W 1 X 1 1 Y 4 1 11 — 22 unknown (?) not sequenced sum of seq² 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 oomcaa³ 22 22 22 21 22 21 22 22 21 22 22 13 16 19 22 10 22 11 mcaa⁴ A S I S C R S S Q S L L H S — N G Y rel. oomcaa⁵ 100% 100% 100% 95% 100% 95% 100% 100% 95% 100% 100% 59% 73% 86% 100% 45% 100% 50% pos occupied⁶ 1 1 1 2 1 2 1 1 2 1 1 3 4 3 1 5 1 5 CDRI Framework II amino acid¹ 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 A B C D 1 11 E 1 F 7 G 22 H 1 1 I 1 22 K 1 15 L 22 16 14 21 M N 12 9 P 22 21 Q 6 22 22 12 R 7 8 7 S 21 T 8 V 1 W 22 X 1 Y 21 15 — unknown (?) not sequenced 1 1 1 sum of seq² 22 22 22 22 22 22 22 22 22 22 22 22 21 21 21 22 22 22 oomcaa³ 12 21 22 11 22 15 16 22 15 22 22 22 21 21 12 14 21 22 mcaa⁴ N Y L D W Y L Q K P G Q S P Q L L I rel. oomcaa⁵ 55% 95% 100% 50% 100% 68% 73% 100% 68% 100% 100% 100% 100% 100% 57% 64% 95% 100% pos occupied⁶ 4 2 1 4 1 2 2 1 2 1 1 1 1 1 3 3 2 1 Frame- work II CDR II Framework III amino acid¹ 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 14 B C D 7 22 1 E F 21 G 12 1 22 21 22 H I K 5 L 14 1 M N 18 P 22 Q 1 R 1 22 20 1 S 2 22 2 22 1 22 21 T 1 1 V 6 22 1 W X Y 21 1 — unknown (?) not sequenced 1 1 1 sum of seq² 21 21 21 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 oomcaa³ 21 14 12 22 18 22 14 22 22 22 22 22 20 21 22 21 21 22 mcaa⁴ Y L G S N R A S G V P D R F S G S G rel. oomcaa⁵ 100% 67% 57% 100% 82% 100% 64% 100% 100% 100% 100% 100% 91% 95% 100% 95% 95% 100% pos occupied⁶ 1 4 4 1 4 1 3 1 1 1 1 1 3 2 1 2 2 1 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 A 20 B C D 1 22 1 21 E 19 20 F 22 G 21 1 21 H I 1 21 K 19 L 21 1 M N P 1 Q 1 R 20 S 22 20 1 T 22 21 1 V 21 21 W X Y — unknown (?) 1 not sequenced 1 1 1 1 1 1 1 1 1 1 1 1 sum of seq² 22 22 22 22 22 22 21 21 21 21 21 21 21 21 21 21 21 21 oomcaa³ 22 21 22 22 22 21 21 19 21 20 20 21 19 20 20 21 21 21 mcaa⁴ S G T D F T L K I S R V E A E D V G rel. oomcaa⁵ 100% 95% 100% 100% 100% 95% 100% 90% 100% 95% 95% 100% 90% 95% 95% 100% 100% 100% pos occupied⁶ 1 2 1 1 1 1 1 3 1 2 2 1 3 2 2 1 1 1 Framework III CDR III amino acid¹ 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 A 14 1 B 1 1 C 21 D E F 1 G 6 1 2 H 1 7 I 1 1 3 K L 1 12 2 2 M 21 N P 2 16 1 1 Q 20 13 1 R 1 S 3 2 T 8 7 V 19 W 6 2 X Y 21 21 7 — 14 17 17 17 17 17 unknown (?) not sequenced 1 1 1 1 1 1 1 1 1 1 2 5 5 5 5 5 5 5 sum of seq² 21 21 21 21 21 21 21 21 21 21 20 17 17 17 17 17 17 17 oomcaa³ 19 21 21 21 21 20 14 12 13 7 16 14 17 17 17 17 17 7 mcaa⁴ V Y Y C M Q A L Q T P — — — — — — Y rel. oomcaa⁵ 90% 100% 100% 100% 100% 95% 67% 57% 62% 33% 80% 82% 100% 100% 100% 100% 100% 41% pos occupied⁶ 3 1 1 1 1 2 3 3 3 7 3 3 1 1 1 1 1 7 CDR III Framework IV amino acid¹ 97 98 99 100 101 102 103 104 105 106 A 107 108 sum A 71 B 1 3 C 43 D 112 E 13 71 F 17 72 G 17 2 16 1 233 H 26 I 14 94 K 12 13 66 L 11 219 M 37 N 56 P 159 Q 14 159 R 4 12 126 S 325 T 17 16 140 V 5 146 W 31 X 3 Y 123 — 13 134 unknown (?) 2 not sequenced 5 5 5 6 6 6 6 6 7 8 9 9 10 211 sum of seq² 17 17 17 16 16 16 16 16 15 14 13 13 12 oomcaa³ 17 17 17 14 16 16 12 11 13 14 13 13 12 mcaa⁴ T F G Q G T K L E I — K R rel. oomcaa⁵ 100% 100% 100% 88% 100% 100% 75% 69% 87% 100% 100% 100% 100% pos occupied⁶ 1 1 1 2 1 1 2 2 3 1 1 1 1

TABLE 4C Analysis of V kappa subgroup 3 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 5 2 27 1 B 1 C 2 D 2 14 6 E 76 27 146 1 F 1 1 G 1 82 1 152 1 1 H 1 I 75 1 K 3 1 L 4 1 104 1 150 129 1 M 5 13 N 5 P 124 147 Q 123 R 1 175 S 119 3 1 150 1 141 T 2 117 147 5 1 1 V 1 89 1 1 1 22 1 1 W 1 1 22 1 X Y — unknown (?) not sequenced sum of seq² 88 88 117 118 118 123 123 124 126 149 151 152 152 152 152 152 153 181 oomcaa³ 76 75 89 104 117 123 119 124 82 147 150 150 129 141 147 152 146 175 mcaa⁴ E I V L T Q S P G T L S L S P G E R rel. oomcaa⁵ 86% 85% 76% 88% 99% 100% 97% 100% 65% 99% 99% 99% 85% 93% 97% 100% 95% 97% pos occupied⁶ 6 6 3 3 2 1 4 1 4 3 2 2 3 4 6 1 3 7 Framework I CDRI amino acid¹ 19 20 21 22 23 24 25 26 27 A B C D E F 28 29 30 A 178 2 166 1 1 B C 181 1 D 1 1 E 1 F 7 1 1 G 1 1 1 2 7 H 17 1 I 5 2 24 4 1 K 5 1 L 173 1 1 8 1 M N 9 3 12 P Q 159 R 176 1 1 10 10 3 S 180 7 175 87 72 86 151 T 174 7 2 1 1 1 3 V 4 1 1 1 76 68 W 1 5 X Y 1 1 1 — 72 182 182 182 182 182 unknown (?) 1 not sequenced sum of seq² 182 182 182 182 181 182 182 181 181 182 182 182 182 182 182 182 182 181 oomcaa³ 178 174 173 180 181 176 166 175 159 87 182 182 182 182 182 76 86 151 mcaa⁴ A T L S C R A S Q S — — — — — V S S rel. oomcaa⁵ 98% 96% 95% 99% 100% 97% 91% 97% 88% 48% 100% 100% 100% 100% 100% 42% 47% 83% pos occupied⁶ 2 4 3 3 1 3 5 6 6 8 1 1 1 1 1 6 11 10 CDRI Framework II amino acid¹ 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 A 1 181 176 B C D 2 1 E 1 1 1 F 7 1 1 1 G 3 1 2 1 184 H 2 1 12 1 1 I 1 178 K 1 153 1 L 1 176 3 2 1 179 174 1 M 3 N 25 32 1 P 1 170 5 184 Q 1 1 183 167 1 181 R 18 16 1 1 27 5 182 S 118 4 5 T 8 1 1 3 V 1 7 3 2 3 9 W 185 X Y 1 115 183 — unknown (?) 1 1 not sequenced sum of seq² 181 182 183 184 185 185 185 185 184 184 184 184 184 185 185 183 183 183 oomcaa³ 118 115 176 181 185 183 183 167 153 170 184 181 176 184 182 179 174 178 mcaa⁴ S Y L A W Y Q Q K P G Q A P R L L I rel. oomcaa⁵ 65% 63% 96% 98% 100% 99% 99% 90% 83% 92% 100% 98% 96% 99% 98% 98% 95% 97% pos occupied⁶ 13 12 2 3 1 3 2 4 6 6 1 3 3 2 3 3 2 4 Frame- work II CRD II Framework III amino acid¹ 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 4 147 176 1 68 3 B C 1 D 43 2 4 112 1 E 1 F 4 183 G 125 2 10 179 184 3 178 H 9 1 1 I 1 168 1 K 7 1 1 L 1 M 1 1 N 1 53 2 1 P 2 2 2 177 Q 1 R 1 4 180 182 2 1 S 3 6 4 179 74 1 5 7 180 179 T 11 2 44 164 2 1 2 3 2 V 3 19 3 15 3 1 W 1 1 X Y 165 2 — unknown (?) 1 not sequenced sum of seq² 183 183 183 183 183 183 185 185 185 185 185 185 185 185 185 185 185 185 oomcaa³ 165 125 147 179 74 180 176 164 179 168 177 112 182 183 180 184 179 178 mcaa⁴ Y G A S S R A T G I P D R F S G S G rel. oomcaa⁵ 90% 68% 80% 98% 40% 98% 95% 89% 97% 91% 96% 61% 98% 99% 97% 99% 97% 96% pos occupied⁶ 6 7 6 3 6 4 5 7 3 3 3 5 3 3 3 2 4 5 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 A 5 3 1 3 3 174 B 1 C 2 D 152 1 3 182 E 1 30 149 175 F 183 2 1 178 G 177 3 1 2 H I 1 3 178 1 1 K 1 L 182 178 1 1 M 1 N 1 1 5 P 149 Q 1 34 R 2 1 111 3 S 185 3 7 2 169 65 34 1 T 177 172 179 8 4 1 V 1 4 6 1 3 W 1 X Y 1 1 — unknown (?) not sequenced sum of seq² 185 185 185 184 184 184 184 184 184 184 184 184 184 184 182 184 184 184 oomcaa³ 185 177 177 152 183 172 182 179 178 169 111 178 149 149 175 182 178 174 mcaa⁴ S G T D F T L T I S R L E P E D F A rel. oomcaa⁵ 100% 96% 96% 83% 99% 93% 99% 97% 97% 92% 60% 97% 81% 81% 96% 99% 97% 95% pos occupied⁶ 1 5 4 4 2 5 2 3 4 5 5 2 3 3 4 3 6 6 Framework III CDR III amino acid¹ 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 A 1 8 3 3 B C 1 182 2 1 2 D 8 5 E 2 2 1 F 2 1 4 5 2 7 G 1 104 15 1 1 2 1 H 1 1 7 4 1 2 I 9 1 1 4 K 2 1 1 L 7 1 1 2 7 5 42 M 5 1 1 2 N 28 71 1 P 1 139 24 7 Q 1 181 155 1 1 3 1 3 R 1 34 2 3 2 2 19 S 2 2 33 58 102 15 2 1 T 8 2 13 1 1 2 1 V 159 7 3 1 2 W 69 24 X Y 1 183 176 1 2 134 1 1 43 — 3 3 7 127 167 169 169 169 169 8 unknown (?) not sequenced 14 14 14 14 14 14 14 sum of seq² 184 184 184 183 183 183 183 183 183 182 182 169 169 169 169 169 169 169 oomcaa³ 159 183 176 182 181 155 134 104 71 102 139 127 167 169 169 169 169 43 mcaa⁴ V Y Y C Q Q Y G N S P — — — — — — Y rel. oomcaa⁵ 86% 99% 96% 99% 99% 85% 73% 57% 39% 56% 76% 75% 99% 100% 100% 100% 100% 25% pos occupied⁶ 7 2 5 2 3 8 8 11 13 8 11 12 2 1 1 1 1 18 CDR III Framework IV amino acid¹ 97 98 99 100 101 102 103 104 105 106 A 107 108 sum A 1 1345 B 2 C 375 D 1 23 564 E 3 141 759 F 166 6 765 G 166 41 166 1 1804 H 1 64 I 143 803 K 1 152 157 489 L 54 1 2 1596 M 3 36 N 1 3 255 P 2 9 1 1 1147 Q 114 1 1 1314 R 9 2 4 134 1326 S 8 2 2629 T 154 162 1 1 1593 V 111 11 646 W 287 X Y 1 1014 — 1 1 1 1 1 1 1 1 1 1 166 1 1 2151 unknown (?) 4 not sequenced 17 16 16 16 16 16 15 16 16 16 17 17 45 337 sum of seq² 166 167 167 167 167 167 168 167 167 167 166 166 138 oomcaa³ 154 166 166 114 166 162 152 111 141 143 166 157 134 mcaa⁴ T F G Q G T K V E I — K R rel. oomcaa⁵ 93% 99% 99% 68% 99% 97% 90% 66% 84% 86% 100% 95% 97% pos occupied⁶ 5 2 2 6 2 5 7 4 5 7 1 5 4

TABLE 4D Analysis of V kappa subgroup 4 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 24 1 B C 1 1 D 25 26 E 25 F G 1 24 H I 26 K 1 L 1 26 26 M 24 N 1 P 26 1 Q 1 25 R 26 S 26 25 26 1 T 26 V 25 1 26 W X Y — unknown (?) not sequenced 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 sum of seq² 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 26 oomcaa³ 25 26 25 24 26 25 26 26 26 25 26 24 26 26 26 24 25 26 mcaa⁴ D I V M T Q S P D S L A V S L G E R rel. oomcaa⁵ 96% 100% 96% 92% 100% 96% 100% 100% 100% 96% 100% 92% 100% 100% 100% 92% 96% 100% pos occupied⁶ 2 1 2 3 1 2 1 1 1 2 1 3 1 1 1 3 2 1 Framework I CDRI amino acid¹ 19 20 21 22 23 24 25 26 27 A B C D E F 28 29 30 A 26 1 1 B C 33 D 1 1 1 E F G H I 26 1 K 33 2 30 L 2 31 M N 26 30 31 1 P 1 1 Q 32 1 R 1 1 1 S 31 33 33 32 32 1 T 26 1 V 28 2 W X Y 32 — unknown (?) not sequenced 7 7 7 7 sum of seq² 26 26 26 26 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 26 26 26 26 33 33 31 33 32 33 28 31 32 32 32 30 31 30 mcaa⁴ A T I N C K S S Q S V L Y S S N N K rel. oomcaa⁵ 100% 100% 100% 100% 100% 100% 94% 100% 97% 100% 85% 94% 97% 97% 97% 91% 94% 91% pos occupied⁶ 1 1 1 1 1 1 3 1 2 1 5 2 2 2 2 3 3 4 CDRI Framework II amino acid³¹ 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 A 32 2 B C D E 1 F G 32 H 2 I 32 K 33 32 L 33 29 33 M 1 N 33 P 31 31 33 Q 32 33 32 R 1 1 1 S 2 T 1 V 4 W 33 X Y 33 31 — unknown (?) not sequenced sum of seq² 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 33 33 33 32 33 31 32 33 33 31 32 32 31 33 32 29 33 32 mcaa⁴ N Y L A W Y Q Q K P G Q P P K L L I rel. oomcaa⁵ 100% 100% 100% 97% 100% 94% 97% 100% 100% 94% 97% 97% 94% 100% 97% 88% 100% 97% pos occupied⁶ 1 1 1 2 1 2 2 1 1 2 2 2 2 1 2 2 1 2 Frame- work II CDR II Framework III amino acid¹ 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 30 B C D 33 E 32 F 33 G 33 1 33 33 H I 1 K L M N 2 P 1 33 1 Q R 33 32 S 1 31 1 33 32 33 T 2 1 29 V 1 33 W 33 X Y 33 — unknown (?) not sequenced sum of seq² 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 33 33 30 31 29 33 32 33 33 33 33 33 32 33 32 33 33 33 mcaa⁴ Y W A S T R E S G V P D R F S G S G rel. oomcaa⁵ 100% 100% 91% 94% 88% 100% 97% 100% 100% 100% 100% 100% 97% 100% 97% 100% 100% 100% pos occupied⁶ 1 1 3 3 4 1 2 1 1 1 1 1 2 1 2 1 1 1 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 A 33 32 B C D 32 33 E 33 F 32 G 33 1 H I 33 K L 33 32 M 1 N 2 1 P Q 32 R 1 S 33 30 32 T 33 33 33 1 V 1 33 W X Y — unknown (?) not sequenced sum of seq² 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 33 oomcaa³ 33 33 33 32 32 33 33 33 33 30 32 32 32 33 33 33 33 32 mcaa⁴ S G T D F T L T I S S L Q A E D V A rel. oomcaa⁵ 100% 100% 100% 97% 97% 100% 100% 100% 100% 91% 97% 97% 97% 100% 100% 100% 100% 97% pos occupied⁶ 1 1 1 2 2 1 1 1 1 3 2 2 2 1 1 1 1 2 Framework III CDR III amino acid¹ 85 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 A 1 B C 33 D 1 1 E F 1 1 G 2 H 1 3 I 2 K L 1 2 1 3 1 M N 4 4 P 1 29 1 4 Q 30 32 1 1 R 1 1 2 S 2 23 2 1 T 2 22 V 33 W 2 X Y 33 31 31 29 1 — 13 15 15 15 15 15 3 unknown (?) not sequenced 18 18 18 18 18 18 18 sum of seq² 33 33 33 33 33 33 33 33 33 33 33 15 15 15 15 15 15 15 oomcaa³ 33 33 31 33 30 32 31 29 23 22 29 13 15 15 15 15 15 4 mcaa⁴ V Y Y C Q Q Y Y S T P — — — — — — P rel. oomcaa⁵ 100% 100% 94% 100% 91% 97% 94% 88% 70% 67% 88% 87% 100% 100% 100% 100% 100% 27% pos occupied⁶ 1 1 3 1 2 2 2 4 6 7 3 3 1 1 1 1 1 8 CDR III Framework IV amino acid¹ 97 98 99 100 101 102 103 104 105 106 A 107 108 sum A 183 B C 68 D 154 E 14 105 F 15 82 G 15 4 15 228 H 6 I 14 135 K 14 13 158 L 4 258 M 1 27 N 1 136 P 1 195 Q 11 1 264 R 1 1 1 11 116 S 2 1 499 T 12 14 236 V 9 196 W 1 69 X Y 254 — 15 106 unknown (?) not sequenced 18 18 18 18 18 18 18 18 18 18 18 18 22 518 sum of seq² 15 15 15 15 15 15 15 15 15 15 15 15 11 oomcaa³ 12 15 15 11 15 14 14 9 14 14 15 13 11 mcaa⁴ T F G Q G T K V E I — K R rel. oomcaa⁵ 80% 100% 100% 73% 100% 93% 93% 60% 93% 93% 100% 87% 100% pos occupied⁶ 3 1 1 2 1 2 2 4 2 2 1 3 1

TABLE 5A Analysis of V lambda subgroup 1 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 19 18 20 B C D E 1 F G 22 42 H 2 I 1 1 K 14 L 1 41 1 M N P 41 41 1 41 Q 22 1 41 42 R 25 S 39 41 41 1 1 T 41 19 1 V 1 38 20 1 1 42 W X Y Z 16 — 41 unknown (?) not 2 2 1 1 1 1 1 1 1 1 1 1 1 1 sequenced sum of seq² 40 40 41 41 41 41 41 41 41 41 41 41 41 41 42 42 42 42 42 oomcaa³ 22 39 38 41 41 41 41 41 41 41 20 41 22 20 41 42 42 25 42 mcaa⁴ Q S V L T Q P P S — V S G A P G Q R V rel. oomcaa⁵ 55% 98% 93% 100% 100% 100% 100% 100% 100% 100% 49% 100% 54% 49% 98% 100% 100% 60% 100% pos 3 2 4 1 1 1 1 1 1 1 4 1 3 4 2 1 1 5 1 occupied⁶ CDR I amino acid¹ 20 21 22 23 24 25 26 27 D E 28 29 30 31 A 32 33 34 35 A 2 1 2 2 1 B C 42 D 3 3 1 3 1 E 1 F 1 1 1 1 G 42 3 1 2 39 4 2 H 2 2 2 I 1 41 1 37 1 K 1 1 L 1 1 M 1 N 2 1 37 13 31 2 1 9 P 1 Q 1 R 1 1 5 S 1 42 38 34 34 38 13 1 1 3 19 T 38 3 4 3 2 1 1 7 2 V 1 2 40 W 42 X Y 4 1 20 7 Z — 36 unknown (?) not 1 1 1 1 sequenced sum of seq² 42 42 42 42 42 42 42 42 42 42 42 42 42 42 41 41 41 41 42 oomcaa³ 38 41 42 42 38 42 34 34 38 37 37 39 13 31 36 20 40 19 42 mcaa⁴ T I S C S G S S S N I G N N — Y V S W rel. oomcaa⁵ 90% 98% 100% 100% 90% 100% 81% 81% 90% 88% 88% 93% 31% 74% 88% 49% 98% 46% 100% pos 4 2 1 1 3 1 4 6 4 4 5 3 8 7 5 10 2 7 1 occupied⁶ Framework II amino acid¹ 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 A 4 40 1 B C D 1 13 10 8 E 2 5 1 F 1 4 1 G 39 1 H 1 1 6 1 1 1 I 40 1 K 1 35 1 1 18 L 1 31 41 40 1 1 M 1 1 1 N 1 3 28 30 2 P 42 1 42 Q 39 34 15 R 2 1 1 4 7 2 40 S 1 9 2 3 1 T 36 1 1 V 1 5 1 2 1 W 1 X Y 40 40 1 1 Z — unknown (?) not sequenced sum of seq² 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 oomcaa³ 40 39 34 31 42 39 36 40 42 35 41 40 40 40 13 28 30 18 40 mcaa⁴ Y Q Q L P G T A P K L L I Y D N N K R rel. oomcaa⁵ 95% 93% 81% 74% 100% 93% 86% 95% 100% 83% 98% 95% 95% 95% 31% 67% 71% 43% 95% pos 3 3 4 5 1 4 4 3 1 4 2 2 3 3 10 5 4 9 3 occupied⁶ CDR II amino acid¹ 55 56 A B C D E 57 58 59 60 61 62 63 64 65 66 A B A 1 5 B C D 38 E F 38 G 41 2 36 H 1 I 17 3 K 38 L 1 1 M N P 38 38 Q R 42 4 S 2 40 2 42 42 T 1 V 24 1 W X Y Z — 41 41 41 41 42 42 42 unknown (?) not 1 1 1 1 1 1 sequenced sum of seq² 41 41 41 41 41 41 42 41 41 41 41 42 42 42 42 42 42 42 42 oomcaa³ 38 40 41 41 41 41 42 41 24 38 38 42 38 42 36 42 38 42 42 mcaa⁴ P S — — — — — G V P D R F S G S K — — rel. oomcaa⁵ 93% 98% 100% 100% 100% 100% 100% 100% 59% 93% 93% 100% 90% 100% 86% 100% 90% 100% 100% pos 3 2 1 1 1 1 1 1 2 3 3 1 3 1 3 1 2 1 1 occupied⁶ Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 A 1 3 41 24 2 38 1 B C D 1 1 41 37 E 1 24 42 1 F G 40 17 1 42 15 H 1 2 I 41 1 K L 42 41 M N 1 P 2 Q 31 R 8 S 42 1 42 24 20 20 1 T 38 18 21 17 3 V 1 1 1 1 1 W 1 2 X Y Z — unknown (?) not sequenced sum of seq² 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 42 oomcaa³ 42 40 38 42 41 24 42 24 41 21 42 41 31 20 24 41 42 38 37 mcaa⁴ S G T S A S L A I T G L Q S E D E A D rel. oomcaa⁵ 100% 95% 90% 100% 98% 57% 100% 57% 98% 50% 100% 98% 74% 48% 57% 98% 100% 90% 88% pos 1 3 3 1 2 2 1 3 2 3 1 2 5 5 4 2 1 3 5 occupied⁶ CDR III amino acid¹ 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 97 98 A 22 15 1 16 4 1 B C 42 D 39 17 7 E 1 1 F 2 1 36 G 14 1 17 1 5 1 H 1 1 I 1 1 K 1 L 1 37 1 1 M 1 N 2 2 9 1 P 1 6 Q 3 R 5 1 2 2 S 4 17 35 18 1 1 T 22 1 1 1 V 1 1 1 2 9 34 W 38 7 X Y 42 39 3 1 3 Z — 2 4 35 39 38 38 1 unknown (?) not 1 1 1 1 1 1 1 1 1 3 3 3 3 3 3 4 sequenced sum of seq² 42 42 42 41 41 41 41 41 41 41 41 41 39 39 38 38 39 39 36 oomcaa³ 42 39 42 22 22 38 39 17 35 37 18 17 35 39 38 38 9 34 36 mcaa⁴ Y Y C A T W D D S L S G — — — — V V F rel. oomcaa⁵ 100% 93% 100% 54% 54% 93% 95% 41% 85% 90% 44% 41% 90% 100% 100% 100% 23% 87% 100% pos 1 3 1 5 3 2 2 8 3 5 8 6 5 1 1 1 10 6 1 occupied⁶ Framework IV amino acid¹ 99 100 101 102 103 104 105 106 A 107 108 sum A 285 B C 84 D 224 E 1 81 F 87 G 36 31 36 26 559 H 25 I 188 K 30 141 L 25 34 344 M 5 N 1 176 P 1 296 Q 3 1 18 251 R 1 2 156 S 1 2 720 T 3 36 1 36 359 V 11 36 1 282 W 1 92 X Y 202 Z 16 — 524 unknown (?) not 4 6 6 6 6 6 6 6 6 10 22 141 sequenced sum of seq² 36 36 36 36 36 36 36 36 36 31 19 oomcaa³ 36 31 36 36 30 25 36 36 34 26 18 mcaa⁴ G G G T K L T V L G Q rel. oomcaa⁵ 100% 86% 100% 100% 83% 69% 100% 100% 94% 84% 95% pos 1 4 1 1 5 2 1 1 3 4 2 occupied⁶

TABLE 5B Analysis of V lambda subgroup 2 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 35 30 6 1 1 B C D 1 E F G 42 42 H 2 1 I 1 28 K L 40 3 1 M N P 42 6 40 Q 22 4 41 42 R 6 1 S 41 40 42 42 43 T 42 1 V 1 2 36 14 W X Y Z 16 — 42 unknown (?) 1 not 3 1 1 3 1 1 1 1 1 1 1 1 sequenced sum of seq² 40 42 42 40 42 42 42 42 42 42 42 42 43 43 43 43 43 43 43 oomcaa³ 22 41 35 40 42 41 42 30 40 42 36 42 42 42 40 42 42 43 28 mcaa⁴ Q S A L T Q P A S — V S G S P G Q S I rel. oomcaa⁵ 55% 98% 83% 100% 100% 98% 100% 71% 95% 100% 86% 100% 98% 98% 93% 98% 98% 100% 65% pos 3 2 4 1 1 1 1 3 3 1 2 1 2 2 2 2 2 1 3 occupied⁶ CDR I amino acid¹ 20 21 22 23 24 25 26 27 D E 28 29 30 31 A 32 33 34 35 A 3 1 1 1 B C 42 1 1 D 39 1 4 5 E 1 F 1 1 4 G 43 1 39 26 H 1 1 1 I 41 1 6 K 4 L 1 4 M N 1 3 4 1 4 3 28 P 1 Q R 1 2 S 42 3 3 35 38 5 1 2 4 1 42 T 43 36 39 3 1 1 V 37 41 W 43 X Y 1 1 37 29 Z — 1 unknown (?) 1 not 1 1 1 1 sequenced sum of seq² 43 43 42 42 43 43 43 43 43 43 43 43 43 43 43 43 42 42 43 oomcaa³ 43 41 42 42 36 43 39 35 38 39 37 39 26 37 28 29 41 42 43 mcaa⁴ T I S C T G T S S D V G G Y N Y V S W rel. oomcaa⁵ 100% 95% 100% 100% 84% 100% 91% 81% 88% 91% 86% 91% 60% 86% 65% 67% 98% 100% 100% pos 1 3 1 1 4 1 3 7 4 2 2 5 7 5 7 6 2 1 1 occupied⁶ Framework II amino acid¹ 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 A 1 4 40 B C D 1 2 20 1 2 1 E 20 2 F 2 7 1 G 36 2 2 1 H 2 34 1 I 1 1 9 43 1 K 40 41 1 21 L 1 1 38 6 M 26 1 N 2 1 8 12 P 41 43 Q 41 39 2 R 1 1 2 43 S 1 2 21 3 T 1 7 V 1 3 4 2 39 W X Y 41 5 34 2 Z — unknown (?) 1 1 not sequenced sum of seq² 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 oomcaa³ 41 41 39 34 41 36 40 40 43 41 38 26 43 34 20 39 21 21 43 mcaa⁴ Y Q Q H P G K A P K L M I Y D V S K R rel. oomcaa⁵ 95% 95% 91% 79% 95% 84% 93% 93% 100% 95% 88% 60% 100% 79% 47% 91% 49% 49% 100% pos 2 2 3 5 3 4 4 2 1 2 3 4 1 3 4 4 8 8 1 occupied⁶ CDR II amino acid¹ 55 56 A B C D E 57 58 59 60 61 62 63 64 65 66 A B A 2 B C 1 D 17 E F 42 G 43 1 41 H 2 I 3 K 42 L 1 1 M N 19 P 43 15 Q R 43 1 S 43 28 2 43 42 T V 39 W X Y 2 Z — 43 43 43 43 43 43 43 unknown (?) not sequenced sum of seq² 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 oomcaa³ 43 43 43 43 43 43 43 43 39 28 19 43 42 43 41 42 42 43 43 mcaa⁴ P S — — — — — G V S N R F S G S K — — rel. oomcaa⁵ 100% 100% 100% 100% 100% 100% 100% 100% 91% 65% 44% 100% 98% 100% 95% 98% 98% 100% 100% pos 1 1 1 1 1 1 1 1 3 2 6 1 2 1 2 2 2 1 1 occupied⁶ Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 A 3 1 43 36 43 B C D 1 2 3 42 39 E 1 38 43 F G 39 42 1 H 2 I 35 K 1 L 43 43 M N 38 1 1 1 P 2 Q 41 R 2 S 42 1 43 42 T 1 41 43 1 2 V 8 3 W X Y Z — unknown (?) 1 1 not 1 sequenced sum of seq² 42 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 oomcaa³ 42 39 38 41 43 43 43 43 35 42 42 43 41 36 38 42 43 43 39 mcaa⁴ S G N T A S L T I S G L Q A E D E A D rel. oomcaa⁵ 100% 91% 88% 95% 100% 100% 100% 100% 81% 98% 98% 100% 95% 84% 88% 98% 100% 100% 91% pos 1 3 4 3 1 1 1 1 2 2 2 1 2 4 4 2 1 1 3 occupied⁶ CDR III amino acid¹ 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 97 98 A 2 1 21 1 1 1 B C 43 11 D 3 1 2 1 E 1 1 F 3 3 1 1 5 42 G 1 21 3 4 1 H 1 I 1 1 1 2 1 7 K 3 L 1 1 6 5 M 1 1 N 5 7 5 1 P 1 4 Q 1 2 R 2 3 1 5 S 1 30 41 12 23 14 9 1 T 16 4 4 3 21 V 1 11 28 W 5 X Y 43 39 39 1 6 4 Z — 1 3 36 42 43 43 43 unknown (?) 2 not 1 1 1 1 sequenced sum of seq² 43 43 43 43 42 43 43 43 43 43 42 43 43 43 43 43 43 42 42 oomcaa³ 43 39 43 30 41 39 21 21 23 14 21 36 42 43 43 43 11 28 42 mcaa⁴ Y Y C S S Y A G S S T — — — — — V V F rel. oomcaa⁵ 100% 91% 100% 70% 98% 91% 49% 49% 53% 33% 50% 84% 98% 100% 100% 100% 26% 67% 100% pos 1 3 1 3 2 3 7 7 8 11 6 5 2 1 1 1 13 5 1 occupied⁶ Framework IV amino acid¹ 99 100 101 102 103 104 105 106 A 107 108 sum A 1 280 B C 99 D 188 E 107 F 113 G 42 33 42 19 567 H 48 I 1 184 K 36 189 L 28 40 264 M 29 N 1 146 P 238 Q 1 14 250 R 1 2 4 121 S 1 2 831 T 7 41 40 398 V 14 42 1 327 W 48 X Y 1 285 Z 16 — 555 unknown (?) 8 not 1 1 1 2 2 1 1 1 2 15 28 80 sequenced sum of seq² 42 42 42 41 41 42 42 42 41 25 14 oomcaa³ 42 33 42 41 36 28 40 42 40 19 14 mcaa⁴ G G G T K L T V L G Q rel. oomcaa⁵ 100% 79% 100% 100% 88% 67% 95% 100% 98% 76% 100% pos 1 4 1 1 5 2 3 1 2 3 1 occupied⁶

TABLE 5C Analysis of V lambda subgroup 3 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 1 1 2 7 20 1 27 B C D 5 10 E 20 1 1 F 1 1 1 1 G 1 37 H I K 2 L 37 4 1 9 M N P 26 35 1 27 1 Q 4 4 38 36 R S 13 14 1 1 28 37 18 T 36 1 38 V 8 1 2 34 36 10 W X Y 23 Z — 20 38 unknown (?) not sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 oomcaa³ 20 23 20 37 36 38 26 35 28 38 34 37 36 20 27 37 36 38 27 mcaa⁴ — Y E L T Q P P S — V S V A P G Q T A rel. oomcaa⁵ 53% 61% 53% 97% 95% 100% 68% 92% 74% 100% 89% 97% 95% 53% 71% 97% 95% 100% 71% pos 4 3 5 2 3 1 4 3 4 1 2 2 3 2 4 2 2 1 3 occupied⁶ CDR I amino acid¹ 20 21 22 23 24 25 26 27 D E 28 29 30 31 A 32 33 34 35 A 1 5 1 1 21 3 B C 38 5 D 30 1 10 3 1 E 2 2 1 3 6 F 1 2 G 9 38 1 23 4 H 1 2 9 I 38 9 1 K 7 2 13 L 28 M 1 1 N 2 4 9 1 2 1 2 P 1 3 Q 10 4 R 25 2 10 1 1 S 9 1 19 10 11 2 8 14 T 3 33 1 1 4 V 1 15 W 38 X Y 1 8 20 1 4 Z — 38 38 37 unknown (?) not 1 1 sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 37 37 37 38 38 38 oomcaa³ 25 38 33 38 19 38 30 10 38 38 28 23 11 13 37 20 21 14 38 mcaa⁴ R I T C S G D S — — L G S K — Y A S W rel. oomcaa⁵ 66% 100% 87% 100% 50% 100% 79% 26% 100% 100% 74% 61% 29% 35% 100% 54% 55% 37% 100% pos 4 1 5 1 3 1 5 9 1 1 3 5 9 9 1 7 4 7 1 occupied⁶ Framework II amino acid¹ 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 A 23 1 1 B C D 9 22 2 8 E 1 5 3 3 F 3 2 1 G 36 9 2 H 1 1 3 1 I 1 28 1 K 32 2 6 1 13 L 2 6 33 1 M 1 1 N 1 19 9 P 36 1 38 Q 37 35 1 36 9 1 R 1 4 2 1 1 1 38 S 1 2 14 10 1 T 2 4 V 1 31 4 37 9 W X Y 35 35 Z — unknown (?) not sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 oomcaa³ 35 37 35 32 36 36 36 23 38 31 33 37 28 35 9 22 19 13 38 mcaa⁴ Y Q Q K P G Q A P V L V I Y D D N K R rel. oomcaa⁵ 92% 97% 92% 84% 95% 95% 95% 61% 100% 82% 87% 97% 74% 92% 24% 58% 50% 34% 100% pos 2 2 3 4 2 2 3 3 1 3 3 2 3 3 7 8 7 9 1 occupied⁶ CDR II amino acid¹ 55 56 A B C D E 57 58 59 60 61 62 63 64 65 66 A B A 1 B C D 9 E 27 F 38 G 38 38 H I 37 K L M N 21 P 37 1 36 Q R 38 S 1 36 1 38 38 12 T 5 V W X Y Z — 38 38 38 38 38 38 38 unknown (?) 1 not 1 1 1 sequenced sum of seq² 38 38 38 38 38 38 38 38 37 37 37 38 38 38 38 38 38 38 38 oomcaa³ 37 36 38 38 38 38 38 38 37 36 27 38 38 38 38 38 21 38 38 mcaa⁴ P S — — — — — G I P E R F S G S N — — rel. oomcaa⁵ 97% 95% 100% 100% 100% 100% 100% 100% 100% 97% 73% 100% 100% 100% 100% 100% 55% 100% 100% pos 2 3 1 1 1 1 1 1 1 2 2 1 1 1 1 1 3 1 1 occupied⁶ Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 A 1 36 1 1 11 1 34 38 B C D 38 37 E 10 14 38 1 F G 37 28 10 H 1 I 1 1 37 1 1 K 1 L 38 2 M 10 N 28 1 P Q 1 25 R 1 10 1 S 37 2 11 23 1 T 1 6 37 25 36 12 13 2 V 2 1 14 1 1 1 W X Y Z — unknown (?) not sequenced sum of seq² 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 38 oomcaa³ 37 37 28 37 36 25 38 36 37 23 28 14 25 34 14 38 38 38 37 mcaa⁴ S G N T A T L T I S G V Q A E D E A D rel. oomcaa⁵ 97% 97% 74% 97% 95% 66% 100% 95% 97% 61% 74% 37% 66% 89% 37% 100% 100% 100% 97% pos 2 2 5 2 2 4 1 3 2 5 2 3 5 4 6 1 1 1 2 occupied⁶ CDR III amino acid¹ 86 87 88 89 90 91 92 93 94 95 A B C D E F 96 97 98 A 13 3 2 1 2 4 B C 38 D 32 1 1 6 E 1 2 2 F 2 2 35 G 3 14 3 1 3 1 H 12 1 I 4 K 1 L 1 1 1 1 1 4 2 M 1 1 1 N 10 2 1 2 10 1 P 1 3 1 Q 25 1 1 R 10 1 2 2 S 1 14 1 28 26 13 1 1 T 1 3 7 2 V 11 18 28 W 23 1 X Y 38 36 1 1 1 3 1 3 Z — 10 15 31 36 37 36 1 unknown (?) not 1 1 1 1 2 1 1 1 1 1 1 1 3 sequenced sum of seq² 38 38 38 38 38 38 37 37 37 37 36 37 37 37 37 37 37 37 35 oomcaa³ 38 36 38 25 14 23 32 28 26 14 10 15 31 36 37 36 18 28 35 mcaa⁴ Y Y C Q S W D S S G N — — — — — V V F rel. oomcaa⁵ 100% 95% 100% 66% 37% 61% 86% 76% 70% 38% 28% 41% 84% 97% 100% 97% 49% 76% 100% pos 1 2 1 5 3 5 4 7 8 6 9 8 5 2 1 2 9 6 1 occupied⁶ Framework IV amino acid¹ 99 100 101 102 103 104 105 106 A 107 108 sum A 265 B C 1 82 D 225 E 2 145 F 90 G 35 31 35 24 461 H 32 I 160 K 30 110 L 28 33 233 M 17 N 126 P 1 249 Q 7 275 R 2 154 S 2 501 T 4 35 35 347 V 7 35 308 W 62 X Y 211 Z — 603 unknown (?) 1 not 3 3 3 3 4 3 3 3 4 11 28 89 sequenced sum of seq² 35 35 35 35 34 35 35 35 34 27 7 oomcaa³ 35 31 35 35 30 28 35 35 33 24 7 mcaa⁴ G G G T K L T V L G Q rel. oomcaa⁵ 100% 89% 100% 100% 88% 80% 100% 100% 97% 89% 100% pos 1 2 1 1 3 2 1 1 2 3 1 occupied⁶

TABLE 6A Analysis of V heavy chain subgroup 1A Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A 1 14 60 24 1 B C D E 1 2 1 2 64 F G 58 1 64 H 2 I 2 K 2 57 64 60 L 2 59 3 M 1 N 6 P 63 Q 53 56 2 45 R 1 3 S 60 3 1 40 63 T 1 V 2 55 1 55 61 64 W X Y Z 3 — unknown (?) not 11 10 10 10 10 10 10 10 6 6 6 6 6 6 6 6 6 6 6 sequenced sum of seq² 59 60 60 60 60 60 60 60 64 64 64 64 64 64 64 64 64 64 64 oomcaa³ 53 55 56 59 55 45 60 58 60 64 61 57 64 63 64 40 63 64 60 mcaa⁴ Q V Q L V Q S G A E V K K P G S S V K rel. oomcaa⁵ 90% 92% 93% 98% 92% 75% 100% 97% 94% 100% 95% 89% 100% 98% 100% 63% 98% 100% 94% pos 4 4 3 2 4 3 1 2 3 1 2 3 1 2 1 2 2 1 3 occupied⁶ CDR I amino acid¹ 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 35 36 A 62 1 41 B C 63 D 1 E F 69 3 3 G 1 69 41 1 23 H 1 1 1 I 1 61 1 K 63 1 1 L 1 2 M 4 N 2 5 4 P 1 Q R 1 1 1 1 S 63 68 1 40 60 2 60 T 1 2 68 25 3 3 4 V 64 1 W 70 X Y 27 64 Z — 70 70 unknown (?) not 6 6 6 6 5 2 1 sequenced sum of seq² 64 64 64 64 65 68 69 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 64 63 63 63 62 68 69 41 68 69 40 60 70 70 64 41 61 60 70 mcaa⁴ V S C K A S G G T F S S — — Y A I S W rel. oomcaa⁵ 100% 98% 98% 98% 95% 100% 100% 59% 97% 99% 57% 86% 100% 100% 91% 59% 87% 86% 100% pos 1 2 2 2 3 1 1 4 3 2 6 5 1 1 4 6 4 5 1 occupied⁶ Framework II amino acid¹ 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A B C A 70 1 5 B C D 1 E 69 F 2 G 1 68 69 1 69 39 1 H 1 I 1 65 38 K L 1 68 1 1 M 67 2 N 4 P 68 1 44 Q 69 69 R 70 1 1 1 4 S 1 1 1 22 T 1 2 4 V 69 1 2 2 16 W 1 67 26 X Y 1 Z — 70 70 unknown (?) not sequenced sum of seq² 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 69 70 69 70 68 68 69 69 68 69 67 67 69 39 65 38 44 70 70 mcaa⁴ V R Q A P G Q G L E W M G G I I P — — rel. oomcaa⁵ 99% 100% 99% 100% 97% 97% 99% 99% 97% 99% 96% 96% 99% 56% 93% 54% 63% 100% 100% pos 2 1 2 1 3 3 2 2 3 2 4 4 2 4 4 6 5 1 1 occupied⁶ CDR II amino acid¹ 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 A 1 34 69 43 B C D 15 1 2 E 1 F 3 39 1 48 3 4 G 68 1 3 67 H 1 I 34 4 1 44 K 1 2 1 47 1 1 L 2 4 1 1 22 2 1 3 M 4 21 N 3 22 9 59 18 P 1 7 Q 1 1 1 1 1 70 64 R 1 2 2 1 69 S 1 1 1 2 1 5 T 1 3 34 26 4 3 66 65 24 V 1 1 65 3 W X Y 20 1 68 Z — unknown (?) not sequenced sum of seq² 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 34 39 68 34 34 59 68 69 70 47 48 64 67 69 65 66 44 65 43 mcaa⁴ I F G T A N Y A Q K F Q G R V T I T A rel. oomcaa⁵ 49% 56% 97% 49% 49% 84% 97% 99% 100% 67% 69% 91% 96% 99% 93% 94% 63% 93% 61% pos 10 6 3 11 6 7 3 2 1 4 2 5 3 2 3 3 4 2 3 occupied⁶ Framework III amino acid¹ 72 73 74 75 76 77 78 79 80 81 82 A B C 83 84 85 86 87 A 64 1 3 1 B C D 70 2 26 70 E 33 64 44 F G 1 H 1 1 I 1 1 3 1 1 K 8 3 L 3 63 70 M 67 1 N 4 1 16 P Q 1 3 R 1 3 23 1 62 S 70 62 1 41 49 67 1 T 27 67 1 69 2 3 2 4 67 V 3 3 4 1 W X Y 68 Z — unknown (?) not sequenced sum of seq² 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 oomcaa³ 70 33 70 67 62 69 64 68 67 64 63 41 49 70 62 67 44 70 67 mcaa⁴ D E S T S T A Y M E L S S L R S E D T rel. oomcaa⁵ 100% 47% 100% 96% 89% 99% 91% 97% 96% 91% 90% 59% 70% 100% 89% 96% 63% 100% 96% pos 1 5 1 2 4 2 4 3 2 4 3 6 6 1 4 2 2 1 4 occupied⁶ CDR III amino acid¹ 88 89 90 91 92 93 94 95 96 97 98 99 100 A B C D E F A 70 66 2 16 1 1 1 4 1 2 2 1 1 B C 70 1 1 16 2 1 1 7 2 1 D 16 5 3 3 5 4 3 4 1 E 9 2 1 1 F 1 1 2 1 3 2 3 1 2 2 G 2 14 13 20 10 14 5 20 15 16 3 3 4 H 1 1 1 1 I 2 2 5 2 2 2 2 1 1 K 5 2 1 1 L 2 1 4 4 2 5 2 1 1 4 2 1 M 1 1 2 1 1 1 1 N 2 2 1 2 1 2 2 2 2 P 20 3 1 3 2 2 2 4 2 1 Q 1 1 1 1 1 R 55 1 5 7 8 1 4 2 1 16 S 1 1 5 5 5 5 21 5 11 8 4 3 T 1 3 3 5 4 1 3 4 2 5 2 1 V 64 3 3 2 4 3 3 3 4 2 2 2 1 2 W 1 1 3 1 1 2 3 X Y 69 68 1 2 3 20 5 4 9 1 2 11 20 10 Z — 1 2 2 3 6 11 11 14 23 26 26 unknown (?) 1 not 2 2 2 4 4 4 4 5 5 5 5 5 sequenced sum of seq² 70 70 70 70 70 70 70 68 68 68 66 66 66 66 65 65 65 65 65 oomcaa³ 70 64 69 68 70 66 55 16 20 20 20 16 21 20 15 16 23 26 26 mcaa⁴ A V Y Y C A R A P G Y C S G — — — — — rel. oomcaa⁵ 100% 91% 99% 97% 100% 94% 79% 24% 29% 29% 30% 24% 32% 30% 23% 25% 35% 40% 40% pos 1 5 2 2 1 3 8 10 14 18 15 18 15 15 17 17 15 12 11 occupied⁶ Framework IV amino acid¹ G H I J K 101 102 103 104 105 106 107 108 109 110 111 112 113 sum A 1 1 1 2 1 670 B C 165 D 1 14 59 1 1 308 E 1 1 1 297 F 1 28 2 2 226 G 15 1 1 7 58 59 1 1 928 H 1 14 I 1 3 4 286 K 3 1 325 L 1 1 3 1 40 1 386 M 10 1 3 189 N 1 1 4 1 176 P 4 1 1 1 5 1 238 Q 52 494 R 1 351 S 2 1 2 1 53 51 972 T 1 1 54 11 1 51 1 736 V 1 15 1 1 54 54 1 699 W 1 5 1 59 1 243 X Y 6 9 10 7 1 34 1 542 Z 3 — 31 34 46 39 21 1 1 578 unknown (?) 1 1 2 3 8 not 5 5 5 5 5 5 5 9 9 10 11 14 14 14 15 16 16 17 406 sequenced sum of seq² 65 65 65 65 65 65 65 61 61 60 59 56 56 56 55 54 54 53 oomcaa³ 31 34 46 39 28 59 34 59 58 52 59 54 40 54 51 54 53 51 mcaa⁴ — — — — F D Y W G Q G T L V T V S S rel. oomcaa⁵ 48% 52% 71% 60% 43% 91% 52% 97% 95% 87% 100% 96% 71% 96% 93% 100% 98% 96% pos 11 10 8 7 6 6 9 3 4 7 1 3 5 3 2 1 2 3 occupied⁶

TABLE 6B Analysis of V heavy chain subgroup 18 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 32 34 B C D E 1 5 1 35 F G 27 35 H 1 1 I K 3 1 34 33 L 3 26 1 M 1 1 N P 1 33 1 Q 21 20 26 R 1 1 2 S 27 1 34 T 1 1 V 3 21 20 35 35 W X Y Z — unknown (?) not sequenced 15 15 15 13 13 13 13 13 6 5 5 5 5 5 5 5 5 5 sum of seq² 25 25 25 27 27 27 27 27 34 35 35 35 35 35 35 35 35 35 oomcaa³ 21 21 20 26 20 26 27 27 32 35 35 34 33 33 35 34 34 35 mcaa⁴ Q V Q L V Q S G A E V K K P G A S V rel. oomcaa⁵ 84% 84% 80% 96% 74% 96% 100% 100% 94% 100% 100% 97% 94% 94% 100% 97% 97% 100% pos occupied⁶ 3 3 4 2 4 2 1 1 3 1 1 2 2 3 1 2 2 1 Framework I CDR I amino acid¹ 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 A 30 2 6 B C 35 D 1 5 E 3 1 F 2 39 2 2 G 1 40 1 14 1 H 3 1 I 1 1 1 9 K 33 28 L 1 1 5 M 23 N 1 1 3 1 P 1 Q 2 1 1 R 2 2 1 S 35 40 5 2 15 2 1 T 2 3 32 34 1 V 34 1 1 1 1 2 2 W X Y 36 1 32 19 Z — 40 40 unknown (?) not sequenced 5 5 5 5 5 5 sum of seq² 35 35 35 35 35 35 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 33 34 35 35 28 30 40 40 36 32 39 34 15 40 40 32 19 23 mcaa⁴ K V S C K A S G Y T F T S — — Y Y M rel. oomcaa⁵ 94% 97% 100% 100% 80% 86% 100% 100% 90% 80% 98% 85% 38% 100% 100% 80% 48% 58% pos occupied⁶ 2 2 1 1 4 4 1 1 4 4 2 6 10 1 1 5 11 5 CDR I Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A 39 1 1 B C D 1 1 1 E 1 39 F 2 1 G 1 39 28 39 1 H 34 I 3 34 K 1 L 2 1 37 1 M 37 2 4 N 3 35 P 1 34 1 Q 1 1 39 39 1 R 37 1 10 4 S 1 1 2 T 4 1 V 38 1 W 40 40 33 X Y 1 Z — unknown (?) not sequenced sum of seq² 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 34 40 38 37 39 39 34 39 39 28 37 39 40 37 39 33 34 35 mcaa⁴ H W V R Q A P G Q G L E W M G W I N rel. oomcaa⁵ 85% 100% 95% 93% 98% 98% 85% 98% 98% 70% 93% 98% 100% 93% 98% 83% 85% 88% pos occupied⁶ 5 1 2 4 2 2 4 2 2 4 3 2 1 2 2 4 4 5 CDR II amino acid¹ A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 7 1 1 2 27 2 1 B C D 1 1 4 E 1 1 2 2 1 1 F 1 4 39 G 1 9 1 39 15 6 1 34 H 2 1 1 I 1 1 K 1 2 2 8 36 1 L 1 1 M N 20 12 1 17 18 1 P 31 Q 36 37 R 3 1 2 1 2 37 S 1 20 1 2 11 1 T 3 35 2 1 1 V 1 1 W 3 X Y 2 33 Z — 40 40 unknown (?) not sequenced sum of seq² 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 31 40 40 20 20 39 17 35 18 33 27 36 36 39 37 34 37 mcaa⁴ P — — N S G N T N Y A Q K F Q G R rel. oomcaa⁵ 78% 100% 100% 50% 50% 98% 43% 88% 45% 83% 68% 90% 90% 98% 93% 85% 93% pos occupied⁶ 4 1 1 9 8 2 8 4 8 4 4 4 5 2 3 4 2 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B A 1 2 12 35 B C D 35 1 4 E 1 35 F 3 1 G 1 1 2 H 1 I 1 1 13 22 1 K 1 L 1 2 39 M 23 1 1 37 1 N 4 7 1 2 P 3 Q R 34 1 4 2 16 S 1 37 27 1 35 20 T 39 40 1 38 5 1 39 1 V 38 4 1 W X Y 39 Z — unknown (?) not sequenced sum of seq² 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 oomcaa³ 38 39 23 40 34 35 38 37 22 27 39 35 39 37 35 39 35 20 mcaa⁴ V T M T R D T S I S T A Y M E L S S rel. oomcaa⁵ 95% 98% 58% 100% 85% 88% 95% 93% 55% 68% 98% 88% 98% 93% 88% 98% 88% 50% pos occupied⁶ 3 2 4 1 6 3 3 2 4 5 2 3 2 3 3 2 5 4 Framework III CDR III amino acid¹ C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 A 1 2 40 37 1 6 1 1 B C 37 1 3 D 19 40 1 7 5 2 3 E 19 2 1 F 2 2 1 1 1 3 G 1 7 7 5 5 9 H 1 2 I 1 1 1 1 3 1 K 1 1 1 L 39 2 1 2 4 4 4 3 M 2 2 1 1 N 1 P 1 1 6 4 Q 1 R 37 1 31 5 1 1 3 S 1 36 1 1 1 3 3 1 4 3 T 1 40 2 1 1 2 2 1 V 1 33 1 7 1 1 1 W 1 1 2 X Y 38 35 5 5 4 2 Z — 1 1 4 6 unknown (?) not sequenced 1 1 1 1 1 1 3 3 3 3 3 sum of seq² 40 40 40 40 40 40 40 39 39 39 39 39 39 37 37 37 37 37 oomcaa³ 39 37 36 19 40 40 40 33 38 35 37 37 31 7 7 5 5 9 mcaa⁴ L R S D D T A V Y Y C A R D G D G G rel. oomcaa⁵ 98% 93% 90% 48% 100% 100% 100% 85% 97% 90% 95% 95% 79% 19% 19% 14% 14% 24% pos occupied⁶ 2 4 4 3 1 1 1 5 2 4 3 3 8 10 12 18 13 13 CDR III Framework IV amino acid¹ 100 A B C D E F G H I J K 101 102 103 104 105 106 A 2 3 1 3 1 5 B C 2 1 D 1 5 4 1 2 2 1 2 27 2 E 1 1 2 1 1 1 F 2 1 1 1 1 2 15 1 G 4 7 1 3 2 2 1 1 3 1 27 26 H 1 1 1 I 1 1 1 1 1 1 7 K 1 1 1 1 1 2 L 1 2 1 1 2 1 2 M 1 4 N 1 1 1 1 3 1 1 1 P 1 1 3 2 1 1 1 Q 1 2 1 23 R 1 1 1 S 6 3 2 2 1 1 3 T 5 1 1 1 1 1 1 V 3 1 2 1 1 2 1 1 6 W 2 1 1 1 4 29 X Y 3 4 3 3 2 1 2 5 6 2 11 Z — 8 10 11 14 20 23 25 25 25 23 18 11 6 3 unknown (?) 3 not sequenced 3 4 4 4 4 4 4 4 4 4 4 4 4 4 11 13 13 14 sum of seq² 37 36 36 36 36 36 36 36 36 36 36 36 36 36 29 27 27 26 oomcaa³ 8 10 11 14 20 23 25 25 25 23 18 15 27 11 29 27 23 26 mcaa⁴ — — — — — — — — — — — F D Y W G Q G rel. oomcaa⁵ 22% 28% 31% 39% 56% 64% 69% 69% 69% 64% 50% 42% 75% 31% 100% 100% 85% 100% pos occupied⁶ 12 12 17 14 13 10 9 8 7 8 8 5 5 10 1 1 4 1 Framework IV amino acid¹ 107 108 109 110 111 112 113 sum A 340 B C 79 D 179 E 159 F 130 G 1 450 H 51 I 3 113 K 194 L 12 1 204 M 2 144 N 138 P 128 Q 253 R 1 247 S 1 18 18 432 T 21 6 16 1 390 V 21 18 342 W 158 X Y 294 Z — 394 unknown (?) 3 not sequenced 19 19 19 20 20 21 22 458 sum of seq² 21 21 21 20 20 19 18 oomcaa³ 21 12 21 16 18 18 18 mcaa⁴ T L V T V S S rel. oomcaa⁵ 100% 57% 100% 80% 90% 95% 100% pos occupied⁶ 1 4 1 3 3 2 1

TABLE 6C Analysis of V heavy chain subgroup 2 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 3 B C D E 1 6 2 F G 6 H I 1 K 3 6 1 L 6 6 6 M N 1 P 1 6 6 1 Q 2 4 R 2 S 4 T 6 1 2 5 5 V 5 1 6 W X Y Z 3 — unknown (?) not sequenced 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 sum of seq² 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 oomcaa³ 3 5 6 6 3 6 4 6 6 3 6 6 6 6 5 4 5 6 mcaa⁴ Z V T L K E S G P A L V K P T Q T L rel. oomcaa⁵ 50% 83% 100% 100% 50% 100% 67% 100% 100% 50% 100% 100% 100% 100% 83% 67% 83% 100% pos occupied⁶ 3 2 1 1 3 1 3 1 1 3 1 1 1 1 2 2 2 1 Framework I CDR I amino acid¹ 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 A 1 1 1 B C 7 2 D 1 E F 3 6 1 G 7 4 3 H I 1 K L 6 2 1 6 M 5 N 2 P Q R 2 1 S 1 6 6 6 2 4 T 6 6 6 1 3 1 V 2 2 7 W X Y 1 Z — unknown (?) not sequenced 1 1 1 sum of seq² 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 oomcaa³ 6 6 6 7 6 3 6 7 6 6 6 6 3 4 4 5 3 7 mcaa⁴ T L T C T F S G F S L S T S G M G V rel. oomcaa⁵ 100% 100% 100% 100% 86% 43% 86% 100% 86% 86% 86% 86% 43% 57% 57% 71% 43% 100% pos occupied⁶ 1 1 1 1 2 3 2 1 2 2 2 2 3 4 3 2 4 1 CDR I Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A 6 7 B C D 2 E 7 F 2 G 3 1 7 1 H 2 I 7 6 K 6 L 7 7 2 1 1 M N P 5 7 Q 6 R 7 1 1 2 S 4 1 T V W 7 7 1 X 1 Y 1 Z — unknown (?) not sequenced sum of seq² 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 oomcaa³ 4 7 7 7 6 5 7 7 6 6 7 7 7 7 7 2 6 2 mcaa⁴ S W I R Q P P G K A L E W L A H I D rel. oomcaa⁵ 57% 100% 100% 100% 86% 71% 100% 100% 86% 86% 100% 100% 100% 100% 100% 29% 86% 29% pos occupied⁶ 2 1 1 1 2 3 1 1 2 2 1 1 1 1 1 4 2 5 CDR II amino acid¹ A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A B C D 3 6 5 E 1 1 F 1 1 G H 1 1 I K 1 6 4 L 7 M N 3 P 2 Q R 2 1 2 7 S 2 2 6 7 4 T 4 3 V W 4 1 X 1 1 1 Y 1 3 4 Z — 6 7 7 unknown (?) not sequenced sum of seq² 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 oomcaa³ 6 7 7 4 3 6 5 6 3 4 6 4 7 7 4 4 7 mcaa⁴ — — — W D D D K Y Y S T S L K S R rel. oomcaa⁵ 86% 100% 100% 57% 43% 86% 71% 86% 43% 57% 86% 57% 100% 100% 57% 57% 100% pos occupied⁶ 2 1 1 3 3 2 3 2 3 4 2 3 1 1 3 2 1 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B A B C D 6 1 E F 1 G H I 6 2 1 K 6 6 L 7 6 M 7 N 1 5 6 P Q 7 R 1 1 S 1 5 7 2 T 6 2 6 5 5 V 1 7 7 W X Y Z — 1 1 unknown (?) not sequenced sum of seq² 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 oomcaa³ 7 6 6 5 6 6 6 7 6 5 7 7 7 6 5 7 5 6 mcaa⁴ L T I S K D T S K N Q V V L T M T N rel. oomcaa⁵ 100% 86% 86% 71% 86% 86% 86% 100% 86% 71% 100% 100% 100% 86% 71% 100% 71% 86% pos occupied⁶ 1 2 2 2 2 2 2 1 2 2 1 1 1 2 2 1 3 2 Framework III CDR III amino acid¹ C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 A 1 5 5 B C 7 D 6 7 E F G 2 1 1 H 1 1 I 3 2 K 1 L M 5 N 1 1 2 P 7 1 1 1 Q 1 R 6 1 1 S 1 1 1 T 7 7 1 1 V 1 6 2 1 1 1 1 W 1 X Y 7 7 2 Z — 1 unknown (?) not sequenced 1 1 1 1 1 sum of seq² 7 7 7 7 7 7 7 7 7 7 7 7 7 6 6 6 6 6 oomcaa³ 5 6 7 6 7 7 5 7 7 7 7 5 6 3 1 2 2 1 mcaa⁴ M D P V D T A T Y Y C A R I H N I G rel. oomcaa⁵ 71% 86% 100% 86% 100% 100% 71% 100% 100% 100% 100% 71% 86% 50% 17% 33% 33% 17% pos occupied⁶ 3 2 1 2 1 1 2 1 1 1 1 2 2 4 6 4 5 6 CDR III Framework IV amino acid¹ 100 A B C D E F G H I J K 101 102 103 104 105 106 A 1 2 1 B C D 6 E 2 1 F 3 G 1 2 1 1 1 1 6 6 H I K 1 L 1 1 1 1 M 1 2 N 1 P 1 1 Q 3 R 1 2 S T 1 V 1 1 3 W 1 1 6 X Y 1 2 1 1 1 2 1 Z — 2 2 3 4 4 4 6 5 3 unknown (?) not sequenced 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 sum of seq² 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 oomcaa³ 2 2 2 2 3 4 4 4 6 5 3 3 6 3 6 6 3 6 mcaa⁴ E A — — — — — — — — — F D V W G Q G rel. oomcaa⁵ 33% 33% 33% 33% 50% 67% 67% 67% 100% 83% 50% 50% 100% 50% 100% 100% 50% 100% pos occupied⁶ 5 5 4 5 3 3 3 3 1 2 3 3 1 4 1 1 3 1 Framework IV amino acid¹ 107 108 109 110 111 112 113 sum A 1 35 B C 16 D 43 E 21 F 18 G 55 H 6 I 29 K 1 42 L 3 78 M 20 N 23 P 1 41 Q 23 R 41 S 6 3 82 T 6 1 5 102 V 6 6 68 W 29 X 4 Y 35 Z 3 — 56 unknown (?) not sequenced 1 1 1 1 1 1 4 54 sum of seq² 6 6 6 6 6 6 3 oomcaa³ 6 3 6 5 6 6 3 mcaa⁴ T L V T V S S rel. oomcaa⁵ 100% 50% 100% 83% 100% 100% 100% pos occupied⁶ 1 4 1 2 1 1 1

TABLE 6D Analysis of V heavy chain subgroup 3 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 1 1 12 1 3 1 B 1 1 1 C D 1 1 16 E 110 9 15 166 9 8 2 8 F 4 1 1 G 181 193 174 1 202 134 H 5 4 I 9 K 5 3 26 L 1 5 176 43 140 1 205 M 12 1 1 N 1 P 1 194 Q 41 138 1 3 12 162 1 R 6 4 62 S 178 2 8 206 T 1 4 1 V 5 147 1 118 62 195 W 1 X Y Z 8 — unknown (?) not sequenced 47 47 45 33 32 32 32 31 10 7 6 6 6 6 6 4 4 4 sum of seq² 165 165 167 179 180 180 180 181 202 205 206 206 206 206 206 208 208 208 oomcaa³ 110 147 138 176 118 166 178 181 193 174 140 195 162 194 202 134 206 205 mcaa⁴ E V Q L V E S G G G L V Q P G G S L rel. oomcaa⁵ 67% 89% 83% 98% 66% 92% 99% 100% 96% 85% 68% 95% 79% 94% 98% 64% 99% 99% pos occupied⁶ 5 4 7 4 5 4 3 1 2 5 3 4 7 4 4 4 3 4 Framework I CDR I amino acid¹ 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 A 183 192 1 1 17 80 B C 1 209 D 7 26 3 7 E 8 3 1 1 10 F 1 201 201 5 G 2 207 3 13 31 H 1 4 I 2 3 17 1 1 1 15 K 15 4 7 L 201 6 3 3 3 M 1 193 N 10 10 35 8 3 P 1 2 1 Q R 191 11 7 S 207 4 2 209 15 174 103 17 8 T 2 4 4 1 163 9 15 V 8 7 9 1 6 2 7 1 W 30 X 1 Y 1 154 19 Z — 210 210 unknown (?) not sequenced 4 3 3 3 3 3 3 1 1 2 1 2 2 2 2 sum of seq² 208 209 209 209 209 209 209 211 211 210 211 210 210 210 210 210 210 212 oomcaa³ 191 201 207 209 183 192 209 207 201 163 201 174 103 210 210 154 80 193 mcaa⁴ R L S C A A S G F T F S S — — Y A M rel. oomcaa⁵ 92% 96% 99% 100% 88% 92% 100% 98% 95% 78% 95% 83% 49% 100% 100% 73% 38% 91% pos occupied⁶ 3 2 3 1 7 5 1 3 4 8 4 7 14 1 1 9 10 4 CDR I Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A 1 1 187 1 1 77 42 1 B 3 C 1 1 D 2 1 E 1 1 198 3 F 7 1 2 G 1 2 209 207 33 11 10 H 88 6 I 12 3 3 191 K 1 202 1 37 L 2 3 1 2 1 211 5 12 1 M 1 1 N 34 13 7 P 1 4 191 1 Q 209 1 1 7 7 R 207 7 8 1 24 1 17 S 72 3 14 3 1 102 11 9 118 T 10 4 5 3 5 4 V 197 2 3 204 49 2 W 212 210 1 8 X Y 3 1 22 5 Z — unknown (?) not sequenced 1 1 1 sum of seq² 212 212 211 211 211 212 212 212 212 212 212 212 212 212 212 212 212 212 oomcaa³ 88 212 197 207 209 187 191 209 202 207 211 198 210 204 102 49 191 118 mcaa⁴ H W V R Q A P G K G L E W V S V I S rel. oomcaa⁵ 42% 100% 93% 98% 99% 88% 90% 99% 95% 98% 100% 93% 99% 96% 48% 23% 90% 56% pos occupied⁶ 9 1 3 3 3 9 5 4 4 4 2 5 3 3 3 15 9 11 CDR II amino acid¹ A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 2 14 7 9 1 2 174 33 B 1 1 2 C 1 D 7 94 8 3 11 17 160 E 2 1 2 1 8 3 2 1 2 F 1 1 8 1 3 2 G 46 4 163 85 5 1 5 4 5 212 1 H 1 1 4 I 1 1 3 37 2 8 K 2 30 3 1 1 61 199 8 L 1 1 1 1 M 8 2 1 N 9 2 13 11 1 51 4 2 2 P 1 1 1 1 6 8 18 1 Q 10 3 2 2 2 R 5 1 2 16 5 4 5 6 201 S 43 1 74 17 82 48 11 4 193 T 2 13 12 3 3 42 97 5 7 V 1 6 2 10 2 204 W 6 2 X 4 3 4 1 1 Y 58 8 9 151 210 1 Z — 14 178 178 2 1 1 unknown (?) not sequenced sum of seq² 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 oomcaa³ 58 178 178 94 163 85 51 97 151 210 174 160 193 204 199 212 201 mcaa⁴ Y — — D G G N T Y Y A D S V K G R rel. oomcaa⁵ 27% 84% 84% 44% 77% 40% 24% 46% 71% 99% 82% 75% 91% 96% 94% 100% 95% pos occupied⁶ 19 5 5 12 9 12 19 12 15 2 9 8 3 2 6 1 4 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B A 1 57 1 8 1 B 2 C D 199 38 2 2 1 10 E 6 4 5 F 207 13 G 1 4 H 1 1 2 2 I 14 208 1 2 2 3 1 1 K 186 6 3 L 1 1 188 209 3 1 M 1 2 10 3 2 205 N 5 170 2 188 3 181 10 P 1 Q 7 199 R 211 1 1 2 8 S 2 7 211 153 8 10 56 3 6 186 T 189 1 142 1 4 2 V 1 3 1 11 1 1 W X 2 2 4 1 Y 1 1 194 Z — unknown (?) not sequenced 1 1 sum of seq² 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 212 oomcaa³ 207 189 208 211 211 199 170 153 186 188 142 188 194 209 199 205 181 186 mcaa⁴ F T I S R D N S K N T L Y L Q M N S rel. oomcaa⁵ 98% 89% 98% 100% 100% 94% 81% 73% 88% 89% 67% 89% 92% 99% 94% 97% 85% 88% pos occupied⁶ 5 5 3 2 2 4 4 3 8 7 6 5 5 3 6 4 11 7 Framework III CDR III amino acid¹ C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 A 149 1 1 207 173 2 15 9 11 7 13 B C 1 210 5 2 1 13 5 D 5 15 209 2 54 7 6 11 7 E 1 190 11 2 11 6 3 F 1 15 1 9 6 3 5 G 1 1 6 4 1 2 8 34 26 35 34 17 H 1 1 3 11 3 4 I 8 2 4 15 10 6 11 K 30 60 4 3 5 2 11 L 212 18 1 6 11 7 26 13 M 2 1 6 1 1 N 1 1 2 20 4 3 4 6 P 9 1 3 4 29 10 6 5 Q 1 5 3 9 2 4 R 177 103 9 30 19 4 10 S 1 1 3 9 8 11 16 28 T 3 28 207 1 25 15 7 6 20 6 12 V 9 187 10 1 7 7 15 13 7 W 1 3 4 3 6 5 X 1 Y 211 194 12 9 8 16 14 Z — 1 3 4 12 21 unknown (?) not sequenced 1 1 1 1 1 1 1 1 7 12 13 14 14 sum of seq² 212 212 211 211 211 211 211 211 211 211 211 211 211 205 200 199 198 198 oomcaa³ 212 177 149 190 209 207 207 187 211 194 210 173 103 54 30 35 34 28 mcaa⁴ L R A E D T A V Y Y C A R D R G G S rel. oomcaa⁵ 100% 83% 70% 90% 99% 98% 98% 89% 100% 92% 100% 82% 49% 26% 15% 18% 17% 14% pos occupied⁶ 1 5 10 4 4 4 2 7 1 4 2 5 14 18 20 21 20 20 CDR III Framework IV amino acid¹ 100 A B C D E F G H I J K 101 102 103 104 105 106 A 7 9 6 2 3 5 5 9 13 2 1 1 B 1 C 1 2 11 3 2 1 D 10 4 2 3 10 3 3 1 3 2 146 2 E 1 13 1 1 1 1 F 4 5 5 6 3 5 7 2 1 1 65 1 2 G 35 17 14 23 10 5 1 5 3 2 32 6 140 130 H 3 2 9 2 1 3 1 2 8 1 4 I 4 4 3 1 3 10 3 3 2 1 2 15 K 3 1 13 L 4 12 8 2 6 3 10 3 2 1 10 1 M 2 1 32 N 4 3 2 2 6 2 5 2 1 P 5 6 9 8 2 3 2 1 3 9 17 Q 1 1 1 1 1 1 111 R 9 7 5 5 2 3 1 1 2 4 8 S 27 25 24 8 11 9 3 2 3 1 1 1 7 1 T 9 17 17 1 2 5 1 9 3 1 V 15 4 3 6 2 12 1 1 1 1 34 1 W 6 7 2 4 1 6 10 158 X 1 1 Y 17 5 8 18 20 13 20 25 28 32 28 82 Z — 35 54 73 87 102 110 126 135 134 120 91 71 21 9 2 2 2 2 unknown (?) 3 2 1 1 3 2 not sequenced 14 14 15 19 21 22 23 23 23 25 25 26 25 27 50 67 75 78 sum of seq² 198 197 196 192 190 189 188 188 188 186 186 185 186 184 161 144 136 133 oomcaa³ 35 54 73 87 102 110 126 135 134 120 91 71 146 82 158 140 111 130 mcaa⁴ G — — — — — — — — — — — D Y W G Q G rel. oomcaa⁵ 18% 27% 37% 45% 54% 58% 67% 72% 71% 65% 49% 38% 78% 45% 98% 97% 82% 98% pos occupied⁶ 19 20 19 20 17 14 14 12 12 13 12 8 11 12 3 4 6 3 Framework IV amino acid¹ 107 108 109 110 111 112 113 sum A 2 1767 B 13 C 470 D 1121 E 832 F 807 G 1 2743 H 179 I 1 1 651 K 933 L 91 2 1881 M 6 496 N 1 844 P 1 1 568 Q 949 R 1413 S 118 110 3009 T 123 27 122 1 1426 V 1 125 119 1851 W 686 X 26 Y 1598 Z 8 — 2 2 2 2 2 1 1 2023 unknown (?) 12 not sequenced 81 83 84 86 89 92 97 1650 sum of seq² 130 128 127 125 122 119 114 oomcaa³ 123 91 125 122 119 118 110 mcaa⁴ T L V T V S S rel. oomcaa⁵ 95% 71% 98% 98% 98% 99% 96% pos occupied⁶ 6 6 2 3 3 2 4

TABLE 6E Analysis of V heavy chain subgroup 4 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 19 1 1 B C D E 32 44 F G 54 1 53 2 H 4 2 I K 1 54 L 7 54 53 19 1 53 M N P 33 51 1 Q 52 50 51 20 7 R 1 S 33 52 T 1 52 V 47 1 34 W 20 X Y Z 1 — unknown (?) not sequenced 3 3 3 3 4 4 4 3 3 4 4 3 3 4 4 4 4 4 sum of seq² 54 54 54 54 53 53 53 54 54 53 53 54 54 53 53 53 53 53 oomcaa³ 52 47 50 54 51 32 33 54 33 53 53 34 54 51 52 44 52 53 mcaa⁴ Q V Q L Q E S G P G L V K P S E T L rel. oomcaa⁵ 96% 87% 93% 100% 96% 60% 62% 100% 61% 100% 100% 63% 100% 96% 98% 83% 98% 100% pos occupied⁶ 3 2 2 1 2 3 2 1 4 1 1 3 1 3 2 3 2 1 Framework I CDR I amino acid¹ 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 A 1 22 1 B C 53 1 D 1 4 1 1 1 E F 1 22 1 1 G 53 53 21 3 4 H 1 2 I 1 1 32 K 1 L 50 M N 1 1 2 2 P 2 3 Q 1 R 1 3 2 1 S 52 2 35 51 1 52 25 5 9 1 T 53 29 2 1 V 1 55 1 1 W 1 2 56 X Y 19 1 48 52 Z — 45 39 unknown (?) not sequenced 3 4 4 4 2 2 2 2 2 2 1 1 1 1 1 1 sum of seq² 54 53 53 53 55 55 55 55 55 55 56 56 56 56 56 56 56 56 oomcaa³ 52 50 53 53 29 55 35 53 53 51 32 52 25 45 39 48 52 56 mcaa⁴ S L T C T V S G G S I S S — — Y Y W rel. oomcaa⁵ 96% 94% 100% 100% 53% 100% 64% 96% 96% 93% 57% 93% 45% 80% 70% 86% 93% 100% pos occupied⁶ 3 3 1 1 5 1 3 3 3 3 4 3 7 6 6 7 4 1 CDR I Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A 8 1 1 B C D 1 1 E 1 56 22 F 1 1 1 G 8 55 55 56 1 H 2 I 51 54 1 54 K 54 L 1 1 55 2 M N 1 21 P 50 49 2 Q 56 1 1 R 57 3 2 9 1 S 44 1 3 7 1 T 3 1 1 V 3 1 3 W 57 56 X Y 1 15 32 Z — unknown (?) not sequenced sum of seq² 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 oomcaa³ 44 57 51 57 56 50 49 55 54 55 55 56 56 54 56 22 54 32 mcaa⁴ S W I R Q P P G K G L E W I G E I Y rel. oomcaa⁵ 77% 100% 89% 100% 98% 88% 86% 96% 95% 96% 96% 98% 98% 95% 98% 39% 95% 56% pos occupied⁶ 5 1 5 1 2 5 2 3 2 2 2 2 2 3 2 8 2 6 CDR II amino acid¹ A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 1 1 B C D 1 2 E F 3 G 1 57 1 1 H 24 2 I 1 1 K 1 53 L 1 55 M N 2 40 53 P 54 1 Q R 2 3 56 S 52 49 1 2 56 56 T 8 5 1 54 1 1 1 V 1 1 W X Y 23 11 54 Z — 57 57 57 unknown (?) not sequenced 1 1 1 1 sum of seq² 57 57 57 57 57 57 57 57 57 57 56 56 56 56 57 57 57 oomcaa³ 57 57 57 24 52 57 49 54 40 54 53 54 56 55 53 56 56 mcaa⁴ — — — H S G S T N Y N P S L K S R rel. oomcaa⁵ 100% 100% 100% 42% 91% 100% 86% 95% 70% 95% 95% 96% 100% 98% 93% 98% 98% pos occupied⁶ 1 1 1 5 2 1 7 4 6 2 3 3 1 2 3 2 2 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B A 1 1 1 B C D 1 55 1 E 1 1 F 1 54 1 G 1 H I 1 1 48 3 1 1 K 1 51 3 46 2 L 1 3 1 3 1 55 53 M 7 2 1 1 N 2 1 54 3 3 1 P Q 1 54 1 1 R 2 2 2 S 1 56 1 57 1 57 2 1 44 55 T 51 1 52 1 4 V 53 2 50 1 2 W X Y Z — unknown (?) not sequenced 1 1 sum of seq² 56 56 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 oomcaa³ 53 51 48 56 50 55 52 57 51 54 54 54 57 55 46 53 44 55 mcaa⁴ V T I S V D T S K N Q F S L K L S S rel. oomcaa⁵ 95% 91% 84% 98% 88% 96% 91% 100% 89% 95% 95% 95% 100% 96% 81% 93% 77% 96% pos occupied⁶ 4 5 3 2 4 3 5 1 6 2 2 4 1 3 8 4 7 3 Framework III CDR III amino acid¹ C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 A 55 57 57 56 3 3 3 2 5 B C 57 1 D 57 6 5 5 5 E 6 1 1 2 1 F 4 1 1 G 25 9 10 8 10 H 1 1 I 3 1 2 4 K 2 1 L 2 1 2 6 7 3 5 M 1 1 1 4 3 N 3 P 4 5 3 1 Q 1 1 R 1 54 4 12 2 5 5 S 1 2 1 1 1 4 8 8 1 T 53 55 1 1 2 1 3 4 V 54 1 55 1 1 4 2 2 5 4 W 1 2 1 2 2 X Y 57 56 1 4 5 3 Z — 1 2 unknown (?) not sequenced 1 1 1 1 1 sum of seq² 57 57 57 57 57 57 57 57 57 57 57 57 57 56 56 56 56 56 oomcaa³ 54 53 55 57 57 55 57 55 57 56 57 56 54 25 12 10 8 10 mcaa⁴ V T A A D T A V Y Y C A R G R G G G rel. oomcaa⁵ 95% 93% 96% 100% 100% 96% 100% 96% 100% 98% 100% 98% 95% 45% 21% 18% 14% 18% pos occupied⁶ 3 3 3 1 1 2 1 3 1 2 1 2 4 12 16 16 16 16 CDR III Framework IV amino acid¹ 100 A B C D E F G H I J K 101 102 103 104 105 106 A 4 2 2 4 2 1 1 1 12 B C 1 D 4 3 2 4 3 1 1 2 1 41 E 1 3 1 2 1 F 2 3 2 2 1 1 31 G 11 4 7 7 6 1 1 1 2 1 9 41 40 H 1 1 2 1 I 1 3 2 3 1 1 9 K 2 2 1 3 L 3 2 4 1 5 3 3 1 4 M 1 2 1 9 N 2 1 1 5 1 1 2 P 1 2 1 1 1 2 3 1 2 1 3 2 Q 1 1 1 3 1 29 R 3 2 3 1 2 2 1 1 4 S 2 5 7 4 2 1 1 1 1 1 T 4 3 3 1 1 1 1 V 4 7 3 1 2 1 12 W 4 5 1 1 2 2 1 3 2 46 X Y 6 4 2 3 4 8 4 8 3 5 8 2 16 Z — 4 6 9 11 16 23 27 29 34 31 14 4 unknown (?) 1 1 1 1 not sequenced 2 3 3 6 7 8 9 9 10 11 11 11 11 10 11 16 17 17 sum of seq² 55 54 54 51 50 49 48 48 47 46 46 46 46 47 46 41 40 40 oomcaa³ 11 7 9 11 16 23 27 29 34 31 14 31 41 16 46 41 29 40 mcaa⁴ G V — — — — — — — — — F D Y W G Q G rel. oomcaa⁵ 20% 13% 17% 22% 32% 47% 56% 60% 72% 67% 30% 67% 89% 34% 100% 100% 73% 100% pos occupied⁶ 16 16 18 18 13 15 13 10 9 8 5 4 4 8 1 1 6 1 Framework IV amino acid¹ 107 108 109 110 111 112 113 sum A 1 1 332 B C 113 D 210 E 176 F 135 G 1 674 H 1 45 I 1 282 K 278 L 19 540 M 9 43 N 1 204 P 2 281 Q 334 R 1 250 S 36 33 986 T 33 8 34 532 V 36 36 488 W 267 X Y 455 Z 1 — 466 unknown (?) 4 not sequenced 20 20 21 21 21 21 22 426 sum of seq² 37 37 36 36 36 36 35 oomcaa³ 33 19 36 34 36 36 33 mcaa⁴ T L V T V S S rel. oomcaa⁵ 89% 51% 100% 94% 100% 100% 94% pos occupied⁶ 5 4 1 3 1 1 2

TABLE 6F Analysis of V heavy chain subgroup 5 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 1 1 89 1 1 B C 1 D 2 E 88 1 2 4 93 92 F 1 G 1 92 94 H I K 94 94 L 1 91 2 95 M 3 N P 1 1 94 Q 3 92 1 90 3 R 1 1 1 1 S 92 94 T V 90 89 1 91 W X Y Z — unknown (?) not sequenced 5 5 5 5 4 4 4 4 2 2 2 2 2 2 2 2 2 2 sum of seq² 92 92 92 92 93 93 93 93 95 95 95 95 95 95 95 95 95 95 oomcaa³ 88 90 92 91 89 90 92 92 89 93 91 94 94 94 94 92 94 95 mcaa⁴ E V Q L V Q S G A E V K K P G E S L rel. oomcaa⁵ 96% 98% 100% 99% 96% 97% 99% 99% 94% 98% 96% 99% 99% 99% 99% 97% 99% 100% pos occupied⁶ 3 3 1 2 4 3 2 2 4 2 3 2 2 2 2 2 2 1 Framework I CDR I amino acid¹ 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 A 3 2 4 B C 96 1 1 D 2 2 E 2 1 F 3 6 97 2 G 92 93 1 H 1 4 I 96 4 93 K 77 89 1 L 1 M 1 1 1 N 1 2 4 14 2 P 1 Q 1 4 R 17 1 1 2 1 S 94 1 90 84 10 61 2 2 T 2 5 75 16 2 V 1 W 93 X Y 90 87 Z — 97 97 unknown (?) not sequenced 1 1 1 1 1 1 1 1 1 sum of seq² 96 96 96 96 96 96 96 96 96 97 97 97 97 97 97 97 97 97 oomcaa³ 77 96 94 96 89 92 90 93 90 84 97 75 61 97 97 87 93 93 mcaa⁴ K I S C K G S G Y S F T S — — Y W I rel. oomcaa⁵ 80% 100% 98% 100% 93% 96% 94% 97% 94% 87% 100% 77% 63% 100% 100% 90% 96% 96% pos occupied⁶ 4 1 2 1 5 3 4 3 2 7 1 5 8 1 1 5 4 4 CDR I Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A 8 1 1 1 B C 1 D 1 14 E 3 97 F 1 2 G 72 97 96 95 H 1 3 I 1 75 92 K 1 94 L 2 94 2 2 1 M 1 92 89 1 N P 1 96 2 1 Q 97 1 R 95 1 1 14 S 15 1 T 1 1 3 1 V 93 2 5 1 1 2 W 97 94 X Y 3 76 Z — unknown (?) not sequenced sum of seq² 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 oomcaa³ 72 97 93 95 97 92 96 97 94 96 94 97 94 89 95 75 92 76 mcaa⁴ G W V R Q M P G K G L E W M G I I Y rel. oomcaa⁵ 74% 100% 96% 98% 100% 95% 99% 100% 97% 99% 97% 100% 97% 92% 98% 77% 95% 78% pos occupied⁶ 5 1 4 3 1 5 2 1 2 2 3 1 2 4 3 7 5 6 CDR II amino acid¹ A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 1 2 1 6 1 B C 1 1 1 D 8 93 77 2 E 2 3 2 F 2 91 G 69 1 1 94 H 1 15 I 4 1 1 K 2 L 1 4 M N 2 14 2 P 93 1 95 1 1 Q 91 81 R 1 78 3 1 S 1 16 96 2 2 95 1 95 1 T 1 85 2 1 V 1 W X Y 12 92 Z — 97 97 unknown (?) not sequenced sum of seq² 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 oomcaa³ 93 97 97 69 93 96 77 85 78 92 95 95 95 91 91 94 81 mcaa⁴ P — — G D S D T R Y S P S F Q G Q rel. oomcaa⁵ 96% 100% 100% 71% 96% 99% 79% 88% 80% 95% 98% 98% 98% 94% 94% 97% 84% pos occupied⁶ 5 1 1 6 4 2 6 4 5 4 3 3 3 4 4 3 3 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B A 88 1 91 B C 1 D 97 1 E 2 1 F 1 3 1 G 3 1 H 3 I 3 88 91 K 93 L 2 96 M 3 1 N 7 2 2 P 1 1 Q 1 93 R 1 1 1 1 1 3 S 1 95 96 1 87 2 1 1 90 91 T 96 4 2 94 2 1 V 93 2 9 2 1 W 95 X Y 94 Z — unknown (?) not sequenced sum of seq² 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97 oomcaa³ 93 96 88 95 88 97 93 96 91 87 94 91 94 96 93 95 90 91 mcaa⁴ V T I S A D K S I S T A Y L Q W S S rel. oomcaa⁵ 96% 99% 91% 98% 91% 100% 96% 99% 94% 90% 97% 94% 97% 99% 96% 98% 93% 94% pos occupied⁶ 3 2 5 2 2 1 4 2 4 4 3 5 4 2 3 3 5 4 Framework III CDR III amino acid¹ C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 A 1 96 93 92 1 1 2 3 B C 95 1 1 D 96 3 3 3 3 E 1 1 1 1 2 F 2 6 1 3 G 4 1 9 11 12 12 H 10 1 2 I 2 9 3 2 2 K 91 1 1 1 1 1 3 L 97 2 11 2 3 1 1 M 84 2 1 1 N 2 1 2 P 5 1 4 3 1 Q 1 3 2 1 1 R 3 92 7 9 2 2 S 96 5 1 1 3 2 6 4 T 1 1 1 88 1 1 1 3 2 1 2 V 1 2 2 4 4 1 W 1 2 1 X Y 94 89 1 6 3 6 Z — 1 1 unknown (?) not sequenced 1 2 2 2 2 52 52 52 52 52 sum of seq² 97 97 97 97 97 97 97 97 96 95 95 95 95 45 45 45 45 45 oomcaa³ 97 91 96 96 96 88 93 84 94 89 95 92 92 11 9 11 12 12 mcaa⁴ L K A S D T A M Y Y C A R L G G G G rel. oomcaa⁵ 100% 94% 99% 99% 99% 91% 96% 87% 98% 94% 100% 97% 97% 24% 20% 24% 27% 27% pos occupied⁶ 1 5 2 2 2 4 2 5 2 2 1 3 4 13 16 14 18 16 CDR III Framework IV amino acid¹ 100 A B C D E F G H I J K 101 102 103 104 105 106 A 4 3 2 1 1 4 2 B C 1 2 1 D 1 2 1 1 2 2 1 1 2 37 1 E 1 1 1 1 1 F 3 2 1 26 2 G 5 2 4 3 10 2 1 5 41 41 H 1 1 1 I 1 1 4 1 1 1 1 9 K 1 2 3 L 2 5 1 1 1 2 M 1 1 1 1 10 N 1 1 2 1 2 P 2 1 1 1 1 2 Q 4 2 1 2 3 34 R 2 1 2 3 S 4 5 3 5 3 2 2 1 1 2 T 6 3 3 6 1 1 1 V 1 2 1 11 W 1 2 1 1 1 43 X Y 9 8 7 2 1 2 6 8 9 9 10 1 13 Z — 2 8 10 16 23 30 30 31 32 30 22 7 2 2 unknown (?) 1 1 1 1 not sequenced 52 52 52 52 52 52 52 52 52 52 52 53 52 52 54 56 56 56 sum of seq² 45 45 45 45 45 45 45 45 45 45 45 44 45 45 43 41 41 41 oomcaa³ 9 8 10 16 23 30 30 31 32 30 22 26 37 13 43 41 34 41 mcaa⁴ Y Y — — — — — — — — — F D Y W G Q G rel. oomcaa⁵ 20% 18% 22% 36% 51% 67% 67% 69% 71% 67% 49% 59% 82% 29% 100% 100% 83% 100% pos occupied⁶ 15 16 15 14 11 11 9 8 4 6 6 4 5 10 1 1 4 1 Framework IV amino acid¹ 107 108 109 110 111 112 113 sum A 1 611 B C 205 D 458 E 404 F 256 G 1065 H 44 I 2 588 K 650 L 25 1 549 M 8 303 N 64 P 1 1 414 Q 612 R 351 S 40 39 1545 T 40 8 39 604 V 40 41 594 W 432 X Y 738 Z — 635 unknown (?) 4 not sequenced 56 56 56 56 56 56 57 1678 sum of seq² 41 41 41 41 41 41 40 oomcaa³ 40 25 40 39 41 40 39 mcaa⁴ T L V T V S S rel. oomcaa⁵ 98% 61% 98% 95% 100% 98% 98% pos occupied⁶ 2 3 2 2 1 2 2

TABLE 6G Analysis of V heavy chain subgroup 6 Framework I amino acid¹ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 A 1 B C D E F G 52 67 H I K 68 L 52 68 1 67 M N P 68 67 Q 52 52 51 52 68 R 1 1 S 52 1 68 T 68 V 52 66 1 W X Y Z — unknown (?) not sequenced 22 22 22 22 22 22 22 22 6 6 6 6 6 6 6 6 6 6 sum of seq² 52 52 52 52 52 52 52 52 68 68 68 66 68 68 68 68 68 68 oomcaa³ 52 52 52 52 51 52 52 52 68 67 68 66 68 67 68 68 68 67 mcaa⁴ Q V Q L Q Q S G P G L V K P S Q T L rel. oomcaa⁵ 100% 100% 100% 100% 98% 100% 100% 100% 100% 99% 100% 97% 100% 99% 100% 100% 100% 99% pos occupied⁶ 1 1 1 1 2 1 1 1 1 2 1 3 1 2 1 1 1 2 Framework I CDR I amino acid¹ 19 20 21 22 23 24 25 26 27 28 29 30 31 A B 32 33 34 A 1 67 66 67 B C 68 D 68 1 E F 2 1 1 G 1 69 3 1 2 H I 64 2 K 3 L 1 68 M N 1 2 66 P 1 Q R 2 1 S 66 1 1 69 69 68 66 67 3 T 67 2 1 4 1 V 1 4 70 6 W 1 74 X Y 1 Z — unknown (?) 1 not sequenced 6 6 5 5 5 5 5 5 5 5 4 4 sum of seq² 68 68 69 69 69 69 69 69 69 69 70 70 74 74 74 74 74 74 oomcaa³ 66 68 67 68 67 64 69 69 68 69 70 68 66 66 67 66 67 74 mcaa⁴ S L T C A I S G D S V S S N S A A W rel. oomcaa⁵ 97% 100% 97% 99% 97% 93% 100% 100% 99% 100% 100% 97% 89% 89% 91% 89% 91% 100% pos occupied⁶ 3 1 3 2 3 3 1 1 2 1 1 2 5 6 3 4 5 1 CDR I Framework II CDR II amino acid¹ 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 A 1 1 B C D 1 E 74 F 1 2 G 74 74 1 H 1 I 1 70 K 1 1 L 1 74 74 M N 70 P 73 Q 72 R 74 73 73 S 1 74 1 73 T 73 V 2 W 74 74 X Y 1 72 Z — unknown (?) not sequenced sum of seq² 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 oomcaa³ 70 74 70 74 72 74 73 73 73 74 74 74 74 74 74 73 73 72 mcaa⁴ N W I R Q S P S R G L E W L G R T Y rel. oomcaa⁵ 95% 100% 95% 100% 97% 100% 99% 99% 99% 100% 100% 100% 100% 100% 100% 99% 99% 97% pos occupied⁶ 5 1 4 1 3 1 2 2 2 1 1 1 1 1 1 2 2 2 CDR II amino acid¹ A B C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 A 1 73 1 B C 1 D 68 1 E 1 3 7 1 F 1 1 7 G 1 1 1 8 H 1 1 I 1 K 1 66 1 67 L 1 5 2 M N 1 2 65 1 1 P 1 1 Q 2 1 R 72 1 1 1 3 73 S 1 72 2 2 1 1 73 66 T 5 4 V 58 72 W 73 X Y 72 60 1 72 Z — 74 unknown (?) not sequenced sum of seq² 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 oomcaa³ 72 72 74 72 66 73 60 65 68 72 73 58 73 72 67 66 73 mcaa⁴ Y R — S K W Y N D Y A V S V K S R rel. oomcaa⁵ 97% 97% 100% 97% 89% 99% 81% 88% 92% 97% 99% 78% 99% 97% 91% 89% 99% pos occupied⁶ 3 3 1 3 5 2 7 6 5 3 2 7 2 2 5 2 2 Framework III amino acid¹ 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 A B A 2 6 1 B C D 2 73 3 E 2 F 71 1 G H 1 2 1 I 65 2 71 1 1 K 1 70 4 L 4 1 1 74 72 M 1 1 N 69 74 63 P 66 Q 72 71 R 1 1 1 S 1 2 1 73 74 1 73 T 69 1 71 1 2 1 V 4 2 1 2 1 W X Y Z — unknown (?) not sequenced sum of seq² 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 74 oomcaa³ 65 69 71 69 66 73 71 73 70 74 72 71 74 74 71 72 63 73 mcaa⁴ I T I N P D T S K N Q F S L Q L N S rel. oomcaa⁵ 88% 93% 96% 93% 89% 99% 96% 99% 95% 100% 97% 96% 100% 100% 96% 97% 85% 99% pos occupied⁶ 4 4 3 4 4 2 4 2 3 1 3 3 1 1 3 3 7 2 Framework III CDR III amino acid¹ C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 A 1 74 69 11 1 3 12 4 B C 73 1 1 D 73 19 4 3 7 4 E 73 10 4 2 1 2 F 3 1 1 1 1 1 G 1 1 16 4 15 15 11 H 1 1 I 2 1 2 2 K 1 1 1 1 1 1 L 1 8 4 2 3 M 1 2 1 N 1 1 3 1 2 1 P 70 10 4 5 Q 1 1 1 1 R 1 69 1 7 8 1 8 S 1 3 3 5 5 5 7 6 T 73 74 1 1 1 4 3 4 V 73 70 3 1 4 5 1 9 W 1 6 8 3 X Y 73 70 6 4 2 2 Z — 2 3 7 14 unknown (?) not sequenced 1 1 2 2 1 sum of seq² 74 74 73 74 74 74 74 74 74 74 74 74 74 73 72 71 71 72 oomcaa³ 73 73 70 73 73 74 74 70 73 70 73 69 69 19 10 15 15 14 mcaa⁴ V T P E D T A V Y Y C A R D P G G — rel. oomcaa⁵ 99% 99% 96% 99% 99% 100% 100% 95% 99% 95% 99% 93% 93% 26% 14% 21% 21% 19% pos occupied⁶ 2 2 2 2 2 1 1 3 2 3 2 4 4 14 20 19 15 17 CDR III Framework IV amino acid¹ 100 A B C D E F G H I J K 101 102 103 104 105 106 A 3 2 5 8 10 1 B C 1 1 1 D 3 1 6 1 1 1 62 E 2 1 2 1 F 2 3 2 1 38 4 2 G 8 6 2 5 1 8 6 1 17 49 50 H 1 1 1 1 1 1 1 2 I 5 1 9 K 1 1 1 L 2 1 1 5 8 5 M 1 5 11 N 1 1 3 2 1 1 3 P 3 5 1 1 4 6 Q 1 1 40 R 8 3 1 1 5 1 2 S 7 3 4 2 1 1 4 1 T 4 6 3 1 1 V 4 9 5 1 1 2 21 W 2 4 4 4 65 X Y 2 6 6 2 4 2 1 8 8 12 12 19 Z — 23 25 33 41 47 53 54 57 56 50 28 12 4 2 unknown (?) 6 1 5 not sequenced 1 1 1 1 1 1 1 1 1 1 1 1 1 5 8 23 24 23 sum of seq² 72 72 72 72 72 72 72 72 72 72 72 72 72 68 65 50 49 50 oomcaa³ 23 25 33 41 47 53 54 57 56 50 28 38 62 21 65 49 40 50 mcaa⁴ — — — — — — — — — — — F D V W G Q G rel. oomcaa⁵ 32% 35% 46% 57% 65% 74% 75% 79% 78% 69% 39% 53% 86% 31% 100% 98% 82% 100% pos occupied⁶ 16 16 13 13 11 8 8 4 5 7 6 6 5 9 1 2 4 1 Framework IV amino acid¹ 107 108 109 110 111 112 113 sum A 2 494 B C 147 D 1 403 E 186 F 2 150 G 571 H 18 I 3 1 304 K 1 293 L 26 632 M 8 31 N 436 P 1 387 Q 539 R 495 S 1 43 46 1271 T 45 4 45 640 V 2 46 48 647 W 5 398 X Y 518 Z — 585 unknown (?) 13 not sequenced 24 25 25 28 25 28 26 580 sum of seq² 49 48 48 45 48 45 47 oomcaa³ 45 26 46 45 48 43 46 mcaa⁴ T L V T V S S rel. oomcaa⁵ 92% 54% 96% 100% 100% 96% 98% pos occupied⁶ 3 7 3 1 1 2 2

Appendix to Tables 1A-C

A. References of Rearranged Sequences

References of Rearranged Human Kappa Sequences Used for Alignment

1 Alescio-Zonta, L. & Baglioni, C (1970) Eur. J. Biochem., 15, 450-463.

2 Andrews, D. W. & Capra, J. D. (1981) Biochemistry, 20, 5816-5822.

3 Andris, J. S., Ehrlich, P. H., Ostberg, L. & Capra. J. D. (1992) J. Immunol., 149, 4053-4059.

4 Atkinson, P. M., Lampman, G. W., Furie, B. C., Naparstek, Y., Schwartz, R. S., Stollar, B. D. & Furie, B. (1985) J. Clin. Invest., 75. 1138-1143.

5 Aucouturier, P., Bauwens, M., Khamlichi, A. A., Denoroy, L. Spinelli, S., Touchard, G., Preud'homme, J.-L. & Cogne, M. (1993) J. Immunol., 150, 03561-3568.

6 Avila, M. A., Vazques, J., Danielsson, L., Fernandez De Cossio, M. E. & Borrebaeck, C. A. K. (1993) Gene, 127, 273-274.

7 Barbas Iil, C. F., Crowe, Jr., J. E., Cababa, D., Jones, T. M., Zebedee, S. L., Murphy, B. R., Chanock, R. M. & Burton, D. R. (1992) Proc. Natl. Acad. Sci. Usa, 89, 10164-10168.

8 Barbas, C. F., Iii, et al. (1993) J-Mol-Biol., 230, 812-23.

9 Bentley, D. L. & Rabbitts, T. H. (1980) Nature, 288, 730-733.

10 Bentley, D. L. & Rabbitts, T. H. (1983) Cell, 32, 181-189.

11 Bentley, D. L. (1984) Nature, 307, 77-80.

12 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K. & Teng, N. N. H. (1993) J. Immunol., 151, 5011-5021.

13 Blaison, G., Kuntz, J.-L. & Pasquali, J.-L. (1991) Eur. J. Immunol., 21, 1221-1227.

14 Braun, H., Leibold, W., Barnikol, H. U. & Hilschmann, N. (1971) Z. Physiol. Chem., 352, 647-651; (1972) Z. Physiol. Chem., 353, 1284-1306.

15 Capra, J. D. & Kehoe, J. M. (1975) Adv. Immunology, 20, 1-40.; Andrews, D. W. & Capra, J. D. (1981) Proc. Nat. Acad. Sci. Usa, 78, 3799-3803.

16 Capra, J. D. & Kehoe, J. M. (1975) Adv. Immunology, 20, 1-40.; Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C. Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322-1325.

17 Chastagner, P., Theze, J. & Zouali, M. (1991) Gene, 101, 305-306.

18 Chen, P. P., Robbins, D. L., Jirik, F. R. Kipps, T. J. & Carson, D. A. (1987) J. Exp. Med, 166, 1900-1905.

19 Chen, P. P., Robbins, D. L., Jirik, F. R., Kipps, T. J. & Carson, D. A. (1987) J. Exp. Med. 166, 1900-1905; Liu, M.-F., Robbins, D. L., Crowley, J. J., Sinha, S., Kozin, F., Kipps, T. J., Carson, D. A. & Chen. P. P. (1989) J. Immunol., 142, 688-694.

20 Chersi, A. & Natali, P. G. (1978) Immunochemistry, 15, 585-589.

21 Co, M. S., Deschamps, M., Whitley, R. J. & Queen, C. (1991) Proc. Natl. Acad. Sci. Usa, 88. 2869-2873.

22 Cuisinier, A.-M., Fumoux. F., Fougereau, M. & Tonnelle, C. (1992) Mol. Immunol., 29, 1363-1373.

23 Davidson, A., Manheimer-Lory, A., Aranow, C., Peterson, R., Hannigan, N. & Diamond, B. (1990) J. Clin. Invest., 85, 1401-1409.

24 Denomme, G. A., Mahmoudi, M., Edwards, J. Y., Massicotte, H., Cairns, E. & Bell, D. A. (1993) Hum. Antibod. Hybridomas, 4, 98-103.

25 Dersimonian, H., Mcadam, K. P. W. J., Mackworth-Young, C. & Stollar, B. D. (1989) J. Immunol., 142, 4027-4033.

26 Dreyer, W. J., Gray, W. R. & Hood, L. (1967) Cold Spring Harbor Symp. Quantitative Biol., 32, 353-367.

27 Ebeling, S. B., Schutte, M. E. M. & Logtenberg, T. (1993) Eur. J. Immunol., 23, 1405-1408.

28 Eulitz, M. & Kley, H.-P. (1977) Immunochem., 14, 289-297.

29 Eulitz, M. & Linke. R. P. (1982) Z. Physiol. Chem., 363, 1347-1358.

30 Eulitz, M., Breuer, M., Eblen, A., Weiss, D. T. & Solomon, A. (1990) In Amyloid And Amyloidosis, Eds J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic

31 Eulitz, M., Gotze, D. & Hilschmann, N. (1972) Z. Physiol. Chem., 353, 487-491; Eulitz, M. & Hilschmann, N. (1974) Z. Physiol. Chem., 355, 842-866.

32 Eulitz, M., Kley, H. P. & Zeitler, H. J. (1979) Z. Physiol. Chem., 360, 725-734.

33 Ezaki, I., Kanda, H., Sakai, K., Fukui, N., Shingu, M., Nobunaga, M. & Watanabe, T. (1991) Arthritis And Rheumatism, 34, 343-350.

34 Felgenhauer, M., Kohl, J. & Ruker, F. (1990) Nucl. Acids Res., 18, 4927.

35 Ferri, G., Stoppini, M., ladarola, P., Bellotti, V. & Merlini, G. (1989) Biochim. Biophys. Acta, 995, 103-108.

36 Gillies, S. D., Dorai, H., Wesolowski, J., Majeau, G., Young, D., Boyd, J., Gardner, J. & James, K. (1989) Bio/Tech., 7, 799-804.

37 Goni, F. & Frangione, B. (1983) Proc. Nat. Acad. Sci. Usa, 80, 4837-4841.

38 Goni, F. R., Chen, P. P., Mcginnis, D., Arjonilla, M. L., Fernandez. J., Carson, D., Solomon, A., Mendez, E. & Frangione, B. (1989) J. Immunol., 142, 3158-3163.

39 Gorman, S. D., Clark, M. R., Routledge, E. G., Cobbold, S. P. & Waldmann, H. (1991) Proc. Natl. Acad. Sci. Usa, 88, 4181-4185.

40 Gottlieb, P. D., Cunningham, B. A., Rutishauser, U. & Edelman, G. M. (1970) Biochemistry, 9, 3155-3161.

41 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R. & Winter, G. (1993) Embo J., 12, 725-734.

42 Hieter, P. A., Max, E. E., Seidman, J. G., Maizel. J. V., Jr. & Leder, P. (1980) Cell, 22, 197-207; Klobeck, H. G., Meindl, A., Combriato, G., Solomon. A. & Zachau, H. G. (1985) Nucl. Acids Res., 13, 6499-6513; Weir, L. & Leder, P. (1986)

43 Hilschmann, N. & Craig, L. C. (1965) Proc. Nat. Acad. Sci. Usa, 53, 1403-1409; Hilschmann, N. (1967) Z. Physiol. Chem., 348, 1077-1080.

44 Hilschmann, N. & Craig, L. C. (1965) Proc. Nat. Acad. Sci. Usa, 53, 1403-1409; Hilschmann, N. (1967) Z. Physiol. Chem., 348, 1718-1722; Hilschmann, N. (1969) Naturwissenschaften, 56, 195-205.

45 Hirabayashi, Y., Munakata, Y., Sasaki, T. & Sano, H. (1992) Nucl. Acids Res., 20, 2601.

46 Jaenichen, H.-R., Pech, M., Lindenmaier, W., Wildgruber, N. & Zachau, H. G. (1984) Nuc. Acids Res., 12, 5249-5263.

47 Jirik, F. R., Sorge, J., Fong, S., Heitzmann, J. G., Curd, J. G., Chen, P. P., Goldfien, R. & Carson, D. A. (1986) Proc. Nat. Acad. Sci. Usa, 83, 2195-2199.

48 Kaplan, A. P. & Metzger, H. (1969) Biochemistry, 8, 3944-3951.; Klapper, D. G. & Capra, J. D. (1976) Ann. Immunol. (Inst. Pasteur). 127c, 261-271.

49 Kennedy, M. A. (1991) J. Exp. Med., 173, 1033-1036.

50 Kim, H. S. & Deutsch, H. F. (1988) Immunol., 64, 573-579.

51 Kipps, T. J., Tomhave, E., Chen, P. P. & Carson, D. A. (1988) J. Exp. Med., 167, 840-852.

52 Kipps, T. J., Tomhave, E., Chen, P. P. & Fox, R. I. (1989) J. Immunol., 142, 4261-4268.

53 Klapper, D. G. & Capra, J. D. (1976) Ann. Immunol. (Inst. Pasteur), 127c. 261-271.

54 Klein, U., Kuppers, R. & Rajewsky, K. (1993) Eur. J. Immunol., 23, 3272-3277.

55 Klobeck, H. G. Mcindl, A., Combriato, G., Solomon., A. & Zachau, H. G. (1985) Nucl. Acids Res., 13, 6499-6513.

56 Klobeck, H. G., Bornkammm, G. W., Combriato, G., Mocikat, R., Pohlenz, H. D. & Zachau, H. G. (1985) Nucl. Acids Res., 13, 6515-6529.

57 Klobeck, H. G., Combriato, G. & Zachau, H. G. (1984) Nuc. Acids Res., 12, 6995-7006.

58 Klobeck, H. G., Solomon, A. & Zachau, H. G. (1984) Nature, 309, 73-76.

59 Knight, G. B., Agnello, V., Bonagura, V., Barnes, J. L., Panka. D. J. & Zhang, O.-X. (1993) J. Exp. Med., 178, 1903-1911.

60 Kohler, H., Shimizu, A., Paul, C. & Putnam, F. W. (1970) Science, 169, 56-59. (Kaplan, A. P. & Metzger, H. (1969) Biochemistry, 8, 3944-3951.)

61 Kratzin, H., Yang, C. Y., Krusche, J. U. & Hilschmann, N. (1980) Z. Physiol. Chem., 361, 1591-1598.

62 Kunicki, T. J., Annis, D. S., Gorski, J. & Nugent, D. J. (1991) J. Autoimmunity, 4, 433-446.

63 Larrick, J. W., Wallace, E. F., Coloma, M. J., Bruderer, U., Lang, A. B. & Fry, K. E. (1992) Immunological Reviews, 130, 69-85.

64 Laure, C. J., Watanabe, S. & Hilschmann, N. (1973) Z. Physiol. Chem., 354, 1503-1504.

65 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C., Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322-1325.

66 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C., Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322-1325.

67 Ledford, D. K., Goni, F., Pizzolato, M., Franklin, E. C., Solomon, A. & Frangione, B. (1983) J. Immunol., 131, 1322-1325. Pons-Estel, B., Goni, F., Solomon, A. & Frangione, B. (1984) J. Exp. Med., 160, 893.

68 Levy, S., Mendel, E., Kon, S., Avnur, Z. & Levy, R. (1988) J. Exp. Med., 168, 475-489.

69 Liepnieks, J. J., Dwulet, F. E. & Benson, M. D. (1990) Mol. Immunol., 27, 481-485.

70 Manheimer-Lory, A., Katz, J. B., Pillinger, M., Ghossein, C., Smith, A. & Diamond, B. (1991) J. Exp. Med., 174, 1639-1652.

71 Mantovani, L., Wilder, R. L. & Casali, P. (1993) J. Immunol., 151, 473-488.

72 Mariette, X., Tsapis, A. & Brouet, J.-C. (1993) Eur. J. Immunol., 23, 846-851.

73 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J., Grifriths, A. D. & Winter, G. (1991) J. Mol. Biol, 222, 581-597.

74 Marsh, P., Mills, F. & Gould, H. (1985) Nuc. Acids Res., 13, 6531-6544.

75 Middaugh, C. R. & Litman, G. W. (1987) J. Biol. Chem., 262, 3671-3673.

76 Milstein, C. & Deverson, E. V. (1971) Biochem. J., 123, 945-958.

77 Milstein, C. (1969) Febs Letters, 2, 301-304.

78 Milstein, C. (1969) Febs Letters, 2, 301-304.

79 Milstein, C. P. & Deverson, E. V. (1974) Eur. J. Biochem., 49, 377-391.

80 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D. & Hersh, E. M. (1993) Mol. Immunol., 30, 1543-1551.

81 Nakatani, T., Nomura, N., Horigome, K., Ohtsuka, H. & Noguchi, H. (1989) Bio/Tech., 7, 805-810.

82 Newkirk, M., Chen, P. P., Carson, D., Posnett, D. & Capra, J. D. (1986) Mol. Immunol., 23, 239-244.

83 Newkirk, M. M., Gram, H., Heinrich, G. F., Ostberg, L. Capra, J. D. & Wasserman, R. L. (1988) J. Clin. Invest., 81, 1511-1518.

84 Newkirk, M. M., Mageed, R. A., Jefferis, R., Chen, P. P. & Capra, J. D. (1987) J. Exp. Med., 166, 550-564.

85 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos, M., Kozin, F., Carson, D. A. & Chen, P. P. (1992) J. Exp. Med., 175, 831-842.

86 Palm, W. & Hilschmann, N. (1973) Z. Physiol. Chem., 354, 1651-1654; (1975) Z. Physiol. Chem., 356, 167-191.

87 Pascual, V., Victor, K., Lelsz, D., Spellerberg, M. B., Hamblin, T. J., Thompson, K. M., Randen, I., Natvig, J., Capra, J. D. & Stevenson, F. K. (1991) J. Immunol., 146, 4385-4391.

88 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M., Forre, O., Fu, S.-M., Natvig, J. B. & Capra, J. D. (1992) Scand. J. Immunol., 36, 349-362.

89 Pech, M. & Zachau, H. G. (1984) Nuc. Acids Res., 12, 9229-9236.

90 Pech, M., Jaenichen, H.-R., Pohlenz, H.-D., Neumaier, P. S., Klobeck, H.-G. & Zachau, H. G. (1984) J. Mol. Biol., 176, 189-204.

91 Pons-Estel, B., Goni, F., Solomon, A. & Frangione, B. (1984) J. Exp. Med., 160, 893-904.

92 Portolano, S., Mclachlan, S. M. & Rapoport, B. (1993) J. Immunol., 151, 2839-2851.

93 Portolano, S., Seto, P., Chazenbalk, G. D., Nagayama, Y., Mclachlan, S. M. & Rapoport, B. (1991) Biochem. Biophys. Res. Commun., 179, 372-377.

94 Pratt, L. F., Rassenti, L., Larrick, J., Robbins, B., Banks, P. M. & Kipps, T. J. (1989) J. Immunol., 143, 699-705.

95 Prelli, F., Tummolo, D., Solomon, A. & Frangione, B. (1986) J. Immunol., 136, 4169-4173.

96 Putnam, F. W., Whitley, E. J., Jr., Paul, C. & Davidson, J. N. (1973) Biochemistry, 12, 3763-3780.

97 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O., Capra, J. D. & Natvig, J. B. (1993) Eur. J. Immunol., 23, 1220-1225.

98 Rassenti, L. Z., Pratt, L. F., Chen, P. P., Carson, D. A. & Kipps, T. J. (1991) J. Immunol., 147, 1060-1066.

99 Reidl, L. S., Friedman, D. F., Goldman, J., Hardy, R. R., Jefferies, L. C. & Silberstein, L. E. (1991) J. Immunol., 147, 3623-3631.

100 Riechmann, L., Clark, M., Waldmann, H. & Winter, G. (1988) Nature, 332, 323-327.

101 Riesen, W., Rudikoff, S., Oriol, R. & Potter, M. (1975) Biochemistry, 14, 1052-1057; Riesen, W. F., Braun, D. G. & Jaton, J. C. (1976) Proc. Nat. Acad. Sci. Usa, 73, 2096-2100; Riesen, W. F. & Jaton, J. C. (1976) Biochemistry, 15, 3829.

102 Rodilla Sala, E., Kratzin, D. H., Pick, A. I. & Hilschmann, N. (1990) In Amyloid And Arnyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic

103 Schiechl, H. & Hilschmann, N. (1971) Z. Physiol. Chem., 352, 111-115; (1972) Z. Physiol. Chem., 353, 345-370.

104 Schneider, M. & Hilschmann, N. (1974) Z. Physiol. Chem., 355, 1164-1168.

105 Shearman, C. W., Pollock, D., White, G., Hehir, K., Moore, G. P., Kanzy, E. J. & Kurrle, R. (1991) J. Immunol., 147, 4366-4373.

106 Shinoda, T. (1973) J. Biochem., 73, 433-446.

107 Shinoda, T. (1975) J. Biochem., 77, 1277-1296.

108 Shinoda, T., Takenawa, T., Hoshi, A. & Isobe, T. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic Publishers, Dordrecht/Boston/London, Pp.157

109 Silberstein, L. E., Litwin, S. & Carmack, C. E. (1989) J. Exp. Med., 169, 1631-1643.

110 Sims, M. J., Hassal, D. G. Brett, S., Rowan. W., Lockyer, M. J., Angel, A., Lewis, A. P., Hale, G., Waldmann, H. & Crowe, J. S. (1993) J. Immunol., 151, 2296-2308.

111 Spatz, L. A., Wong, K. K., Williams, M., Desai, R., Golier, J., Berman, J. E., Alt, F. W. & Latov, N. (1990) J. Immunol., 144, 2821-2828.

112 Stavnezer, J., Kekish, O., Batter, D., Grenier, J., Balazs, I., Henderson, E. & Zegers, B. J. M. (1985) Nucl. Acids Res., 13, 3495-3514.

113 Straubinger, B., Thiebe, R., Pech, M. & Zachau, H. G. (1988) Gene. 69.209-214.

114 Suter, L., Barnikol, H. U., Watanabe, S. & Hilschmann, N. (1969) Z. Physiol. Chem, 350, 275-278; (1972) Z. Physiol. Chem., 353, 189-208.

115 Tempest, P. R., Bremner, P., Lambert, M., Taylor, G., Furze, J. M., Carr, F. J. & Harris, W. J. (1991) Bio/Tech., 9, 266-271.

116 Titani, K., Shinoda, T. & Putnam, F. W. (1969) J. Biol. Chem., 244, 3550-3560.

117 Toft, K. G., Olstad, O. K., Sletten, K. & Westermark, P. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre. G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic

118 Van Es, J. H., Aanstoot, H., Gmelig-Meyling, F. H. J., Derksen, R. H. W. M. & Logtenberg, T. (1992) J. Immunol., 149, 2234-2240.

119 Victor, K. D., Pascual, V., Lefvert, A. K. & Capra, J. D. (1992) Mol. Immunol., 29, 1501-1506.

120 Victor, K. D., Pascual, V., Williams, C. L., Lennon, V. A. & Capra, J. D. (1992) Eur. J. Immunol., 22, 2231-2236.

121 Victor, K. D., Randen, I., Thompson, K., Forre, O., Natvig, J. B., Fu, S. M. & Capra, J. D. (1991) J. Clin. Invest., 87, 1603-1613.

122 Wagner, S. D. & Luzzatto, L. (1993) Eur. J. Immunol., 23, 391-397.

123 Watanabe, S. & Hilschmann, N. (1970) Z. Physiol. Chem., 351, 1291-1295.

124 Weisbart, R. H., Wong, A. L., Noritake, D., Kacena, A., Chan, G., Ruland, C., Chin, E., Chen, I. S. Y. & Rosenblatt, J. D. (1991) J. Immunol., 147, 2795-2801.

125 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M. & Marcus, D. M. (1992) J. Immunol., 149, 2518-2529.

126 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) Eur. J. Immunol., 22, 1719-1728.

References of Rearranged Human Lambdo Sequences Used for Alignment

1 Alexandre, D., Chuchana, P., Brockly, F., Blancher, A., Lefranc, G. & Lefrane, M.-P. (1989) Nuc. Acids Res., 17, 3975.

2 Anderson, M. L. M., Brown, L., Mckenzie, E., Kellow, J. E. & Young, B. D. (1985) Nuc.Acids Res., 13, 2931-2941.

3 Andris, J. S., Brodeur, B. R. & Capra. J. D. (1993, Mol.Immunol., 30, 1601-1616.

4 Andris, J. S., Ehrlich, P. H., Ostberg, L & Capra, J. D. (1992) J.Immunol., 149, 4053-4069.

5 Baczko, K., Braun, D. G., Hess, M. & Hilschmann, N. (1970) Z.Physiol.Chem., 351, 763-767; Baczko, K., Braun, D. G. & Hilschmann, N. (1974) Z.Physiol.Chem., 355,131-154.

6 Berinstein, N., Levy. S. & Levy, R. (1989) Science, 244, 337-339.

7 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K. & Teng, N. N. H. (1993) J.Immunol., 151, 5011-5021.

8 Cairns, E., Kwong, P. C., Misener, V., Ip, P., Bell, D. A. & Siminovitch, K. A. (1989) J.Immunol., 143, 685-691.

9 Carroll, W. L., Yu, M., Link, M. P. & Korsmeyer, S. J. (1989) J.Immunol., 143, 692-698.

10 Chen, B. L. & Poljak, R. J. (1974) Biochemistry, 13, 1295-1302.

11 Chen, B. L, Chiu, Y. Y. H., Humphrey, R. L. & Poljak, R. J. (1978) Biochim.Biophys.Acta, 537, 9-21.

12 Combriato, G. & Klobeck. H. G. (1991) Eur.J.Immunol., 21, 1513-1522.

13 Cuisinier, A.-M., Fumoux. F., Fougereau, M. & Tonnelle. C. (1992) Mol.Immunol., 29, 1363-1373.

14 Dwulet, F. E., Strako, K. & Benson. M. D. (1985) ScandJ.Immunol., 22, 653-660.

15 Elahna, P., Livneh, A, Manheimer-Lory, A. J. & Diamond, B. (1991) J.Immunol., 147, 2771-2776.

16 Engelhard, M., Hess, M. & Hilschmann, N. (1974) Z.Physiol.Chem., 355, 85-88; Engelhard, M. & Hilschmann, N. (1975) Z.Physiol.Chem., 356, 1413-1444.

17 Eulitz, M. (1974) Eur.J.Biochem., 50, 49-69.

18 Eulitz, M., Breuer, M. & Linke, R. P. (1987) Biol.Che.Hoppe-Seyler, 368, 863-870.

19 Eulitz, M., Murphy, C., Weiss, D. T. & Solomon, A. (1991) J.Immunol., 146. 3091-3096.

20 Fett, J. W. & Deutsch, H. F. (1974) Biochemistry, 13, 4102-4114.

21 Fett. J. W. & Deutsch, H. F. (1976) Immunochem., 13, 149-155.; Jabusch, J. R. & Deutsch, H. F. (1982) Mol.Immunol., 19, 901-906.

22 Furey, W. Jr., Wang, B. C., Yoo, CS. & Sax. M. (1983) J.Mol.Biol., 167, 661-692.

23 Fykse, E. -M., Sletten. K., Husby. G. & Cornwell, G. G., Iii (1988) Biochem.J., 256, 973-980.

24 Garver, F. A. & Hilschmann, N. (1971) Febs Letters, 16, 128-132; (1972) EurJ.Biochem., 26, 10-32.

25 Gawinowicz, M. A, Merlini, G., Birken, S., Osserman, E. F. & Kabat, E. A (1991) J.Immunol., 147, 915-920.

26 Ghiso, J., Solomon. A. & Frangione, B. (1986) J.Immunol., 136, 716-719.

27 Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye. J. M., Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., Hughes-Jones N. C., Hoogenboom, H. R. & Winter, G. (1993) Embo J., 12, 725-734.

28 Gullasken, N., Idso, H., Nilsen, R., Sletten, K., Husby, G. & Cornwell, G. G. (1990) in Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K.Sletten & P. Westermark. Kluwer Academic

29 Harindranath, N., Goldfarb, I. S., Ikematsu, H., Burastero, S. E., Wilder. R. L., Notkins, A. L. & Casali, P. (1991) Int.Immunol., 3.865-875.

30 Holm, E., Sletten, K. & Husby, G. (1986) Biochem.J., 239, 545-551.

31 Hughes-Jones, N. C., Bye, J. M., Beale, D. & Coadwell, J. (1990) Biochem.J., 268, 135-140.

32 Kametani, F., Yoshimura, K., Tonoike, H., Hoshi, A., Shinoda, T. & Isobe, T. (1985) Biochem.Biophys.Res.Commun., 126, 848-852.

33 Kiefer, C. R., Mcguire, B. S., Jr., Osserman, E. F. & Garver, F. A. (1983) J.Immunol., 131, 1871-1875.

34 Kiefer, C. R., Patton, H. M., Jr., Mcquire, B. S., Jr. & Garver, F. A. (1980) J.Immunol., 124, 301-306.

35 Kishimoto, T., Okajima, H., Okumoto, T. & Taniguchi, M. (1989) Nucl.Acids Res., 17, 4385.

36 Klafki, H.-W., Kratzin, H. D., Pick. A. I., Eckart, K. & Hilschmann. N. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic

37 Kohler, H., Rudofsky, S. & Kluskens, L. (1975) J.Immunology, 114, 415-421.

38 Kojima, M., Odani, S. & Ikenaka, T. (1980) Mol.Immunol., 17, 1407-1414.

39 Komori, S., Yamasaki, N., Shigeta, M., Isojima, S. & Watanabe, T. (1988) Clin.Exp.Immunol., 71, 508-516.

40 Kratzin, H. D., Palm, W., Stangel. M., Schmidt, W. E., Friedrich. J. & Hilschmann, N. (1989) Biol.Chem.Hoppe-Seyler, 370 263-272.

41 Kratzin, H. D., Pick, A. I., Stangel, M. & Hilschmann, N. (1990) In Amyloid And Amyloidosis, Eds. J. B. Natvig, O. Forre. G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic Publishers, Dordrecht/Boston/London, Pp. 181.

42 Langer, B., Steinmetz-Kayne, M. & Hilschmann, N. (1968) Z. Physiol.Chem., 349, 945-951.

43 Larrick, J. W., Danielsson, L. Brenner, C. A., Wallace, E. F., Abrahamson, M., Fry, K. E. & Borrebaeck, C. A. K. (1989) Bio/Tech., 7. 934-938.

44 Levy, S., Mendel, E., Kon. S., Avnur, Z. & Levy, R. (1988) J.Exp.Med., 168, 475-489.

45 Lewis, A. P., Lemon, S. M., Barber, K. A., Murphy, P., Parry, N. R., Peakman, T. C., Sims, M. J., Worden, J. & Crowe, J. S. (1993) J.Immunol., 151, 2829-2838.

46 Liu, V. Y. S., Low, T. L. K., Infante, A. & Putnam, F. W. (1976) Science, 193, 1017-1020; Infante, A. & Putnam, F. W. (1979) J.Biol.Chem., 254, 9006-9016.

47 Lopez De Castro, J. A., Chiu, Y. Y. H. & Poljak, R. J. (1978) Biochemistry, 17, 1718-1723.

48 Mantovani, L., Wilder, R. L. & Casali, P. (1993) J.Immunol., 151, 473-488.

49 Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mccafferty, J., Griffiths. A. D. & Winter, G. (1991) J.Mol.Biol., 222, 581-597.

50 Mihaesco, E., Roy, J.-P., Congy, N., Peran-Rivat, L. & Mihaesco, C. (1985) EurJ.Biochem., 150, 349-357.

51 Milstein. C., Clegg, J. B. & Jarvis, J. M. (1968) Biochem.J., 110, 631-652.

52 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D. & Hersh, E. M. (1993) Mol.Immunol., 30,1543-1551.

53 Nabeshima, Y. & Ikenaka, T. (1979) Mol.Immunol, 16, 439-444.

54 Olee, B. T., Lu, E. W., Huang, D.-F., Soto-Gil, R. W., Deftos, M., Kozin, F., Carson, D. A. & Chen, P. P. (1992) J.Exp.Med., 175, 831-842.

55 Pascual, V., Victor, K., Randen, I., Thompson, K., Steinitz, M., Forre, O., Fu, S.-M., Natvig. J. B. & Capra, J. D. (1992) Scand.J.Immunol., 36, 349-362.

56 Paul, E., Iliev, A. A., Livneh, A. & Diamond, B. (1992) J.Immunol., 149, 3588-3595.

57 Pick, A. I., Kratzin, H. D., Barnikol-Watanabe, S. & Hilschmann, N. (1990) In Amyloid And Amyloidosis. Eds. J. B. Natvig. O. Forre, G. Husby, A. Husebekk, B. Skogen, K. Sletten & P. Westermark, Kluwer Academic

58 Ponstingl, H. & Hilschmann, N. (1969) Z.Physiol.Chem., 350, 1148-1152; (1971) Z.Physiol.Chem, 352, 859-877.

59 Ponstingl, H., Hess, M. & Hilschmann, N. (1968) Z.Physiol.Chem., 349, 867-871; (1971) Z.Physiol.Chem., 352, 247-266.

60 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O., Capra, J. D. & Natvig, J. B. (1993) EurJ.Immunol., 23, 1220-1225.

61 Scholz, R. & Hilschmann, N. (1975) Z.Physiol.Chem., 356, 1333-1335.

62 Settmacher, U., Jahn, S., Siegel, P., Von Baehr, R. & Hansen, A. (1993) Mol.Immunol, 30, 953-954.

63 Shinoda, T., Titani, K. & Putnam, F. W. (1970) J.Biol.Chem., 245, 4475-4487.

64 Sletten, K., Husby, G. & Natvig, J. B. (1974) Scand.J.Immunol., 3, 833-836.; Sletten. K., Natvig, J. B., Husby, G. & Juul, J. (1981) BiochemJ., 195, 561-572.

65 Solomon, A, Frangione. B. & Franklin, E. C. (1982) J.Clin.Invest, 70, 453-460.; Frangione, B., Moloshok, T. & Solomon, A. (1983) J.Immunol., 131, 2490-2493.

66 Takahashi, N., Takayasu, T., Isobe, T., Shinoda, T., Okuyama, T. & Shimizu, A. (1979) J.Biochem., 86, 1523-1535.

67 Takahashi, N., Takayasu, T., Shinoda, T., Ito, S., Okuyama, T. & Shimizu. A. (1980) Biomed.Res., 1, 321-333.

68 Takahashi, Y., Takahashi, N., Tetaert, D. & Putnam, F. W. (1983) Proc.Nat.Acad.Sci.Usa, 80, 3686-3690.

69 Takayasu, T., Takahashi, N., Shinoda, T., Okuyama, T. & Tomioka, H. (1980) J.Biochem., 89, 421-436.

70 Titani., K., Wikier, M., Shinoda, T. & Putnam, F. W. (1970) J.Biol.Chem., 245, 2171-2176.

71 Toft, K. G., Sletten, K. & Husby, G. (1985) Biol.Chem.Hoppe-Seyler, 366, 617-625.

72 Tonoike. H., Kametani, F., Hoshi, A., Shinoda, T. & Isobe, T. (1985) Biochem.Biophys.Res.Commun., 126, 1228-1234.

73 Tonoike, H., Kametani, F., Hoshi, A., Shinoda, T. & Isobe, T. (1985) Febs Letters, 185, 139-141.

74 Tsujimoto, Y. & Croce, C. M. (1984) Nucl.Acids Res., 12, 8407-8414.

75 Tsunetsugu-Yokota. Y., Minekawa, T., Shigemoto, K., Shirasawa. T. & Takemori, T. (1992) Mol.Immunol., 29, 723-728.

76 Tveteraas, T., Sletten. K. & Westermark, P. (1985) Biochem.J., 232, 183-190.

77 Vasicek, T. J. & Leder, P. (1990) J.Exp.Med., 172, 609-620.

78 Victor, K. D., Randen, I., Thompson, K., Forre, O., Natvig. J. B., Fu, S. M. & Capra, J. D. (1991) J.Clin.Invest., 87, 1603-1613.

79 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M. & Marcus, D. M. (1992) J.Immunol., 149, 2518-2529.

80 Wikler, M. & Putnam, F. W. (1970) J.Biol.Chem., 245, 4488-4507.

81 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) EurJ.Immunol., 22, 1719-1728.

82 Yago, K., Zenita, K., Ohwaki, I., Harada, Y., Nozawa, S., Tsukazaki, K., Iwamori, M., Endo. N., Yasuda, N., Okuma, M. & Kannagi, R. (1993) Mol.Immunol., 30, 1481-1489.

83 Yamasaki, N., Komori, S. & Watanabe, T. (1987) Mol.Immunol., 24, 981-985.

84 Zhu, D., Kim. H. S. & Deutsch, H. F. (1983) Mol.Immunol., 20, 1107-1116.

85 Zhu, D., Zhang, H., Zhu. N. & Luo, X. (1986) Scientia Sinica, 29, 746-755.

References of Rearranged Human Heavy Chain Sequences Used for Alignment

1 Adderson, E. E., Azmi. F. H., Wilson. P. M., Shackelford, P. G. & Carroll, W. L. (1993) J.Immunol., 151, 800-809.

2 Adderson, E. E., Shackelford, P. G., Quinn, A. & Carroll, W. L. (1991) J.Immunol. 147, 1667-1674.

3 Akahori, Y., Kurosawa, Y., Kamachi, Y., Torii, S. & Matsuoka, H. (1990) J.Clin.Invest, 85, 1722-1727.

4 Andris, J. S., Brodeur, B. R. & Capra, J. D. (1993) Mol.Immunol., 30, 1601-1616.

5 Andris, J. S., Ehrlich, P. H., Ostberg, L. & Capra, J. D. (1992) J.Immunol., 149, 4053-4059.

6 Andris. J. S., Johnson, S., Zolla-Pazner, S. & Capra, J. D. (1991) Proc.NatlAcad.Sci.Usa, 88, 7783-7787.

7 Anker, R., Conley, M. E. & Pollok, B. A. (1989) J.Exp.Med., 169, 2109-2119.

8 Atkinson. P. M., Lampman, G. W., Furie, B. C., Naparstek, Y., Schwartz, R. S., Stollar, B. D. & Furie. B. (1985) J.Clin.Invest., 75, 1138-1143.; Lampman, G. W., Furie, B., Schwartz, R. S., Stollar, B. D. & Furie, B. C. (1989)

9 Avila, M. A., Vazques, J., Danielsson, L., Fernandez De Cossio, M. E. & Borrebaeck, C. A. K. (1993) Gene, 127, 273-274.

10 Bakkus, M. H. C., Heirman, C., Van Riet, I., Van Camp. B. & Thielemans, K. (1992) Blood, 80, 2326-2335.

11 Barbas Iii, C. F., Crowe, Jr., J. E., Cababa, D., Jones, T. M., Zebedee, S. L., Murphy, B. R., Chanock. R. M. & Burton. D. R. (1992) Proc.Natl.Acad.Sci.Usa, 89, 10164-10168.

12 Barbas, C. F., Iii, Collet, T. A., Amberg, W. Roben, P., Binley, J. M., Hoekstra, D., Cababa, D., Jones, T. M., Williamson, R. A., Pilkington. G. R., Haigwood, N. L., Cabezas, E., Satterthwait, A. C., Sanz, I. & Burton, D. R. (1993) J.Mol.Biol., 230, 812-823.

13 Berman, J. E., Humphries, C. G., Barth, J., Alt, F. W. & Tucker, P. W. (1991) J.Exp.Med., 173, 1529-1535.

14 Berman. J. E., Mellis, S. J., Pollock, R., Smith. C. L., Suh, H., Heinke, B., Kowal, C., Surti, U., Chess, L, Cantor, C. R & Alt, F. W. (1988) Embo J., 7, 727-738.

15 Bhat, N. M., Bieber, M. M., Chapman, C. J., Stevenson, F. K. & Teng, N. N. H. (1993) J.Immunol., 151, 5011-5021.

16 Bird, J., Galili, N., Link, M., Stites, D. & Sklar, J. (1988) J.Exp.Med., 168, 229-245.

17 Cai, J., Humphries, C., Richardson, A. & Tucker, P. W. (1992) J.Exp.Med., 176, 1073-1081.

18 Cairns, E., Kwong, P. C., Misener, V., Ip, P., Bell, D. A. & Siminovitch, K. A (1989) J.Immunol., 143, 685-691.

19 Capra, J. D. & Hopper, J. E. (1976) Immunochemistry, 13, 995-999; Hopper, J. E., Noyes, C., Heinrikson, R. & Kessel, J. W. (1976) J.Immunol., 116, 743-746.

20 Capra, J. D. & Kehoe. J. M. (1974) Proc.Nat.Acad.Sci.Usa, 71, 845-848.

21 Carroll, W. L., Yu, M., Link, M. P. & Korsmeyer, S. J. (1989) J.Immunol., 143, 692-698.

22 Chen, P. P., Liu. M.-F., Glass, C. A., Sinha, S., Kipps, T. J. & Carson, D. A. (1989) Arthritis & Rheumatism, 32, 72-76; Kipps, T. J., Tomhave, E., Pratt, L. F., Duffy, S., Chen, P. P. & Carson, D. A. (1989) Proc.Natl.Acad.Sci.Usa, 86, 5913-5917.

23 Chiu, Y. Y. H., Lopez De Castro, J. A. & Poljak. R. J. (1979) Biochemistry, 18, 553-560.

24 Cleary, M. L., Meeker, T. C., Levy, S., Lee, E., Trela, M., Sklar, J. & Levy, R. (1986) Cell, 44, 97-106.

25 Cuisinier, A.-M., Fumoux. F., Fougereau, M. & Tonnelle, C. (1992) Mol.Immunol., 29, 1363-1373.

26 Cuisinier, A.-M., Gauthier, L., Boubli, L., Fougereau, M. & Tonnelle, C. (1993) EurJ.Immunol., 23, 110-118.

27 Cunningham, B. A., Gottlieb. P. D., Pflumm, M. N. & Edelman, G. M. (1971) Progress In Immunology (B. Amos, Ed.), Academic Press, N.Y., Pp.3-24.

28 Cunningham, B. A., Rutishauser, U., Gall, W. E., Gottlieb, P. D., Waxdal, M. J. & Edelman, G. M. (1970) Biochemistry, 9, 3161-3170.

29 Deane, M. & Norton, J. D. (1990) EurJ.Immunol., 20, 2209-2217.

30 Deane, M. & Norton, J. D. (I991) Leukemia, 5, 646-650.

31 Dersimonian, H., Schwartz, R. S., Barrett. K. J. & Stollar, B. D. (1987) J.Immunol., 139, 2496-2501.

32 Dersimonian, H., Schwartz, R. S., Barrett, K. J. & Stollar, B. D. (1987) J.Immunol, 139, 2496-2501; Chen, P. P., Liu, M.-F., Sinha, S. & Carson, D. A. (1988) Arth.Rheum., 31, 1429-1431.

33 Desai, R., Spatz, L., Matsuda, T., Ilyas, A. A., Berman, J. E., Alt, F. W., Kabat, E. A. & Latov, N. (1990) J.Neuroimmunol., 26, 35-41.

34 Ezaki, I., Kanda, H., Sakai, K., Fukui, N., Shingu, M., Nobunaga, M. & Watanabe, T. (1991) Arthritis And Rheumatism, 34, 343-350.

35 Felgenhauer, M., Kohl, J. & Ruker, F. (1990) Nucl.Acids Res., 18, 4927.

36 Florent, G., Lehman, D. & Putnam, F. W. (1974) Biochemistry, 13, 2482-2498.

37 Friedlander, R. M., Nussenzweig, M. C. & Leder, P. (1990) Nucl.Acids Res., 18, 4278.

38 Gawinowicz, M. A., Merlini, G., Birken. S., Osserman, E. F. & Kabat, E. A. (1991) J.Immunol., 147, 915-920.

39 Gillies, S. D., Dorai, H., Wesolowski, J., Majeau, G., Young, D., Boyd, J., Gardner, J. & James, K. (1989) Bio/Tech., 7, 799-804.

40 Goni, F. & Frangione, B. (1983) Proc.Nat.Acad.Sci.Usa, 80, 4837-4841.

41 Gorman, S. D., Clark, M. R., Routledge, E. G., Cobbold, S. P. & Waldmann, H. (1991) Proc.Natl.Acad.Sci.Usa, 88, 4181-4185.

42 Griffiths, A. D., Malmqist, M., Marks, J. D., Bye, J. M., Embleton, M. J., Mccafferty, J., Baier, M., Holliger, K. P., Gorick, B. D., Hughes-Jones, N. C., Hoogenboom, H. R. & Winter, G. (1993) Embo J., 12, 725-734.

43 Grillot-Courvalin, C., Brouet, J.-C., Piller, F., Rassenti, L. Z., Labaume, S., Silverman, G. J., Silberstein, L. & Kipps, T. J. (1992) EurJ.Immunol., 22, 1781-1788.

44 Guillaume, T., Rubinstein, D. B., Young, F., Tucker, L., Logtenberg, T., Schwartz, R. S. & Barrett. K. L. (1990) J.Immunol., 145, 1934-1945; Young, F., Tucker. L., Rubinstein, D., Guillaume, T., Andre-Schwartz, J., Barrett, K. J., Schwartz, R. S. & Logtenberg, T. (1990)

45 Harindranath, N., Goldfarb, I. S., Ikematsu, H., Burastero, S. E., Wilder, R. L. Notkins, A. L. & Casali, P. (1991) Int.Immunol., 3, 865-875.

46 Hilison, J. L., Oppliger, I. R., Sasso, E. H., Milner, E. C. B. & Wener, M. H. (1992) J.Immunol., 149, 3741-3752.

47 Hirabayashi, Y., Munakata, Y., Sasaki, T. & Sano, H. (1992) Nucl.Acids Res., 20, 2601.

48 Hoch, S. & Schwaber, J. (1987) J.Immunol., 139, 1689-1693.

49 Huang, C., Stewarl A. K., Schwartz, R. S., & Stollar, B. D. (1992) J.Clin.Invest., 89, 1331-1343.

50 Hughes-Jones, N. C., Bye, J. M., Beale, D. & Coadwell, J. (1990) Biochem.J., 268, 135-140.

51 Ikematsu, H., Harindranath, N., Ueki, Y., Notkins, A. L. & Casali, P. (1993) J.Immunol., 150, 1325-1337.

52 Ikematsu, H., Kasaian, M. T., Schettino, E. W. & Casali, P. (1993) J.Immunol., 151, 3604-3616.

53 Kelly, P. J., Pascual, V., Capra, J. D. & Lipsky, P. E. (1992) J.Immunol., 148, 1294-1301.

54 Kipps, T. J. & Duffy, S. F. (1991) J.Clin.Invest., 87, 2087-2096.

55 Kipps, T. J., Tomhave, E., Pratt, L. F., Duffy, S., Chen, P. P. & Carson, D. A. (1989) Proc.Natl.Acad.Sci.Usa, 86, 5913-5917.

56 Kishimoto, T., Okajima, H., Okumoto, T. & Taniguchi, M. (1989) Nucl.Acids Res., 17, 4385.

57 Knight, G. B., Agnello, V., Bonagura, V., Barnes, J. L., Panka, D. J. & Zhang, Q.-X (1993) J.Exp.Med., 178, 1903-1911.

58 Kohler, H., Shimizu, A., Paul, C., Moore, V. & Putnam, F. W. (1970) Nature, 227, 1318-1320; Florent, G., Lehman, D. & Putnam, F. W. (1974) Biochemistry, 13, 2482-2498

59 Komori, S., Yamasaki, N., Shigeta, M., Isojima, S. & Watanabe, T. (1988) Clin.Exp.Immunol., 71, 508-516.

60 Kon, S., Levy, S. & Levy, R. (1987) Proc.Natl.Acad.Sci.Usa, 84, 5053-5057.

61 Kratzin, H., Altevogt P., Ruban, E., Kortt, A., Staroscik, K. & Hilschmann, N. (1975) Z.Physiol.Chem., 356, 1337-1342; Kratzin, H., Altevogt, P., Kortt, A., Ruban, E. & Hilschmann, N. (1978) Z.Physiol.Chem., 359, 1717-1745.

62 Kudo, A., Ishihara, T., Nishimura, Y. & Watanabe, T. (1985) Gene, 33, 181-189.

63 Kunicki, T. J., Annis, D. S., Gorski, J. & Nugent, D. J. (1991) J.Autoimmunity, 4, 433-446.

64 Larrick, J. W., Wallace, E. F., Coloma, M. J., Bruderer, U., Lang, A. B. & Fry, K. E. (1992) Immunological Reviews, 130, 69-85.

65 Lehman, D. W. & Putnam, F. W. (1980) Proc.Nat.Acad.Sci.Usa, 77, 3239-3243.

66 Lewis, A. P., Lemon, S. M., Barber, K. A., Murphy, P., Parry, N. R., Peakman, T. C, Sims, M. J., Worden, J. & Crowe, J. S. (1993) J.Immunol., 151, 2829-2838.

67 Liu, V. Y. S., Low, T. L. K., Infante, A. & Putnam, F. W. (1976) Science, 193, 1017-1020.

68 Logtenberg, T., Young, F. M., Van Es, J., Gmelig-Meyling, F. H. J., Berman, J. E. & Alt, F. W. (1989) J.Autoimmunity, 2, 203-213.

69 Logtenberg, T., Young, F. M., Van Es, J. H., Gmelig-Meyling, F. H. J. & Alt, F. W. (1989) J.Exp.Med., 170, 1347-1355.

70 Manheimer-Lory, A., Katz, J. B., Pillinger, M., Ghossein, C., Smith, A. & Diamond, B. (1991) J.Exp.Med., 174, 1639-1652.

71 Mantovani, L, Wilder, R. L. & Casali, P. (1993) J.Immunol., 151, 473-488.

72 Mariette, X., Tsapis, A. & Brouet, J.-C. (1993) EurJ.Immunol., 23, 846-851.

73 Marks, J. D., Hoogenboom, H. R., Bonnert T. P., Mccafferty, J., Griffiths, A. D. & Winter, G. (1991) J.Mol.Biol., 222, 581-597.

74 Meeker, T. C., Grimaldi, J., O'rourke, R., Loeb, J. Juliusson, G. & Einhorn, S. (1988) J.Immol., 141, 3994-3998.

75 Milili, M., Fougereau, M., Guglielmi, P. & Schiff, C. (1991) Mol.Immunol., 28, 753-761.

76 Moran, M. J., Andris, J. S., Matsumato, Y.-I., Capra, J. D. & Hersh, E. M. (1993) Mol.Immunol., 30, 1543-1551.

77 Mortari, F., Wang, J.-Y. & Schroeder, Jr., H. W. (1993) J.Immunol., 150, 1348-1357.

78 Newkirk, M. M., Gram, H., Heinrich, G. F., Ostberg, L., Capra, J. D. & Wasserman, R. L. (1988) J.Clin.Invest., 81, 1511-1518.

79 Newkirk, M. M., Mageed, R. A., Jefferis, R., Chen, P. P. & Capra, J. D. (1987) J.Exp.Med., 166, 550-564.

80 Nickerson, K. G., Berman, J., Glickman, E., Chess, L & Alt, F. W. (1989) J.Exp.Med., 169, 1391-1403.

81 Olee, B. T., Lu, E. W, Huang, D.-F., Soto-Gil, R. W., Deftos, M., Kozin, F., Carson, D. A. & Chen, P. P. (1992) J.Exp.Med., 175, 831-842.

82 Pascual, V., Randen, I., Thompson, K., Sioud, M. Forre, O., Natvig, J. & Capra, J. D. (1990) J.Clin.Invest., 86, 1320-1328.

83 Pascual, V., Randen, I., Thompson. K., Sioud, M. Forre, O., Natvig, J. & Capra, J. D. (1990) J.Clin.Invest., 86, 1320-1328; Randen, I., Brown, D., Thompson, K. M., Hughes-Jones. N., Pascual, V., Victor, K., Capra, J. D., Forre, O. & Natvig, J. B. (1992)

84 Pascual. V., Victor, K., Lelsz, D., Spellerberg. M. B., Hamblin, T. J., Thompson, K. M., Randen, I., Natvig. J., Capra, J. D. & Stevenson, F. K. (1991) J.Immunol., 146, 4385-4391.

85 Pascual, V., Victor., K, Randen, I., Thompson, K., Steinitz, M., Forre, O., Fu, S.-M., Natvig, J. B. & Capra. J. D. (1992) Scand.J.Immunol., 36, 349-362.

86 Pascual, V., Victor, K., Spellerberg. M., Hamblin, T. J., Stevenson, F. K. & Capra. J. D. (1992) J.Immunol., 149, 2337-2344.

87 Ponstingl, H., Schwarz, J., Reichel, W. & Hilschmann, N. (1970) Z.Physiol.Chem., 351, 1591-1594.; Ponstingl, H. & Hilschmann, N. (1976) Z.Physiol.Chem., 357, 1571-1604.

88 Portolano, S., Mclachlan, S. M. & Rapoport, B. (1993) J.Immunol., 151, 2839-2851.

89 Portolano, S., Seto, P., Chazenbalk. G. D., Nagayama, Y., Mclachlan, S. M. & Rapoport, B. (1991) Biochem.Biophys.Res.Commun., 179, 372-377.

90 Pratt, L. F., Szubin, R., Carson, D. A. & Kipps. T. J. (1991) J.Immunol., 147, 2041-2046.

91 Press, E. M. & Hogg, N. M. (1970) Biochem.J., 117, 641-660.

92 Putnam, F. W., Shimizu, A., Paul., C., Shinoda, T. & Kohler, H. (1971) Ann.N.Y.Acad.Sci., 190, 83-103.

93 Putnam, F. W., Takahashi, N., Tetaert, D., Debuire, B. & Lin, L. C. (1981) Proc.Nat.Acad.Sci.Usa; 78, 6168-6172.; Tabhashi, N., Tetaert. D., Debuire, B., Lin, L. & Putnam, F. W. (1982) Proc.Nat.Acad.Sci.Usa, 79, 2850-2854.

94 Raaphorst, F. M., Timmers, E., Kenter, M. J. H., Van Tol. M. J. D., Vossen, J. M. & Schuurman, R. K. B. (1992) EurJ.Immunol., 22, 247-251.

95 Rabbitts. T. H., Bentley, D. L., Dunnicik; W., Forster. A., Matthyssens, G. & Milstein, C. (1980) Cold Spring Harb.Symp.Quanti.Biol., 45, 867-878; Matthyssens, G. & Rabbitts, T. H. (1980) Proc.Nat.Acad.Sci.Usa, 77, 6561-6565.

96 Randen, I., Pascual, V., Victor, K., Thompson, K. M., Forre, O., Capra, J. D. & Natvig, J. B. (1993) EurJ.Immunol., 23, 1220-1225.

97 Rassenti, L. Z. & Kipps. T. J. (1993) J.Exp.Med., 177, 1039-1046.

98 Reidl, L. S., Friedman, D. F., Goldman, J., Hardy. R. R., Jefferies, L. C. & Silberstein, L. E. (1991) J.Immunol., 147, 3623-3631.

99 Roudier, J., Silverman, G. J., Chen, P. P., Carson, D. A & Kipps, T. J. (1990) J.Immunol., 144, 1526-1530.

100 Sanz, I., Casali, P., Thomas, J. W., Notkins, A. L. & Capra, J. D. (1989) J.Immunol., 142, 4054-4061.

101 Sanz, I., Dang. H., Takei, M., Talal, N. & Capra, J. D. (1989) J.Immunol., 142, 883-887.

102 Schmidt, W. E, Jung, H-. D., Palm, W. & Hilschmann, N. (1983) Z.Physiol.Chem., 364, 713-747.

103 Schroeder, H. W., Jr. & Wang, J. Y. (1990) Proc.NatlAcad.Sci.Usa, 87, 6146-6150.

104 Schroeder, H. W., Jr., Hillson, J. L. & Perlmutter, R. M. (1987) Science, 238, 791-793.

105 Schroeder, H. W., Jr., Hillson, J. L. & Perlmutter, R. M. (1987) Science, 238, 791-793; Chen, P. P., Liu, M.-F., Glass, C. A., Sinha. S., Kipps, T. J. & Carson, D. A. (1989) Arthritis & Rheumatism, 32, 72-76.

106 Schroeder, H. W., Jr., Hillson, J. L. & Perlmutter, R. M. (1987) Science, 238, 791-793; Chen, P. P., Liu, M.-F., Sinha, S. & Carson, D. A. (1988) Arth.Rheum., 31, 1429-1431.

107 Schutte, M. E., Ebeling, S. B., Akkermans, K. E., Gmelig-Meyling, F. H. & Logtenberg, T. (1991) EurJ.Immunol., 21, 1115-1121.

108 Schutte, M. E., Ebeling, S. B., Akkermans, K. E., Gmelig-Meyling, F. H. J. & Logtenberg, T. (1991) EurJ.Immunol., 21, 1115-1121.

109 Settmacher, U., Jahn, S., Siegel, P., Von Baehr, R. & Hansen, A. (1993) Mol.Immunol., 30, 953-954.

110 Shen, A., Humphries, C., Tucker, P. & Blattner, F. (1987) Proc.Natl.Acad.Sci.Usa, 84, 8563-8567.

111 Shimizu, A., Nussenzweig, M. C., Mizuta, T.-R., Leder. P. & Honjo, T. (1989) Proc.Natl.Acad.Sci.Usa, 86, 8020-8023.

112 Shin, E. K., Matsuda, F., Fujikura, J., Akamizu, T., Sugawa, H., Mori, T. & Honjo, T. (1993) EurJ.Immunol., 23, 2365-2367.

113 Silberstein, L. E., Litwin, S. & Carmack, C. E. (1989) J.Exp.Med., 169, 1631-1643.

114 Singal, D. P., Frame, B., Joseph, S., Blajchman, M. A. & Leber, B. F. (1993) Immunogenet., 38, 242.

115 Spatz, L. A., Wong, K. K., Williams, M., Desai, R., Golier, J., Berman, J. E, Alt, F. W. & Latov, N. (1990) J.Immunol., 144, 2821-2828.

116 Steiner, L. A., Garcia-Pardo, A. & Margolies, M. N. (1979) Biochemistry, 18, 4068-4080.

117 Stewart, A. K., Huang, C., Stollar, B. D. & Schwartz, R. S. (1993) J.Exp.Med., 177, 409-418.

118 Thomas. J. W. (1993) J.Immunol., 150, 1375-1382.

119 Torano, A. & Putnam, F. W. (1978) Proc.Nat.Acad.Sci.Usa, 75, 966-969.

120 Van Der Heijden, R. W. J., Bunschoten, H., Pascual, V., Uytdehaag, F. G. C. M., Osterhaus, A. D. M. E. & Capra, J. D. (1990) J.Immunol., 144, 2835-2839.

121 Van Der Stoep. N., Van Der Linden, J. & Logtenberg, T. (1993) J.Exp.Med., 177, 99-107.

122 Van Es, J. H., Gmelig-Meyling, F. H. J. & Logtenberg, T. (1992) Eur.J.Immunol., 22, 2761-2764.

123 Varade, W. S., Marin, E., Kittelberger, A. M. & Insel, R. A. (1993) J.Immunol., 150, 4985-4995.

124 Victor, K. D., Pascual, V., Lefvert, A. K. & Capra, J. D. (1992) Mol.Immunol., 29, 1501-1506.

125 Victor, K. D, Pascual, V., Williams, C. L., Lennon, V. A. & Capra, J. D. (1992) Eur.J.Immunol., 22, 2231-2236.

126 Watanabe, S., Barnikol, H. U., Horn, J., Bertram, J. & Hilschmann, N. (1973) Z.Physiol.Chem, 354, 1505-1509.

127 Weng, N.-P., Yu-Lee, L.-Y., Sanz, I., Patten, B. M. & Marcus, D. M. (1992) J.Immunol., 149, 2518-2529.

128 White, M. B., Word, C. J., Humphries, C. G., Blattner, F. R. & Tucker, P. W. (1990) Mol.Cell.Biol., 10, 3690-3699.

129 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) Eur.J.Immunol., 22, 1719-1728.

130 Yago, K., Zenita, K., Ohwaki, I., Harada, Y., Nozawa, S., Tsukazaki, K., Iwamori, M., Endo, N., Yasuda, N., Okuma, M. & Kannagi, R. (1993) Mol.Immunol., 30, 1481-1489.

131 Zelenetz, A. D., Chen, T. T. & Levy, R. (1992) J.Exp.Med., 176, 1137-1148.

B. References of Germline Sequences

References of Human Germline Kappa Sequences

1 Cox. J. P. L., Tomlinson, I. M. & Winter, G. (1994) Eur.J.Immunol., 24, 827-836.

2 Huber, C., & Al. (1993) Eur.J.Immunol., 23, 2868.

3 Klobeck. H. G., Bornkammm, G. W., Combriato, G., Mocikat, R., Pohlenz, H. D. & Zachau, H. G. (1985) Nucl.Acids Res., 13, 6515-6529.

4 Lautner-Rieske, A., Huber, C., Meindi, A., Pargent, W., Schäble, K. F., Thiebe. R., Zocher. I. & Zachau, H. G. (1992) Eur.J.Immunol. 22, 1023.

5 Lorenz, W., Schäble, K. F., Thiebe, R., Stavnezer, J. & Zachau, H. G. (1988) Mol.Immunol., 25, 479.

6 Pargent, W., Meindl, A., Thiebe, R., Mitzel, S. & Zachau, H. G. (1991) Eur.J.Immunol., 21, 1821-1827.

7 Pech, M. & Zachau, H. G. (1984) Nuc.Acids Res., 12, 9229-9236.

8 Pech, M., Jaenichen, H.-R., Pohlenz, H.-D., Neumaier, P. S., Klobeck, H.-G. & Zachau, H. G. (1984) J.Mol.Biol., 176, 189-204.

9 Scott, M. G., Crimmins, D. L., Mccourt, D. W., Chung, G., Schable, K. F., Thiebe, R., Quenzel, E.-M., Zachau, H. G. & Nahm, M. H. (1991) J.Immunol., 147, 4007-4013.

10 Stavnezer, J., Kekish, O., Batter, D., Grenier, J., Balazs, I., Henderson, E. & Zegers, B. J. M. (1985) Nucl.Acids Res., 13, 3495-3514.

11 Straubinger, B., Huber, E., Lorenz. W., Osterholzer, E., Pargent, W., Pech, M., Pohlenz, H.-D., Zimmer, F.-J. & Zachau. H. G. (1988) J.Mol.Biol., 199, 23-34.

12 Straubinger, B., Thiebe, R., Huber, C., Osterholzer, E. & Zachau, H. G. (1988) Biol.Chem.Hoppe-Seyer, 369, 601-607.

References of Human Germline Lambda Sequences

1 Williams, S. C. & Winter, G. (1993) Eur.J.Immunol., 23, 1456-1461.

2 Siminovitch, K. A., Misener, V., Kwong, P. C., Song, Q.-L. & Chen, P. P. (1989) J.Clin.Invest., 84, 1675-1678.

3 Brockly, F., Alexandre, D., Chuchana, P., Huck. S., Lefranc, G. & Lefranc, M.-P. (1989) Nuc.Acids.Res., 17, 3976.

4 Daley, M. D., Peng, H.-O., Misener, V., Liu, X.-Y., Chen, P. P. & Siminovitch, K. A. (1992) Mol.Immunol., 29, 1515-1518.

5 Deftos, M., Soto-Gil, R., Quan, M., Olee, T. & Chen, P. P. (1994) Scand. J. Immunol., 39, 95.

6 Stiernholm, N. B. J., Kuzniar, B. & Berinstein, N. L. (1994) J. Immunol., 152, 4969-4975.

7 Combriato. G. & Klobeck H. G. (1991) Eur.J.Immunol., 21, 1513-1522.

8 Anderson. M. L. M., Szajnert M. F., Kaplan, J. C., Mccoll, L. & Young, B. D. (1984) Nuc.Acids Res., 12, 6647-6661.

References of Human Germline Heavy Chain Sequences

1 Adderson, E. E., Azmi, F. H., Wilson, P. M., Shackelford, P. G. & Carroll, W. L (1993) J.Immunol., 151, 800-809.

2 Andris, J. S., Brodeur, B. R. & Capra, J. D. (1993) Mol.Immunol., 30, 1601-1616.

3 Berman, J. E., Mellis, S. J., Pollock, R., Smith, C. L., Suh, H., Heinke, B., Kowal, C., Surti, U., Chess, L., Cantor, C. R & Alt, F. W. (1988) Embo J., 7,727-738.

4 Buluwela, L. & Rabbitts, T. H. (1988) Eur.J.Immunol., 18, 1843-1845.; Buluwela. L., Albertson, D. G., Sherrington, P., Rabbitts, P. H., Spurr, N. & Rabbitts, T. H. (1988) Embo J., 7, 2003-2010.

5 Chen, P. P, Liu, M.-F., Sinha, S. & Carson, D. A. (1988) Arth.Rheum., 31, 1429-1431.

6 Chen, P. P., Liu, M.-F., Glass, C. A., Sinha, S., Kipps, T. J. & Carson, D. A. (1989) Arthritis & Rheumatism, 32, 72-76.

7 Cook. G. P. et al. (1994) Nature Genetics 7, 162-168.

8 Haino, M. et al., (1994). J. Biol. Chem. 269, 2619-2626

9 Humphries, C. G., Shen, A., Kuziel, W. A., Capra, J. D., Blattner, F. R. & Tucker, P. W. (1988) Nature, 331, 446-449.

10 Kodaira, M., Kinashi, T., Umemura, I., Matsuda, F., Noma, T., Ono, Y. & Honjo, T. (1986) J.Mol.Biol., 190, 529-541.

11 Lee, K. H., Matsuda, F., Kinashi, T., Kodaira, M. & Honjo, T. (1987) J.Mol.Biol., 195, 761-768.

12 Matsuda, F., Lee, K. H., Nakai, S., Sato, T., Kodaira, M., Zong, S. Q., Ohno, H., Fukuhara, S. & Honjo. T. (1988) Embo J., 7, 1047-1051.

13 Matsuda. F., Shin. E. K., Hirabayashi, Y., Nagaoka. H., Yoshida, M. C., Zong, S. O., & Honjo, T. (1990) Embo J., 9, 2501-2506.

14 Matsuda, F., Shin, E. K, Nagaoka. H., Matsumura, R., Haino, M., Fukita. Y., Taka-Ishi, S., Imai, T., Riley, J. H., Anand, R. &, Al. (1993) Nature Genet. 3,88-94

15 Nagaoka, H., Ozawa, K., Matsuda, F., Hayashida. H., Matsumura, R., Haino, M., Shin, E. K., Fukita, Y., Imai, T., Anand, R., Yokoyama, K., Eki, T., Soeda, E. & Honjo, T. (1993). (Temporal)

16 Rechavi, G., Bienz, B., Ram, D., Ben-Neriah, Y., Cohen, J. B., Zakut, R. & Givol, D. (1982) Proc.Nat.Acad.Sci.Usa, 79, 4405-4409.

17 Sanz, I., Kelly, P., Williams, C., Scholl, S., Tucker, P. & Capra. J. D. (1989) Embo J., 8, 3741-3748.

18 Shin, E. K., Matsuda, F., Fujikura, J., Akamizu, T., Sugawa, H., Mori, T. & Honjo, T. (1993) Eur.J.Immnunol., 23, 2365-2367.

19 Tomlinson, Im., Walter, G., Marks, Jd., Llewelyn, Mb. & Winter. G. (1992) J.Mol.Biol. 227, 776-798.

20 Van Der Maarel, S., Van Dijk, K. W., Alexander, C. M., Sasso, E. H., Bull, A. & Milner, E. C. B. (1993) J.Immunol., 150, 2858-2868.

21 Van Dijk, K. W., Mortari, F., Kirkham, P. M., Schroeder, Jr., H. W. & Milner, E. C. B. (1993) Eur.J.Immunol., 23, 832-839.

22 Van Es, J. H., Aanstoot, H., Gmelig-Meyiing, F. H. J., Derksen, R. H. W. M. & Logtenberg, T. (1992) J.Immunol., 149, 2234-2240.

23 Weng, N.-P., Snyder, J. G., Yu-Lee, L.-Y. & Marcus, D. M. (1992) Eur.J.Immunol., 22, 1075-1082.

24 Winkler, T. H., Fehr, H. & Kalden, J. R. (1992) Eur.J.Immunol., 22, 1719-1728.

25 Olee, T., Yang, P. M., Siminovitch, K. A., Olsen, N. J., Hillson, J. L., Wu, J., Kozin, F., Carson, D. A. et Chen, P. P. (1991) J. Clin.Invest. 88, 193-203.

26 Chen, P. P. & Yang, P. M. (1990) Scand. J. Immunol. 31, 593-599.

27 Tomlinson, M., Walter, G., Cook&Winter, G. (Unpublished)

373 20 amino acids amino acid <Unknown> linear protein 1 Ala Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser 20 82 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide” 2 TCAGCGGGTG GCGGTTCTGG CGGCGGTGGG AGCGGTGGCG GTGGTTCTGG CGGTGGTGGT 60 TCCGATATCG GTCCACGTAC GG 82 83 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide” 3 AATTCCGTAC GTGGACCGAT ATCGGAACCA CCACCGCCAG AACCACCGCC ACCGCTCCCA 60 CCGCCGCCAG AACCGCCACC CGC 83 69 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide misc_feature 28..45 /product= ”6 random codons by trinucleotide mutagenesis (19aa, no Cys)“ 4 GATACGGCCG TGTATTATTG CGCGCGTNNK NNKNNKNNKN NKNNKGATTA TTGGGGCCAA 60 GGCACCCTG 69 84 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide misc_feature 28..57 /product= “10 random codons by trinucleotide mutagenesis (19aa, no Cys)” misc_feature 58..60 /product= “random codon by trinucleotide mutagenesis (TTT/ATG)” misc_feature 64..66 /product= “random codon by trinucleotide mutagenesis (GTT/TAT)” 5 GATACGGCCG TGTATTATTG CGCGCGTNNK NNKNNKNNKN NKNNKNNKNN KNNKNNKWTK 60 GATKWTTGGG GCCAAGGCAC CCTG 84 21 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide” 6 GATACGGCCG TGTATTATTG C 21 17 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide” 7 CAGGGTGCCT TGGCCCC 17 17 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide” 8 GCAGAAGGCG AACGTCC 17 80 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide misc_feature 39..41 /product= ”random codon (mixture of GCT, CGT, CAT, TCT, TAT)“ misc_feature 42..53 /product= ”random codons by trinucleotide mutagenesis (19 aa, no Cys)“ misc_feature 57..59 /product= ”random codon by trinucleotide mutagenesis (19 aa, no Cys)“ 9 TGGAAGCTGA AGACGTGGGC GTGTATTATT GCCAGCAGBV TNNKNNKNNK NNKCCGNNKT 60 TTGGCCAGGG TACGAAAGTT 80 18 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 10 AACTTTCGTA CCCTGGCC 18 108 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide misc_feature 21..23 /product= “random codon by trinucleotide mutagenesis (19aa, no Cys)” misc_feature 27..35 /product= “random codons by trinucleotide mutagenesis (19 aa, no Cys)” misc_feature 36..41 /product= “random codons by mixed monomers (A/G A/C/G T)” misc_feature 42..44 /product= “random codon by trinucleotide mutagenesis (19aa, no Cys)” misc_feature 48..50 /product= “random codon by trinucleotide mutagenesis (19aa, no Cys)” 11 AGGGTCTCGA GTGGGTGAGC NNKATTNNKN NKNNKRVTRV TNNKACCNNK TATGCGGATA 60 GCGTGAAAGG CCGTTTTACC ATTTCACGTG ATAATTCGAA AAACACCA 108 105 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide misc_feature 21..23 /product= ”random codon by trinucleotide mutagenesis (19aa, no Cys)“ misc_feature 27..32 /product= ”random codons by trinucleotide mutagenesis (19aa, no Cys)“ misc_feature 33..38 /product= ”random codons by mixed monomers (A/G A/C/G T)“ misc_feature 39..41 /product= ”random codon by trinucleotide mutagenesis (19aa, no Cys)“ misc_feature 45..47 /product= ”random codon by trinucleotide mutagenesis (19aa, no Cys)“ 12 AGGGTCTCGA GTGGGTGAGC NNKATTNNKN NKRVTRVTNN KACCNNKTAT GCGGATAGCG 60 TGAAAGGCCG TTTTACCATT TCACGTGATA ATTCGAAAAA CACCA 105 20 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 13 TGGTGTTTTT CGAATTATCA 20 108 amino acids amino acid <Unknown> linear protein 14 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 100 105 113 amino acids amino acid <Unknown> linear protein 15 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 85 90 95 Leu Gln Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg 109 amino acids amino acid <Unknown> linear protein 16 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Asn Ser Pro 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 100 105 114 amino acids amino acid <Unknown> linear protein 17 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 Tyr Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg 112 amino acids amino acid <Unknown> linear protein 18 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 112 amino acids amino acid <Unknown> linear protein 19 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85 90 95 Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 108 amino acids amino acid <Unknown> linear protein 20 Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln Thr 1 5 10 15 Ala Arg Ile Thr Cys Ser Gly Asp Ser Leu Gly Ser Lys Tyr Ala Ser 20 25 30 Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Asp 35 40 45 Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn 50 55 60 Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp 65 70 75 80 Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Ser Ser Gly Asn Val Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 119 amino acids amino acid <Unknown> linear protein 21 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Pro Gly Tyr Cys Ser Gly Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 117 amino acids amino acid <Unknown> linear protein 22 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Asn Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Asp Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 120 amino acids amino acid <Unknown> linear protein 23 Glx Val Thr Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Asp Trp Asp Asp Asp Lys Tyr Tyr Ser Thr Ser 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile His Asn Ile Gly Glu Ala Phe Asp Val Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 117 amino acids amino acid <Unknown> linear protein 24 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Ser Tyr Asp Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Gly Gly Ser Gly Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 118 amino acids amino acid <Unknown> linear protein 25 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Tyr His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Arg Gly Gly Gly Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 119 amino acids amino acid <Unknown> linear protein 26 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Leu Gly Gly Gly Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 119 amino acids amino acid <Unknown> linear protein 27 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 50 55 60 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Asp Pro Gly Gly Phe Asp Val Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 109 amino acids amino acid <Unknown> linear protein 28 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 100 105 114 amino acids amino acid <Unknown> linear protein 29 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln His 85 90 95 Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr 110 amino acids amino acid <Unknown> linear protein 30 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro 85 90 95 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 100 105 110 115 amino acids amino acid <Unknown> linear protein 31 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg Thr 115 109 amino acids amino acid <Unknown> linear protein 32 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro 85 90 95 Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 amino acids amino acid <Unknown> linear protein 33 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr 85 90 95 Pro Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 107 amino acids amino acid <Unknown> linear protein 34 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Ser Cys Ser Gly Asp Ala Leu Gly Asp Lys Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 120 amino acids amino acid <Unknown> linear protein 35 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 120 amino acids amino acid <Unknown> linear protein 36 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 121 amino acids amino acid <Unknown> linear protein 37 Gln Val Gln Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asp Lys Tyr Tyr Ser Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 120 amino acids amino acid <Unknown> linear protein 38 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 119 amino acids amino acid <Unknown> linear protein 39 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 120 amino acids amino acid <Unknown> linear protein 40 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 123 amino acids amino acid <Unknown> linear protein 41 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Gly Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 50 55 60 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 327 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..327 /product= ”V kappa 1“ 42 GAT ATC CAG ATG ACC CAG AGC CCG TCT AGC CTG AGC GCG AGC GTG GGT 48 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 GAT CGT GTG ACC ATT ACC TGC AGA GCG AGC CAG GGC ATT AGC AGC TAT 96 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 CTG GCG TGG TAC CAG CAG AAA CCA GGT AAA GCA CCG AAA CTA TTA ATT 144 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 TAT GCA GCC AGC AGC TTG CAA AGC GGG GTC CCG TCC CGT TTT AGC GGC 192 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 TCT GGA TCC GGC ACT GAT TTT ACC CTG ACC ATT AGC AGC CTG CAA CCT 240 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 GAA GAC TTT GCG ACC TAT TAT TGC CAG CAG CAT TAT ACC ACC CCG CCG 288 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 ACC TTT GGC CAG GGT ACG AAA GTT GAA ATT AAA CGT ACG 327 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 100 105 109 amino acids amino acid linear protein 43 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 100 105 342 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..342 /product= ”V kappa 2“ 44 GAT ATC GTG ATG ACC CAG AGC CCA CTG AGC CTG CCA GTG ACT CCG GGC 48 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 110 115 120 125 GAG CCT GCG AGC ATT AGC TGC AGA AGC AGC CAA AGC CTG CTG CAT AGC 96 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 130 135 140 AAC GGC TAT AAC TAT CTG GAT TGG TAC CTT CAA AAA CCA GGT CAA AGC 144 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 145 150 155 CCG CAG CTA TTA ATT TAT CTG GGC AGC AAC CGT GCC AGT GGG GTC CCG 192 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 160 165 170 GAT CGT TTT AGC GGC TCT GGA TCC GGC ACC GAT TTT ACC CTG AAA ATT 240 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 175 180 185 AGC CGT GTG GAA GCT GAA GAC GTG GGC GTG TAT TAT TGC CAG CAG CAT 288 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln His 190 195 200 205 TAT ACC ACC CCG CCG ACC TTT GGC CAG GGT ACG AAA GTT GAA ATT AAA 336 Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 210 215 220 CGT ACG 342 Arg Thr 114 amino acids amino acid linear protein 45 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 20 25 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln His 85 90 95 Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr 330 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..330 /product= ”V kappa 3“ 46 GAT ATC GTG CTG ACC CAG AGC CCG GCG ACC CTG AGC CTG TCT CCG GGC 48 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 115 120 125 130 GAA CGT GCG ACC CTG AGC TGC AGA GCG AGC CAG AGC GTG AGC AGC AGC 96 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 135 140 145 TAT CTG GCG TGG TAC CAG CAG AAA CCA GGT CAA GCA CCG CGT CTA TTA 144 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 150 155 160 ATT TAT GGC GCG AGC AGC CGT GCA ACT GGG GTC CCG GCG CGT TTT AGC 192 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser 165 170 175 GGC TCT GGA TCC GGC ACG GAT TTT ACC CTG ACC ATT AGC AGC CTG GAA 240 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 180 185 190 CCT GAA GAC TTT GCG GTG TAT TAT TGC CAG CAG CAT TAT ACC ACC CCG 288 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro 195 200 205 210 CCG ACC TTT GGC CAG GGT ACG AAA GTT GAA ATT AAA CGT ACG 330 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 215 220 110 amino acids amino acid linear protein 47 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro 85 90 95 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 100 105 110 345 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..345 /product= ”V kappa 4“ 48 GAT ATC GTG ATG ACC CAG AGC CCG GAT AGC CTG GCG GTG AGC CTG GGC 48 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 115 120 125 GAA CGT GCG ACC ATT AAC TGC AGA AGC AGC CAG AGC GTG CTG TAT AGC 96 Glu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Ser Val Leu Tyr Ser 130 135 140 AGC AAC AAC AAA AAC TAT CTG GCG TGG TAC CAG CAG AAA CCA GGT CAG 144 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 145 150 155 CCG CCG AAA CTA TTA ATT TAT TGG GCA TCC ACC CGT GAA AGC GGG GTC 192 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 160 165 170 CCG GAT CGT TTT AGC GGC TCT GGA TCC GGC ACT GAT TTT ACC CTG ACC 240 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 175 180 185 190 ATT TCG TCC CTG CAA GCT GAA GAC GTG GCG GTG TAT TAT TGC CAG CAG 288 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 195 200 205 CAT TAT ACC ACC CCG CCG ACC TTT GGC CAG GGT ACG AAA GTT GAA ATT 336 His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 210 215 220 AAA CGT ACG 345 Lys Arg Thr 225 115 amino acids amino acid linear protein 49 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 100 105 110 Lys Arg Thr 115 327 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..327 /product= ”V lambda 1“ 50 CAG AGC GTG CTG ACC CAG CCG CCT TCA GTG AGT GGC GCA CCA GGT CAG 48 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 120 125 130 CGT GTG ACC ATC TCG TGT AGC GGC AGC AGC AGC AAC ATT GGC AGC AAC 96 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 135 140 145 TAT GTG AGC TGG TAC CAG CAG TTG CCC GGG ACG GCG CCG AAA CTG CTG 144 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 150 155 160 ATT TAT GAT AAC AAC CAG CGT CCC TCA GGC GTG CCG GAT CGT TTT AGC 192 Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 165 170 175 GGA TCC AAA AGC GGC ACC AGC GCG AGC CTT GCG ATT ACG GGC CTG CAA 240 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln 180 185 190 195 AGC GAA GAC GAA GCG GAT TAT TAT TGC CAG CAG CAT TAT ACC ACC CCG 288 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro 200 205 210 CCT GTG TTT GGC GGC GGC ACG AAG TTA ACC GTT CTT GGC 327 Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 215 220 109 amino acids amino acid linear protein 51 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro 85 90 95 Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 330 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..330 /product= ”V lambda 2“ 52 CAG AGC GCA CTG ACC CAG CCA GCT TCA GTG AGC GGC TCA CCA GGT CAG 48 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 110 115 120 125 AGC ATT ACC ATC TCG TGT ACG GGT ACT AGC AGC GAT GTG GGC GGC TAT 96 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 130 135 140 AAC TAT GTG AGC TGG TAC CAG CAG CAT CCC GGG AAG GCG CCG AAA CTG 144 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 145 150 155 ATG ATT TAT GAT GTG AGC AAC CGT CCC TCA GGC GTG AGC AAC CGT TTT 192 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 160 165 170 AGC GGA TCC AAA AGC GGC AAC ACC GCG AGC CTG ACC ATT AGC GGC CTG 240 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 175 180 185 CAA GCG GAA GAC GAA GCG GAT TAT TAT TGC CAG CAG CAT TAT ACC ACC 288 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr 190 195 200 205 CCG CCT GTG TTT GGC GGC GGC ACG AAG TTA ACC GTT CTT GGC 330 Pro Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 210 215 110 amino acids amino acid linear protein 53 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr 85 90 95 Pro Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 321 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..321 /product= ”V lambda 3“ 54 AGC TAT GAA CTG ACC CAG CCG CCT TCA GTG AGC GTT GCA CCA GGT CAG 48 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 115 120 125 ACC GCG CGT ATC TCG TGT AGC GGC GAT GCG CTG GGC GAT AAA TAC GCG 96 Thr Ala Arg Ile Ser Cys Ser Gly Asp Ala Leu Gly Asp Lys Tyr Ala 130 135 140 AGC TGG TAC CAG CAG AAA CCC GGG CAG GCG CCA GTT CTG GTG ATT TAT 144 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 145 150 155 GAT GAT TCT GAC CGT CCC TCA GGC ATC CCG GAA CGC TTT AGC GGA TCC 192 Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 160 165 170 AAC AGC GGC AAC ACC GCG ACC CTG ACC ATT AGC GGC ACT CAG GCG GAA 240 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Glu 175 180 185 190 GAC GAA GCG GAT TAT TAT TGC CAG CAG CAT TAT ACC ACC CCG CCT GTG 288 Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Val 195 200 205 TTT GGC GGC GGC ACG AAG TTA ACC GTT CTT GGC 321 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 210 215 107 amino acids amino acid linear protein 55 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 1 5 10 15 Thr Ala Arg Ile Ser Cys Ser Gly Asp Ala Leu Gly Asp Lys Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Val 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 361 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..360 /product= ”VH1A“ 56 CAG GTG CAA TTG GTT CAG TCT GGC GCG GAA GTG AAA AAA CCG GGC AGC 48 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 110 115 120 AGC GTG AAA GTG AGC TGC AAA GCC TCC GGA GGC ACT TTT AGC AGC TAT 96 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 125 130 135 GCG ATT AGC TGG GTG CGC CAA GCC CCT GGG CAG GGT CTC GAG TGG ATG 144 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 140 145 150 155 GGC GGC ATT ATT CCG ATT TTT GGC ACG GCG AAC TAC GCG CAG AAG TTT 192 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 160 165 170 CAG GGC CGG GTG ACC ATT ACC GCG GAT GAA AGC ACC AGC ACC GCG TAT 240 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 175 180 185 ATG GAA CTG AGC AGC CTG CGT AGC GAA GAT ACG GCC GTG TAT TAT TGC 288 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 190 195 200 GCG CGT TGG GGC GGC GAT GGC TTT TAT GCG ATG GAT TAT TGG GGC CAA 336 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 205 210 215 GGC ACC CTG GTG ACG GTT AGC TCA G 361 Gly Thr Leu Val Thr Val Ser Ser 220 225 120 amino acids amino acid linear protein 57 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 361 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..360 /product= ”VH1B“ 58 CAG GTG CAA TTG GTT CAG AGC GGC GCG GAA GTG AAA AAA CCG GGC GCG 48 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 125 130 135 AGC GTG AAA GTG AGC TGC AAA GCC TCC GGA TAT ACC TTT ACC AGC TAT 96 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 140 145 150 TAT ATG CAC TGG GTC CGC CAA GCC CCT GGG CAG GGT CTC GAG TGG ATG 144 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 155 160 165 GGC TGG ATT AAC CCG AAT AGC GGC GGC ACG AAC TAC GCG CAG AAG TTT 192 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 170 175 180 CAG GGC CGG GTG ACC ATG ACC CGT GAT ACC AGC ATT AGC ACC GCG TAT 240 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 185 190 195 200 ATG GAA CTG AGC AGC CTG CGT AGC GAA GAT ACG GCC GTG TAT TAT TGC 288 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 205 210 215 GCG CGT TGG GGC GGC GAT GGC TTT TAT GCG ATG GAT TAT TGG GGC CAA 336 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 220 225 230 GGC ACC CTG GTG ACG GTT AGC TCA G 361 Gly Thr Leu Val Thr Val Ser Ser 235 240 120 amino acids amino acid linear protein 59 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 364 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..363 /product= ”VH2“ 60 CAG GTG CAA TTG AAA GAA AGC GGC CCG GCC CTG GTG AAA CCG ACC CAA 48 Gln Val Gln Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 125 130 135 ACC CTG ACC CTG ACC TGT ACC TTT TCC GGA TTT AGC CTG TCC ACG TCT 96 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 140 145 150 GGC GTT GGC GTG GGC TGG ATT CGC CAG CCG CCT GGG AAA GCC CTC GAG 144 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 155 160 165 TGG CTG GCT CTG ATT GAT TGG GAT GAT GAT AAG TAT TAT AGC ACC AGC 192 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asp Lys Tyr Tyr Ser Thr Ser 170 175 180 CTG AAA ACG CGT CTG ACC ATT AGC AAA GAT ACT TCG AAA AAT CAG GTG 240 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 185 190 195 200 GTG CTG ACT ATG ACC AAC ATG GAC CCG GTG GAT ACG GCC ACC TAT TAT 288 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 205 210 215 TGC GCG CGT TGG GGC GGC GAT GGC TTT TAT GCG ATG GAT TAT TGG GGC 336 Cys Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly 220 225 230 CAA GGC ACC CTG GTG ACG GTT AGC TCA G 364 Gln Gly Thr Leu Val Thr Val Ser Ser 235 240 121 amino acids amino acid linear protein 61 Gln Val Gln Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asp Lys Tyr Tyr Ser Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 361 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..360 /product= ”VH3“ 62 GAA GTG CAA TTG GTG GAA AGC GGC GGC GGC CTG GTG CAA CCG GGC GGC 48 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 125 130 135 AGC CTG CGT CTG AGC TGC GCG GCC TCC GGA TTT ACC TTT AGC AGC TAT 96 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 140 145 150 GCG ATG AGC TGG GTG CGC CAA GCC CCT GGG AAG GGT CTC GAG TGG GTG 144 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 155 160 165 AGC GCG ATT AGC GGT AGC GGC GGC AGC ACC TAT TAT GCG GAT AGC GTG 192 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 170 175 180 185 AAA GGC CGT TTT ACC ATT TCA CGT GAT AAT TCG AAA AAC ACC CTG TAT 240 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 190 195 200 CTG CAA ATG AAC AGC CTG CGT GCG GAA GAT ACG GCC GTG TAT TAT TGC 288 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 205 210 215 GCG CGT TGG GGC GGC GAT GGC TTT TAT GCG ATG GAT TAT TGG GGC CAA 336 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 220 225 230 GGC ACC CTG GTG ACG GTT AGC TCA G 361 Gly Thr Leu Val Thr Val Ser Ser 235 240 120 amino acids amino acid linear protein 63 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 358 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..357 /product= ”VH4“ 64 CAG GTG CAA TTG CAA GAA AGT GGT CCG GGC CTG GTG AAA CCG AGC GAA 48 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 125 130 135 ACC CTG AGC CTG ACC TGC ACC GTT TCC GGA GGC AGC ATT AGC AGC TAT 96 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 140 145 150 TAT TGG AGC TGG ATT CGC CAG CCG CCT GGG AAG GGT CTC GAG TGG ATT 144 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 155 160 165 GGC TAT ATT TAT TAT AGC GGC AGC ACC AAC TAT AAT CCG AGC CTG AAA 192 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 170 175 180 AGC CGG GTG ACC ATT AGC GTT GAT ACT TCG AAA AAC CAG TTT AGC CTG 240 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 185 190 195 200 AAA CTG AGC AGC GTG ACG GCG GCG GAT ACG GCC GTG TAT TAT TGC GCG 288 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 205 210 215 CGT TGG GGC GGC GAT GGC TTT TAT GCG ATG GAT TAT TGG GGC CAA GGC 336 Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly 220 225 230 ACC CTG GTG ACG GTT AGC TCA G 358 Thr Leu Val Thr Val Ser Ser 235 119 amino acids amino acid linear protein 65 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 361 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..360 /product= ”VH5“ 66 GAA GTG CAA TTG GTT CAG AGC GGC GCG GAA GTG AAA AAA CCG GGC GAA 48 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 120 125 130 135 AGC CTG AAA ATT AGC TGC AAA GGT TCC GGA TAT TCC TTT ACG AGC TAT 96 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 140 145 150 TGG ATT GGC TGG GTG CGC CAG ATG CCT GGG AAG GGT CTC GAG TGG ATG 144 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 155 160 165 GGC ATT ATT TAT CCG GGC GAT AGC GAT ACC CGT TAT TCT CCG AGC TTT 192 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 170 175 180 CAG GGC CAG GTG ACC ATT AGC GCG GAT AAA AGC ATT AGC ACC GCG TAT 240 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 185 190 195 CTT CAA TGG AGC AGC CTG AAA GCG AGC GAT ACG GCC ATG TAT TAT TGC 288 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 200 205 210 215 GCG CGT TGG GGC GGC GAT GGC TTT TAT GCG ATG GAT TAT TGG GGC CAA 336 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 220 225 230 GGC ACC CTG GTG ACG GTT AGC TCA G 361 Gly Thr Leu Val Thr Val Ser Ser 235 120 amino acids amino acid linear protein 67 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 370 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..369 /product= ”VH6“ 68 CAG GTG CAA TTG CAA CAG TCT GGT CCG GGC CTG GTG AAA CCG AGC CAA 48 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 125 130 135 ACC CTG AGC CTG ACC TGT GCG ATT TCC GGA GAT AGC GTG AGC AGC AAC 96 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 140 145 150 AGC GCG GCG TGG AAC TGG ATT CGC CAG TCT CCT GGG CGT GGC CTC GAG 144 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Gly Arg Gly Leu Glu 155 160 165 TGG CTG GGC CGT ACC TAT TAT CGT AGC AAA TGG TAT AAC GAT TAT GCG 192 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 170 175 180 GTG AGC GTG AAA AGC CGG ATT ACC ATC AAC CCG GAT ACT TCG AAA AAC 240 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 185 190 195 200 CAG TTT AGC CTG CAA CTG AAC AGC GTG ACC CCG GAA GAT ACG GCC GTG 288 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 205 210 215 TAT TAT TGC GCG CGT TGG GGC GGC GAT GGC TTT TAT GCG ATG GAT TAT 336 Tyr Tyr Cys Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 220 225 230 TGG GGC CAA GGC ACC CTG GTG ACG GTT AGC TCA G 370 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 235 240 123 amino acids amino acid linear protein 69 Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 20 25 30 Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Gly Arg Gly Leu Glu 35 40 45 Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 50 55 60 Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 65 70 75 80 Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 49 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 70 GAATGCATAC GCTGATATCC AGATGACCCA GAGCCCGTCT AGCCTGAGC 49 56 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 71 CGCTCTGCAG GTAATGGTCA CACGATCACC CACGCTCGCG CTCAGGCTAG ACGGGC 56 58 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 72 GACCATTACC TGCAGAGCGA GCCAGGGCAT TAGCAGCTAT CTGGCGTGGT ACCAGCAG 58 71 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 73 CTTTGCAAGC TGCTGGCTGC ATAAATTAAT AGTTTCGGTG CTTTACCTGG TTTCTGCTGG 60 TACCACGCCA G 71 67 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 74 CAGCCAGCAG CTTGCAAAGC GGGGTCCCGT CCCGTTTTAG CGGCTCTGGA TCCGGCACTG 60 ATTTTAC 67 67 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 75 GATAATAGGT CGCAAAGTCT TCAGGTTGCA GGCTGCTAAT GGTCAGGGTA AAATCAGTGC 60 CGGATCC 67 54 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 76 CGATATCGTG ATGACCCAGA GCCCACTGAG CCTGCCAGTG ACTCCGGGCG AGCC 54 66 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 77 GCCGTTGCTA TGCAGCAGGC TTTGGCTGCT TCTGCAGCTA ATGCTCGCAG GCTCGCCCGG 60 AGTCAC 66 62 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 78 CTGCTGCATA GCAACGGCTA TAACTATCTG GATTGGTACC TTCAAAAACC AGGTCAAAGC 60 CC 62 71 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 79 CGATCCGGGA CCCCACTGGC ACGGTTGCTG CCCAGATAAA TTAATAGCTG CGGGCTTTGA 60 CCTGGTTTTT G 71 69 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 80 AGTGGGGTCC CGGATCGTTT TAGCGGCTCT GGATCCGGCA CCGATTTTAC CCTGAAAATT 60 AGCCGTGTG 69 54 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 81 CCATGCAATA ATACACGCCC ACGTCTTCAG CTTCCACACG GCTAATTTTC AGGG 54 38 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 82 GAATGCATAC GCTGATATCG TGCTGACCCA GAGCCCGG 38 67 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 83 CGCTCTGCAG CTCAGGGTCG CACGTTCGCC CGGAGACAGG CTCAGGGTCG CCGGGCTCTG 60 GGTCAGC 67 56 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 84 CCCTGAGCTG CAGAGCGAGC CAGAGCGTGA GCAGCAGCTA TCTGGCGTGG TACCAG 56 72 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 85 GCACGGCTGC TCGCGCCATA AATTAATAGA CGCGGTGCTT GACCTGGTTT CTGCTGGTAC 60 CACGCCAGAT AG 72 67 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 86 GCGCGAGCAG CCGTGCAACT GGGGTCCCGG CGCGTTTTAG CGGCTCTGGA TCCGGCACGG 60 ATTTTAC 67 66 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 87 GATAATACAC CGCAAAGTCT TCAGGTTCCA GGCTGCTAAT GGTCAGGGTA AAATCCGTGC 60 CGGATC 66 49 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 88 GAATGCATAC GCTGATATCG TGATGACCCA GAGCCCGGAT AGCCTGGCG 49 56 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 89 GCTTCTGCAG TTAATGGTCG CACGTTCGCC CAGGCTCACC GCCAGGCTAT CCGGGC 56 74 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 90 CGACCATTAA CTGCAGAAGC AGCCAGAGCG TGCTGTATAG CAGCAACAAC AAAAACTATC 60 TGGCGTGGTA CCAG 74 63 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 91 GATGCCCAAT AAATTAATAG TTTCGGCGGC TGACCTGGTT TCTGCTGGTA CCACGCCAGA 60 TAG 63 74 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 92 AAACTATTAA TTTATTGGGC ATCCACCCGT GAAAGCGGGG TCCCGGATCG TTTTAGCGGC 60 TCTGGATCCG GCAC 74 73 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 93 GATAATACAC CGCCACGTCT TCAGCTTGCA GGGACGAAAT GGTCAGGGTA AAATCAGTGC 60 CGGATCCAGA GCC 73 48 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 94 GAATGCATAC GCTCAGAGCG TGCTGACCCA GCCGCCTTCA GTGAGTGG 48 71 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 95 CAATGTTGCT GCTGCTGCCG CTACACGAGA TGGTCACACG CTGACCTGGT GCGCCACTCA 60 CTGAAGGCGG C 71 59 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 96 GGCAGCAGCA GCAACATTGG CAGCAACTAT GTGAGCTGGT ACCAGCAGTT GCCCGGGAC 59 68 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 97 CCGGCACGCC TGAGGGACGC TGGTTGTTAT CATAAATCAG CAGTTTCGGC GCCGTCCCGG 60 GCAACTGC 68 60 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 98 CCCTCAGGCG TGCCGGATCG TTTTAGCGGA TCCAAAAGCG GCACCAGCGC GAGCCTTGCG 60 48 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 99 CCGCTTCGTC TTCGCTTTGC AGGCCCGTAA TCGCAAGGCT CGCGCTGG 48 49 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 100 GAATGCATAC GCTCAGAGCG CACTGACCCA GCCAGCTTCA GTGAGCGGC 49 64 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 101 CGCTGCTAGT ACCCGTACAC GAGATGGTAA TGCTCTGACC TGGTGAGCCG CTCACTGAAG 60 CTGG 64 64 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 102 GTACGGGTAC TAGCAGCGAT GTGGGCGGCT ATAACTATGT GAGCTGGTAC CAGCAGCATC 60 CCGG 64 68 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 103 CGCCTGAGGG ACGGTTGCTC ACATCATAAA TCATCAGTTT CGGCGCCTTC CCGGGATGCT 60 GCTGGTAC 68 62 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 104 CAACCGTCCC TCAGGCGTGA GCAACCGTTT TAGCGGATCC AAAAGCGGCA ACACCGCGAG 60 CC 62 53 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 105 CCGCTTCGTC TTCCGCTTGC AGGCCGCTAA TGGTCAGGCT CGCGGTGTTG CCG 53 47 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 106 GAATGCATAC GCTAGCTATG AACTGACCCA GCCGCCTTCA GTGAGCG 47 68 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 107 CGCCCAGCGC ATCGCCGCTA CACGAGATAC GCGCGGTCTG ACCTGGTGCA ACGCTCACTG 60 AAGGCGGC 68 58 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 108 GGCGATGCGC TGGGCGATAA ATACGCGAGC TGGTACCAGC AGAAACCCGG GCAGGCGC 58 70 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 109 GCGTTCCGGG ATGCCTGAGG GACGGTCAGA ATCATCATAA ATCACCAGAA CTGGCGCCTG 60 CCCGGGTTTC 70 64 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 110 CAGGCATCCC GGAACGCTTT AGCGGATCCA ACAGCGGCAA CACCGCGACC CTGACCATTA 60 GCGG 64 41 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 111 CCGCTTCGTC TTCCGCCTGA GTGCCGCTAA TGGTCAGGGT C 41 37 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 112 GCTCTTCACC CCTGTTACCA AAGCCCAGGT GCAATTG 37 79 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 113 GGCTTTGCAG CTCACTTTCA CGCTGCTGCC CGGTTTTTTC ACTTCCGCGC CAGACTGAAC 60 CAATTGCACC TGGGCTTTG 79 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 114 GAAAGTGAGC TGCAAAGCCT CCGGAGGCAC TTTTAGCAGC TATGCGATTA GCTGGGTGCG 60 CCAAGCCCCT GGGCAGGGTC 80 81 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 115 GCCCTGAAAC TTCTGCGCGT AGTTCGCCGT GCCAAAAATC GGAATAATGC CGCCCATCCA 60 CTCGAGACCC TGCCCAGGGG C 81 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 116 GCGCAGAAGT TTCAGGGCCG GGTGACCATT ACCGCGGATG AAAGCACCAG CACCGCGTAT 60 ATGGAACTGA GCAGCCTGCG 80 50 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 117 GCGCGCAATA ATACACGGCC GTATCTTCGC TACGCAGGCT GCTCAGTTCC 50 79 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 118 GGCTTTGCAG CTCACTTTCA CGCTCGCGCC CGGTTTTTTC ACTTCCGCGC CGCTCTGAAC 60 CAATTGCACC TGGGCTTTG 79 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 119 GAAAGTGAGC TGCAAAGCCT CCGGATATAC CTTTACCAGC TATTATATGC ACTGGGTCCG 60 CCAAGCCCCT GGGCAGGGTC 80 81 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 120 GCCCTGAAAC TTCTGCGCGT AGTTCGTGCC GCCGCTATTC GGGTTAATCC AGCCCATCCA 60 CTCGAGACCC TGCCCAGGGG C 81 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 121 GCGCAGAAGT TTCAGGGCCG GGTGACCATG ACCCGTGATA CCAGCATTAG CACCGCGTAT 60 ATGGAACTGA GCAGCCTGCG 80 76 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 122 GGTACAGGTC AGGGTCAGGG TTTGGGTCGG TTTCACCAGG GCCGGGCCGC TTTCTTTCAA 60 TTGCACCTGG GCTTTG 76 85 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 123 CTGACCCTGA CCTGTACCTT TTCCGGATTT AGCCTGTCCA CGTCTGGCGT TGGCGTGGGC 60 TGGATTCGCC AGCCGCCTGG GAAAG 85 83 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 124 GCGTTTTCAG GCTGGTGCTA TAATACTTAT CATCATCCCA ATCAATCAGA GCCAGCCACT 60 CGAGGGCTTT CCCAGGCGGC TGG 83 78 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 125 GCACCAGCCT GAAAACGCGT CTGACCATTA GCAAAGATAC TTCGAAAAAT CAGGTGGTGC 60 TGACTATGAC CAACATGG 78 53 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 126 GCGCGCAATA ATAGGTGGCC GTATCCACCG GGTCCATGTT GGTCATAGTC AGC 53 51 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 127 CGAAGTGCAA TTGGTGGAAA GCGGCGGCGG CCTGGTGCAA CCGGGCGGCA G 51 64 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 128 CATAGCTGCT AAAGGTAAAT CCGGAGGCCG CGCAGCTCAG ACGCAGGCTG CCGCCCGGTT 60 GCAC 64 70 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 129 GATTTACCTT TAGCAGCTAT GCGATGAGCT GGGTGCGCCA AGCCCCTGGG AAGGGTCTCG 60 AGTGGGTGAG 70 71 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 130 GGCCTTTCAC GCTATCCGCA TAATAGGTGC TGCCGCCGCT ACCGCTAATC GCGCTCACCC 60 ACTCGAGACC C 71 73 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 131 CGGATAGCGT GAAAGGCCGT TTTACCATTT CACGTGATAA TTCGAAAAAC ACCCTGTATC 60 TGCAAATGAA CAG 73 62 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 132 CACGCGCGCA ATAATACACG GCCGTATCTT CCGCACGCAG GCTGTTCATT TGCAGATACA 60 GG 62 70 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 133 GGTCAGGCTC AGGGTTTCGC TCGGTTTCAC CAGGCCCGGA CCACTTTCTT GCAATTGCAC 60 CTGGGCTTTG 70 76 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 134 GAAACCCTGA GCCTGACCTG CACCGTTTCC GGAGGCAGCA TTAGCAGCTA TTATTGGAGC 60 TGGATTCGCC AGCCGC 76 77 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 135 GATTATAGTT GGTGCTGCCG CTATAATAAA TATAGCCAAT CCACTCGAGA CCCTTCCCAG 60 GCGGCTGGCG AATCCAG 77 79 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 136 CGGCAGCACC AACTATAATC CGAGCCTGAA AAGCCGGGTG ACCATTAGCG TTGATACTTC 60 GAAAAACCAG TTTAGCCTG 79 69 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 137 GCGCGCAATA ATACACGGCC GTATCCGCCG CCGTCACGCT GCTCAGTTTC AGGCTAAACT 60 GGTTTTTCG 69 37 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 138 GCTCTTCACC CCTGTTACCA AAGCCGAAGT GCAATTG 37 79 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 139 CCTTTGCAGC TAATTTTCAG GCTTTCGCCC GGTTTTTTCA CTTCCGCGCC GCTCTGAACC 60 AATTGCACTT CGGCTTTGG 79 75 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 140 CCTGAAAATT AGCTGCAAAG GTTCCGGATA TTCCTTTACG AGCTATTGGA TTGGCTGGGT 60 GCGCCAGATG CCTGG 75 78 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 141 CGGAGAATAA CGGGTATCGC TATCGCCCGG ATAAATAATG CCCATCCACT CGAGACCCTT 60 CCCAGGCATC TGGCGCAC 78 77 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 142 CGATACCCGT TATTCTCCGA GCTTTCAGGG CCAGGTGACC ATTAGCGCGG ATAAAAGCAT 60 TAGCACCGCG TATCTTC 77 68 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 143 GCGCGCAATA ATACATGGCC GTATCGCTCG CTTTCAGGCT GCTCCATTGA AGATACGCGG 60 TGCTAATG 68 81 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 144 GAAATCGCAC AGGTCAGGCT CAGGGTTTGG CTCGGTTTCA CCAGGCCCGG ACCAGACTGT 60 TGCAATTGCA CCTGGGCTTT G 81 79 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 145 GCCTGACCTG TGCGATTTCC GGAGATAGCG TGAGCAGCAA CAGCGCGGCG TGGAACTGGA 60 TTCGCCAGTC TCCTGGGCG 79 78 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 146 CACCGCATAA TCGTTATACC ATTTGCTACG ATAATAGGTA CGGCCCAGCC ACTCGAGGCC 60 ACGCCCAGGA GACTGGCG 78 78 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 147 GGTATAACGA TTATGCGGTG AGCGTGAAAA GCCGGATTAC CATCAACCCG GATACTTCGA 60 AAAACCAGTT TAGCCTGC 78 68 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 148 GCGCGCAATA ATACACGGCC GTATCTTCCG GGGTCACGCT GTTCAGTTGC AGGCTAAACT 60 GGTTTTTC 68 69 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 149 GGCTGAAGAC GTGGGCGTGT ATTATTGCCA GCAGCATTAT ACCACCCCGC CGACCTTTGG 60 CCAGGGTAC 69 71 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 150 GCGGAAAAAT AAACACGCTC GGAGCAGCCA CCGTACGTTT AATTTCAACT TTCGTACCCT 60 GGCCAAAGGT C 71 70 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 151 GAGCGTGTTT ATTTTTCCGC CGAGCGATGA ACAACTGAAA AGCGGCACGG CGAGCGTGGT 60 GTGCCTGCTG 70 71 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 152 CAGCGCGTTG TCTACTTTCC ACTGAACTTT CGCTTCACGC GGATAAAAGT TGTTCAGCAG 60 GCACACCACG C 71 69 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 153 GAAAGTAGAC AACGCGCTGC AAAGCGGCAA CAGCCAGGAA AGCGTGACCG AACAGGATAG 60 CAAAGATAG 69 74 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 154 GTTTTTCATA ATCCGCTTTG CTCAGGGTCA GGGTGCTGCT CAGAGAATAG GTGCTATCTT 60 TGCTATCCTG TTCG 74 71 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 155 GCAAAGCGGA TTATGAAAAA CATAAAGTGT ATGCGTGCGA AGTGACCCAT CAAGGTCTGA 60 GCAGCCCGGT G 71 57 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 156 GGCATGCTTA TCAGGCCTCG CCACGATTAA AAGATTTAGT CACCGGGCTG CTCAGAC 57 48 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 157 GGCGTCTAGA GGCCAAGGCA CCCTGGTGAC GGTTAGCTCA GCGTCGAC 48 63 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 158 GTGCTTTTGC TGCTCGGAGC CAGCGGAAAC ACGCTTGGAC CTTTGGTCGA CGCTGAGCTA 60 ACC 63 66 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 159 CTCCGAGCAG CAAAAGCACC AGCGGCGGCA CGGCTGCCCT GGGCTGCCTG GTTAAAGATT 60 ATTTCC 66 65 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 160 CTGGTCAGCG CCCCGCTGTT CCAGCTCACG GTGACTGGTT CCGGGAAATA ATCTTTAACC 60 AGGCA 65 60 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 161 AGCGGGGCGC TGACCAGCGG CGTGCATACC TTTCCGGCGG TGCTGCAAAG CAGCGGCCTG 60 65 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 162 GTGCCTAAGC TGCTGCTCGG CACGGTCACA ACGCTGCTCA GGCTATACAG GCCGCTGCTT 60 TGCAG 65 61 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 163 GAGCAGCAGC TTAGGCACTC AGACCTATAT TTGCAACGTG AACCATAAAC CGAGCAACAC 60 C 61 59 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 164 GCGCGAATTC GCTTTTCGGT TCCACTTTTT TATCCACTTT GGTGTTGCTC GGTTTATGG 59 333 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 7..321 /product= ”C kappa“ 165 CGTACG GTG GCT GCT CCG AGC GTG TTT ATT TTT CCG CCG AGC GAT GAA 48 Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 125 130 135 CAA CTG AAA AGC GGC ACG GCG AGC GTG GTG TGC CTG CTG AAC AAC TTT 96 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 140 145 150 TAT CCG CGT GAA GCG AAA GTT CAG TGG AAA GTA GAC AAC GCG CTG CAA 144 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 155 160 165 AGC GGC AAC AGC CAG GAA AGC GTG ACC GAA CAG GAT AGC AAA GAT AGC 192 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 170 175 180 185 ACC TAT TCT CTG AGC AGC ACC CTG ACC CTG AGC AAA GCG GAT TAT GAA 240 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 190 195 200 AAA CAT AAA GTG TAT GCG TGC GAA GTG ACC CAT CAA GGT CTG AGC AGC 288 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 205 210 215 CCG GTG ACT AAA TCT TTT AAT CGT GGC GAG GCC TGATAAGCAT GC 333 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Ala 220 225 105 amino acids amino acid linear protein 166 Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 1 5 10 15 Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 20 25 30 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 35 40 45 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr 50 55 60 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 65 70 75 80 Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val 85 90 95 Thr Lys Ser Phe Asn Arg Gly Glu Ala 100 105 327 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 6..317 /product= ”CH1“ 167 GCTCA GCG TCG ACC AAA GGT CCA AGC GTG TTT CCG CTG GCT CCG AGC 47 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 110 115 AGC AAA AGC ACC AGC GGC GGC ACG GCT GCC CTG GGC TGC CTG GTT AAA 95 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 120 125 130 135 GAT TAT TTC CCG GAA CCA GTC ACC GTG AGC TGG AAC AGC GGG GCG CTG 143 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 140 145 150 ACC AGC GGC GTG CAT ACC TTT CCG GCG GTG CTG CAA AGC AGC GGC CTG 191 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 155 160 165 TAT AGC CTG AGC AGC GTT GTG ACC GTG CCG AGC AGC AGC TTA GGC ACT 239 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 170 175 180 CAG ACC TAT ATT TGC AAC GTG AAC CAT AAA CCG AGC AAC ACC AAA GTG 287 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 185 190 195 GAT AAA AAA GTG GAA CCG AAA AGC GAA TTC TGATAAGCTT 327 Asp Lys Lys Val Glu Pro Lys Ser Glu Phe 200 205 104 amino acids amino acid linear protein 168 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Glu Phe 100 408 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 85..396 /product= ”C lambda“ 169 GAAGACGAAG CGGATTATTA TTGCCAGCAG CATTATACCA CCCCGCCTGT GTTTGGCGGC 60 GGCACGAAGT TAACCGTTCT TGGC CAG CCG AAA GCC GCA CCG AGT GTG ACG 111 Gln Pro Lys Ala Ala Pro Ser Val Thr 105 110 CTG TTT CCG CCG AGC AGC GAA GAA TTG CAG GCG AAC AAA GCG ACC CTG 159 Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu 115 120 125 GTG TGC CTG ATT AGC GAC TTT TAT CCG GGA GCC GTG ACA GTG GCC TGG 207 Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp 130 135 140 145 AAG GCA GAT AGC AGC CCC GTC AAG GCG GGA GTG GAG ACC ACC ACA CCC 255 Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro 150 155 160 TCC AAA CAA AGC AAC AAC AAG TAC GCG GCC AGC AGC TAT CTG AGC CTG 303 Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu 165 170 175 ACG CCT GAG CAG TGG AAG TCC CAC AGA AGC TAC AGC TGC CAG GTC ACG 351 Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr 180 185 190 CAT GAG GGG AGC ACC GTG GAA AAA ACC GTT GCG CCG ACT GAG GCC 396 His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Ala 195 200 205 TGATAAGCAT GC 408 104 amino acids amino acid linear protein 170 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 1 5 10 15 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 20 25 30 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 35 40 45 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 50 55 60 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 65 70 75 80 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 85 90 95 Lys Thr Val Ala Pro Thr Glu Ala 100 78 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 171 GAAGACAAGC GGATTATTAT TGCCAGCAGC ATTATACCAC CCCGCCTGTG TTTGGCGGCG 60 GCACGAAGTT AACCGTTC 78 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 172 CAATTCTTCG CTGCTCGGCG GAAACAGCGT CACACTCGGT GCGGCTTTCG GCTGGCCAAG 60 AACGGTTAAC TTCGTGCCGC 80 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 173 CGCCGAGCAG CGAAGAATTG CAGGCGAACA AAGCGACCCT GGTGTGCCTG ATTAGCGACT 60 TTTATCCGGG AGCCGTGACA 80 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 174 TGTTTGGAGG GTGTGGTGGT CTCCACTCCC GCCTTGACGG GGCTGCTATC TGCCTTCCAG 60 GCCACTGTCA CGGCTCCCGG 80 94 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 175 CCACACCCTC CAAACAAAGC AACAACAAGT ACGCGGCCAG CAGCTATCTG AGCCTGACGC 60 CTGAGCAGTG GAAGTCCCAC AGAAGCTACA GCTG 94 80 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 176 GCATGCTTAT CAGGCCTCAG TCGGCGCAAC GGTTTTTTCC ACGGTGCTCC CCTCATGCGT 60 GACCTGGCAG CTGTAGCTTC 80 843 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene“ CDS 1..843 /product= ”VH3-Vk2“ 177 ATG AAA CAA AGC ACT ATT GCA CTG GCA CTC TTA CCG TTG CTC TTC ACC 48 Met Lys Gln Ser Thr Ile Ala Leu Ala Leu Leu Pro Leu Leu Phe Thr 105 110 115 120 CCT GTT ACC AAA GCC GAC TAC AAA GAT GAA GTG CAA TTG GTG GAA AGC 96 Pro Val Thr Lys Ala Asp Tyr Lys Asp Glu Val Gln Leu Val Glu Ser 125 130 135 GGC GGC GGC CTG GTG CAA CCG GGC GGC AGC CTG CGT CTG AGC TGC GCG 144 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala 140 145 150 GCC TCC GGA TTT ACC TTT AGC AGC TAT GCG ATG AGC TGG GTG CGC CAA 192 Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln 155 160 165 GCC CCT GGG AAG GGT CTC GAG TGG GTG AGC GCG ATT AGC GGT AGC GGC 240 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly 170 175 180 GGC AGC ACC TAT TAT GCG GAT AGC GTG AAA GGC CGT TTT ACC ATT TCA 288 Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 185 190 195 200 CGT GAT AAT TCG AAA AAC ACC CTG TAT CTG CAA ATG AAC AGC CTG CGT 336 Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg 205 210 215 GCG GAA GAT ACG GCC GTG TAT TAT TGC GCG CGT TGG GGC GGC GAT GGC 384 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Gly Gly Asp Gly 220 225 230 TTT TAT GCG ATG GAT TAT TGG GGC CAA GGC ACC CTG GTG ACG GTT AGC 432 Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 235 240 245 TCA GCG GGT GGC GGT TCT GGC GGC GGT GGG AGC GGT GGC GGT GGT TCT 480 Ser Ala Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 250 255 260 GGC GGT GGT GGT TCC GAT ATC GTG ATG ACC CAG AGC CCA CTG AGC CTG 528 Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu 265 270 275 280 CCA GTG ACT CCG GGC GAG CCT GCG AGC ATT AGC TGC AGA AGC AGC CAA 576 Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln 285 290 295 AGC CTG CTG CAT AGC AAC GGC TAT AAC TAT CTG GAT TGG TAC CTT CAA 624 Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln 300 305 310 AAA CCA GGT CAA AGC CCG CAG CTA TTA ATT TAT CTG GGC AGC AAC CGT 672 Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg 315 320 325 GCC AGT GGG GTC CCG GAT CGT TTT AGC GGC TCT GGA TCC GGC ACC GAT 720 Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 330 335 340 TTT ACC CTG AAA ATT AGC CGT GTG GAA GCT GAA GAC GTG GGC GTG TAT 768 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr 345 350 355 360 TAT TGC CAG CAG CAT TAT ACC ACC CCG CCG ACC TTT GGC CAG GGT ACG 816 Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr 365 370 375 AAA GTT GAA ATT AAA CGT ACG GAA TTC 843 Lys Val Glu Ile Lys Arg Thr Glu Phe 380 385 281 amino acids amino acid linear protein 178 Met Lys Gln Ser Thr Ile Ala Leu Ala Leu Leu Pro Leu Leu Phe Thr 1 5 10 15 Pro Val Thr Lys Ala Asp Tyr Lys Asp Glu Val Gln Leu Val Glu Ser 20 25 30 Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala 35 40 45 Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln 50 55 60 Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly 65 70 75 80 Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 85 90 95 Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg 100 105 110 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Trp Gly Gly Asp Gly 115 120 125 Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 130 135 140 Ser Ala Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 145 150 155 160 Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu 165 170 175 Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln 180 185 190 Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln 195 200 205 Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg 210 215 220 Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 225 230 235 240 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr 245 250 255 Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr 260 265 270 Lys Val Glu Ile Lys Arg Thr Glu Phe 275 280 15 amino acids amino acid <Unknown> linear protein internal 179 Cys Ala Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp 1 5 10 15 12 amino acids amino acid <Unknown> linear protein internal 180 Cys Ala Arg Phe Gly Lys Met Asn Tyr Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 181 Cys Ala Arg His Arg Thr Glu Trp His Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 182 Cys Ala Arg Val Arg Glu Leu Tyr His Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 183 Cys Ala Arg Lys Phe Leu Lys Ala Arg Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 184 Cys Ala Arg Trp Asn Thr Thr Gly Tyr Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 185 Cys Ala Arg Ile Asn Glu Ala Gln Pro Asp Tyr Trp 1 5 10 11 amino acids amino acid <Unknown> linear protein internal 186 Cys Ala Arg Thr Ala Ile Thr Arg Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 187 Cys Ala Arg Trp Tyr Asn Arg Asn Ser Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 188 Cys Ala Arg Ser Val Gly Asp Ser Lys Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 189 Cys Ala Arg Ser Lys Thr Phe Ala Ala Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 190 Cys Ala Arg Val Ala Pro Gln Tyr Asp Asp Tyr Trp 1 5 10 12 amino acids amino acid <Unknown> linear protein internal 191 Cys Ala Arg Met Gln Ser Glu Trp Met Asp Tyr Trp 1 5 10 17 amino acids amino acid <Unknown> linear protein internal 192 Cys Ala Arg Tyr Phe Val His Phe Leu Tyr Thr Met Val Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 193 Cys Ala Arg Met Ala Leu Arg Ala Ser Gly Lys Tyr Ile Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 194 Cys Ala Arg Lys Asn Gln Met Val Phe His Ala Arg Lys Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 195 Cys Ala Arg Thr Gln Ser Phe Trp Glu Gln Gln Lys Val Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 196 Cys Ala Arg Tyr Pro Tyr Arg Ser Asn Phe Phe Met Pro Met Asp Val 1 5 10 15 Trp 16 amino acids amino acid <Unknown> linear protein internal Modified-site 3..4 /product= ”see Figure 10C“ /label= R*G /note= ”* denotes codon with one-base deletion, causes shift of reading fr...“ 197 Cys Ala Arg Gly Ser Gly Ser Glu His Trp Ser Ile Phe Asp Val Trp 1 5 10 15 17 amino acids amino acid <Unknown> linear protein internal 198 Cys Ala Arg Arg Asn Pro Trp Asn Val Asn Tyr Leu His Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 199 Cys Ala Arg Met Lys Pro Met Leu Asn Arg Asp Gly Thr Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 200 Cys Ala Arg Lys Gly Ser Glu Phe Leu Glu Thr Asp Val Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 201 Cys Ala Arg Ser Trp Thr Asn Asp Lys Pro Asn Phe Ile Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 202 Cys Ala Arg Tyr Ala Gly Thr Thr Phe Lys Gln Gly Pro Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 203 Cys Ala Arg Lys Arg Met Met Gln Asn Pro Arg Phe Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 204 Cys Ala Arg Arg Ser Lys Gln Lys Arg Lys Met Arg Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 205 Cys Ala Arg Arg Asn Gly Lys Arg His Leu Arg His Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 206 Cys Ala Arg Arg Lys Met Arg Lys Arg Ile Lys Arg Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 207 Cys Ala Arg Tyr Arg Lys Ile Met Lys Trp Lys Asn Ser Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 208 Cys Ala Arg Leu Ile Glu Val His Pro Ser Phe Asp Gln Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 209 Cys Ala Arg Arg Lys Pro Met Phe Leu Lys Lys Ala Val Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 210 Cys Ala Arg Arg Lys Phe His Arg Tyr Ser Thr Val Lys Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 211 Cys Ala Arg Arg Lys Thr Met Arg Ser Arg Val Lys Tyr Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 212 Cys Ala Arg Lys Lys Arg Ser Trp Arg Arg Met Asp Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 213 Cys Ala Arg Arg Asn Pro Arg Arg Gly Arg Met Asn Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 214 Cys Ala Arg Lys Gly Lys Lys Lys Phe Ala Arg Pro Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 215 Cys Ala Arg Arg Met Val His Lys Gly Lys Arg Lys Ile Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 216 Cys Ala Arg Arg Lys His Ile Thr Tyr Pro Arg Lys Gln Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 217 Cys Ala Arg Arg Trp Thr Lys Arg Arg Ser Phe Ala Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 218 Cys Ala Arg Lys Lys Leu Lys Gln Tyr Thr Phe Ser Arg Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 219 Cys Ala Arg Thr Arg Pro Trp Gln Ala Thr Arg Lys Gly Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 220 Cys Ala Arg Asn Gln Trp Glu Phe Lys Asn Arg Arg Lys Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 221 Cys Ala Arg Lys Arg Trp Met Trp Pro Ile Gly Lys Arg Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 222 Cys Ala Arg Tyr Ser Leu Trp Arg Leu Asp Glu Tyr Phe Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 223 Cys Ala Arg Val Pro Trp Gly Asp Phe Trp Ser Trp His Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 224 Cys Ala Arg Asn Gly Leu Glu Pro Arg His Arg Lys Met Met Asp Tyr 1 5 10 15 Trp 12 amino acids amino acid <Unknown> linear protein internal 225 Cys Ala Arg Ile Met Lys Ala Pro Pro Asp Tyr Trp 1 5 10 17 amino acids amino acid <Unknown> linear protein internal 226 Cys Ala Arg Arg Lys Thr Trp His Trp Phe Tyr Lys Arg Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 227 Cys Ala Arg Trp Lys Asp Met Trp Ser Gln Val Tyr Val Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 228 Cys Ala Arg Asn Lys Gln Gln Met Arg Phe Arg Arg Phe Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 229 Cys Ala Arg Asn Met Leu Ala Leu Ser Arg Gly Lys Glu Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 230 Cys Ala Arg Asn Met Arg Leu Met Arg Met Arg Lys Asn Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 231 Cys Ala Arg Tyr Ile Lys Gln Ala Lys Arg Lys Leu Ala Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 232 Cys Ala Arg Tyr Asn Arg His Ala Trp Gln Lys Met Gln Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 233 Cys Ala Arg Tyr Val Lys Tyr Ala Arg Asn Lys Met Gln Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 234 Cys Ala Arg Tyr Lys Arg Gly Ala Trp Met Lys Thr Met Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 235 Cys Ala Arg Arg Lys Pro Leu Arg Arg Ile Met Lys Trp Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 236 Cys Ala Arg Tyr Arg Lys Arg Ala Ser Arg Gln Met Gln Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 237 Cys Ala Arg Gln Arg Tyr Arg Ser Lys Ile Lys Gly His Phe Asp Val 1 5 10 15 Trp 16 amino acids amino acid <Unknown> linear protein internal 238 Cys Ala Arg Trp Arg Asp Phe Asn Ser Tyr Asp Pro Met Asp Tyr Trp 1 5 10 15 17 amino acids amino acid <Unknown> linear protein internal 239 Cys Ala Arg Met Ala Asp Leu Asp Asn Tyr Trp Val Gln Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 240 Cys Ala Arg Leu Gln Ala Tyr Leu Lys Pro His His Trp Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 241 Cys Ala Arg Arg Leu Ile Glu Gln Ala Arg Asp His Val Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 242 Cys Ala Arg Ser Trp His Asn Ser Gln Phe Thr Gln Ser Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 243 Cys Ala Arg Val Asp His Phe Gln Thr Glu Asn Glu Trp Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 244 Cys Ala Arg Asp Trp Pro Thr Leu Ile Phe Trp Tyr Trp Phe Asp Tyr 1 5 10 15 Trp 12 amino acids amino acid <Unknown> linear protein internal 245 Cys Ala Arg Gly Phe Gly Phe Thr Glu Asp Tyr Trp 1 5 10 17 amino acids amino acid <Unknown> linear protein internal 246 Cys Ala Arg Gln Phe Asp Glu Asp Ser Phe Val Arg Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 247 Cys Ala Arg Ile Leu Lys Glu Ser Ser Lys Ser Arg Gln Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 248 Cys Ala Arg Glu Gln Asp Glu Tyr Gly Ala Ile Arg Ile Met Asp Tyr 1 5 10 15 Trp 18 amino acids amino acid <Unknown> linear protein internal 249 Cys Ala Arg Asn His Phe Glu Ala Ser Trp Pro Arg Arg Gln Met Asp 1 5 10 15 Val Trp 17 amino acids amino acid <Unknown> linear protein internal 250 Cys Ala Arg Glu Asn Glu Trp Val Asp Met Ile Leu Asp Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 251 Cys Ala Arg Gln Tyr Ser Glu Thr Arg Trp Val Arg Lys Phe Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 252 Cys Ala Arg Gln Phe Lys Glu Ser Lys Thr Arg Arg Lys Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 253 Cys Ala Arg Lys Lys Thr Gln Tyr Val His Asp Trp Arg Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 254 Cys Ala Arg Arg Trp Arg Glu Thr Lys Ser Lys Arg Phe Phe Asp Val 1 5 10 15 Trp 12 amino acids amino acid <Unknown> linear protein internal 255 Cys Ala Arg Asp Tyr Ile Met Glu Phe Asp Tyr Trp 1 5 10 17 amino acids amino acid <Unknown> linear protein internal 256 Cys Ala Arg Gln Phe Glu Glu Thr Lys Gln Arg Arg Leu Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 257 Cys Ala Arg Asp Gln Gly Phe Tyr Ala Ile Asp Tyr Val Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 258 Cys Ala Arg Val Phe Thr Tyr Met Tyr Asn Tyr Phe Arg Phe Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 259 Cys Ala Arg Val Phe Phe Glu Gln Met Glu Val Val Arg Met Asp Val 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 260 Cys Ala Arg Glu Lys Glu Tyr Arg Leu Ser Trp Ser Gln Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 261 Cys Ala Arg Tyr Pro Ser Arg Trp Ala Pro Asn Trp Tyr Met Asp Tyr 1 5 10 15 Trp 17 amino acids amino acid <Unknown> linear protein internal 262 Cys Ala Arg Asp Gly Gly Phe Lys Pro Leu Thr His Phe Phe Asp Val 1 5 10 15 Trp 143 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 263 ACATGTAAGC TTCCCCCCCC CCTTAATTAA CCCCCCCCCC TGTACACCCC CCCCCCGCTA 60 GCCCCCCCCC CCAGATCTCC CCCCCCCCGA CGTCCCCCCT CTAGACCCCC CCCCCGCATG 120 CCCCCCCCCC CGAATTCGAC GTC 143 1947 base pairs nucleic acid double circular other nucleic acid /desc = ”synthetic vector“ CDS 132..989 /product= ”Amp resistance“ 264 CAGGTGGCAC TTTTCGGGGA AATGTGCGCG GAACCCCTAT TTGTTTATTT TTCTAAATAC 60 ATTCAAATAT GTATCCGCTC ATGAGACAAT AACCCTGATA AATGCTTCAA TAATATTGAA 120 AAAGGAAGAG T ATG AGT ATT CAA CAT TTC CGT GTC GCC CTT ATT CCC TTT 170 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe 285 290 TTT GCG GCA TTT TGC CTT CCT GTT TTT GCT CAC CCA GAA ACG CTG GTG 218 Phe Ala Ala Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val 295 300 305 310 AAA GTA AAA GAT GCT GAA GAT CAG TTG GGT GCA CGA GTG GGT TAC ATC 266 Lys Val Lys Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile 315 320 325 GAA CTG GAT CTC AAC AGC GGT AAG ATC CTT GAG AGT TTT CGC CCC GAA 314 Glu Leu Asp Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu 330 335 340 GAA CGT TTT CCA ATG ATG AGC ACT TTT AAA GTT CTG CTA TGT GGC GCG 362 Glu Arg Phe Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala 345 350 355 GTA TTA TCC CGT ATT GAC GCC GGG CAA GAG CAA CTC GGT CGC CGC ATA 410 Val Leu Ser Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile 360 365 370 CAC TAT TCT CAG AAT GAC TTG GTT GAG TAC TCA CCA GTC ACA GAA AAG 458 His Tyr Ser Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys 375 380 385 390 CAT CTT ACG GAT GGC ATG ACA GTA AGA GAA TTA TGC AGT GCT GCC ATA 506 His Leu Thr Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile 395 400 405 ACC ATG AGT GAT AAC ACT GCG GCC AAC TTA CTT CTG ACA ACG ATC GGA 554 Thr Met Ser Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr Ile Gly 410 415 420 GGA CCG AAG GAG CTA ACC GCT TTT TTG CAC AAC ATG GGG GAT CAT GTA 602 Gly Pro Lys Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp His Val 425 430 435 ACT CGC CTT GAT CGT TGG GAA CCG GAG CTG AAT GAA GCC ATA CCA AAC 650 Thr Arg Leu Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn 440 445 450 GAC GAG CGT GAC ACC ACG ATG CCT GTA GCA ATG GCA ACA ACG TTG CGC 698 Asp Glu Arg Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr Leu Arg 455 460 465 470 AAA CTA TTA ACT GGC GAA CTA CTT ACT CTA GCT TCC CGG CAA CAA TTA 746 Lys Leu Leu Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu 475 480 485 ATA GAC TGG ATG GAG GCG GAT AAA GTT GCA GGA CCA CTT CTG CGC TCG 794 Ile Asp Trp Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser 490 495 500 GCC CTT CCG GCT GGC TGG TTT ATT GCT GAT AAA TCT GGA GCC GGT GAG 842 Ala Leu Pro Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu 505 510 515 CGT GGG TCT CGC GGT ATC ATT GCA GCA CTG GGG CCA GAT GGT AAG CCC 890 Arg Gly Ser Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro 520 525 530 TCC CGT ATC GTA GTT ATC TAC ACG ACG GGG AGT CAG GCA ACT ATG GAT 938 Ser Arg Ile Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp 535 540 545 550 GAA CGA AAT AGA CAG ATC GCT GAG ATA GGT GCC TCA CTG ATT AAG CAT 986 Glu Arg Asn Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His 555 560 565 TGG TAACTGTCAG ACCAAGTTTA CTCATATATA CTTTAGATTG ATTTAAAACT 1039 Trp TCATTTTTAA TTTAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA TGACCAAAAT 1099 CCCTTAACGT GAGTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA TCAAAGGATC 1159 TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA AACCACCGCT 1219 ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA AGGTAACTGG 1279 CTTCAGCAGA GCGCAGATAC CAAATACTGT CCTTCTAGTG TAGCCGTAGT TAGGCCACCA 1339 CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT TACCAGTGGC 1399 TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT AGTTACCGGA 1459 TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT TGGAGCGAAC 1519 GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCTATGA GAAAGCGCCA CGCTTCCCGA 1579 AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG AGCGCACGAG 1639 GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC GCCACCTCTG 1699 ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA AAAACGCCAG 1759 CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA TGTAAGCTTC 1819 CCCCCCCCCT TAATTAACCC CCCCCCCTGT ACACCCCCCC CCCGCTAGCC CCCCCCCCCA 1879 GATCTCCCCC CCCCCGACGT CCCCCCTCTA GACCCCCCCC CCGCATGCCC CCCCCCCCGA 1939 ATTCACGT 1947 286 amino acids amino acid linear protein 265 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala 1 5 10 15 Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys 20 25 30 Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp 35 40 45 Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe 50 55 60 Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser 65 70 75 80 Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser 85 90 95 Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr 100 105 110 Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser 115 120 125 Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr Ile Gly Gly Pro Lys 130 135 140 Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp His Val Thr Arg Leu 145 150 155 160 Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg 165 170 175 Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu 180 185 190 Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp 195 200 205 Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser Ala Leu Pro 210 215 220 Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 225 230 235 240 Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245 250 255 Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn 260 265 270 Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp 275 280 285 142 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 266 GACGTCTTAA TGTGAGTTAG CTCACTCATT AGGCACCCCA GGCTTTACAC TTTATGCTTC 60 CGGCTCGTAT GTTGTGTGGA ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCTATG 120 ACCATGATTA CGAATTTCTA GA 142 520 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene cassette“ CDS 1..510 /product= ”gIIIp ss with myc-tag, amber codon“ 267 GAA TTC GAG CAG AAG CTG ATC TCT GAG GAG GAT CTG TAG GGT GGT GGC 48 Glu Phe Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu * Gly Gly Gly 290 295 300 TCT GGT TCC GGT GAT TTT GAT TAT GAA AAG ATG GCA AAC GCT AAT AAG 96 Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys 305 310 315 GGG GCT ATG ACC GAA AAT GCC GAT GAA AAC GCG CTA CAG TCT GAC GCT 144 Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala 320 325 330 AAA GGC AAA CTT GAT TCT GTC GCT ACT GAT TAC GGT GCT GCT ATC GAT 192 Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp 335 340 345 350 GGT TTC ATT GGT GAC GTT TCC GGC CTT GCT AAT GGT AAT GGT GCT ACT 240 Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr 355 360 365 GGT GAT TTT GCT GGC TCT AAT TCC CAA ATG GCT CAA GTC GGT GAC GGT 288 Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly 370 375 380 GAT AAT TCA CCT TTA ATG AAT AAT TTC CGT CAA TAT TTA CCT TCC CTC 336 Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu 385 390 395 CCT CAA TCG GTT GAA TGT CGC CCT TTT GTC TTT GGC GCT GGT AAA CCA 384 Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Gly Ala Gly Lys Pro 400 405 410 TAT GAA TTT TCT ATT GAT TGT GAC AAA ATA AAC TTA TTC CGT GGT GTC 432 Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val 415 420 425 430 TTT GCG TTT CTT TTA TAT GTT GCC ACC TTT ATG TAT GTA TTT TCT ACG 480 Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr 435 440 445 TTT GCT AAC ATA CTG CGT AAT AAG GAG TCT TGATAAGCTT 520 Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser 450 455 12 amino acids amino acid linear protein 268 Glu Phe Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 1 5 10 123 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 269 GGGGGGGGGG AAGCTTGACC TGTGAAGTGA AAAATGGCGC AGATTGTGCG ACATTTTTTT 60 TGTCTGCCGT TTAATTAAAG GGGGGGGGGG GCCGGCCTGG GGGGGGGTGT ACAGGGGGGG 120 GGG 123 470 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 270 GCTAGCACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT ACGCGCAGCG 60 TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC CCTTCCTTTC 120 TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGCATCCCT TTAGGGTTCC 180 GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA TTAGGGTGAT GGTTCTCGTA 240 GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTTGAC GTTGGAGTCC ACGTTCTTTA 300 ATAGTGGACT CTTGTTCCAA ACTGGAACAA CACTCAACCC TATCTCGGTC TATTCTTTTG 360 ATTTATAAGG GATTTTGCCG ATTTCGGCCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA 420 AATTTAACGC GAATTTTAAC AAAATATTAA CGTTTACAAT TTCATGTACA 470 733 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 271 AGATCTGACC AAAATCCCTT AACGTGAGTT TTCGTTCCAC TGAGCGTCAG ACCCCGTAGA 60 AAAGATCAAA GGATCTTCTT GAGATCCTTT TTTTCTGCGC GTAATCTGCT GCTTGCAAAC 120 AAAAAAACCA CCGCTACCAG CGGTGGTTTG TTTGCCGGAT CAAGAGCTAC CAACTCTTTT 180 TCCGAAGGTA ACTGGCTACA GCAGAGCGCA GATACCAAAT ACTGTTCTTC TAGTGTAGCC 240 GTAGTTAGGC CACCACTTCA AGAACTCTGT AGCACCGCCT ACATACCTCG CTCTGCTAAT 300 CCTGTTACCA GTGGCTGCTG CCAGTGGCGA TAAGTCGTGT CTTACCGGGT TGGACTCAAG 360 ACGATAGTTA CCGGATAAGG CGCAGCGGTC GGGCTGAACG GGGGGTTCGT GCACACAGCC 420 CAGCTTGGAG CGAACGACCT ACACCGAACT GAGATACCTA CAGCGTGAGC TATGAGAAAG 480 CGCCACGCTT CCCGAAGGGA GAAAGGCGGA CAGGTATCCG GTAAGCGGCA GGGTCGGAAC 540 AGGAGAGCGC ACGAGGGAGC TTCCAGGGGG AAACGCCTGG TATCTTTATA GTCCTGTCGG 600 GTTTCGCCAC CTCTGACTTG AGCGTCGATT TTTGTGATGC TCGTCAGGGG GGCGGAGCCT 660 ATGGAAAAAC GCCAGCAACG CGGCCTTTTT ACGGTTCCTG GCCTTTTGCT GGCCTTTTGC 720 TCACATGGCT AGC 733 813 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene cassette“ CDS 102..758 /product= ”cat resistance“ 272 GGGACGTCGG GTGAGGTTCC AACTTTCACC ATAATGAAAT AAGATCACTA CCGGGCGTAT 60 TTTTTGAGTT ATCGAGATTT TCAGGAGCTA AGGAAGCTAA A ATG GAG AAA AAA 113 Met Glu Lys Lys ATC ACT GGA TAT ACC ACC GTT GAT ATA TCC CAA TGG CAT CGT AAA GAA 161 Ile Thr Gly Tyr Thr Thr Val Asp Ile Ser Gln Trp His Arg Lys Glu 175 180 185 190 CAT TTT GAG GCA TTT CAG TCA GTT GCT CAA TGT ACC TAT AAC CAG ACC 209 His Phe Glu Ala Phe Gln Ser Val Ala Gln Cys Thr Tyr Asn Gln Thr 195 200 205 GTT CAG CTG GAT ATT ACG GCC TTT TTA AAG ACC GTA AAG AAA AAT AAG 257 Val Gln Leu Asp Ile Thr Ala Phe Leu Lys Thr Val Lys Lys Asn Lys 210 215 220 CAC AAG TTT TAT CCG GCC TTT ATT CAC ATT CTT GCC CGC CTG ATG AAT 305 His Lys Phe Tyr Pro Ala Phe Ile His Ile Leu Ala Arg Leu Met Asn 225 230 235 GCT CAC CCG GAG TTC CGT ATG GCA ATG AAA GAC GGT GAG CTG GTG ATA 353 Ala His Pro Glu Phe Arg Met Ala Met Lys Asp Gly Glu Leu Val Ile 240 245 250 TGG GAT AGT GTT CAC CCT TGT TAC ACC GTT TTC CAT GAG CAA ACT GAA 401 Trp Asp Ser Val His Pro Cys Tyr Thr Val Phe His Glu Gln Thr Glu 255 260 265 270 ACG TTT TCA TCG CTC TGG AGT GAA TAC CAC GAC GAT TTC CGG CAG TTT 449 Thr Phe Ser Ser Leu Trp Ser Glu Tyr His Asp Asp Phe Arg Gln Phe 275 280 285 CTA CAC ATA TAT TCG CAA GAT GTG GCG TGT TAC GGT GAA AAC CTG GCC 497 Leu His Ile Tyr Ser Gln Asp Val Ala Cys Tyr Gly Glu Asn Leu Ala 290 295 300 TAT TTC CCT AAA GGG TTT ATT GAG AAT ATG TTT TTC GTC TCA GCC AAT 545 Tyr Phe Pro Lys Gly Phe Ile Glu Asn Met Phe Phe Val Ser Ala Asn 305 310 315 CCC TGG GTG AGT TTC ACC AGT TTT GAT TTA AAC GTA GCC AAT ATG GAC 593 Pro Trp Val Ser Phe Thr Ser Phe Asp Leu Asn Val Ala Asn Met Asp 320 325 330 AAC TTC TTC GCC CCC GTT TTC ACT ATG GGC AAA TAT TAT ACG CAA GGC 641 Asn Phe Phe Ala Pro Val Phe Thr Met Gly Lys Tyr Tyr Thr Gln Gly 335 340 345 350 GAC AAG GTG CTG ATG CCG CTG GCG ATT CAG GTT CAT CAT GCC GTT TGT 689 Asp Lys Val Leu Met Pro Leu Ala Ile Gln Val His His Ala Val Cys 355 360 365 GAT GGC TTC CAT GTC GGC AGA ATG CTT AAT GAA TTA CAA CAG TAC TGC 737 Asp Gly Phe His Val Gly Arg Met Leu Asn Glu Leu Gln Gln Tyr Cys 370 375 380 GAT GAG TGG CAG GGC GGG GCG TAATTTTTTT AAGGCAGTTA TTGGGTGCCC 788 Asp Glu Trp Gln Gly Gly Ala 385 TTAAACGCCT GGTGCTAGAT CTTCC 813 219 amino acids amino acid linear protein 273 Met Glu Lys Lys Ile Thr Gly Tyr Thr Thr Val Asp Ile Ser Gln Trp 1 5 10 15 His Arg Lys Glu His Phe Glu Ala Phe Gln Ser Val Ala Gln Cys Thr 20 25 30 Tyr Asn Gln Thr Val Gln Leu Asp Ile Thr Ala Phe Leu Lys Thr Val 35 40 45 Lys Lys Asn Lys His Lys Phe Tyr Pro Ala Phe Ile His Ile Leu Ala 50 55 60 Arg Leu Met Asn Ala His Pro Glu Phe Arg Met Ala Met Lys Asp Gly 65 70 75 80 Glu Leu Val Ile Trp Asp Ser Val His Pro Cys Tyr Thr Val Phe His 85 90 95 Glu Gln Thr Glu Thr Phe Ser Ser Leu Trp Ser Glu Tyr His Asp Asp 100 105 110 Phe Arg Gln Phe Leu His Ile Tyr Ser Gln Asp Val Ala Cys Tyr Gly 115 120 125 Glu Asn Leu Ala Tyr Phe Pro Lys Gly Phe Ile Glu Asn Met Phe Phe 130 135 140 Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asp Leu Asn Val 145 150 155 160 Ala Asn Met Asp Asn Phe Phe Ala Pro Val Phe Thr Met Gly Lys Tyr 165 170 175 Tyr Thr Gln Gly Asp Lys Val Leu Met Pro Leu Ala Ile Gln Val His 180 185 190 His Ala Val Cys Asp Gly Phe His Val Gly Arg Met Leu Asn Glu Leu 195 200 205 Gln Gln Tyr Cys Asp Glu Trp Gln Gly Gly Ala 210 215 2755 base pairs nucleic acid double circular other nucleic acid /desc = ”synthetic vector“ CDS 3..509 /product= ”gIIIp ss, myc tag, amber codon“ CDS complement (1853..2509) /product= ”cat resistance“ 274 AA TTC GAG CAG AAG CTG ATC TCT GAG GAG GAT CTG TAG GGT GGT GGC 47 Phe Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu * Gly Gly Gly 220 225 230 TCT GGT TCC GGT GAT TTT GAT TAT GAA AAG ATG GCA AAC GCT AAT AAG 95 Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys 235 240 245 250 GGG GCT ATG ACC GAA AAT GCC GAT GAA AAC GCG CTA CAG TCT GAC GCT 143 Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala 255 260 265 AAA GGC AAA CTT GAT TCT GTC GCT ACT GAT TAC GGT GCT GCT ATC GAT 191 Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp 270 275 280 GGT TTC ATT GGT GAC GTT TCC GGC CTT GCT AAT GGT AAT GGT GCT ACT 239 Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr 285 290 295 GGT GAT TTT GCT GGC TCT AAT TCC CAA ATG GCT CAA GTC GGT GAC GGT 287 Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val Gly Asp Gly 300 305 310 GAT AAT TCA CCT TTA ATG AAT AAT TTC CGT CAA TAT TTA CCT TCC CTC 335 Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu 315 320 325 330 CCT CAA TCG GTT GAA TGT CGC CCT TTT GTC TTT GGC GCT GGT AAA CCA 383 Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Gly Ala Gly Lys Pro 335 340 345 TAT GAA TTT TCT ATT GAT TGT GAC AAA ATA AAC TTA TTC CGT GGT GTC 431 Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe Arg Gly Val 350 355 360 TTT GCG TTT CTT TTA TAT GTT GCC ACC TTT ATG TAT GTA TTT TCT ACG 479 Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val Phe Ser Thr 365 370 375 TTT GCT AAC ATA CTG CGT AAT AAG GAG TCT TGATAAGCTT GACCTGTGAA 529 Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser 380 385 GTGAAAAATG GCGCAGATTG TGCGACATTT TTTTTGTCTG CCGTTTAATT AAAGGGGGGG 589 GGGGGCCGGC CTGGGGGGGG GTGTACATGA AATTGTAAAC GTTAATATTT TGTTAAAATT 649 CGCGTTAAAT TTTTGTTAAA TCAGCTCATT TTTTAACCAA TAGGCCGAAA TCGGCAAAAT 709 CCCTTATAAA TCAAAAGAAT AGACCGAGAT AGGGTTGAGT GTTGTTCCAG TTTGGAACAA 769 GAGTCCACTA TTAAAGAACG TGGACTCCAA CGTCAAAGGG CGAAAAACCG TCTATCAGGG 829 CGATGGCCCA CTACGAGAAC CATCACCCTA ATCAAGTTTT TTGGGGTCGA GGTGCCGTAA 889 AGCACTAAAT CGGAACCCTA AAGGGAGCCC CCGATTTAGA GCTTGACGGG GAAAGCCGGC 949 GAACGTGGCG AGAAAGGAAG GGAAGAAAGC GAAAGGAGCG GGCGCTAGGG CGCTGGCAAG 1009 TGTAGCGGTC ACGCTGCGCG TAACCACCAC ACCCGCCGCG CTTAATGCGC CGCTACAGGG 1069 CGCGTGCTAG CCATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA AAAGGCCGCG 1129 TTGCTGGCGT TTTTCCATAG GCTCCGCCCC CCTGACGAGC ATCACAAAAA TCGACGCTCA 1189 AGTCAGAGGT GGCGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC CCCTGGAAGC 1249 TCCCTCGTGC GCTCTCCTGT TCCGACCCTG CCGCTTACCG GATACCTGTC CGCCTTTCTC 1309 CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA GGTATCTCAG TTCGGTGTAG 1369 GTCGTTCGCT CCAAGCTGGG CTGTGTGCAC GAACCCCCCG TTCAGCCCGA CCGCTGCGCC 1429 TTATCCGGTA ACTATCGTCT TGAGTCCAAC CCGGTAAGAC ACGACTTATC GCCACTGGCA 1489 GCAGCCACTG GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCTTG 1549 AAGTGGTGGC CTAACTACGG CTACACTAGA AGAACAGTAT TTGGTATCTG CGCTCTGCTG 1609 TAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT CCGGCAAACA AACCACCGCT 1669 GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG CAGATTACGC GCAGAAAAAA AGGATCTCAA 1729 GAAGATCCTT TGATCTTTTC TACGGGGTCT GACGCTCAGT GGAACGAAAA CTCACGTTAA 1789 GGGATTTTGG TCAGATCTAG CACCAGGCGT TTAAGGGCAC CAATAACTGC CTTAAAAAAA 1849 TTACGCCCCG CCCTGCCACT CATCGCAGTA CTGTTGTAAT TCATTAAGCA TTCTGCCGAC 1909 ATGGAAGCCA TCACAAACGG CATGATGAAC CTGAATCGCC AGCGGCATCA GCACCTTGTC 1969 GCCTTGCGTA TAATATTTGC CCATAGTGAA AACGGGGGCG AAGAAGTTGT CCATATTGGC 2029 TACGTTTAAA TCAAAACTGG TGAAACTCAC CCAGGGATTG GCTGAGACGA AAAACATATT 2089 CTCAATAAAC CCTTTAGGGA AATAGGCCAG GTTTTCACCG TAACACGCCA CATCTTGCGA 2149 ATATATGTGT AGAAACTGCC GGAAATCGTC GTGGTATTCA CTCCAGAGCG ATGAAAACGT 2209 TTCAGTTTGC TCATGGAAAA CGGTGTAACA AGGGTGAACA CTATCCCATA TCACCAGCTC 2269 ACCGTCTTTC ATTGCCATAC GGAACTCCGG GTGAGCATTC ATCAGGCGGG CAAGAATGTG 2329 AATAAAGGCC GGATAAAACT TGTGCTTATT TTTCTTTACG GTCTTTAAAA AGGCCGTAAT 2389 ATCCAGCTGA ACGGTCTGGT TATAGGTACA TTGAGCAACT GACTGAAATG CCTCAAAATG 2449 TTCTTTACGA TGCCATTGGG ATATATCAAC GGTGGTATAT CCAGTGATTT TTTTCTCCAT 2509 TTTAGCTTCC TTAGCTCCTG AAAATCTCGA TAACTCAAAA AATACGCCCG GTAGTGATCT 2569 TATTTCATTA TGGTGAAAGT TGGAACCTCA CCCGACGTCT AATGTGAGTT AGCTCACTCA 2629 TTAGGCACCC CAGGCTTTAC ACTTTATGCT TCCGGCTCGT ATGTTGTGTG GAATTGTGAG 2689 CGGATAACAA TTTCACACAG GAAACAGCTA TGACCATGAT TACGAATTTC TAGAGCATGC 2749 GGGGGG 2755 11 amino acids amino acid linear protein 275 Phe Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 1 5 10 219 amino acids amino acid linear protein 276 Met Glu Lys Lys Ile Thr Gly Tyr Thr Thr Val Asp Ile Ser Gln Trp 1 5 10 15 His Arg Lys Glu His Phe Glu Ala Phe Gln Ser Val Ala Gln Cys Thr 20 25 30 Tyr Asn Gln Thr Val Gln Leu Asp Ile Thr Ala Phe Leu Lys Thr Val 35 40 45 Lys Lys Asn Lys His Lys Phe Tyr Pro Ala Phe Ile His Ile Leu Ala 50 55 60 Arg Leu Met Asn Ala His Pro Glu Phe Arg Met Ala Met Lys Asp Gly 65 70 75 80 Glu Leu Val Ile Trp Asp Ser Val His Pro Cys Tyr Thr Val Phe His 85 90 95 Glu Gln Thr Glu Thr Phe Ser Ser Leu Trp Ser Glu Tyr His Asp Asp 100 105 110 Phe Arg Gln Phe Leu His Ile Tyr Ser Gln Asp Val Ala Cys Tyr Gly 115 120 125 Glu Asn Leu Ala Tyr Phe Pro Lys Gly Phe Ile Glu Asn Met Phe Phe 130 135 140 Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asp Leu Asn Val 145 150 155 160 Ala Asn Met Asp Asn Phe Phe Ala Pro Val Phe Thr Met Gly Lys Tyr 165 170 175 Tyr Thr Gln Gly Asp Lys Val Leu Met Pro Leu Ala Ile Gln Val His 180 185 190 His Ala Val Cys Asp Gly Phe His Val Gly Arg Met Leu Asn Glu Leu 195 200 205 Gln Gln Tyr Cys Asp Glu Trp Gln Gly Gly Ala 210 215 173 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 277 GACGTCTTAA TGTGAGTTAG CTCACTCATT AGGCACCCCA GGCTTTACAC TTTATGCTTC 60 CGGCTCGTAT GTTGTGTGGA ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCTATG 120 ACCATGTCTA GAATAACTTC GTATAATGTA CGCTATACGA AGTTATCGCA TGC 173 47 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 278 AGATCTCATA ACTTCGTATA ATGTATGCTA TACGAAGTTA TGACGTC 47 1255 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene cassette“ CDS 1..1245 /product= ”gIIIp, GGGGS linker“ 279 GAA TTC GGT GGT GGT GGA TCT GCG TGC GCT GAA ACG GTT GAA AGT TGT 48 Glu Phe Gly Gly Gly Gly Ser Ala Cys Ala Glu Thr Val Glu Ser Cys 220 225 230 235 TTA GCA AAA TCC CAT ACA GAA AAT TCA TTT ACT AAC GTC TGG AAA GAC 96 Leu Ala Lys Ser His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp 240 245 250 GAC AAA ACT TTA GAT CGT TAC GCT AAC TAT GAG GGC TGT CTG TGG AAT 144 Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn 255 260 265 GCT ACA GGC GTT GTA GTT TGT ACT GGT GAC GAA ACT CAG TGT TAC GGT 192 Ala Thr Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly 270 275 280 ACA TGG GTT CCT ATT GGG CTT GCT ATC CCT GAA AAT GAG GGT GGT GGC 240 Thr Trp Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly 285 290 295 TCT GAG GGT GGC GGT TCT GAG GGT GGC GGT TCT GAG GGT GGC GGT ACT 288 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr 300 305 310 315 AAA CCT CCT GAG TAC GGT GAT ACA CCT ATT CCG GGC TAT ACT TAT ATC 336 Lys Pro Pro Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile 320 325 330 AAC CCT CTC GAC GGC ACT TAT CCG CCT GGT ACT GAG CAA AAC CCC GCT 384 Asn Pro Leu Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala 335 340 345 AAT CCT AAT CCT TCT CTT GAG GAG TCT CAG CCT CTT AAT ACT TTC ATG 432 Asn Pro Asn Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met 350 355 360 TTT CAG AAT AAT AGG TTC CGA AAT AGG CAG GGG GCA TTA ACT GTT TAT 480 Phe Gln Asn Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr 365 370 375 ACG GGC ACT GTT ACT CAA GGC ACT GAC CCC GTT AAA ACT TAT TAC CAG 528 Thr Gly Thr Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln 380 385 390 395 TAC ACT CCT GTA TCA TCA AAA GCC ATG TAT GAC GCT TAC TGG AAC GGT 576 Tyr Thr Pro Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly 400 405 410 AAA TTC AGA GAC TGC GCT TTC CAT TCT GGC TTT AAT GAG GAT TTA TTT 624 Lys Phe Arg Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Leu Phe 415 420 425 GTT TGT GAA TAT CAA GGC CAA TCG TCT GAC CTG CCT CAA CCT CCT GTC 672 Val Cys Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val 430 435 440 AAT GCT GGC GGC GGC TCT GGT GGT GGT TCT GGT GGC GGC TCT GAG GGT 720 Asn Ala Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly 445 450 455 GGT GGC TCT GAG GGT GGC GGT TCT GAG GGT GGC GGC TCT GAG GGA GGC 768 Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly 460 465 470 475 GGT TCC GGT GGT GGC TCT GGT TCC GGT GAT TTT GAT TAT GAA AAG ATG 816 Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met 480 485 490 GCA AAC GCT AAT AAG GGG GCT ATG ACC GAA AAT GCC GAT GAA AAC GCG 864 Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala 495 500 505 CTA CAG TCT GAC GCT AAA GGC AAA CTT GAT TCT GTC GCT ACT GAT TAC 912 Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr 510 515 520 GGT GCT GCT ATC GAT GGT TTC ATT GGT GAC GTT TCC GGC CTT GCT AAT 960 Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn 525 530 535 GGT AAT GGT GCT ACT GGT GAT TTT GCT GGC TCT AAT TCC CAA ATG GCT 1008 Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala 540 545 550 555 CAA GTC GGT GAA GGT GAT AAT TCA CCT TTA ATG AAT AAT TTC CGT CAA 1056 Gln Val Gly Glu Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln 560 565 570 TAT TTA CCT TCC ATC CCT CAA TCG GTT GAA TGT CGC CCT TTT GTC TTT 1104 Tyr Leu Pro Ser Ile Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe 575 580 585 GGC GCT GGT AAA CCC TAT GAA TTT TCT ATT GAT TGT GAC AAA ATA AAC 1152 Gly Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn 590 595 600 TTA TTC CGT GGT GTC TTT GCG TTT CTT TTA TAT GTT GCC ACC TTT ATG 1200 Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met 605 610 615 TAT GTA TTT TCT ACG TTT GCT AAC ATA CTG CGT AAT AAG GAG TCT 1245 Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser 620 625 630 TGATAAGCTT 1255 415 amino acids amino acid linear protein 280 Glu Phe Gly Gly Gly Gly Ser Ala Cys Ala Glu Thr Val Glu Ser Cys 1 5 10 15 Leu Ala Lys Ser His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp 20 25 30 Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly Cys Leu Trp Asn 35 40 45 Ala Thr Gly Val Val Val Cys Thr Gly Asp Glu Thr Gln Cys Tyr Gly 50 55 60 Thr Trp Val Pro Ile Gly Leu Ala Ile Pro Glu Asn Glu Gly Gly Gly 65 70 75 80 Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Thr 85 90 95 Lys Pro Pro Glu Tyr Gly Asp Thr Pro Ile Pro Gly Tyr Thr Tyr Ile 100 105 110 Asn Pro Leu Asp Gly Thr Tyr Pro Pro Gly Thr Glu Gln Asn Pro Ala 115 120 125 Asn Pro Asn Pro Ser Leu Glu Glu Ser Gln Pro Leu Asn Thr Phe Met 130 135 140 Phe Gln Asn Asn Arg Phe Arg Asn Arg Gln Gly Ala Leu Thr Val Tyr 145 150 155 160 Thr Gly Thr Val Thr Gln Gly Thr Asp Pro Val Lys Thr Tyr Tyr Gln 165 170 175 Tyr Thr Pro Val Ser Ser Lys Ala Met Tyr Asp Ala Tyr Trp Asn Gly 180 185 190 Lys Phe Arg Asp Cys Ala Phe His Ser Gly Phe Asn Glu Asp Leu Phe 195 200 205 Val Cys Glu Tyr Gln Gly Gln Ser Ser Asp Leu Pro Gln Pro Pro Val 210 215 220 Asn Ala Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly 225 230 235 240 Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly 245 250 255 Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met 260 265 270 Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala 275 280 285 Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr 290 295 300 Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn 305 310 315 320 Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala 325 330 335 Gln Val Gly Glu Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln 340 345 350 Tyr Leu Pro Ser Ile Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe 355 360 365 Gly Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn 370 375 380 Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met 385 390 395 400 Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser 405 410 415 502 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene cassette“ CDS 4..492 /product= ”gIIIp ss“ 281 CGG GAA TTC GGA GGC GGT TCC GGT GGT GGC TCT GGT TCC GGT GAT TTT 48 Glu Phe Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe 420 425 430 GAT TAT GAA AAG ATG GCA AAC GCT AAT AAG GGG GCT ATG ACC GAA AAT 96 Asp Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn 435 440 445 GCC GAT GAA AAC GCG CTA CAG TCT GAC GCT AAA GGC AAA CTT GAT TCT 144 Ala Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser 450 455 460 GTC GCT ACT GAT TAC GGT GCT GCT ATC GAT GGT TTC ATT GGT GAC GTT 192 Val Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val 465 470 475 TCC GGC CTT GCT AAT GGT AAT GGT GCT ACT GGT GAT TTT GCT GGC TCT 240 Ser Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser 480 485 490 AAT TCC CAA ATG GCT CAA GTC GGT GAC GGT GAT AAT TCA CCT TTA ATG 288 Asn Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met 495 500 505 510 AAT AAT TTC CGT CAA TAT TTA CCT TCC CTC CCT CAA TCG GTT GAA TGT 336 Asn Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys 515 520 525 CGC CCT TTT GTC TTT GGC GCT GGT AAA CCA TAT GAA TTT TCT ATT GAT 384 Arg Pro Phe Val Phe Gly Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp 530 535 540 TGT GAC AAA ATA AAC TTA TTC CGT GGT GTC TTT GCG TTT CTT TTA TAT 432 Cys Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr 545 550 555 GTT GCC ACC TTT ATG TAT GTA TTT TCT ACG TTT GCT AAC ATA CTG CGT 480 Val Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg 560 565 570 AAT AAG GAG TCT TGATAAGCTT 502 Asn Lys Glu Ser 575 163 amino acids amino acid linear protein 282 Glu Phe Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp 1 5 10 15 Tyr Glu Lys Met Ala Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala 20 25 30 Asp Glu Asn Ala Leu Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val 35 40 45 Ala Thr Asp Tyr Gly Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser 50 55 60 Gly Leu Ala Asn Gly Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn 65 70 75 80 Ser Gln Met Ala Gln Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn 85 90 95 Asn Phe Arg Gln Tyr Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg 100 105 110 Pro Phe Val Phe Gly Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys 115 120 125 Asp Lys Ile Asn Leu Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val 130 135 140 Ala Thr Phe Met Tyr Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn 145 150 155 160 Lys Glu Ser 47 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 283 GCATGCCATA ACTTCGTATA ATGTACGCTA TACGAAGTTA TAAGCTT 47 1163 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene cassette“ CDS 82..978 /product= ”bla resistance“ 284 GGGGGTGTAC ATTCAAATAT GTATCCGCTC ATGAGACAAT AACCCTGATA AATGCTTCAA 60 TAATATTGAA AAAGGAAGAG T ATG AGT ATT CAA CAT TTC CGT GTC GCC CTT 111 Met Ser Ile Gln His Phe Arg Val Ala Leu 165 170 ATT CCC TTT TTT GCG GCA TTT TGC CTT CCT GTT TTT GCT CAC CCA GAA 159 Ile Pro Phe Phe Ala Ala Phe Cys Leu Pro Val Phe Ala His Pro Glu 175 180 185 ACG CTG GTG AAA GTA AAA GAT GCT GAG GAT CAG TTG GGT GCG CGA GTG 207 Thr Leu Val Lys Val Lys Asp Ala Glu Asp Gln Leu Gly Ala Arg Val 190 195 200 205 GGT TAC ATC GAA CTG GAT CTC AAC AGC GGT AAG ATC CTT GAG AGT TTT 255 Gly Tyr Ile Glu Leu Asp Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe 210 215 220 CGC CCC GAA GAA CGT TTT CCA ATG ATG AGC ACT TTT AAA GTT CTG CTA 303 Arg Pro Glu Glu Arg Phe Pro Met Met Ser Thr Phe Lys Val Leu Leu 225 230 235 TGT GGC GCG GTA TTA TCC CGT ATT GAC GCC GGG CAA GAG CAA CTC GGT 351 Cys Gly Ala Val Leu Ser Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly 240 245 250 CGC CGC ATA CAC TAT TCT CAG AAT GAC TTG GTT GAG TAC TCA CCA GTC 399 Arg Arg Ile His Tyr Ser Gln Asn Asp Leu Val Glu Tyr Ser Pro Val 255 260 265 ACA GAA AAG CAT CTT ACG GAT GGC ATG ACA GTA AGA GAA TTA TGC AGT 447 Thr Glu Lys His Leu Thr Asp Gly Met Thr Val Arg Glu Leu Cys Ser 270 275 280 285 GCT GCC ATA ACC ATG AGT GAT AAC ACT GCG GCC AAC TTA CTT CTG ACA 495 Ala Ala Ile Thr Met Ser Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr 290 295 300 ACG ATC GGA GGA CCG AAG GAG CTA ACC GCT TTT TTG CAC AAC ATG GGG 543 Thr Ile Gly Gly Pro Lys Glu Leu Thr Ala Phe Leu His Asn Met Gly 305 310 315 GAT CAT GTA ACT CGC CTT GAT CGT TGG GAA CCG GAG CTG AAT GAA GCC 591 Asp His Val Thr Arg Leu Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala 320 325 330 ATA CCA AAC GAC GAG CGT GAC ACC ACG ATG CCT GTA GCA ATG GCA ACA 639 Ile Pro Asn Asp Glu Arg Asp Thr Thr Met Pro Val Ala Met Ala Thr 335 340 345 ACG TTG CGC AAA CTA TTA ACT GGC GAA CTA CTT ACT CTA GCT TCC CGG 687 Thr Leu Arg Lys Leu Leu Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg 350 355 360 365 CAA CAG TTA ATA GAC TGG ATG GAG GCG GAT AAA GTT GCA GGA CCA CTT 735 Gln Gln Leu Ile Asp Trp Met Glu Ala Asp Lys Val Ala Gly Pro Leu 370 375 380 CTG CGC TCG GCC CTT CCG GCT GGC TGG TTT ATT GCT GAT AAA TCT GGA 783 Leu Arg Ser Ala Leu Pro Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly 385 390 395 GCC GGT GAG CGT GGG TCT CGC GGT ATC ATT GCA GCA CTG GGG CCA GAT 831 Ala Gly Glu Arg Gly Ser Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp 400 405 410 GGT AAG CCC TCC CGT ATC GTA GTT ATC TAC ACG ACG GGG AGT CAG GCA 879 Gly Lys Pro Ser Arg Ile Val Val Ile Tyr Thr Thr Gly Ser Gln Ala 415 420 425 ACT ATG GAT GAA CGA AAT AGA CAG ATC GCT GAG ATA GGT GCC TCA CTG 927 Thr Met Asp Glu Arg Asn Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu 430 435 440 445 ATT AAG CAT TGG GTA ACT GTC AGA CCA AGT TTA CTC ATA TAT ACT TTA 975 Ile Lys His Trp Val Thr Val Arg Pro Ser Leu Leu Ile Tyr Thr Leu 450 455 460 GAT TGATTTAAAA CTTCATTTTT AATTTAAAAG GATCTAGGTG AAGATCCTTT 1028 Asp TTGATAATCT CATGACCAAA ATCCCTTAAC GTGAGTTTTC GTTCCACTGA GCGTCAGACC 1088 CCGTAGAAAA GATCAAAGGA TCTTCTTGAG ATCCTTTTTG ATAATGGCCG GCCCCCCCCC 1148 TTAATTAAGG GGGGG 1163 299 amino acids amino acid linear protein 285 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala 1 5 10 15 Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys 20 25 30 Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp 35 40 45 Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe 50 55 60 Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser 65 70 75 80 Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser 85 90 95 Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr 100 105 110 Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser 115 120 125 Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr Ile Gly Gly Pro Lys 130 135 140 Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp His Val Thr Arg Leu 145 150 155 160 Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg 165 170 175 Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu 180 185 190 Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp 195 200 205 Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser Ala Leu Pro 210 215 220 Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 225 230 235 240 Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245 250 255 Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn 260 265 270 Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp Val Thr 275 280 285 Val Arg Pro Ser Leu Leu Ile Tyr Thr Leu Asp 290 295 470 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 286 GCTAGCACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGG TGTGGTGGTT ACGCGCAGCG 60 TGACCGCTAC ACTTGCCAGC GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC CCTTCCTTTC 120 TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT TTAGGGTTCC 180 GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA TTAGGGTGAT GGTTCTCGTA 240 GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTTGAC GTTGGAGTCC ACGTTCTTTA 300 ATAGTGGACT CTTGTTCCAA ACTGGAACAA CACTCAACCC TATCTCGGTC TATTCTTTTG 360 ATTTATAAGG GATTTTGCCG ATTTCGGCCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA 420 AATTTAACGC GAATTTTAAC AAAATATTAA CGTTTACAAT TTCATGTACA 470 832 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 287 AGATCTAATA AGATGATCTT CTTGAGATCG TTTTGGTCTG CGCGTAATCT CTTGCTCTGA 60 AAACGAAAAA ACCGCCTTGC AGGGCGGTTT TTCGTAGGTT CTCTGAGCTA CCAACTCTTT 120 GAACCGAGGT AACTGGCTTG GAGGAGCGCA GTCACTAAAA CTTGTCCTTT CAGTTTAGCC 180 TTAACCGGCG CATGACTTCA AGACTAACTC CTCTAAATCA ATTACCAGTG GCTGCTGCCA 240 GTGGTGCTTT TGCATGTCTT TCCGGGTTGG ACTCAAGACG ATAGTTACCG GATAAGGCGC 300 AGCGGTCGGA CTGAACGGGG GGTTCGTGCA TACAGTCCAG CTTGGAGCGA ACTGCCTACC 360 CGGAACTGAG TGTCAGGCGT GGAATGAGAC AAACGCGGCC ATAACAGCGG AATGACACCG 420 GTAAACCGAA AGGCAGGAAC AGGAGAGCGC AGGAGGGAGC CGCCAGGGGG AAACGCCTGG 480 TATCTTTATA GTCCTGTCGG GTTTCGCCAC CACTGATTTG AGCGTCAGAT TTCGTGATGC 540 TTGTCAGGGG GGCGGAGCCT ATGGAAAAAC GGCTTTGCCG CGGCCCTCTC ACTTCCCTGT 600 TAAGTATCTT CCTGGCATCT TCCAGGAAAT CTCCGCCCCG TTCGTAAGCC ATTTCCGCTC 660 GCCGCAGTCG AACGACCGAG CGTAGCGAGT CAGTGAGCGA GGAAGCGGAA TATATCCTGT 720 ATCACATATT CTGCTGACGC ACCGGTGCAG CCTTTTTTCT CCTGCCACAT GAAGCACTTC 780 ACTGACACCC TCATCAGTGC CAACATAGTA AGCCAGTATA CACTCCGCTA GC 832 49 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 288 AGATCTCATA ACTTCGTATA ATGTATGCTA TACGAAGTTA TTCAGATCT 49 96 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 289 TCTAGAGCAT GCGTAGGAGA AAATAAAATG AAACAAAGCA CTATTGCACT GGCACTCTTA 60 CCGTTGCTCT TCACCCCTGT TACCAAAGCC GAATTC 96 120 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 290 TCTAGAGCAT GCGTAGGAGA AAATAAAATG AAACAAAGCA CTATTGCACT GGCACTCTTA 60 CCGTTGCTCT TCACCCCTGT TACCAAAGCC GACTACAAAG ATGAAGTGCA ATTGGAATTC 120 96 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic DNA cassette“ 291 TCTAGAGGTT GAGGTGATTT TATGAAAAAG AATATCGCAT TTCTTCTTGC ATCTATGTTC 60 GTTTTTTCTA TTGCTACAAA TGCATACGCT GAATTC 96 1221 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene cassette“ CDS 79..1158 /product= ”lacI“ 292 GCTAGCATCG AATGGCGCAA AACCTTTCGC GGTATGGCAT GATAGCGCCC GGAAGAGAGT 60 CAATTCAGGG TGGTGAAT GTG AAA CCA GTA ACG TTA TAC GAT GTC GCA GAG 111 Val Lys Pro Val Thr Leu Tyr Asp Val Ala Glu 300 305 310 TAT GCC GGT GTC TCT TAT CAG ACC GTT TCC CGC GTG GTG AAC CAG GCC 159 Tyr Ala Gly Val Ser Tyr Gln Thr Val Ser Arg Val Val Asn Gln Ala 315 320 325 AGC CAC GTT TCT GCG AAA ACG CGG GAA AAA GTG GAA GCG GCG ATG GCG 207 Ser His Val Ser Ala Lys Thr Arg Glu Lys Val Glu Ala Ala Met Ala 330 335 340 GAG CTG AAT TAC ATT CCT AAC CGC GTG GCA CAA CAA CTG GCG GGC AAA 255 Glu Leu Asn Tyr Ile Pro Asn Arg Val Ala Gln Gln Leu Ala Gly Lys 345 350 355 CAG TCG TTG CTG ATT GGC GTT GCC ACC TCC AGT CTG GCC CTG CAC GCG 303 Gln Ser Leu Leu Ile Gly Val Ala Thr Ser Ser Leu Ala Leu His Ala 360 365 370 CCG TCG CAA ATT GTC GCG GCG ATT AAA TCT CGC GCC GAT CAA CTG GGT 351 Pro Ser Gln Ile Val Ala Ala Ile Lys Ser Arg Ala Asp Gln Leu Gly 375 380 385 390 GCC AGC GTG GTC GTG TCG ATG GTA GAA CGA AGC GGC GTC GAA GCC TGT 399 Ala Ser Val Val Val Ser Met Val Glu Arg Ser Gly Val Glu Ala Cys 395 400 405 AAA GCG GCG GTG CAC AAT CTT CTC GCG CAA CGT GTC AGT GGG CTG ATT 447 Lys Ala Ala Val His Asn Leu Leu Ala Gln Arg Val Ser Gly Leu Ile 410 415 420 ATT AAC TAT CCG CTG GAT GAC CAG GAT GCT ATT GCT GTG GAA GCT GCC 495 Ile Asn Tyr Pro Leu Asp Asp Gln Asp Ala Ile Ala Val Glu Ala Ala 425 430 435 TGC ACT AAT GTT CCG GCG TTA TTT CTT GAT GTC TCT GAC CAG ACA CCC 543 Cys Thr Asn Val Pro Ala Leu Phe Leu Asp Val Ser Asp Gln Thr Pro 440 445 450 ATC AAC AGT ATT ATT TTC TCC CAT GAG GAC GGT ACG CGA CTG GGC GTG 591 Ile Asn Ser Ile Ile Phe Ser His Glu Asp Gly Thr Arg Leu Gly Val 455 460 465 470 GAG CAT CTG GTC GCA TTG GGC CAC CAG CAA ATC GCG CTG TTA GCT GGC 639 Glu His Leu Val Ala Leu Gly His Gln Gln Ile Ala Leu Leu Ala Gly 475 480 485 CCA TTA AGT TCT GTC TCG GCG CGT CTG CGT CTG GCT GGC TGG CAT AAA 687 Pro Leu Ser Ser Val Ser Ala Arg Leu Arg Leu Ala Gly Trp His Lys 490 495 500 TAT CTC ACT CGC AAT CAA ATT CAG CCG ATA GCG GAA CGG GAA GGC GAC 735 Tyr Leu Thr Arg Asn Gln Ile Gln Pro Ile Ala Glu Arg Glu Gly Asp 505 510 515 TGG AGT GCC ATG TCC GGT TTT CAA CAA ACC ATG CAA ATG CTG AAT GAG 783 Trp Ser Ala Met Ser Gly Phe Gln Gln Thr Met Gln Met Leu Asn Glu 520 525 530 GGC ATC GTT CCC ACT GCG ATG CTG GTT GCC AAC GAT CAG ATG GCG CTG 831 Gly Ile Val Pro Thr Ala Met Leu Val Ala Asn Asp Gln Met Ala Leu 535 540 545 550 GGC GCA ATG CGT GCC ATT ACC GAG TCC GGG CTG CGC GTT GGT GCG GAC 879 Gly Ala Met Arg Ala Ile Thr Glu Ser Gly Leu Arg Val Gly Ala Asp 555 560 565 ATC TCG GTA GTG GGA TAC GAC GAT ACC GAG GAC AGC TCA TGT TAT ATC 927 Ile Ser Val Val Gly Tyr Asp Asp Thr Glu Asp Ser Ser Cys Tyr Ile 570 575 580 CCG CCG CTG ACC ACC ATC AAA CAG GAT TTT CGC CTG CTG GGG CAA ACC 975 Pro Pro Leu Thr Thr Ile Lys Gln Asp Phe Arg Leu Leu Gly Gln Thr 585 590 595 AGC GTG GAC CGC TTG CTG CAA CTC TCT CAG GGC CAG GCG GTG AAG GGC 1023 Ser Val Asp Arg Leu Leu Gln Leu Ser Gln Gly Gln Ala Val Lys Gly 600 605 610 AAT CAG CTG TTG CCC GTC TCA CTG GTG AAA AGA AAA ACC ACC CTG GCT 1071 Asn Gln Leu Leu Pro Val Ser Leu Val Lys Arg Lys Thr Thr Leu Ala 615 620 625 630 CCC AAT ACG CAA ACC GCC TCT CCC CGC GCG TTG GCC GAT TCA CTG ATG 1119 Pro Asn Thr Gln Thr Ala Ser Pro Arg Ala Leu Ala Asp Ser Leu Met 635 640 645 CAG CTG GCA CGA CAG GTT TCC CGA CTG GAA AGC GGG CAG TGAGGCTACC 1168 Gln Leu Ala Arg Gln Val Ser Arg Leu Glu Ser Gly Gln 650 655 CGATAAAAGC GGCTTCCTGA CAGGAGGCCG TTTTGTTTTG CAGCCCACTT AAG 1221 360 amino acids amino acid linear protein 293 Val Lys Pro Val Thr Leu Tyr Asp Val Ala Glu Tyr Ala Gly Val Ser 1 5 10 15 Tyr Gln Thr Val Ser Arg Val Val Asn Gln Ala Ser His Val Ser Ala 20 25 30 Lys Thr Arg Glu Lys Val Glu Ala Ala Met Ala Glu Leu Asn Tyr Ile 35 40 45 Pro Asn Arg Val Ala Gln Gln Leu Ala Gly Lys Gln Ser Leu Leu Ile 50 55 60 Gly Val Ala Thr Ser Ser Leu Ala Leu His Ala Pro Ser Gln Ile Val 65 70 75 80 Ala Ala Ile Lys Ser Arg Ala Asp Gln Leu Gly Ala Ser Val Val Val 85 90 95 Ser Met Val Glu Arg Ser Gly Val Glu Ala Cys Lys Ala Ala Val His 100 105 110 Asn Leu Leu Ala Gln Arg Val Ser Gly Leu Ile Ile Asn Tyr Pro Leu 115 120 125 Asp Asp Gln Asp Ala Ile Ala Val Glu Ala Ala Cys Thr Asn Val Pro 130 135 140 Ala Leu Phe Leu Asp Val Ser Asp Gln Thr Pro Ile Asn Ser Ile Ile 145 150 155 160 Phe Ser His Glu Asp Gly Thr Arg Leu Gly Val Glu His Leu Val Ala 165 170 175 Leu Gly His Gln Gln Ile Ala Leu Leu Ala Gly Pro Leu Ser Ser Val 180 185 190 Ser Ala Arg Leu Arg Leu Ala Gly Trp His Lys Tyr Leu Thr Arg Asn 195 200 205 Gln Ile Gln Pro Ile Ala Glu Arg Glu Gly Asp Trp Ser Ala Met Ser 210 215 220 Gly Phe Gln Gln Thr Met Gln Met Leu Asn Glu Gly Ile Val Pro Thr 225 230 235 240 Ala Met Leu Val Ala Asn Asp Gln Met Ala Leu Gly Ala Met Arg Ala 245 250 255 Ile Thr Glu Ser Gly Leu Arg Val Gly Ala Asp Ile Ser Val Val Gly 260 265 270 Tyr Asp Asp Thr Glu Asp Ser Ser Cys Tyr Ile Pro Pro Leu Thr Thr 275 280 285 Ile Lys Gln Asp Phe Arg Leu Leu Gly Gln Thr Ser Val Asp Arg Leu 290 295 300 Leu Gln Leu Ser Gln Gly Gln Ala Val Lys Gly Asn Gln Leu Leu Pro 305 310 315 320 Val Ser Leu Val Lys Arg Lys Thr Thr Leu Ala Pro Asn Thr Gln Thr 325 330 335 Ala Ser Pro Arg Ala Leu Ala Asp Ser Leu Met Gln Leu Ala Arg Gln 340 345 350 Val Ser Arg Leu Glu Ser Gly Gln 355 360 2380 base pairs nucleic acid double circular other nucleic acid /desc = ”synthetic vector“ CDS complement (51..707) /product= ”cat resistance“ 294 GATCTAGCAC CAGGCGTTTA AGGGCACCAA TAACTGCCTT AAAAAAATTA CGCCCCGCCC 60 TGCCACTCAT CGCAGTACTG TTGTAATTCA TTAAGCATTC TGCCGACATG GAAGCCATCA 120 CAAACGGCAT GATGAACCTG AATCGCCAGC GGCATCAGCA CCTTGTCGCC TTGCGTATAA 180 TATTTGCCCA TAGTGAAAAC GGGGGCGAAG AAGTTGTCCA TATTGGCTAC GTTTAAATCA 240 AAACTGGTGA AACTCACCCA GGGATTGGCT GAGACGAAAA ACATATTCTC AATAAACCCT 300 TTAGGGAAAT AGGCCAGGTT TTCACCGTAA CACGCCACAT CTTGCGAATA TATGTGTAGA 360 AACTGCCGGA AATCGTCGTG GTATTCACTC CAGAGCGATG AAAACGTTTC AGTTTGCTCA 420 TGGAAAACGG TGTAACAAGG GTGAACACTA TCCCATATCA CCAGCTCACC GTCTTTCATT 480 GCCATACGGA ACTCCGGGTG AGCATTCATC AGGCGGGCAA GAATGTGAAT AAAGGCCGGA 540 TAAAACTTGT GCTTATTTTT CTTTACGGTC TTTAAAAAGG CCGTAATATC CAGCTGAACG 600 GTCTGGTTAT AGGTACATTG AGCAACTGAC TGAAATGCCT CAAAATGTTC TTTACGATGC 660 CATTGGGATA TATCAACGGT GGTATATCCA GTGATTTTTT TCTCCATTTT AGCTTCCTTA 720 GCTCCTGAAA ATCTCGATAA CTCAAAAAAT ACGCCCGGTA GTGATCTTAT TTCATTATGG 780 TGAAAGTTGG AACCTCACCC GACGTCTAAT GTGAGTTAGC TCACTCATTA GGCACCCCAG 840 GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA TTGTGAGCGG ATAACAATTT 900 CACACAGGAA ACAGCTATGA CCATGATTAC GAATTTCTAG ACCCCCCCCC CGCATGCCAT 960 AACTTCGTAT AATGTACGCT ATACGAAGTT ATAAGCTTGA CCTGTGAAGT GAAAAATGGC 1020 GCAGATTGTG CGACATTTTT TTTGTCTGCC GTTTAATTAA AGGGGGGGGG GGGCCGGCCT 1080 GGGGGGGGGT GTACATGAAA TTGTAAACGT TAATATTTTG TTAAAATTCG CGTTAAATTT 1140 TTGTTAAATC AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAAAATCC CTTATAAATC 1200 AAAAGAATAG ACCGAGATAG GGTTGAGTGT TGTTCCAGTT TGGAACAAGA GTCCACTATT 1260 AAAGAACGTG GACTCCAACG TCAAAGGGCG AAAAACCGTC TATCAGGGCG ATGGCCCACT 1320 ACGAGAACCA TCACCCTAAT CAAGTTTTTT GGGGTCGAGG TGCCGTAAAG CACTAAATCG 1380 GAACCCTAAA GGGAGCCCCC GATTTAGAGC TTGACGGGGA AAGCCGGCGA ACGTGGCGAG 1440 AAAGGAAGGG AAGAAAGCGA AAGGAGCGGG CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC 1500 GCTGCGCGTA ACCACCACAC CCGCCGCGCT TAATGCGCCG CTACAGGGCG CGTGCTAGCG 1560 GAGTGTATAC TGGCTTACTA TGTTGGCACT GATGAGGGTG TCAGTGAAGT GCTTCATGTG 1620 GCAGGAGAAA AAAGGCTGCA CCGGTGCGTC AGCAGAATAT GTGATACAGG ATATATTCCG 1680 CTTCCTCGCT CACTGACTCG CTACGCTCGG TCGTTCGACT GCGGCGAGCG GAAATGGCTT 1740 ACGAACGGGG CGGAGATTTC CTGGAAGATG CCAGGAAGAT ACTTAACAGG GAAGTGAGAG 1800 GGCCGCGGCA AAGCCGTTTT TCCATAGGCT CCGCCCCCCT GACAAGCATC ACGAAATCTG 1860 ACGCTCAAAT CAGTGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG CGTTTCCCCC 1920 TGGCGGCTCC CTCCTGCGCT CTCCTGTTCC TGCCTTTCGG TTTACCGGTG TCATTCCGCT 1980 GTTATGGCCG CGTTTGTCTC ATTCCACGCC TGACACTCAG TTCCGGGTAG GCAGTTCGCT 2040 CCAAGCTGGA CTGTATGCAC GAACCCCCCG TTCAGTCCGA CCGCTGCGCC TTATCCGGTA 2100 ACTATCGTCT TGAGTCCAAC CCGGAAAGAC ATGCAAAAGC ACCACTGGCA GCAGCCACTG 2160 GTAATTGATT TAGAGGAGTT AGTCTTGAAG TCATGCGCCG GTTAAGGCTA AACTGAAAGG 2220 ACAAGTTTTA GTGACTGCGC TCCTCCAAGC CAGTTACCTC GGTTCAAAGA GTTGGTAGCT 2280 CAGAGAACCT ACGAAAAACC GCCCTGCAAG GCGGTTTTTT CGTTTTCAGA GCAAGAGATT 2340 ACGCGCAGAC CAAAACGATC TCAAGAAGAT CATCTTATTA 2380 219 amino acids amino acid linear protein 295 Met Glu Lys Lys Ile Thr Gly Tyr Thr Thr Val Asp Ile Ser Gln Trp 1 5 10 15 His Arg Lys Glu His Phe Glu Ala Phe Gln Ser Val Ala Gln Cys Thr 20 25 30 Tyr Asn Gln Thr Val Gln Leu Asp Ile Thr Ala Phe Leu Lys Thr Val 35 40 45 Lys Lys Asn Lys His Lys Phe Tyr Pro Ala Phe Ile His Ile Leu Ala 50 55 60 Arg Leu Met Asn Ala His Pro Glu Phe Arg Met Ala Met Lys Asp Gly 65 70 75 80 Glu Leu Val Ile Trp Asp Ser Val His Pro Cys Tyr Thr Val Phe His 85 90 95 Glu Gln Thr Glu Thr Phe Ser Ser Leu Trp Ser Glu Tyr His Asp Asp 100 105 110 Phe Arg Gln Phe Leu His Ile Tyr Ser Gln Asp Val Ala Cys Tyr Gly 115 120 125 Glu Asn Leu Ala Tyr Phe Pro Lys Gly Phe Ile Glu Asn Met Phe Phe 130 135 140 Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asp Leu Asn Val 145 150 155 160 Ala Asn Met Asp Asn Phe Phe Ala Pro Val Phe Thr Met Gly Lys Tyr 165 170 175 Tyr Thr Gln Gly Asp Lys Val Leu Met Pro Leu Ala Ile Gln Val His 180 185 190 His Ala Val Cys Asp Gly Phe His Val Gly Arg Met Leu Asn Glu Leu 195 200 205 Gln Gln Tyr Cys Asp Glu Trp Gln Gly Gly Ala 210 215 3488 base pairs nucleic acid double circular other nucleic acid /desc = ”synthetic vector“ CDS complement (1341..1997) /product= ”cat resistance“ CDS complement (2521..3417) /product= ”bla resistance“ 296 GTACATGAAA TTGTAAACGT TAATATTTTG TTAAAATTCG CGTTAAATTT TTGTTAAATC 60 AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAAAATCC CTTATAAATC AAAAGAATAG 120 ACCGAGATAG GGTTGAGTGT TGTTCCAGTT TGGAACAAGA GTCCACTATT AAAGAACGTG 180 GACTCCAACG TCAAAGGGCG AAAAACCGTC TATCAGGGCG ATGGCCCACT ACGAGAACCA 240 TCACCCTAAT CAAGTTTTTT GGGGTCGAGG TGCCGTAAAG CACTAAATCG GAACCCTAAA 300 GGGAGCCCCC GATTTAGAGC TTGACGGGGA AAGCCGGCGA ACGTGGCGAG AAAGGAAGGG 360 AAGAAAGCGA AAGGAGCGGG CGCTAGGGCG CTGGCAAGTG TAGCGGTCAC GCTGCGCGTA 420 ACCACCACAC CCGCCGCGCT TAATGCGCCG CTACAGGGCG CGTGCTAGCG GAGTGTATAC 480 TGGCTTACTA TGTTGGCACT GATGAGGGTG TCAGTGAAGT GCTTCATGTG GCAGGAGAAA 540 AAAGGCTGCA CCGGTGCGTC AGCAGAATAT GTGATACAGG ATATATTCCG CTTCCTCGCT 600 CACTGACTCG CTACGCTCGG TCGTTCGACT GCGGCGAGCG GAAATGGCTT ACGAACGGGG 660 CGGAGATTTC CTGGAAGATG CCAGGAAGAT ACTTAACAGG GAAGTGAGAG GGCCGCGGCA 720 AAGCCGTTTT TCCATAGGCT CCGCCCCCCT GACAAGCATC ACGAAATCTG ACGCTCAAAT 780 CAGTGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG CGTTTCCCCC TGGCGGCTCC 840 CTCCTGCGCT CTCCTGTTCC TGCCTTTCGG TTTACCGGTG TCATTCCGCT GTTATGGCCG 900 CGTTTGTCTC ATTCCACGCC TGACACTCAG TTCCGGGTAG GCAGTTCGCT CCAAGCTGGA 960 CTGTATGCAC GAACCCCCCG TTCAGTCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT 1020 TGAGTCCAAC CCGGAAAGAC ATGCAAAAGC ACCACTGGCA GCAGCCACTG GTAATTGATT 1080 TAGAGGAGTT AGTCTTGAAG TCATGCGCCG GTTAAGGCTA AACTGAAAGG ACAAGTTTTA 1140 GTGACTGCGC TCCTCCAAGC CAGTTACCTC GGTTCAAAGA GTTGGTAGCT CAGAGAACCT 1200 ACGAAAAACC GCCCTGCAAG GCGGTTTTTT CGTTTTCAGA GCAAGAGATT ACGCGCAGAC 1260 CAAAACGATC TCAAGAAGAT CATCTTATTA GATCTAGCAC CAGGCGTTTA AGGGCACCAA 1320 TAACTGCCTT AAAAAAATTA CGCCCCGCCC TGCCACTCAT CGCAGTACTG TTGTAATTCA 1380 TTAAGCATTC TGCCGACATG GAAGCCATCA CAAACGGCAT GATGAACCTG AATCGCCAGC 1440 GGCATCAGCA CCTTGTCGCC TTGCGTATAA TATTTGCCCA TAGTGAAAAC GGGGGCGAAG 1500 AAGTTGTCCA TATTGGCTAC GTTTAAATCA AAACTGGTGA AACTCACCCA GGGATTGGCT 1560 GAGACGAAAA ACATATTCTC AATAAACCCT TTAGGGAAAT AGGCCAGGTT TTCACCGTAA 1620 CACGCCACAT CTTGCGAATA TATGTGTAGA AACTGCCGGA AATCGTCGTG GTATTCACTC 1680 CAGAGCGATG AAAACGTTTC AGTTTGCTCA TGGAAAACGG TGTAACAAGG GTGAACACTA 1740 TCCCATATCA CCAGCTCACC GTCTTTCATT GCCATACGGA ACTCCGGGTG AGCATTCATC 1800 AGGCGGGCAA GAATGTGAAT AAAGGCCGGA TAAAACTTGT GCTTATTTTT CTTTACGGTC 1860 TTTAAAAAGG CCGTAATATC CAGCTGAACG GTCTGGTTAT AGGTACATTG AGCAACTGAC 1920 TGAAATGCCT CAAAATGTTC TTTACGATGC CATTGGGATA TATCAACGGT GGTATATCCA 1980 GTGATTTTTT TCTCCATTTT AGCTTCCTTA GCTCCTGAAA ATCTCGATAA CTCAAAAAAT 2040 ACGCCCGGTA GTGATCTTAT TTCATTATGG TGAAAGTTGG AACCTCACCC GACGTCTAAT 2100 GTGAGTTAGC TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG 2160 TTGTGTGGAA TTGTGAGCGG ATAACAATTT CACACAGGAA ACAGCTATGA CCATGATTAC 2220 GAATTTCTAG ACCCCCCCCC CGCATGCCAT AACTTCGTAT AATGTACGCT ATACGAAGTT 2280 ATAAGCTTGA CCTGTGAAGT GAAAAATGGC GCAGATTGTG CGACATTTTT TTTGTCTGCC 2340 GTTTAATTAA GGGGGGGGGC CGGCCATTAT CAAAAAGGAT CTCAAGAAGA TCCTTTGATC 2400 TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG 2460 AGATTATCAA AAAGGATCTT CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA 2520 ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC CAATGCTTAA TCAGTGAGGC 2580 ACCTATCTCA GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA 2640 GATAACTACG ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA 2700 CCCACGCTCA CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG 2760 CAGAAGTGGT CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAACTGTT GCCGGGAAGC 2820 TAGAGTAAGT AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT 2880 CGTGGTGTCA CGCTCGTCGT TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG 2940 GCGAGTTACA TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT 3000 CGTTGTCAGA AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA 3060 TTCTCTTACT GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA 3120 GTCATTCTGA GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA 3180 TAATACCGCG CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG 3240 GCGAAAACTC TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGCGC 3300 ACCCAACTGA TCCTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG 3360 AAGGCAAAAT GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT 3420 CTTCCTTTTT CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT 3480 ATTTGAAT 3488 219 amino acids amino acid linear protein 297 Met Glu Lys Lys Ile Thr Gly Tyr Thr Thr Val Asp Ile Ser Gln Trp 1 5 10 15 His Arg Lys Glu His Phe Glu Ala Phe Gln Ser Val Ala Gln Cys Thr 20 25 30 Tyr Asn Gln Thr Val Gln Leu Asp Ile Thr Ala Phe Leu Lys Thr Val 35 40 45 Lys Lys Asn Lys His Lys Phe Tyr Pro Ala Phe Ile His Ile Leu Ala 50 55 60 Arg Leu Met Asn Ala His Pro Glu Phe Arg Met Ala Met Lys Asp Gly 65 70 75 80 Glu Leu Val Ile Trp Asp Ser Val His Pro Cys Tyr Thr Val Phe His 85 90 95 Glu Gln Thr Glu Thr Phe Ser Ser Leu Trp Ser Glu Tyr His Asp Asp 100 105 110 Phe Arg Gln Phe Leu His Ile Tyr Ser Gln Asp Val Ala Cys Tyr Gly 115 120 125 Glu Asn Leu Ala Tyr Phe Pro Lys Gly Phe Ile Glu Asn Met Phe Phe 130 135 140 Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asp Leu Asn Val 145 150 155 160 Ala Asn Met Asp Asn Phe Phe Ala Pro Val Phe Thr Met Gly Lys Tyr 165 170 175 Tyr Thr Gln Gly Asp Lys Val Leu Met Pro Leu Ala Ile Gln Val His 180 185 190 His Ala Val Cys Asp Gly Phe His Val Gly Arg Met Leu Asn Glu Leu 195 200 205 Gln Gln Tyr Cys Asp Glu Trp Gln Gly Gly Ala 210 215 299 amino acids amino acid linear protein 298 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala 1 5 10 15 Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys 20 25 30 Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp 35 40 45 Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe 50 55 60 Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser 65 70 75 80 Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser 85 90 95 Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr 100 105 110 Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser 115 120 125 Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr Ile Gly Gly Pro Lys 130 135 140 Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp His Val Thr Arg Leu 145 150 155 160 Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg 165 170 175 Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu 180 185 190 Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp 195 200 205 Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser Ala Leu Pro 210 215 220 Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 225 230 235 240 Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245 250 255 Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn 260 265 270 Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp Val Thr 275 280 285 Val Arg Pro Ser Leu Leu Ile Tyr Thr Leu Asp 290 295 2728 base pairs nucleic acid double circular other nucleic acid /desc = ”synthetic vector“ CDS complement (471..1367) /product= ”bla resistance“ 299 GATCTCATAA CTTCGTATAA TGTATGCTAT ACGAAGTTAT GACGTCTAAT GTGAGTTAGC 60 TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA 120 TTGTGAGCGG ATAACAATTT CACACAGGAA ACAGCTATGA CCATGATTAC GAATTTCTAG 180 ACCCCCCCCC CGCATGCCAT AACTTCGTAT AATGTACGCT ATACGAAGTT ATAAGCTTGA 240 CCTGTGAAGT GAAAAATGGC GCAGATTGTG CGACATTTTT TTTGTCTGCC GTTTAATTAA 300 GGGGGGGGGC CGGCCATTAT CAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG 360 GGTCTGACGC TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG AGATTATCAA 420 AAAGGATCTT CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA 480 TATATGAGTA AACTTGGTCT GACAGTTACC CAATGCTTAA TCAGTGAGGC ACCTATCTCA 540 GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG 600 ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA 660 CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT 720 CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAACTGTT GCCGGGAAGC TAGAGTAAGT 780 AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTCA 840 CGCTCGTCGT TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG GCGAGTTACA 900 TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA 960 AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT 1020 GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA 1080 GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG 1140 CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACTC 1200 TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGCGC ACCCAACTGA 1260 TCCTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT 1320 GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT 1380 CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT 1440 ACATGAAATT GTAAACGTTA ATATTTTGTT AAAATTCGCG TTAAATTTTT GTTAAATCAG 1500 CTCATTTTTT AACCAATAGG CCGAAATCGG CAAAATCCCT TATAAATCAA AAGAATAGAC 1560 CGAGATAGGG TTGAGTGTTG TTCCAGTTTG GAACAAGAGT CCACTATTAA AGAACGTGGA 1620 CTCCAACGTC AAAGGGCGAA AAACCGTCTA TCAGGGCGAT GGCCCACTAC GAGAACCATC 1680 ACCCTAATCA AGTTTTTTGG GGTCGAGGTG CCGTAAAGCA CTAAATCGGA ACCCTAAAGG 1740 GAGCCCCCGA TTTAGAGCTT GACGGGGAAA GCCGGCGAAC GTGGCGAGAA AGGAAGGGAA 1800 GAAAGCGAAA GGAGCGGGCG CTAGGGCGCT GGCAAGTGTA GCGGTCACGC TGCGCGTAAC 1860 CACCACACCC GCCGCGCTTA ATGCGCCGCT ACAGGGCGCG TGCTAGCGGA GTGTATACTG 1920 GCTTACTATG TTGGCACTGA TGAGGGTGTC AGTGAAGTGC TTCATGTGGC AGGAGAAAAA 1980 AGGCTGCACC GGTGCGTCAG CAGAATATGT GATACAGGAT ATATTCCGCT TCCTCGCTCA 2040 CTGACTCGCT ACGCTCGGTC GTTCGACTGC GGCGAGCGGA AATGGCTTAC GAACGGGGCG 2100 GAGATTTCCT GGAAGATGCC AGGAAGATAC TTAACAGGGA AGTGAGAGGG CCGCGGCAAA 2160 GCCGTTTTTC CATAGGCTCC GCCCCCCTGA CAAGCATCAC GAAATCTGAC GCTCAAATCA 2220 GTGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG TTTCCCCCTG GCGGCTCCCT 2280 CCTGCGCTCT CCTGTTCCTG CCTTTCGGTT TACCGGTGTC ATTCCGCTGT TATGGCCGCG 2340 TTTGTCTCAT TCCACGCCTG ACACTCAGTT CCGGGTAGGC AGTTCGCTCC AAGCTGGACT 2400 GTATGCACGA ACCCCCCGTT CAGTCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG 2460 AGTCCAACCC GGAAAGACAT GCAAAAGCAC CACTGGCAGC AGCCACTGGT AATTGATTTA 2520 GAGGAGTTAG TCTTGAAGTC ATGCGCCGGT TAAGGCTAAA CTGAAAGGAC AAGTTTTAGT 2580 GACTGCGCTC CTCCAAGCCA GTTACCTCGG TTCAAAGAGT TGGTAGCTCA GAGAACCTAC 2640 GAAAAACCGC CCTGCAAGGC GGTTTTTTCG TTTTCAGAGC AAGAGATTAC GCGCAGACCA 2700 AAACGATCTC AAGAAGATCA TCTTATTA 2728 299 amino acids amino acid linear protein 300 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala 1 5 10 15 Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys 20 25 30 Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp 35 40 45 Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe 50 55 60 Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser 65 70 75 80 Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser 85 90 95 Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr 100 105 110 Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser 115 120 125 Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr Ile Gly Gly Pro Lys 130 135 140 Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp His Val Thr Arg Leu 145 150 155 160 Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg 165 170 175 Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu 180 185 190 Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp 195 200 205 Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser Ala Leu Pro 210 215 220 Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 225 230 235 240 Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245 250 255 Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn 260 265 270 Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp Val Thr 275 280 285 Val Arg Pro Ser Leu Leu Ile Tyr Thr Leu Asp 290 295 45 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 301 TATGAGATCT CATAACTTCG TATAATGTAC GCTATACGAA GTTAT 45 45 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 302 TAATAACTTC GTATAGCATA CATTATACGA AGTTATGAGA TCTCA 45 91 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 303 CATTTTTTGC CCTCGTTATC TACGCATGCG ATAACTTCGT ATAGCGTACA TTATACGAAG 60 TTATTCTAGA CATGGTCATA GCTGTTTCCT G 91 52 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 304 GGGGGGAATT CGGTGGTGGT GGATCTGCGT GCGCTGAAAC GGTTGAAAGT TG 52 32 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 305 CCCCCCCAAG CTTATCAAGA CTCCTTATTA CG 32 34 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 306 GGGGGGGGAA TTCGGAGGCG GTTCCGGTGG TGGC 34 74 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 307 GGGGGGGGAA TTCGAGCAGA AGCTGATCTC TGAGGAGGAT CTGTAGGGTG GTGGCTCTGG 60 TTCCGGTGAT TTTG 74 37 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 308 CCATAACTTC GTATAATGTA CGCTATACGA AGTTATA 37 45 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 309 AGCTTATAAC TTCGTATAGC GTACATTATA CGAAGTTATG GCATG 45 76 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 310 AGCTTGACCT GTGAAGTGAA AAATGGCGCA GATTGTGCGA CATTTTTTTT GTCTGCCGTT 60 TAATTAAAGG GGGGGT 76 75 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 311 GTACACCCCC CCCCAGGCCG GCCCCCCCCC CCCTTTAATT AAACGGCAGA CAAAAAAAAT 60 GTCGCACAAT CTGCG 75 35 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 312 GGGGGGGTGT ACATTCAAAT ATGTATCCGC TCATG 35 22 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 313 GGGTTACATC GAACTGGATC TC 22 59 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 314 CCAGTTCGAT GTAACCCACT CGCGCACCCA ACTGATCCTC AGCATCTTTT ACTTTCACC 59 43 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 315 ACTCTAGCTT CCCGGCAACA GTTAATAGAC TGGATGGAGG CGG 43 24 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 316 CTGTTGCCGG GAAGCTAGAG TAAG 24 58 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 317 CCCCCCCTTA ATTAAGGGGG GGGGCCGGCC ATTATCAAAA AGGATCTCAA GAAGATCC 58 37 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 318 GGGGGGGGCT AGCACGCGCC CTGTAGCGGC GCATTAA 37 38 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 319 CCCCCCCTGT ACATGAAATT GTAAACGTTA ATATTTTG 38 36 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 320 GGGCGATGGC CCACTACGAG AACCATCACC CTAATC 36 32 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 321 GGGGGGAGAT CTAATAAGAT GATCTTCTTG AG 32 45 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 322 GAGTTGGTAG CTCAGAGAAC CTACGAAAAA CCGCCCTGCA AGGCG 45 24 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 323 GTAGGTTCTC TGAGCTACCA ACTC 24 43 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 324 GTTTCCCCCT GGCGGCTCCC TCCTGCGCTC TCCTGTTCCT GCC 43 24 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 325 AGGAGGGAGC CGCCAGGGGG AAAC 24 26 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 326 GACATCAGCG CTAGCGGAGT GTATAC 26 43 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 327 GATCTCATAA CTTCGTATAA TGTATGCTAT ACGAAGTTAT TCA 43 45 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 328 GATCTGAATA ACTTCGTATA GCATACATTA TACGAAGTTA TGAGA 45 35 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 329 GGGGGGGAGA TCTGACCAAA ATCCCTTAAC GTGAG 35 35 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 330 GGTATCTGCG CTCTGCTGTA GCCAGTTACC TTCGG 35 35 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 331 CCCCCCCGCT AGCCATGTGA GCAAAAGGCC AGCAA 35 23 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 332 GGGACGTCGG GTGAGGTTCC AAC 23 29 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 333 CCATACGGAA CTCCGGGTGA GCATTCATC 29 16 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 334 CCGGAGTTCC GTATGG 16 19 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 335 ACGTTTAAAT CAAAACTGG 19 69 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 336 CCAGTTTTGA TTTAAACGTA GCCAATATGG ACAACTTCTT CGCCCCCGTT TTCACTATGG 60 GCAAATATT 69 26 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 337 GGAAGATCTA GCACCAGGCG TTTAAG 26 27 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 338 GAGGCCGGCC ATCGAATGGC GCAAAAC 27 31 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 339 CGCGTACCGT CCTCATGGGA GAAAATAATA C 31 83 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 340 CCATGAGGAC GGTACGCGAC TGGGCGTGGA GCATCTGGTC GCATTGGGTC ACCAGCAAAT 60 CCGCTGTTAG CTGGCCCATT AAG 83 42 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 341 GTCAGCGGCG GGATATAACA TGAGCTGTCC TCGGTATCGT CG 42 30 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 342 GTTATATCCC GCCGCTGACC ACCATCAAAC 30 65 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ conflict replace(42..44, ”“) /note= ”in Fig.35b, M41, LAC6 T4T; but see Fig.35a, M41 LAC6 pos.1055-1119 on complementary strand, 1076 to 1078 TAT“ 343 CATCAGTGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC GTATTGGGAG CCAGGGTGGT 60 TTTTC 65 73 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 344 GGTTAATTAA CCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGCATCAG 60 TGAATCGGCC AAC 73 50 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 345 CTAGACTAGT GTTTAAACCG GACCGGGGGG GGGCTTAAGG GGGGGGGGGG 50 50 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 346 CTAGCCCCCC CCCCCCTTAA GCCCCCCCCC GGTCCGGTTT AAACACTAGT 50 50 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 347 CTAGACTAGT GTTTAAACCG GACCGGGGGG GGGCTTAAGG GGGGGGGGGG 50 82 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 348 CCCCCCCTTA AGTGGGCTGC AAAACAAAAC GGCCTCCTGT CAGGAAGCCG CTTTTATCGG 60 GTAGCCTCAC TGCCCGCTTT CC 82 40 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 349 GTTGTTGTGC CACGCGGTTA GGAATGTAAT TCAGCTCCGC 40 19 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 350 AACCGCGTGG CACAACAAC 19 41 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 351 CTTCGTTCTA CCATCGACAC GACCACGCTG GCACCCAGTT G 41 20 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 352 GTGTCGATGG TAGAACGAAG 20 67 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 353 CCACAGCAAT AGCATCCTGG TCATCCAGCG GATAGTTAAT AATCAGCCCA CTGACACGTT 60 GCGCGAG 67 22 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 354 GACCAGGATG CTATTGCTGT GG 22 37 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 355 CAGCGCGATT TGCTGGTGGC CCAATGCGAC CAGATGC 37 18 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 356 CACCAGCAAA TCGCGCTG 18 37 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 357 CCCGGACTCG GTAATGGCAC GCATTGCGCC CAGCGCC 37 18 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 358 GCCATTACCG AGTCCGGG 18 29 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 359 AATTCCACCA TCATCACCAT TGACGTCTA 29 29 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 360 AGCTTAGACG TCAATGGTGA TGATGGTGG 29 1289 base pairs nucleic acid double linear other nucleic acid /desc = ”synthetic gene cassette“ CDS complement (280..1137) /product= ”bla resistance“ 361 CGCGTTAACC TCAGGTGACC AAGCCCCTGG CCAAGGTCCC GTACGTTCGA AGATTACCAT 60 CACGTGGATC CGGTACCAGG CCGGCCATTA TCAAAAAGGA TCTCAAGAAG ATCCTTTGAT 120 CTTTTCTACG GGGTCTGACG CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT 180 GAGATTATCA AAAAGGATCT TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC 240 AATCTAAAGT ATATATGAGT AAACTTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC 300 ACCTATCTCA GCGATCTGTC TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA 360 GATAACTACG ATACGGGAGG GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA 420 CCCACGCTCA CCGGCTCCAG ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG 480 CAGAAGTGGT CCTGCAACTT TATCCGCCTC CATCCAGTCT ATTAACTGTT GCCGGGAAGC 540 TAGAGTAAGT AGTTCGCCAG TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT 600 CGTGGTGTCA CGCTCGTCGT TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG 660 GCGAGTTACA TGATCCCCCA TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT 720 CGTTGTCAGA AGTAAGTTGG CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA 780 TTCTCTTACT GTCATGCCAT CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA 840 GTCATTCTGA GAATAGTGTA TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA 900 TAATACCGCG CCACATAGCA GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG 960 GCGAAAACTC TCAAGGATCT TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC 1020 ACCCAACTGA TCTTCAGCAT CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG 1080 AAGGCAAAAT GCCGCAAAAA AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT 1140 CTTCCTTTTT CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT 1200 ATTTGAATGT ACTCGGCCGC ACGAGCTGCA GGCGCCATTA ATGGCTCGAG CGCGCTTCAG 1260 CGCTTTGTCT TCCGGATGTA CATGAAATT 1289 286 amino acids amino acid linear protein 362 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala 1 5 10 15 Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys 20 25 30 Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp 35 40 45 Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe 50 55 60 Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser 65 70 75 80 Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser 85 90 95 Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr 100 105 110 Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser 115 120 125 Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr Ile Gly Gly Pro Lys 130 135 140 Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp His Val Thr Arg Leu 145 150 155 160 Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile Pro Asn Asp Glu Arg 165 170 175 Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr Leu Arg Lys Leu Leu 180 185 190 Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln Gln Leu Ile Asp Trp 195 200 205 Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu Arg Ser Ala Leu Pro 210 215 220 Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly Ala Gly Glu Arg Gly Ser 225 230 235 240 Arg Gly Ile Ile Ala Ala Leu Gly Pro Asp Gly Lys Pro Ser Arg Ile 245 250 255 Val Val Ile Tyr Thr Thr Gly Ser Gln Ala Thr Met Asp Glu Arg Asn 260 265 270 Arg Gln Ile Ala Glu Ile Gly Ala Ser Leu Ile Lys His Trp 275 280 285 18 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 363 GCCCTGCAAG CGGAAGAC 18 20 base pairs nucleic acid single linear other nucleic acid 364 GGCTTTCGAA TGGCCAAAGG 20 81 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide misc_feature 25..27 /product= “random codon by trinucleotide mutagenesis (ACT/GTT)” misc_feature 37..39 /product= “random codon by trinucleotides (TTT,CAT,CTT,ATG,CAG)” misc_feature 43..45 /product= “random codon by trinucleotides (18 codons, no Pro, no Cys)” misc_feature 46..48 /product= “random codon by trinucleotides (GAT, GGT, AAT, TCT, TAT)” misc_feature 49..51 /product= “random codon by trinucleotides (GAT, GGT, AAT, TCT)” misc_feature 52..54 /product= “random codon by trinucleotide mutagenesis (19aa, no Cys)” misc_feature 55..57 /product= “random codon by trinucleotides (CCT/TCT)” misc_feature 58..60 /product= “random codon by trinucleotide mutagenesis (19 aa, no Cys)” 365 GCCCTGCAAG CGGAAGACTT TGCGRYTTAT TATTGCHWKC AGNNKDVTDV TNNKYCTNNK 60 ACCTTTGGCC ATTCGAAAGC C 81 81 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide misc_feature 37..39 /product= ”random codon by trinucleotides (TTT,CAT,CTT,ATG,CAG)“ misc_feature 43..45 /product= ”random codon by trinucleotides (18 codons, no Pro, no Cys)“ misc_feature 46..48 /product= ”random codon by trinucleotides (GAT, GGT, AAT, TCT, TAT)“ misc_feature 49..51 /product= ”random codon by trinucleotides (GAT, GGT, AAT, TCT)“ misc_feature 52..54 /product= ”random codon by trinucleotide mutagenesis (19aa, no Cys)“ misc_feature 55..57 /product= ”random codon by trinucleotides (CCT/TCT)“ misc_feature 58..60 /product= ”random codon by trinucleotide mutagenesis (19 aa, no Cys)“ 366 GCCCTGCAAG CGGAAGACGT GGGCGTGTAT TATTGCHWKC AGNNKDVTDV TNNKYCTNNK 60 ACCTTTGGCC ATTCGAAAGC C 81 81 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide misc_feature 37..39 /product= “random codon by trinucleotides (TTT,CAT,CTT,ATG,CAG)” misc_feature 43..45 /product= “random codon by trinucleotides (18 codons, no Pro, no Cys)” misc_feature 46..48 /product= “random codon by trinucleotides (GAT, GGT, AAT, TCT, TAT)” misc_feature 49..51 /product= “random codon by trinucleotides (GAT, GGT, AAT, TCT)” misc_feature 52..54 /product= “random codon by trinucleotide mutagenesis (19aa, no Cys)” misc_feature 55..57 /product= “random codon by trinucleotides (CCT/TCT)” misc_feature 58..60 /product= “random codon by trinucleotide mutagenesis (19 aa, no Cys)” 367 GCCCTGCAAG CGGAAGACGT GGCGGTGTAT TATTGCHWKC AGNNKDVTDV TNNKYCTNNK 60 ACCTTTGGCC ATTCGAAAGC C 81 108 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide misc_feature 41..43 /product= ”random codon by trinucleotides (CGT, TGG, TAT)“ misc_feature 47..61 /product= ”random codons by trinucleotides (18 aa, no Trp, no Cys)“ misc_feature 62..64 /product= ”random codon by trinucleotide mutagenesis (19aa, no Cys)“ 368 CCTGCAAGCG GAAGACGAAG CGGATTATTA TTGCCAGAGC YRKGACNNKN NKNNKNNKNN 60 KNNKGGCGGC GGCACGAAGT TAACCGTTCT TGGCCAGGAA TTCGAGCC 108 105 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide misc_feature 41..43 /product= “random codon by trinucleotides (CGT, TGG, TAT)” misc_feature 47..58 /product= “random codons by trinucleotides (18 aa, no Trp, no Cys)” misc_feature 59..61 /product= “random codon by trinucleotide mutagenesis (19aa, no Cys)” 369 CCTGCAAGCG GAAGACGAAG CGGATTATTA TTGCCAGAGC YRKGACNNKN NKNNKNNKNN 60 KGGCGGCGGC ACGAAGTTAA CCGTTCTTGG CCAGGAATTC GAGCC 105 102 base pairs nucleic acid single linear other nucleic acid /desc = “synthetic oligonucleotide misc_feature 41..43 /product= ”random codon by trinucleotides (CGT, TGG, TAT)“ misc_feature 47..55 /product= ”random codons by trinucleotides (18 aa, no Trp, no Cys)“ misc_feature 56..58 /product= ”random codon by trinucleotide mutagenesis (19aa, no Cys)“ 370 CCTGCAAGCG GAAGACGAAG CGGATTATTA TTGCCAGAGC YRKGACNNKN NKNNKNNKGG 60 CGGCGGCACG AAGTTAACCG TTCTTGGCCA GGAATTCGAG CC 102 17 base pairs nucleic acid single linear other nucleic acid /desc = ”synthetic oligonucleotide“ 371 GGCTCGAATT CCTGGCC 17 157 amino acids amino acid linear protein 372 Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn 1 5 10 15 Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln 20 25 30 Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala 35 40 45 Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn 50 55 60 Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val 65 70 75 80 Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu 85 90 95 Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Gly Ala 100 105 110 Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe 115 120 125 Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val 130 135 140 Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser 145 150 155 157 amino acids amino acid linear protein 373 Gly Gly Gly Ser Gly Ser Gly Asp Phe Asp Tyr Glu Lys Met Ala Asn 1 5 10 15 Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu Gln 20 25 30 Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly Ala 35 40 45 Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly Asn 50 55 60 Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln Val 65 70 75 80 Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr Leu 85 90 95 Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Gly Ala 100 105 110 Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu Phe 115 120 125 Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr Val 130 135 140 Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser 145 150 155 

What is claimed is:
 1. An immunoglobulin polypepide comprising four amino acid consensus framework sub-elements and having interspaced complementarity determining region (CDR) sub-elements, wherein said polypeptide is produced by the steps of: (i) aligning a plurality of known human immunoglobulin sequences; (ii) identifying the conserved framework sub-elements of said known and ligned human immunoglobulin sequences; (iii) comparing amino acids at each corresponding position of said conserved framework sub-elements; (iv) deducing consensus sequences for the framework sub-elements based on said comparing step (iii); (v) synthesizing a nucleic acid molecule capable of encoding said polypeptide, wherein said nucleic acid molecule comprises DNA cleavage sites at the boundary between each consensus framework sub-element and CDR sub-elements; and (vi) allowing the expression of said synthesized DNA molecule as said immunoglobulin polypeptide.
 2. A collection of (poly)peptides comprising a plurality of (poly)peptides wherein each member of said plurality is a polypeptide according to claim
 1. 3. A colectlion of (poly)peptides according to claim 2, comprising specific (poly)peptides wherein the genes encoding said specific (poly)peptides (a) are either homologous, or represent consensus gene sequences derived from at least three homologous genes, and (b) wherein said cleavage sites are unique within each gene sequence, (bb) do not form compatible sites with respect to any single sub-sequence, and (bc) are common to all homologous sub-sequences.
 4. A kit comprising a collection of nucleic acids that ncode a collection of (poly)peptides according to claim 3 and suitable host cells therefor.
 5. A kit comprising a nucleic acid that encodes a (poly)peptide according to claim 1 and a suitable host cell therefor.
 6. A kit comprising a plurality of nucleic acids wherein each member of said plurality is a nucleic acid that encodes a polypeptide according to claim 1 and suitable host cells therefor.
 7. The Immunoglobulin polypeptide according to claim 1, wherein said plurality of known human immunoglobulin sequences are human Vκ immunoglobulin sequences.
 8. The immunoglobulin polypeptide according to claim 1, wherein said plurality of known human immunoglobulin sequences are human Vλ immunoglobulin sequences.
 9. The immunoglobulin polypeptide according to claim 1, wherein said plurality of known human immunoglobulin sequences are human VH immunoglobulin sequences.
 10. A synthetic antibody molecule comprising a variable heavy chain polypeptide sequence and a variable light chain polypeptide sequence, wherein each of said variable polypeptide sequences comprise four framework regions and three complementarity determining regions, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of a sequence selected from the group consisting of VH1A (SEQ ID NO:57), VH1B (SEQ ID NO:59), VH2 (SEQ ID NO:61), VH3 (SEQ ID NO:63), VH4 (SEQ ID NO:65), VH5 (SEQ ID NO:67), and VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of a sequence selected from the group consisting of Vκ1 (SEQ I NO: 43), Vκ2 (SEQ ID NO: 45), Vκ3 (SEQ ID NO: 47), Vκ4 (SEQ ID NO: 49), Vλ1 (SEQ ID NO: 51), Vλ2 (SEQ ID NO: 53), and Vλ3 (SEQ ID NO: 55).
 11. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:57), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ1 (SEQ ID NO: 43).
 12. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:57), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ2 (SEQ ID NO: 45).
 13. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:57), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ3 (SEQ ID NO: 47).
 14. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:57), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ4 (SEQ ID NO: 49).
 15. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:57), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ1 (SEQ ID NO: 51).
 16. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:57), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ2 (SEQ ID NO: 53).
 17. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:57), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ3 (SEQ ID NO: 55).
 18. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1A (SEQ ID NO:59), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ1 (SEQ ID NO: 43).
 19. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1B (SEQ ID NO:59), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ2 (SEQ ID NO: 45).
 20. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1B (SEQ ID NO:59), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ3 (SEQ ID NO: 47).
 21. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1B (SEQ ID NO:59), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ4 (SEQ ID NO: 49).
 22. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1B (SEQ ID NO:59), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ1 (SEQ ID NO: 51).
 23. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1B (SEQ ID NO:59), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ2 (SEQ ID NO: 53).
 24. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH1B (SEQ ID NO:59), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ3 (SEQ ID NO: 55).
 25. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH2 (SEQ ID NO:61), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ1 (SEQ ID NO: 43).
 26. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH2 (SEQ ID NO:61), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ2 (SEQ ID NO: 45).
 27. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH2 (SEQ ID NO:61), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ3 (SEQ ID NO: 47).
 28. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH2 (SEQ ID NO:61), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ4 (SEQ ID NO: 49).
 29. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH2 (SEQ ID NO:61), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ1 (SEQ ID NO: 51).
 30. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH2 (SEQ ID NO:61), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ2 (SEQ ID NO: 53).
 31. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH2 (SEQ ID NO:61), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ3 (SEQ ID NO: 55).
 32. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH3 (SEQ ID NO:63), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ1 (SEQ ID NO: 43).
 33. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH3 (SEQ ID NO:63), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ2 (SEQ ID NO: 45).
 34. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH3 (SEQ ID NO:63), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ3 (SEQ ID NO: 47).
 35. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH3 (SEQ ID NO:63), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ4 (SEQ ID NO: 49).
 36. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH3 (SEQ ID NO:63), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ1 (SEQ ID NO: 51).
 37. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH3 (SEQ ID NO:63), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ2 (SEQ ID NO: 53).
 38. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH3 (SEQ ID NO:63), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ3 (SEQ ID NO: 55).
 39. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH4 (SEQ ID NO:65), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ1 (SEQ ID NO: 43).
 40. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH4 (SEQ ID NO:65), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ2 (SEQ ID NO: 45).
 41. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH4 (SEQ ID NO:65), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ3 (SEQ ID NO: 47).
 42. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH4 (SEQ ID NO:65), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ4 (SEQ ID NO: 49).
 43. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH4 (SEQ ID NO:65), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ1 (SEQ ID NO: 51).
 44. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH4 (SEQ ID NO:65), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ2 (SEQ ID NO: 53).
 45. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH4 (SEQ ID NO:65), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ3 (SEQ ID NO: 55).
 46. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH5 (SEQ ID NO:67), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ1 (SEQ ID NO: 43).
 47. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH5 (SEQ ID NO:67), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ2 (SEQ ID NO: 45).
 48. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH5 (SEQ ID NO:67), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ3 (SEQ ID NO: 47).
 49. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH5 (SEQ ID NO:67), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ4 (SEQ ID NO: 49).
 50. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH5 (SEQ ID NO:67), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ1 (SEQ ID NO: 51).
 51. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH5 (SEQ ID NO:67), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ2 (SEQ ID NO: 53).
 52. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH5 (SEQ ID NO:67), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ3 (SEQ ID NO: 55).
 53. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ1 (SEQ ID NO: 43).
 54. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ2 (SEQ ID NO: 45).
 55. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ3 (SEQ ID NO: 47).
 56. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vκ4 (SEQ ID NO: 49).
 57. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ1 (SEQ ID NO: 51).
 58. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ2 (SEQ ID NO: 53).
 59. The synthetic antibody molecule according to claim 10, wherein the four framework regions of said variable heavy chain comprise the corresponding framework regions of VH6 (SEQ ID NO:69), and wherein the four framework regions of said variable light chain comprise the corresponding framework regions of Vλ3 (SEQ ID NO: 55). 